



(51) International Patent Classification:

C07D 473/34 (2006.01) A61K 31/52 (2006.01)

C07D 473/32 (2006.01) A61P 35/00 (2006.01)

C07D 473/26 (2006.01) A61P 35/02 (2006.01)

(21) International Application Number:

PCT/CN2019/100542

(22) International Filing Date:

14 August 2019 (14.08.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) Inventors; and

(71) Applicants (for SC only): **DENG, Haibin** [CN/CN]; Room 502, Building 19, Lane 1288 Pujian Road, Pudong New District, Shanghai 201204 (CN). **LIU, Jinbiao** [CN/CN]; China Novartis Institutes for BioMedical Research Co., Ltd., 4218 Jinke Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai 201203 (CN). **OYANG, Counde** [US/US]; 1420 Bellingham Way, Sunnyvale, CA 94087 (US). **WANG, Ce** [CN/CN]; China Novartis Institutes for BioMedical Research Co., Ltd., 4218 Jinke Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai 201203 (CN). **XIAO, Qitao** [CN/CN]; China Novartis Institutes for BioMedical Research Co., Ltd., 4218 Jinke Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai 201203 (CN). **XUN, Guoliang** [CN/CN]; Room 303, 53-4# Building Chengshi Huayuan South Xianfu Road, Taicang, Jiangsu 215400 (CN). **ZENG, Haiqiang** [CN/CN]; China Novartis Institutes for BioMedical Research Co., Ltd., 4218 Jinke Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai 201203 (CN).

(74) Agent: SHANGHAI PATENT & TRADEMARK LAW OFFICE, LLC; 435 Guiping Road, Shanghai 200233 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS

(57) Abstract: Disclosed is a compound of Formula (I) : or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. Disclosed is a pharmaceutical composition comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2).



(I)



WO 2021/026803 A1

PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS

FIELD OF THE INVENTION

The present invention relates to compounds, compositions and methods for inhibiting the nuclear SET domain-containing protein 2 (NSD2).

BACKGROUND OF THE INVENTION

The nuclear receptor-binding SET domain protein 2 (NSD2), also known as Wolf-Hirschhorn syndrome candidate 1 (WHSC1) or multiple myeloma SET domain (MMSET) is an epigenetic modifier, and is believed to have a driving role in oncogenesis. Both NSD2 overexpression and point mutations that increase its catalytic activity are associated with several human cancers. (Coussens et al., J. Biol. Chem. 293, 13750-13654 (2018)).

NSD2 is dysregulated by the t(4;14)(p16.3;q32.3) translocation in approximately 15% of multiple myeloma (MM) cases. Increased expression of NSD2 in t(4;14)+ MM cell lines is associated with increased levels of H3K36me2 and reciprocally decreased levels of H3K27me3. Such correlation suggests a causal relationship between NSD2 histone methyltransferase (HMT) activity and the MM oncogene.


High expression of the NSD2 protein has been demonstrated in different human cancer types, including bladder, brain, gastrointestinal, lung, liver, ovary, skin, uterus, breast, prostate and glioblastoma. (Coussens et al., supra; Ezponda et al., Oncogene 32:2882-2890 (2013)). Notably, NSD2 is among the most frequently mutated genes in pediatric cancer genomes. The NSD2 SET domain variant, E1099K, was identified in both acute lymphoblastic leukemia tumors and cell lines with increased H3K36me2 that lack the t(4;14) translocation. Sequence results of >1000 pediatric cancer genomes, representing 21 different cancers, revealed the E1099K variant in 14% of t(12;21) ETV6 -RUNX1 containing acute lymphoblastic leukemia (ALL). NSD2 is also among the most frequently mutated genes found in mantle cell lymphoma tumors, where both E1099K and T1150A variants are observed. The E1099K variant has also been reported in chronic lymphocytic leukemia (CLL), lung and stomach cancers. (Coussens et al., supra). In general, NSD2 upregulation is associated with aggressive tumor behavior and poor prognosis. (Ezponda et al., supra).

NSD2 is a promising target for cancer therapy, and there remains a need for selective inhibitors of NSD2.

SUMMARY OF THE INVENTION

The present invention provides novel compounds that inhibit NSD2; and compositions and methods for treating or preventing a disease or condition mediated by NSD2.

In one aspect, the invention provides a compound of Formula (I):



or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof;
wherein:

A is N or CR⁹ wherein R⁹ is hydrogen or halo;

5 L is a bond or C₁₋₄ alkylene;

R¹ is H; or

R¹ and R² together with NH forms a 5-8 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S as ring members; wherein said 5-8 membered heterocyclyl is unsubstituted or substituted by an oxo substituent;

10 R² is selected from the group consisting of:

(i) hydrogen, C₁₋₆ alkyl, haloC₁₋₆ alkyl, hydroxyC₁₋₆ alkyl, hydroxyhaloC₁₋₆ alkyl, C₁₋₆alkoxyC₁₋₆alkyl, haloC₁₋₆ alkoxyC₁₋₆ alkyl or C₃₋₈ cycloalkoxy(C₁₋₆ alkyl);

(ii) cyano; cyanoC₁₋₆ alkyl; C₁₋₆ alkylthioC₁₋₆alkyl; C₂₋₆ alkenyl; haloC₂₋₆ alkenyl; C₂₋₆ alkynyl; C₁₋₄ alkylSOC₁₋₄alkyl; C₁₋₄ alkylSO₂C₁₋₄alkyl; -SO₂R⁸ or -C(C₁₋₄ alkyl)=N-O(C₁₋₄ alkyl);

15 (iii) C₁₋₄alkylcarbonyl; -(CR^aR^b)_p-C(=O)-OR¹⁰; or -C(=O)-(CR^aR^b)_qR¹¹-; wherein R¹¹ is C₃₋₇ cycloalkyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl, each of which is independently unsubstituted or substituted with C₁₋₆ alkyl or C₁₋₆ alkoxy;

(iv) -(CR^aR^b)_r-C(=O)-NR¹²R¹³ wherein R¹² is hydrogen or C₁₋₆ alkyl; R¹³ is hydrogen, C₁₋₆ alkyl or a 5-6 membered heterocyclic ring; or R¹² and R¹³ together form a 5-6 membered heterocyclic ring; wherein said 5-6 membered heterocyclic ring is unsubstituted or substituted with C₁₋₄ alkyl;

20 (v) 5-6 membered heterocyclylC₀₋₆alkyl or 5-6 membered heterocyclyl(haloC₁₋₄ alkyl) wherein each said heterocyclyl radical is unsubstituted or substituted by oxo; and

(vi) 5-9 membered heteroarylC₀₋₆alkyl or 5-9 membered heteroaryl(haloC₁₋₄alkyl), wherein each said heteroaryl radical is unsubstituted or substituted by C₁₋₄ alkyl, haloC₁₋₄ alkyl, hydroxyC₁₋₄ alkyl, C₁₋₄ alkoxy, haloC₁₋₄ alkoxy, halo, hydroxy, cyano, oxido, aminocarbonylC₀₋₆alkyl, C₁₋₄alkylaminocarbonylC₀₋₆alkyl, diC₁₋₄alkylaminocarbonylC₀₋₆alkyl or C₃₋₇ cycloalkyl;

R^{3a}, R^{3b}, R^{4a}, R^{4b}, R^{5a}, R^{5b}, R^{6a} and R^{6b} are independently hydrogen, halo, cyano, hydroxyl, C₁₋₆ alkyl, haloC₁₋₆ alkyl, hydroxyC₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, haloC₁₋₆ alkoxyC₁₋₆alkyl, hydroxyhaloC₁₋₆ alkyl, aryl, -C(=O)-OR¹⁴ or -(CR^aR^b)_s-C(=O)-NR¹⁵R¹⁶; or

30 R^{3a} and R^{3b}, R^{4a} and R^{4b}, R^{5a} and R^{5b} or R^{6a} and R^{6b} forms an oxo substituent;

R⁷ is H, C₁₋₄ alkoxy, halo or C₁₋₄ alkyl; or 3-8 membered heterocyclyl, which is unsubstituted or substituted by halo;

R⁸ is C₃₋₈ cycloalkyl(C₀₋₆ alkyl); 4-6 membered heterocyclylC₀₋₆alkyl comprising 1-3 heteroatoms selected from N, O and S; aryl or 5-9 membered heteroarylC₀₋₆alkyl comprising 1-3 heteroatoms selected from N, O and S; wherein R⁸ is unsubstituted or substituted by 1-3 R¹⁷;

R¹⁷ is halo, hydroxy, cyano, C₁₋₆ alkyl, haloC₁₋₆ alkyl, C₁₋₆ alkoxy, haloC₁₋₆ alkoxy, -NR^aC(=O)CR^c=C(R^c)₂ or -(CR^aR^b)_t-NR^a-C(=O)-R¹⁸;

R^a, R^b, R^c, R¹⁰, R¹⁴, R¹⁵ and R¹⁶ are independently hydrogen or C₁₋₄ alkyl;

R¹⁸ is C₁₋₄ alkyl or C₁₋₄ haloalkyl; and

p, q, r, s and t are independently 0-4.

In another aspect, the invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) or sub-formulae thereof, or a pharmaceutically acceptable salt thereof; and one or more pharmaceutically acceptable carriers.

In yet another aspect, the invention provides a combination, in particular a pharmaceutical combination, comprising a therapeutically effective amount of a compound of Formula (I) or sub-formulae thereof, or a pharmaceutically acceptable salt thereof; and one or more therapeutically active agent(s).

The compounds of the invention, alone or in combination with one or more therapeutically active agent(s), can be used for treating or preventing a disease or condition mediated by NSD2; and more particularly wherein the disease or condition is characterized by overexpression or undesired upregulation of NSD2.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides compositions and methods for treating or preventing a disease or condition mediated by NSD2.

Definitions

For purposes of interpreting this specification, the following definitions will apply and whenever appropriate, terms used in the singular will also include the plural and vice versa.

As used herein, the term "C₁₋₆alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to six carbon atoms, and which is attached to the rest of the molecule by a single bond. The term "C₁₋₄alkyl" is to be construed accordingly. Examples of C₁₋₆alkyl include, but are not limited to, methyl, ethyl, *n*-propyl, 1-methylethyl (*iso*-propyl), *n*-butyl, *n*-pentyl and 1,1-dimethylethyl (*t*-butyl).

As used herein, the term "C₂₋₆alkenyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one double bond, having from two to six carbon atoms, which is attached to the rest of the molecule by a single bond. The term "C₂₋₄alkenyl" is to be construed accordingly. Examples of C₂₋₆alkenyl

include, but are not limited to, ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl, pent-4-enyl and penta-1,4-dienyl.

As used herein, the term "C₂₋₆alkynyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, having from two to six carbon atoms, and which is attached to the rest of the molecule by a single bond. The term "C₂₋₄alkynyl" is to be construed accordingly. Examples of C₂₋₆alkynyl include, but are not limited to, ethynyl, prop-1-ynyl, but-1-ynyl, pent-1-ynyl, pent-4-ynyl and penta-1,4-diynyl.

As used herein, the term "C₁₋₆alkoxy" refers to a radical of the formula -OR_a where R_a is a C₁₋₆alkyl radical as generally defined above. Examples of C₁₋₆alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentoxy, and hexoxy.

As used herein, the term "C₁₋₆alkoxyC₁₋₆alkyl" refers to a radical of the formula -R_a-O-R_a where each R_a is independently a C₁₋₆alkyl radical as defined above. The oxygen atom may be bonded to any carbon atom in either alkyl radical. Examples of C₁₋₆alkoxy C₁₋₆alkyl include, but are not limited to, methoxy-methyl, methoxy-ethyl, ethoxy-ethyl, 1-ethoxy-propyl and 2-methoxy-butyl.

As used herein, the term "C₁₋₄alkylcarbonyl" refers to a radical of the formula -C(=O)-R_a where R_a is a C₁₋₄alkyl radical as defined above.

As used herein, the term "C₁₋₄alkylthioC₁₋₄alkyl" refers to a radical of the formula

-R_a-S-R_a where each R_a is independently a C₁₋₄alkyl radical as defined above.

As used herein, the term "hydroxyC₁₋₆alkyl" refers to a C₁₋₆alkyl radical as defined above, wherein one of the hydrogen atoms of the C₁₋₆alkyl radical is replaced by OH. Examples of hydroxyC₁₋₆alkyl include, but are not limited to, ethan-1-olyl, 2-methylpropan-1-olyl, hydroxy-methyl, 2-hydroxy-ethyl, 2-hydroxy-propyl, 3-hydroxy-propyl and 5-hydroxy-pentyl.

As used herein, the term "aminocarbonylC₀₋₆alkyl" refers to a radical of the formula -R_a-C(=O)-NH₂ wherein R_a is a single bond or a C₁₋₆alkyl radical as defined above.

As used herein, the term "C₁₋₄alkylaminocarbonylC₀₋₆alkyl" refers to a radical of the formula -R_{a1}-C(=O)-NH-R_{a2} where R_{a1} is a single bond or a C₁₋₆alkyl radical as defined above; and R_{a2} is a C₁₋₆alkyl radical as defined above.

As used herein, the term "diC₁₋₄alkylaminocarbonylC₀₋₆alkyl" refers to a radical of the formula -R_{a1}-C(=O)-N(R_{a2})-R_{a2} where R_{a1} is a single bond or a C₁₋₆alkyl radical as defined above; and each R_{a2} is a C₁₋₄alkyl radical as defined above, and may be the same or different.

As used herein, the term "C₃₋₈cycloalkylC₀₋₆alkyl" refers to a stable monocyclic saturated hydrocarbon radical consisting solely of carbon and hydrogen atoms, having from three to eight carbon atoms, and which is attached to the rest of the molecule by a single bond (i.e., C₃₋₈cycloalkyl) or by a C₁₋₆alkyl radical as defined above. The terms "C₃₋₇cycloalkyl" and "C₃₋₇cycloalkylC₀₋₄alkyl" are to be construed accordingly. Examples of C₃₋₈cycloalkylC₀₋₆alkyl include,

but are not limited to, cyclopropyl, cyclopropyl-methyl, cyclobutyl, cyclobutyl-ethyl, cyclopentyl, cyclopentyl-propyl, cyclohexyl, cyclohepty and cyclooctyl.

As used herein, the term "C₃₋₈cycloalkoxyC₁₋₆alkyl" refers to a radical of the formula -R_a-O-R_b wherein R_a is independently a C₁₋₆alkyl radical as defined above and R_b is a C₃₋₈cycloalkyl as defined above. Examples of C₃₋₈cycloalkoxyC₁₋₆alkyl include but are not limited to cyclopropoxymethyl and cyclobutoxymethyl.

"Halo" refers to bromo, chloro, fluoro or iodo.

As used herein, the term "haloC₁₋₆alkyl" refers to a C₁₋₆alkyl radical, as defined above, substituted by one or more halo radicals, as defined above. Examples of haloC₁₋₆alkyl include, but are not limited to, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,3-dibromopropan-2-yl, 3-bromo-2-fluoropropyl and 1,4,4-trifluorobutan-2-yl. The term "haloC₁₋₄alkyl" is to be construed accordingly.

As used herein, the term "haloC₁₋₆alkoxyC₁₋₄alkyl" refers to a radical of the formula -R_{a1}-O-R_{a2} wherein R_{a1} is a C₁₋₆alkyl radical as defined above; and R_{a2} is a haloC₁₋₆alkyl as defined above. Examples of haloC₁₋₆alkoxyC₁₋₄alkyl include but are not limited to (difluoromethoxy)methyl, (2,2,2-trifluoroethoxy)methyl and (2,2-difluoroethoxy)methyl.

As used herein, the term "hydroxylhaloC₁₋₆alkyl" refers to a haloC₁₋₆alkyl radical, as defined above, substituted by one or more hydroxyl radicals. Examples of hydroxylhaloC₁₋₆alkyl include but are not limited to, 2,2-difluoroethan-1-olyl; 2-fluoroethan-1-olyl; and 2,2,2-trifluoroethan-1-olyl.

As used herein, the term "cyanoC₁₋₆alkyl" refers to a radical of the formula -R_a-CN, where R_a is a C₁₋₄alkyl radical as defined above.

As used herein, the term "haloC₂₋₆alkenyl" refers to a C₂₋₆alkenyl radical, as defined above, substituted by one or more halo radicals, as defined above.

As used herein, the term "heterocyclyl" or "heterocyclic" refers to a stable 4-7 membered non-aromatic monocyclic ring radical comprising 1, 2, or 3, heteroatoms individually selected from nitrogen, oxygen and sulfur. The heterocyclyl radical may be bonded via a carbon atom or heteroatom. The term "5-6 membered heterocyclyl" is to be construed accordingly. Examples of heterocyclyl include, but are not limited to, azetidiny, oxetanyl, pyrrolinyl, pyrrolidyl, tetrahydrofuryl, tetrahydrothienyl, piperidyl, piperazinyl, tetrahydropyranyl or morpholinyl or perhydroazepinyl.

As used herein, the term "heterocyclylC₀₋₆alkyl" refers to a heterocyclic ring as defined above which is attached to the rest of the molecule by a single bond or by a C₁₋₆alkyl radical as defined above.

As used herein, the term "heteroaryl" refers to a 5-9 membered aromatic monocyclic or fused ring radical comprising 1, 2, 3 or 4 heteroatoms individually selected from nitrogen, oxygen and sulfur. The heteroaryl radical may be bonded via a carbon atom or heteroatom. The term "5-6 membered heteroaryl" is to be construed accordingly. Examples of 5-6

membered monocyclic heteroaryls include, but are not limited to, furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazinyl, pyridazinyl, pyrimidyl or pyridyl. Examples of fused heteroaryls include but are not limited to 9-membered heteroaryls such as benzofuranyl; 2,3-dihydrobenzofuranyl, 1,3-dihydroisobenzofuranyl;
5 benzo[d][1,3]dioxol-5-yl; imidazo[1,2-a]pyridinyl; pyrazolo[1,5-a]pyridineyl; 1H-indazolyl and 1H-benzo[d]-imidazolyl.

As used herein, the term "heteroarylC₀₋₆alkyl" refers to a heteroaryl ring as defined above which is attached to the rest of the molecule by a single bond or by a C₁₋₆alkyl radical as defined above.

10 As used herein, the term "heteroaryl(haloC₁₋₄alkyl)" refers to a heteroaryl ring as defined above which is attached to the rest of the molecule by a haloC₁₋₄alkyl as defined above. An illustrative example of an heteroaryl(haloC₁₋₄alkyl) is fluoro(pyridin-2-yl)methyl.

"IC₅₀", as used herein, refers to the molar concentration of an inhibitor or modulator that produces 50% inhibition.

15 "Protected derivatives", as used herein, refers to derivatives of inhibitors in which a reactive site or sites are blocked with protecting groups. Protected derivatives are useful in the preparation of inhibitors or in themselves may be active as inhibitors. Examples of protected group includes, but are not limited to, acetyl, tetrahydropyran, methoxymethyl ether, β-methoxyethoxymethyl ether, *p*-methoxybenzyl, methylthiomethyl ether, pivaloyl, silyl ether, carbobenzyloxy, benzyl, *tert*-butoxycarbonyl, *p*-methoxyphenyl, 9-fluorenylmethyloxycarbonyl, acetals, ketals, acylals, dithianes, methylesters, benzyl esters, *tert*-butyl esters, and silyl esters.
20 A comprehensive list of suitable protecting groups can be found in T.W. Greene, *Protecting Groups in Organic Synthesis*, 3rd edition, John Wiley & Sons, Inc. 1999.

As used herein, the term "subject" refers to mammals, primates (e.g., humans, male or
25 female), dogs, rabbits, guinea pigs, pigs, rats and mice. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.

As used herein, the term "inhibit", "inhibition" or "inhibiting" refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.

30 As used herein, the term "treat", "treating" or "treatment" of any disease or disorder refers to alleviating or ameliorating the disease or disorder (i.e., slowing or arresting the development of the disease or at least one of the clinical symptoms thereof); or alleviating or ameliorating at least one physical parameter or biomarker associated with the disease or disorder, including those which may not be discernible to the patient.

35 As used herein, the term "prevent", "preventing" or "prevention" of any disease or disorder refers to the prophylactic treatment of the disease or disorder; or delaying the onset or progression of the disease or disorder

As used herein, a subject is "in need of" a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.

As used herein, the term "a therapeutically effective amount" of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc.

As used herein, the term "anti-cancer agent" or antineoplastic agent, refers to a therapeutic agent that is useful for treating or controlling the growth of cancerous cells.

As used herein, the term "anti-inflammatory agent" refers to a therapeutic agent that reduces inflammation (redness, swelling and/or pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation.

As used herein, the term "pharmaceutical composition" refers to a compound of the invention, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, in a form suitable for oral or parenteral administration.

As used herein, the term "pharmaceutically acceptable carrier" refers to a substance useful in the preparation or use of a pharmaceutical composition and includes, for example, suitable diluents, solvents, dispersion media, surfactants, antioxidants, preservatives, isotonic agents, buffering agents, emulsifiers, absorption delaying agents, salts, drug stabilizers, binders, excipients, disintegration agents, lubricants, wetting agents, sweetening agents, flavoring agents, dyes, and combinations thereof, as would be known to those skilled in the art (see, for example, Remington The Science and Practice of Pharmacy, 22nd Ed. Pharmaceutical Press, 2013, pp. 1049-1070).

As used herein, the term "a," "an," "the" and similar terms used in the context of the present invention (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context.

Description of Preferred Embodiments

The present invention provides novel compounds that inhibit NSD2; and compositions and methods for treating or preventing a condition mediated by NSD2.

Various enumerated embodiments of the invention are described herein. Features specified in each embodiment may be combined with other specified features to provide further embodiments of the present invention.

Embodiment 1. A compound of Formula (I), or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; as described above.

Embodiment 2. A compound of Formula (I) according to Embodiment 1, or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein A is N.

Embodiment 3. A compound of Formula (I) according to Embodiment 1 or 2, or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein

R^{3a} is hydrogen or halo; and R^{3b} is hydrogen, halo, hydroxyl, C_{1-6} alkoxy or cyano; or

R^{4a} is hydrogen or halo; and R^{4b} is hydrogen, halo, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkyl or halo C_{1-6} alkyl; or

R^{5a} is hydrogen and R^{5b} is hydrogen or C_{1-6} alkyl; or

R^{5a} and R^{5b} together form an oxo substituent.

Embodiment 4. A compound of Formula (I) according to any one of Embodiments 1-3, or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein

R^{6a} is hydrogen or halo;

R^{6b} is hydrogen, halo C_{1-6} alkoxy C_{1-6} alkyl, hydroxy C_{1-6} alkyl, hydroxyhalo C_{1-6} alkyl, carboxyl, phenyl or $-(CR^aR^b)_t-C(O)-NR^{15}R^{16}$;

R^a , R^b , R^{15} and R^{16} are independently hydrogen or C_{1-4} alkyl; and


t is 0-1; or

R^{6a} and R^{6b} together form an oxo substituent.

Embodiment 5. A compound of Formula (I) according to any one of Embodiments 1-4, or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R^7 is H, C_{1-4} alkoxy or halo.


Embodiment 6. A compound of Formula (I) according to any one of Embodiments 1-5, or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R^1 , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^{5a} , R^{5b} , R^{6a} , R^{6b} and R^7 are hydrogen.

Embodiment 7. A compound of Formula (I) according to Embodiment 1, wherein said compound is a compound of Formula (II):



or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof.

Embodiment 8. A compound of Formula (II) according to Embodiment 7, wherein said compound is a compound of Formula (IIA):



or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof.

Embodiment 9. A compound according to any one of Embodiments 1-8, or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof, wherein R^2 is hydrogen, C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, hydroxyhalo C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkyl, halo C_{1-6} alkoxy C_{1-6} alkyl or C_{3-8} cycloalkoxy(C_{1-6} alkyl).

Embodiment 10. A compound according to any one of Embodiments 1-8 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R^2 is C_{1-4} alkylcarbonyl;

$-(CR^aR^b)_p-C(O)-OR^{10}$ wherein R^{10} is hydrogen or C_{1-4} alkyl;

$-C(O)-(CR^aR^b)_q-R^{11}$ wherein R^{11} is C_{3-6} cycloalkyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl, each of which is independently unsubstituted or substituted with C_{1-6} alkyl or C_{1-6} alkoxy; or

$-(CR^aR^b)_r-C(O)-NR^{12}R^{13}$; wherein

R^{12} is hydrogen or C_{1-6} alkyl;

R^{13} is hydrogen, C_{1-6} alkyl or a 5-6 membered heterocyclic ring; or

R^{12} and R^{13} together form a 5-6 membered heterocyclic ring; wherein said 5-6 membered heterocyclic ring is unsubstituted or substituted with C_{1-4} alkyl; and

R^a , R^b and R^{11} are independently hydrogen or C_{1-4} alkyl; and

p , q and r are independently 0-2.

Embodiment 11. A compound according to any one of Embodiments 1-8 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R^2 is selected from the group:

pyridin-2-yl, (pyridin-2-yl)methyl or (pyridin-2-yl)ethyl, wherein said pyridin-2-yl is

independently unsubstituted or substituted with 1-2 C_{1-4} alkyl, C_{1-4} haloalkyl, hydroxyl, hydroxy C_{1-4} alkyl, cyano, C_{1-4} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, halo C_{1-4} alkoxy, halo or C_{3-7} cycloalkyl;

thiazol-4-yl, thiazol-2-ylmethyl, oxazol-2-yl, oxazol-2-ylmethyl, pyridazin-3-yl, pyridazin-3-ylmethyl, pyrazin-2-yl, pyrazin-2-ylmethyl, pyrimidin-4-yl, pyrimidin-4-ylmethyl, each of which is independently unsubstituted or substituted with C_{1-4} alkyl or halo;

1H-pyrazol-3-yl, (1H-pyrazol-3-yl)methyl, 1-methyl-1H-pyrazol-4-yl, (1,2,3-triazol-4-yl), isoxazol-3-yl, each of which is independently unsubstituted or substituted with C₁₋₄ alkyl, halo or C₃₋₇ cycloalkyl;

1,4-dioxan-2-yl;

5 pyridin-2(1H)-onyl; and

pyridin-1-oxide-2-yl.

Embodiment 12. A compound according to any one of Embodiment 1-11 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R⁸ is cyclopropyl; cyclobutyl; cyclohexyl or azetidiny.

10 Embodiment 13. A compound according to any one of Embodiment 1-11 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R⁸ is 2,3-dihydrobenzofuran-5-yl; 1,3-dihydroisobenzofuran-5-yl; benzo[d][1,3]dioxol-5-yl; imidazo[1,2-a]pyridin-6-yl or pyrazolo[1,5-a]pyridine-6-yl.

15 Embodiment 14. A compound according to any one of Embodiment 1-13 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R⁸ is pyridyl, unsubstituted or substituted with 1-2 halo, C₁₋₆ alkyl or C₁₋₆ alkoxy; 1H-indazol-5-yl unsubstituted or substituted with 1-2 halo or C₁₋₆ alkyl; or 1H-benzo[d]-imidazol-6-yl unsubstituted or substituted with C₁₋₆ alkyl.

20 Embodiment 15. A compound according to any one of Embodiment 1-13 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R⁸ is phenyl substituted with 1-3 R¹⁷;

R¹⁷ is halo, hydroxy, cyano, C₁₋₆ alkyl, haloC₁₋₆ alkyl, C₁₋₆ alkoxy, haloC₁₋₆ alkoxy, -NR^dC(O)CR^d=C(R^d)₂ or -(CR^aR^b)_t-NR^d-C(O)-R¹⁸;


R^a, R^b and R^d are independently hydrogen or C₁₋₄ alkyl;

25 R¹⁸ is C₁₋₄ haloalkyl; and

t is 0-1.

30 Embodiment 16. A compound according to any one of Embodiment 1-13 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R⁸ is phenyl substituted with 1-3 R¹⁷; and R¹⁷ is halo, hydroxy, C₁₋₆ alkyl, haloC₁₋₆ alkyl, C₁₋₆ alkoxy or haloC₁₋₆ alkoxy.


Embodiment 17. A compound of Formula (II)



or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof;
wherein:

- R^2 is hydrogen, C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, hydroxyhalo C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkyl, halo C_{1-6} alkoxy C_{1-6} alkyl or C_{3-8} cycloalkoxy(C_{1-6} alkyl);
- R^8 is phenyl substituted with 1-3 R^{17} ; and
- R^{17} is halo, hydroxy, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{1-6} alkoxy or halo C_{1-6} alkoxy.


Embodiment 18. A compound of Formula (II) according to Embodiment 17, wherein said compound is a compound of Formula (IIA):



or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof.

- Embodiment 19. A compound according to any one of Embodiments 1-18 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R^2 is hydrogen; 2,2-difluoroethyl; 2-methyl-propan-1-yl; ethan-1-yl; 2,2-difluoroethan-1-yl; 2-fluoroethan-1-yl; 2,2,2-trifluoroethan-1-yl; difluoromethoxyl; or 2,2,2-trifluoroethoxyl.

Embodiment 20. A compound according to any one of Embodiments 1-18 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R^2 is



Embodiment 21. A compound according to any one of Embodiments 1-20, wherein said compound is a compound from Table 2; or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof.

Embodiment 22. The compound according to Embodiment 21, wherein said compound is selected from the group consisting of:

1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,4,5-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol

1-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol

1-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol

1-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol

1-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol

1-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-methoxy-2-(trifluoromethyl)phenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol

1-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-chloro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol

1-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4,5-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol

1-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,3,4-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol

1-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol

1-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6'-chloro-5'-fluoro-[2,2'-bipyridin]-5-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol;

or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof.

Embodiment 23. The compound according to Embodiment 22, wherein said compound is in the (R) configuration, (S) configuration, or a mixture thereof.

Embodiment 24. The compound according to Embodiment 1, wherein said compound is (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,4,5-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol or (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,4,5-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol; or a pharmaceutically acceptable salt thereof.

Embodiment 25. The compound according to Embodiment 1, wherein said compound is (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol or (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol; or a pharmaceutically acceptable salt thereof.

Embodiment 26. The compound according to Embodiment 1, wherein said compound is (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol or (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol; or a pharmaceutically acceptable salt thereof.

Embodiment 27. The compound according to Embodiment 1, wherein said compound is (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol or (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol; or a pharmaceutically acceptable salt thereof.

Embodiment 28. The compound according to Embodiment 1, wherein said compound is (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol or (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol; or a pharmaceutically acceptable salt thereof.

Embodiment 29. The compound according to Embodiment 1, wherein said compound is (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-methoxy-2-(trifluoromethyl)phenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol or (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-methoxy-2-(trifluoromethyl)phenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol; or a pharmaceutically acceptable salt thereof.

Embodiment 30. The compound according to Embodiment 1, wherein said compound is (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-chloro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol or (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-chloro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol; or a pharmaceutically acceptable salt thereof.

Embodiment 31. The compound according to Embodiment 1, wherein said compound is (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4,5-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol or (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4,5-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol; or a pharmaceutically acceptable salt thereof.

Embodiment 32. The compound according to Embodiment 1, wherein said compound is (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,3,4-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol or (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,3,4-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol; or a
5 pharmaceutically acceptable salt thereof.

Embodiment 33. The compound according to Embodiment 1, wherein said compound is (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol or (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol; or a
10 pharmaceutically acceptable salt thereof.

Embodiment 34. The compound according to Embodiment 1, wherein said compound is (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6'-chloro-5'-fluoro-[2,2'-bipyridin]-5-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol or (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6'-chloro-5'-fluoro-[2,2'-bipyridin]-5-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol; or a
15 pharmaceutically acceptable salt thereof.

Embodiment 35. A pharmaceutical composition comprising a compound according to any one of Embodiments 1-34 and one or more pharmaceutically acceptable carrier.

Embodiment 36. A combination comprising a compound according to any one of Embodiments 1-34 and one or more additional therapeutically active agent.

Embodiment 37. The combination according to Embodiment 36, wherein said one or more additional therapeutically active agent is an anti-cancer agent, an analgesic, an anti-inflammatory agent, or a combination thereof.

Embodiment 38. A compound according to any one of Embodiments 1-34 and optionally in combination with a second therapeutic agent, for use in treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD)2.
25

Embodiment 39. The compound according to Embodiment 38, wherein said second therapeutic agent is an anti-cancer agent, an analgesic, an anti-inflammatory agent or a combination thereof.

Embodiment 40. Use of a compound according to any one of Embodiments 1-34 and optionally in combination with a second therapeutic agent, in the manufacture of a medicament for a disease or condition mediated by NSD2.
30

Embodiment 41. A method for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2), comprising administering to a subject in need thereof, a therapeutically effective amount of a compound according to any one of Embodiments 1-34 and

optionally in combination with a second therapeutic agent; thereby treating said disease or condition mediated by NSD2.

Embodiment 42. A method for treating a disease or condition that benefit from or is treatable by inhibition of nuclear SET domain-containing protein 2 (NSD2), comprising
5 administering to a subject in need thereof, a therapeutically effective amount of a compound according to any one of Embodiments 1-34 and optionally in combination with a second therapeutic agent; thereby treating said disease or condition that benefit from or is treatable by inhibition by NSD2.

Embodiment 43. The method according to Embodiment 41 or 42, wherein said disease or
10 condition mediated by NSD2, or said disease or condition that benefit from or is treatable by inhibition of NSD2, is breast cancer, cervical cancer, skin cancer (particularly squamous cell carcinoma), ovarian cancer, gastric cancer, prostate cancer, pancreatic cancer, lung cancer, hepatocellular carcinoma, head and neck cancer, peripheral nerve sheath tumor, osteosarcoma, multiple myeloma, neuroblastoma, leukemia (particularly acute lymphoblastic leukemia), non-
15 Hodgkin's lymphoma (particularly mantle cell lymphoma), or pulmonary arterial hypertension.

Embodiment 44. The method according to Embodiment 41 or 42, wherein said disease or condition mediated by NSD2, or said disease or condition that benefit from or is treatable by inhibition of NSD2, is lung cancer.

Embodiment 45. The method according to Embodiment 44, wherein said lung cancer is
20 small cell or non-small cell lung cancer.

Embodiment 46. The method according to Embodiment 41 or 42, wherein said disease or condition mediated by NSD2, or said disease or condition that benefit from or is treatable by inhibition of NSD2, is leukemia.

Embodiment 47. The method according to Embodiment 46, wherein said leukemia is acute
25 lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML) or chronic myelomonocytic leukemia (CMML).

Embodiment 48. The method according to Embodiment 41 or 42, wherein said disease or condition mediated by NSD2, or said disease or condition that benefit from or is treatable by inhibition of NSD2, is skin cancer.

Embodiment 49. The method according to Embodiment 48, wherein said skin cancer is
30 melanoma, basal cell carcinoma or squamous cell carcinoma.

Embodiment 50. The method according to Embodiment 41 or 42, wherein said disease or condition mediated by NSD2, or said disease or condition that benefit from or is treatable by inhibition of NSD2, is lymphoma.

Embodiment 51. The method according to Embodiment 50, wherein said lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma.

Embodiment 52. The method according to Embodiment 50, wherein said lymphoma is mantle cell lymphoma or diffuse large B cell lymphoma.

5 Embodiment 53. The method according to Embodiment 41 or 42, wherein said disease or condition mediated by NSD2, or said disease or condition that benefit from or is treatable by inhibition of NSD2, is myeloma.

Embodiment 54. A method according to any one of Embodiment 41-53, wherein said compound is administered orally.

10 Unless specified otherwise, the term "compounds of the present invention" or "compound of the present invention" refers to compounds of Formula (I) subformulae thereof, and exemplified compounds, and salts thereof, as well as all stereoisomers (including diastereoisomers and enantiomers), rotamers, tautomers and isotopically labeled compounds (including deuterium substitutions), as well as inherently formed moieties.

15 Depending on the choice of the starting materials and procedures, the compounds can be present in the form of one of the possible stereoisomers or as mixtures thereof, for example as pure optical isomers, or as stereoisomer mixtures, such as racemates and diastereoisomer mixtures, depending on the number of asymmetric carbon atoms. The present invention is meant to include all such possible stereoisomers, including racemic mixtures, diastereoisomeric mixtures and optically pure forms. Optically active (*R*)- and (*S*)- stereoisomers may be prepared
20 using chiral synthons or chiral reagents, or resolved using conventional techniques. Substituents at atoms with unsaturated double bonds may, if possible, be present in *cis*- (*Z*)- or *trans*- (*E*)- form. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a *cis*- or *trans*-configuration.

25 Any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (*R*)-, (*S*)- or (*R,S*)- configuration. In certain embodiments, each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or
30 at least 99 % enantiomeric excess in the (*R*)- or (*S*)- configuration.

Accordingly, as used herein a compound of the present invention can be in the form of one of the possible stereoisomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (*cis* or *trans*) stereoisomers, diastereoisomers, optical isomers (antipodes), racemates or mixtures thereof.

35 Any resulting mixtures of stereoisomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or

optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.

Any resulting racemates of compounds of the present invention or of intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-*O*-,*O'*-*p*-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic compounds of the present invention or racemic intermediates can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.

Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Isotopes that can be incorporated into compounds of the invention include, for example, isotopes of hydrogen.

Further, incorporation of certain isotopes, particularly deuterium (i.e., ^2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index or tolerability. It is understood that deuterium in this context is regarded as a substituent of a compound of Formula (I) or sub-formulae thereof. The concentration of deuterium, may be defined by the isotopic enrichment factor. The term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this invention is denoted as being deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation). It should be understood that the term "isotopic enrichment factor" can be applied to any isotope in the same manner as described for deuterium.

Other examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as ^3H , ^{11}C , ^{13}C , ^{14}C , ^{15}N , ^{18}F , ^{31}P , ^{32}P , ^{35}S , ^{36}Cl , ^{123}I , ^{124}I , ^{125}I respectively. Accordingly it should be understood that the invention includes compounds that incorporate one or more of any of the aforementioned isotopes, including for example, radioactive isotopes, such as ^3H and

^{14}C , or those into which non-radioactive isotopes, such as ^2H and ^{13}C are present. Such isotopically labelled compounds are useful in metabolic studies (with ^{14}C), reaction kinetic studies (with, for example ^2H or ^3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an ^{18}F or labeled compound may be particularly desirable for PET or SPECT studies. Isotopically-labeled compounds of Formula (I) or sub-formulae thereof can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying examples using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.

The compounds of the present invention are either obtained in the free form, as a salt thereof. As used herein, the terms "salt" or "salts" refers to an acid addition or base addition salt of a compound of the invention. "Salts" include in particular "pharmaceutical acceptable salts". The term "pharmaceutically acceptable salts" refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable. In many cases, the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.

Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.

Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, choline, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.


In another aspect, the present invention provides compounds of the present invention in acetate, ascorbate, adipate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, caprate, chloride/hydrochloride,

chlorotheophyllinate, citrate, ethanedisulfonate, fumarate, gluceptate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, mucate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, sebacate, stearate, succinate, sulfosalicylate, sulfate, tartrate, tosylate trifenate, trifluoroacetate or xinafoate salt form.

Processes for Making Compounds of the Invention

All methods described herein can be performed in any suitable order, unless otherwise indicated or otherwise clearly contradicted by context.

Compounds of Formula (I) can be prepared as generally illustrated in Scheme 1, wherein R^1 , R^2 , R^3 , ... are as defined above. As depicted in Scheme 1, Boc protected 3-CN or 3-CO₂Et piperidine undergoes S_N2 or S_NAr reaction in the presence of strong bases (eg. NaHMDS) and a electrophile containing R₂ to generate compound 2 or 2' with quaternary center, which was further hydrolyzed to corresponding carboxylic acid 3 or primary amide 3' either in basic conditions (eg. LiOH) or oxidative hydrolysis conditions (eg. H₂O₂, NaOH). Acid 3 or amide 3' further undergoes Curtius or Hofmann rearrangement to generate protected quaternary amine 4. After selective Boc de-protection, piperidine 5 reacts with fluorinated pyridine 6 in the presence of organic bases (eg. DIPEA) under heat to yield coupling product 7. Ester 7 is further reduced to benzylic alcohol 8 by mild reducing agent (eg. NaBH₄, LiAlH₄), which undergoes Mitsunobu reaction with Boc protected adenine Intermediate B to provide compound 9. After deprotection under acidic or hydrogenation conditions, chiral target molecule 10 is yielded followed by SFC separation.



Scheme 1

The invention further includes any variant of the present processes; for example, wherein an intermediate product obtainable at any stage thereof is used as starting material and the remaining steps are carried out; wherein starting materials are formed *in situ* under the reaction conditions; or wherein the reaction components are used in the form of their salts or optically pure material. Compounds of the invention and intermediates can also be converted into each other according to methods generally known to those skilled in the art.

Pharmacology and Utility

In one aspect, the invention provides compounds of Formula (I) or subformulae thereof, or a pharmaceutically acceptable salt thereof, that are useful for therapy; particularly, for treating or preventing a disease or condition that is mediated by NSD2.

In another aspect, the invention provides the use of a compound of Formula (I) or subformulae thereof, or a pharmaceutically acceptable salt thereof, for treating a disease or condition that benefit from or is treatable by inhibition of NSD2; and for the manufacture of a medicament for treating a disease or condition that is treatable by inhibition of NSD2.

Examples of diseases or conditions that are mediated by NDS2, or that benefit from or are treatable by inhibition of NSD2, include but is not limited to breast cancer, cervical cancer, skin cancer (particularly skin squamous cell carcinoma), ovarian cancer, gastric cancer, prostate cancer, pancreatic cancer, lung cancer, hepatocellular carcinoma, head and neck cancer, peripheral nerve sheath tumor, osteosarcoma, multiple myeloma, neuroblastoma, leukemia (particularly acute lymphoblastic leukemia), non-Hodgkin's lymphoma (particularly mantle cell lymphoma), and pulmonary arterial hypertension.

Pharmaceutical Compositions, Dosage and Administration

In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

In a further embodiment, the composition comprises at least two pharmaceutically acceptable carriers, such as those described herein. The pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration (e.g. by injection, infusion, transdermal or topical administration), and rectal administration. Topical administration may also pertain to inhalation or intranasal application. The pharmaceutical compositions of the present invention can be made up in a solid form (including, without limitation, capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including, without limitation, solutions, suspensions or emulsions). Tablets may be either film coated or enteric coated according to methods known in the art. Typically, the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with one or more of:

- a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine;

b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also

c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired

5 d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and

e) absorbents, colorants, flavors and sweeteners.

In another aspect, the compounds of the present invention are combined with other therapeutic agents, such as other anti-cancer agents, anti-allergic agents, anti-nausea agents
10 (or anti-emetics), pain relievers, cytoprotective agents, and combinations thereof.

In one embodiment, the other therapeutic agent is an anti-cancer agent or chemotherapeutic agent. Examples of anti-cancer agents considered for use in combination therapies of the invention include but are not limited to erlotinib, bortezomib, fulvestrant, sunitinib, imatinib mesylate, letrozole, finasunate, platins such as oxaliplatin, carboplatin, and cisplatin, finasunate, 15 fluorouracil, rapamycin, leucovorin, lapatinib, lonaframib, sorafenib, gefitinib, capmatinib, topotecan, bryostatins, adefovir, anthracycline, carfilzomib, bicalutamide, dolastatin, auristatins, doxorubicin, vincristine, prednisone or prednisolone, other alkylating agents such as mechlorethamine, chlorambucil, and ifosfamide, antimetabolites such as azathioprine or mercaptopurine, other microtubule inhibitors (vinca alkaloids like vincristine, vinblastine, 20 vinorelbine and vindesine, as well as taxanes), podophyllotoxins (etoposide, teniposide, etoposide phosphate, and epipodophyllotoxins), topoisomerase inhibitors, other cytotoxins such as actinomycin, daunorubicin, valrubicin, idarubicin, edrecolomab, epirubicin, bleomycin, plicamycin, mitomycin, as well as other anticancer antibodies (cetuximab, bevacizumab, 25 ibritumomab, abagovomab, adecatumumab, afutuzumab, alacizumab, alemtuzumab, anatumumab, apolizumab, bavituximab, belimumab, bivatuzumab, mertansine, blinatumumab, brentuximab vedotin, cantuzumab, mertansine, catumaxumab, cetuximab, citatuzumab, mogatuximab, cixutumumab, clivatuzumab, tetraxetan, conatumumab, dacetuzumab, daclizumab, detumomab, ecomaximab, edrecolomab, elotuzumab, epratuzumab, ertumaximab, etaracizumab, 30 farletuzumab, figitumumab, fresolimumab, galiximab, gemtuzumab, vedotin, gemtuzumab, ibritumomab, tiuxetan, inotuzumab, ozogamicin, intetumumab, ipilimumab, iratumumab, labetuzumab, lexatumumab, lintuzumab, lucatumumab, lumiliximab, mapatumumab, matuzumab, milatuzumab, mitumomab, nacolomab, tafentox, naptumomab, tafentox, necitumumab, nimotuzumab, ofatumumab, olaratumab, oportuzumab, monatox, oregovomab, 35 panitumumab, pemtumomab, pertuzumab, pintumomab, pritumumab, ramucirumab, rilatumumab, robatumumab, rituximab, sibrotuzumab, tacatumumab, tetraxetan, taplitumomab, paptax, tenatumumab, ticilimumab, tigatuzumab, tositumomab or ¹³¹I-tositumomab, trastuzumab, tremelimumab, tuocotuzumab, celmoleukin, veltuzumab, visilizumab, volocixumab,

votumumab, zalutumumab, zanolimumab, IGN-101, MDX-010, ABX-EGR, EMD72000, ior-t1, MDX-220, MRA, H-11 scFv, huJ591, TriGem, TriAb, R3, MT-201, G-250, ACA-125, Onyvax-105, CD:-960, Cea-Vac, BrevaRex AR54, IMC-1C11, GlioMab-H, ING-1, anti-LCG MABs, MT-103, KSB-303, Therex, KW2871, anti-HMI.24, Anti-PTHrP, 2C4 antibody, SGN-30, TRAIL-RI MAB, Prostate Cancer antibody, H22xKi-r, ABX-Mai, Imuteran, Monopharm-C), and antibody-drug conjugates comprising any of the above agents (especially auristatins MMAE and MMAF, maytansinoids like DM-1, calicheamycins, or various cytotoxins).

In another embodiment, the compounds of the invention are combined with another therapeutic agent selected from anastrozole (ARIMIDEX[®]), bicalutamide (CASODEX[®]), bleomycin sulfate (BLENOXANE[®]), busulfan (MYLERAN[®]), busulfan injection (BUSULFEX[®]), capecitabine (XELODA[®]), N4-pentoxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin (PARAPLATIN[®]), carmustine (BiCNU[®]), chlorambucil (LEUKERAN[®]), cisplatin (PLATINOL[®]), cladribine (LEUSTATIN[®]), cyclophosphamide (CYTOXAN[®] or NEOSAR[®]), cytarabine, cytosine arabinoside (CYTOSAR-U[®]), cytarabine liposome injection (DEPOCYT[®]), dacarbazine (DTIC-Dome[®]), dactinomycin (actinomycin D, COSMEGAN[®]), daunorubicin hydrochloride (CERUBIDINE[®]), daunorubicin citrate liposome injection (DAUNOXOME[®]), dexamethasone, docetaxel (TAXOTERE[®]), doxorubicin hydrochloride (ADRIAMYCIN[®], RUBEX[®]), etoposide (VEPESID[®]), fludarabine phosphate (FLUDARA[®]), 5-fluorouracil (ADRUCIL[®], EFUDEX[®]), flutamide (EULEXIN[®]), tezacitabine, gemcitabine (difluorodeoxycytidine), hydroxyurea (HYDREA[®]), idarubicin (IDAMYCIN[®]), ifosfamide (IFEX[®]), irinotecan (CAMPTOSAR[®]), L-asparaginase (ELSPAR[®]), leucovorin calcium, melphalan (ALKERAN[®]), 6-mercaptopurine (PURINETHOL[®]), methotrexate (FOLEX[®]), mitoxantrone (NOVANTRONE[®]), gemtuzumab ozogamicin (MYLOTARG[™]), paclitaxel (TAXOL[®]), nab-paclitaxel (ABRAXANE[®]), phoenix (Yttrium90/MX-DTPA), pentostatin, polifeprosan 20 with carmustine implant (GLIADEL[®]), tamoxifen citrate (NOLVADEX[®]), teniposide (VUMON[®]), 6-thioguanine, thiotepa, tirapazamine (TIRAZONE[®]), topotecan hydrochloride for injection (HYCAMPTIN[®]), vinblastine (VELBAN[®]), vincristine (ONCOVIN[®]), and vinorelbine (NAVELBINE[®]).

In another embodiment, the compounds of the present invention are combined with another therapeutic agent capable of inhibiting BRAF, MEK, CDK4/6, SHP-2, HDAC, EGFR, MET, mTOR, PI3K or AKT, or a combination thereof. In a particular embodiment, the compounds of the present invention are combined with another therapeutic agent selected from vemurafinib, dabrafenib, LGX818, trametinib, MEK162, LEE011, PD-0332991, panobinostat, verinostat, romidepsin, cetuximab, gefitinib, erlotinib, lapatinib, panitumumab, vandetanib, INC280, everolimus, simolimus, BMK120, BYL719 or CLR457, or a combination thereof.

In another embodiment, the therapeutic agent for use with the compounds of the present invention is selected based on the disease or condition that is being treated. For example, in the treatment of melanoma, the other therapeutic agent may be selected from aldesleukin (e.g., PROLEUKIN®), dabrafenib (e.g., TAFINLAR®), dacarbazine, recombinant interferon alfa-2b (e.g., INTRON® A), ipilimumab, trametinib (e.g., MEKINIST®), peginterferon alfa-2b (e.g., PEGINTRON®, SYLATRON™), vemurafenib (e.g., ZELBORAF®), and ipilimumab (e.g., YERVOY®).

For the treatment of ovarian cancer, the other therapeutic agent may be selected from doxorubicin hydrochloride (Adriamycin®), carboplatin (PARAPLATIN®), cyclophosphamide (CYTOXAN®, NEOSAR®), cisplatin (PLATINOL®, PLATINOL-AQ®), doxorubicin hydrochloride liposome (DOXIL®, DOX-SL®, EVACET®, LIPODOX®), gemcitabine hydrochloride (GEMZAR®), topotecan hydrochloride (HYCAMTIN®), and paclitaxel (TAXOL®).

For the treatment of thyroid cancer, the other therapeutic agent may be selected from doxorubicin hydrochloride (Adriamycin®), cabozantinib-S-malate (COMETRIQ®), and vandetanib (CAPRELSA®).

For the treatment of colon cancer, the other therapeutic may be selected from fluorouracil (e.g., ADRUCIL®, EFUDEX®, FLUOROPLEX®), bevacizumab (AVASTIN®), irinotecan hydrochloride (CAMPTOSTAR®), capecitabine (XELODA®), cetuximab (ERBITUX®), oxaliplatin (ELOXATIN®), leucovorin calcium (WELLCOVORIN®), regorafenib (STIVARGA®), panitumumab (VECTIBIX®), and ziv-aflibercept (ZALTRAP®).

For the treatment of lung cancer, the other therapeutic may be selected from methotrexate, methotrexate LPF (e.g., FOLEX®, FOLEX PFS®, Abitrexate®, MEXATE®, MEXATE-AQ®), paclitaxel (TAXOL®), paclitaxel albumin-stabilized nanoparticle formulation (ABRAXANE®), afatinib dimaleate (GILOTRIF®), pemetrexed disodium (ALIMTA®), bevacizumab (AVASTIN®), carboplatin (PARAPLATIN®), cisplatin (PLATINOL®, PLATINOL-AQ®), crizotinib (XALKORI®), erlotinib hydrochloride (TARCEVA®), gefitinib (IRESSA®) and gemcitabine hydrochloride (GEMZAR®).

For the treatment of pancreatic cancer, the other therapeutic agent may be selected from fluorouracil (ADRUCIL®), EFUDEX®, FLUOROPLEX®, erlotinib hydrochloride (TARCEVA®), gemcitabine hydrochloride (GEMZAR®), and mitomycin or mitomycin C (MITOZYTREXTM, MUTAMYCIN®).

For the treatment of cervical cancer, the other therapeutic agent may be selected from bleomycin (BLENOXANE®), cisplatin (PLATINOL®, PLATINOL-AQ®) and topotecan hydrochloride (HYCAMTIN®).

For the treatment of head and neck cancer, the other therapeutic agent may be selected from methotrexate, methotrexate LPF (e.g., FOLEX®, FOLEX PFS®, Abitrexate®, MEXATE®, MEXATE-AQ®), fluorouracil (ADRUCIL®, EFUDEX®, FLUOROPLEX®), bleomycin

(BLENOXANE®), cetuximab (ERBITUX®), cisplatin (PLATINOL®, PLATINOL-AQ®) and docetaxel (TAXOTERE®).

For the treatment of leukemia, including chronic myelomonocytic leukemia (CMML), the other therapeutic agent can be selected from bosutinib (BOSULIF®), cyclophosphamide (CYTOXAN®, NEOSAR®), cytarabine (CYTOSAR-U®, TARABINE PFS®), dasatinib (SPRYCEL®), imatinib mesylate (GLEEVEC®), ponatinib (ICLUSIG®), nilotinib (TASIGNA®) and omacetaxine mepesuccinate (SYNRIBO®).

In another aspect, the present invention provides pharmaceutical compositions comprising at least one compound of the present invention (e.g., a compound of Formula (I) or a sub-formulae thereof) or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier suitable for administration to a human or animal subject, either alone or together with other anti-cancer agents.

In combination therapies, compositions will either be formulated together as a combination therapeutic, or as separate compositions. The compound of the invention and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers. The structure of therapeutic agents identified by code numbers, generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications). The other therapeutic agents, which can be used in combination with a compound of the present invention, can be prepared and administered as described in the art, such as in the documents cited above.

Optionally, the pharmaceutical composition may comprise a pharmaceutically acceptable carrier, as described above. The pharmaceutical composition or combination of the present invention can be in unit dosage of about 0.5-1000 mg of active ingredient(s) for a subject of about 50-70 kg, or about 1-500 mg or about 1-250 mg or about 1-150 mg or about 0.5-100 mg, or about 1-50 mg of active ingredients. The therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease. The above-cited dosage properties are demonstrable *in vitro* and *in vivo* tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof. The compounds of the present invention can be applied *in vitro* in the form of solutions, e.g., aqueous solutions, and *in vivo* either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution.

In another aspect, the present invention provides methods of treating human or animal subjects suffering from a cellular proliferative disease, such as cancer, comprising administering

to the subject a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof, either alone or in combination with other anti-cancer agents. In combination therapy, the compound of the present invention and other anti-cancer agent(s) may be administered either simultaneously, concurrently or sequentially with no
5 specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient. Moreover, the compound of the invention and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising the compound of the invention and the other therapeutic agent); (ii) by the physician themselves (or under the
10 guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound of the invention and the other therapeutic agent.

In one embodiment, the compound of the present invention and the other anti-cancer agent(s) is generally administered sequentially in any order by infusion or orally. The dosing
15 regimen may vary depending upon the stage of the disease, physical fitness of the patient, safety profiles of the individual drugs, and tolerance of the individual drugs, as well as other criteria well-known to the attending physician and medical practitioner(s) administering the combination. The compound of the present invention and other anti-cancer agent(s) may be administered within minutes of each other, hours, days, or even weeks apart depending upon
20 the particular cycle being used for treatment. In addition, the cycle could include administration of one drug more often than the other during the treatment cycle and at different doses per administration of the drug.

In yet another aspect, compounds of the present invention may be combined with other anti-cancer agents, anti-allergic agents, anti-nausea agents (or anti-emetics), pain relievers,
25 cytoprotective agents, and combinations thereof.

In some instances, patients may experience allergic reactions to the compounds of the present invention and/or other anti-cancer agent(s) during or after administration. Therefore, anti-allergic agents may be administered to minimize the risk of an allergic reaction. Suitable anti-allergic agents include corticosteroids, such as dexamethasone (e.g., DECADRON®),
30 beclomethasone (e.g., BECLOVENT®), hydrocortisone (also known as cortisone, hydrocortisone sodium succinate, hydrocortisone sodium phosphate; e.g., ALA-CORT®, hydrocortisone phosphate, Solu-CORTEF®, HYDROCORT Acetate® and LANACORT®), prednisolone (e.g., DELTA-Cortel®, ORAPRED®, PEDIAPRED® and PRELONE®), prednisone (e.g., DELTASONE®, LIQUID RED®, METICORTEN® and ORASONE®), methylprednisolone
35 (also known as 6-methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate; e.g., DURALONE®, MEDRALONE®, MEDROL®, M-PREDNISOL® and SOLU-MEDROL®); antihistamines, such as diphenhydramine (e.g., BENADRYL®), hydroxyzine, and

cyproheptadine; and bronchodilators, such as the beta-adrenergic receptor agonists, albuterol (e.g., PROVENTIL®), and terbutaline (BRETHINE®).

In other instances, patients may experience nausea during and after administration of the compound of the present invention and/or other anti-cancer agent(s). Therefore, anti-emetics may be administered in preventing nausea (upper stomach) and vomiting. Suitable anti-emetics include aprepitant (EMEND®), ondansetron (ZOFTRAN®), granisetron HCl (KYTRIL®), lorazepam (ATIVAN®), dexamethasone (DECADRON®), prochlorperazine (COMPAZINE®), casopitant (REZONIC® and Zunrisa®), and combinations thereof.

In yet other instances, medication to alleviate the pain experienced during the treatment period is prescribed to make the patient more comfortable. Common over-the-counter analgesics, such as TYLENOL®, are often used. Opioid analgesic drugs such as hydrocodone/paracetamol or hydrocodone/acetaminophen (e.g., VICODIN®), morphine (e.g., ASTRAMORPH® or AVINZA®), oxycodone (e.g., OXYCONTIN® or PERCOCET®), oxymorphone hydrochloride (OPANA®), and fentanyl (e.g., DURAGESIC®) are also useful for moderate or severe pain.

Furthermore, cytoprotective agents (such as neuroprotectants, free-radical scavengers, cardioprotectors, anthracycline extravasation neutralizers, nutrients and the like) may be used as an adjunct therapy to protect normal cells from treatment toxicity and to limit organ toxicities. Suitable cytoprotective agents include amifostine (ETHYOL®), glutamine, dimesna (TAVOCEPT®), mesna (MESNEX®), dexrazoxane (ZINECARD® or TOTECT®), xaliproden (XAPRILA®), and leucovorin (also known as calcium leucovorin, citrovorum factor and folinic acid).

In yet another aspect, a compound of the present invention may be used in combination with known therapeutic processes, for example, with the administration of hormones or in radiation therapy. In certain instances, a compound of the present invention may be used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy.

In yet another aspect, the present invention provides kits comprising one or more compounds of the present invention and another therapeutic agent as described above. Representative kits include (a) compound of Formula (I) or sub-formulae thereof or a pharmaceutically acceptable salt thereof; and (b) at least one other therapeutic agent e.g., as indicated above; whereby such kit may further comprise a package insert or other labeling including directions for administration. The kits of the invention may be used for administering different dosage forms, for example, oral and parenteral; for administering two or more separate pharmaceutical compositions at different dosage intervals; or for titrating the separate compositions against one another; wherein at least one pharmaceutical composition comprises a compound of Formula (I) or sub-formulae thereof.

EXAMPLES

Temperatures are given in degrees Celsius. The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR. Abbreviations used are those conventional in the art.

5 All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents, and catalysts utilized to synthesis the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art (Houben-Weyl 4th Ed. 1952, Methods of Organic Synthesis, Thieme, Volume 21). Unless otherwise specified, starting materials are generally available from
10 commercial sources.

The Examples herein merely illuminate the invention and does not limit the scope of the invention otherwise claimed. Further, the compounds of the present invention can be produced by organic synthesis methods known to one of ordinary skill in the art as shown in the following examples. Where desired, conventional protecting groups are used to protect reactive
15 functional groups in accordance with standard practice, for example, see T.W. Greene and P.G.M. Wuts in "Protecting Groups in Organic Synthesis", John Wiley and Sons, 1991.

Abbreviations

Abbreviations as used herein, are defined as follows: "1x" for once, "2x" for twice, "3x" for thrice, "°C" for degrees Celsius, "aq" for aqueous, "FCC" for flash column chromatography, "eq" for equivalent or equivalents, "g" for gram or grams, "mg" for milligram or milligrams, "L" for liter or liters, "mL" for milliliter or milliliters, "μL" for microliter or microliters, "N" for normal, "M" for molar, "nM" for nanomolar, "mol" for mole or moles, "mmol" for millimole or millimoles, "min" for minute or minutes, "h" or "hrs" for hour or hours, "RT" for room temperature, "ON" for overnight, "atm" for atmosphere, "psi" for pounds per square inch, "conc." for concentrate, "sat" or "sat'd" for saturated, "MW" for molecular weight, "mw" or "μwave" for microwave, "mp" for melting point, "Wt" for weight, "MS" or "Mass Spec" for mass spectrometry, "ESI" for electrospray ionization mass spectroscopy, "HR" for high resolution, "HRMS" for high resolution mass spectrometry, "LCMS" or "LC-MS" for liquid chromatography mass spectrometry, "HPLC" for high pressure liquid chromatography, "RP HPLC" for reverse phase HPLC, "TLC" or "tlc" for thin layer
25 chromatography, "NMR" for nuclear magnetic resonance spectroscopy, "nOe" for nuclear Overhauser effect spectroscopy, "¹H" for proton, "δ" for delta, "s" for singlet, "d" for doublet, "t" for triplet, "q" for quartet, "m" for multiplet, "br" for broad, "Hz" for hertz, "ee" for "enantiomeric excess" and "α", "β", "R", "r", "S", "s", "E", and "Z" are stereochemical designations familiar to one skilled in the art.

35 The following abbreviations used herein below have the corresponding meanings:

Δ	heat
AIBN	azobisisobutyronitrile
AcOH	acetic acid

	Bn	Benzyl
	Boc	tert-butyloxycarbonyl
	Boc ₂ O	di-tert butyl dicarbonate
	B(OMe) ₃	trimethyl borate
5	BSA	bovine serum albumin
	Cbz	benzyloxycarbonyl
	CbzCl	benzyl chloroformate
	CDCl ₃	chloroform-d
	CD ₃ OD	methanol-d ₄
10	dd	doublet of doublets
	DAST	diethylaminosulfur trifluoride
	DCM	dichloromethane
	DEAD	Diethyl azodicarboxylate
	DIAD	diisopropyl azodicarboxylate
15	DIPEA	N,N-diisopropylethylamine
	DMAP	4-dimethylaminopyridine
	DMEM	Dulbecco Modified Eagle Medium
	DMF	dimethylformamide
	DMP	Dess-Martin periodinane
20	DMSO	dimethylsulfoxide
	DPPA	diphenylphosphoryl azide
	EA	ethyl alcohol
	EtOAc	ethyl acetate
	EtOH	ethanol
25	FBS	fetal bovine serum
	HATU	Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium)
	KHMDS	potassium bis(trimethylsilyl)amide
	LiHMDS	lithium bis(trimethylsilyl)amide
	MeOH	methanol
30	MgSO ₄	magnesium sulfate
	MHz	megahertz
	min	minutes
	m/z	mass to charge ratio
	NaHCO ₃	sodium bicarbonate
35	Na ₂ SO ₄	sodium sulfate
	NBS	N-bromosuccinimide
	NH ₄ Cl	ammonium chloride
	PBu ₃	tributylphosphine

	Pd(dppf)Cl ₂	[1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium (II)
	PE	petroleum ether
	PhI(OAc) ₂	(diacetoxyiodo)benzene
	ppm	parts per million
5	<i>rac</i>	racemic
	SFC	Supercritical fluid chromatography
	TBAF	tetra-n-butylammonium fluoride
	TEA	triethylamine
	TFA	trifluoroacetic acid
10	THF	tetrahydrofuran
	TMSI	trimethylsilyl iodide
	UV	ultraviolet

High performance liquid chromatography (HPLC) was performed using an Agilent 1260 HPLC System (Santa Clara, CA). The analytical column was reversed phase Phenomenex Kinetex C18-2.6 μm, 4.6 x 50 mm. A gradient elution was used (flow rate 2.0 mL/min), starting with 5% methanol/ 95% water and progressing to 95% methanol/ 5% water over a period of 10 minutes. All solvents contained 0.1% formic acid (FA). Compounds were detected by ultraviolet light (UV) absorption at 214, 254 and 300 nm. HPLC solvents were purchased from Sigma Aldrich (St. Louis, MO).

Mass spectrometric analysis was performed on an Agilent System (Agilent 1260 HPLC and an Agilent 6130 mass spectrometer detector; Column: Phenomenex Kinetex 2.6 μm C18, column size 4.6 x 50 mm; column temperature 40°C; gradient: 5 95% methanol in water with 0.1% FA over a 2 min period; flow rate 2.0 mL/min (or Polar gradient 5-50% over 2.0 min, or Non-Polar gradient 50-95% over 2.0 min); Mass Spectrometer molecular weight scan range 100 1000; or 100-1500; capillary voltage 4000 V. All masses were reported as those of the protonated parent ions, unless otherwise indicated.

Nuclear magnetic resonance (NMR) analysis was performed using a Bruker 400 MHz NMR. The spectral reference was either TMS or the known chemical shift of the solvent.

Chiral Preparative HPLC Methods Employed in Purification of Examples

SFC chiral screening was carried out on a Thar Instruments Investigator system. The Thar Investigator system consists of:

- ALIAS autosampler
- Thar Fluid Delivery Module (0 to 10mL/min)
- Thar SFC 10 position column oven
- Waters 2998 PDA
- Thar Automated Back Pressure Regulator


All of the Thar components are part of the SuperPure Discovery Series line. The system flowed at 3.0 mL/min and kept at 38 °C. The system back pressure was set to 100 bar. Each sample was screened through a battery of ten 5 µm columns:

- 5µm 4.6x150mm ChiralPak AD
- 5 • 5µm 4.6x150mm ChiralCel OD
- 5µm 4.6x150mm ChiralCel OJ
- 5µm 4.6x150mm ChiralPak AS
- 5µm 4.6x250mm ChiralPak AY
- 5µm 4.6x250mm ChiralCel OZ
- 10 • 5µm 4.6x150mm ChiralPak IC
- 5µm 4.6x150mm ChiralPak IG
- 5µm 4.6x250mm Regis Whelk-O1
- 5µm 4.6x250mm ChromegaChiral CC4

The system ran a gradient from 5% co-solvent to 50% co-solvent in 9 minutes followed by a
 15 10 minutes hold at 50% co-solvent, a switch back to 5% co-solvent and a 0.5 minute hold at
 initial condition. In between each gradient there was a 4 minute equilibration method that flows 5%
 co-solvent through the next column to be screened. The typical solvents screened were, MeOH,
 EtOH, IPA, MeOH+0.5%NH₃, EtOH+0.5%NH₃, IPA+0.1%NH₃. Once separation was detected
 using one of the gradient methods, an isocratic method can be developed, and if necessary,
 20 scaled up for separation on the Thar Prep 80 system.

Intermediates


Intermediate A: Methyl 2-(3,4-difluorophenyl)-5-fluoroisonicotinate



A mixture of compound methyl 2-bromo-5-fluoroisonicotinate (110 g, 470.04 mmol, 1.0 eq.),
 25 (3,4-difluorophenyl)boronic acid (111.34 g, 705.06 mmol, 1.5 eq), Pd(dppf)Cl₂ (8.60 g, 11.75
 mmol, 0.025 eq) and potassium carbonate (129.92 g, 940.08 mmol, 2.0 eq) in 1,4-dioxane (1.
 Pd(dppf)Cl₂ 1 L) was heated to 100°C for 16 hours under N₂. TLC showed the reaction was
 completed. The mixture was diluted with H₂O (500 mL) and EtOAc(1.3 L) and stirred for 15
 mins. The organic layer was separated, washed with brine (500 mL), dried over Na₂SO₄ and
 30 concentrated, the residue purified by combi-flash (5%~50% EtOAc in PE) and trituration
 (PE:EA=50/1, 100 mL) to afford methyl 2-(3,4-difluorophenyl)-5-fluoroisonicotinate (Intermediate
 A) as white solid. ¹H NMR (CDCl₃ 400MHz): δ 8.56 (d, J=2.0 Hz, 1H), 8.05 (d, J=5.6 Hz, 1H),

7.79 (ddd, $J=2.4, 8.4, 10.8$ Hz, 1H), 7.64 (td, $J=2.8, 8.8$ Hz, 1H), 7.26 - 7.11 (m, 1H), 3.94 (s, 3H).


Intermediate B



To a solution of compound 9H-purin-6-amine (15 g, 111 mmol) in THF (500 mL) were added di-tert butyl dicarbonate (Boc_2O) (96.91g, 444 mmol) and DMAP (1.36g, 11.1 mmol). The resulting mixture was stirred at RT for 16h. The THF was removed *in vacuo*. The residue was partitioned between EtOAc (400 mL) and HCl solution (1.0 M in H_2O) (200 mL). The organic layer was dried over Na_2SO_4 and concentrated to give tert-butyl 6-(bis(tert-butoxycarbonyl)amino)-9H-purine-9-carboxylate (Intermediate B-1).


To a solution of tert-butyl 6-(bis(tert-butoxycarbonyl)amino)-9H-purine-9-carboxylate (Intermediate B-1) (48g, 110 mmol) in MeOH (500 mL) was added sat. NaHCO_3 solution (250 mL). The resulting mixture was heated at 60 °C for 2h. The MeOH was removed *in vacuo*. The residue was extracted with a solution of MeOH: DCM (1: 10) (300 mL* 7 times). The combined organic layers were washed with H_2O (150 mL), dried over Na_2SO_4 and concentrated. The residue was washed with a solution of EtOAc: PE (1: 10) (100 mL) and filtered. The filter cake was dried *in vacuo* to give Intermediate B as white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.70 (s, 1H), 8.48 (s, 1H), 1.36 (s, 18 H). LC-MS: $[\text{M}+\text{H}]^+ = 336.2$.

Intermediate C: Methyl 5-fluoro-2-(3-fluorophenyl)isonicotinate




Methyl 5-fluoro-2-(3-fluorophenyl)isonicotinate (Intermediate C) was prepared by using a procedure similar to that of Intermediate A. ^1H - NMR (400 MHz, CDCl_3) δ 8.66 (s, 1 H), 8.18(d, $J = 6.4$ Hz, 1H), 7.76-7.72 (m, 2H), 7.48-7.42 (m, 1H), 7.15-7.11 (m, 1H), 4.01 (s, 3H).

Intermediate D: Methyl 5-fluoro-2-(3-fluoro-4-methoxyphenyl)isonicotinate



A suspension of methyl 2-bromo-5-fluoroisonicotinate (1.0 g, 4.27 mmol), (3-fluoro-4-methoxyphenyl)boronic acid (1.089 g, 6.41 mmol), Cs_2CO_3 (2.78 g, 8.55 mmol) and $\text{PdCl}_2(\text{dppf})\cdot\text{CH}_2\text{Cl}_2$ adduct (0.349 g, 0.427 mmol) in dioxane (10 mL) was stirred at 100 °C under Ar for 2 hr. Then the mixture was diluted with water, extracted with EtOAc, the organic layer was dried over Na_2SO_4 , filtered and concentrated in vacuum. The residue was purified by CombinFlash (PE/EA, EA: 20~40% for 50mins) to afford methyl 5-fluoro-2-(3-fluoro-4-methoxyphenyl)isonicotinate (Intermediate D) as white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.79 (t, 1H), 8.24 (t, 1H), 7.95- 7.87 (m, 2H), 7.27 (t, 3H), 3.92 (d, 6H). LC-MS: $[\text{M}+\text{H}]^+ = 279.9$.


Intermediate F-2: 2-(2-(difluoromethyl)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane



To a solution of 2-bromo-5-fluorobenzaldehyde (8 g, 39.4 mmol) in DCM (30 mL), was added DAST (10.41 mL, 79 mmol) at 0 °C, then the mixture was stirred at rt for 18 hr under N_2 . The reaction mixture was washed with water, the organic layer was dried over Na_2SO_4 , filtered and concentrated in vacuum. The residue was purified by Combinflash (elution gradient: 0% to 10% EtOAc in n-hexane in 30mins) to afford 1-bromo-2-(difluoromethyl)-4-fluorobenzene (Intermediate F-1) as colorless oil. LC-MS: $[\text{M}+\text{H}]^+ = 225.0, 227.0$.

A suspension of 1-bromo-2-(difluoromethyl)-4-fluorobenzene (Intermediate F-1) (2.2 g, 9.78 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (2.98 g, 11.73 mmol) and KOAc (1.919 g, 19.56 mmol) and $\text{PdCl}_2(\text{dppf})\cdot\text{CH}_2\text{Cl}_2$ (0.798 g, 0.978 mmol) adduct in dioxane (30 mL) was stirred at 110 °C for 3 hr under N_2 atmosphere. The mixture was diluted with water, extracted with EtOAc, the organic layer was dried over Na_2SO_4 , filtered and concentrated in vacuum. The residue was purified by CombinFlash (elution gradient: 0% to 10% EtOAc in PE in 30mins) to afford 2-(2-(difluoromethyl)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Intermediate F-2) as a colorless syrup. LC-MS: $[\text{M}+\text{H}]^+ = 272.3$.

Intermediate L-2: 2-(2-(difluoromethyl)-4,5-difluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane




1-bromo-2-(difluoromethyl)-4,5-difluorobenzene (Intermediate L-1) and 2-(2-(difluoromethyl)-4,5-difluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Intermediate L-2) were prepared following procedures analogous to the preparation of Intermediates F-1 and F-2, respectively.

Intermediate L-1: ^1H NMR (CDCl_3 , 400MHz): δ 7.54-7.45 (m, 2H), 6.97-6.70 (t, $J_1 = 54.8$ Hz, $J_2 = 109.6$ Hz, 1H).

Intermediate L-2: ^1H NMR (CDCl_3 , 400MHz): δ 7.75-7.66 (m, 1H), 7.57-7.50 (m, 1H), 7.47-7.14 (m, 1H), 1.36 (s, 12H).

Intermediate O-1: 6-Bromo-2-chloro-3-fluoropyridine



To a solution of 6-bromo-2-chloro-3-fluoropyridine (3.0 g, 0.014 mol, 1.0 eq.) and $i\text{-Pr}_3\text{O}_3\text{B}$ (4.0 g, 0.021 mol, 1.5 eq.) in anhydrous THF (30 mL) was added $n\text{-BuLi}$ (9 mL, 0.021 mol, 2.5M sol., 1.5 eq.) dropwise at -78°C . The resulting mixture was stirred at -78°C for 1 hour and warmed to 20°C for another 1 hour. LCMS showed that the reaction was completed. The reaction was quenched with saturated NH_4Cl (50 mL), acidified with conc. HCl to pH=4, stirred for 1 hour at 20°C . Extracted with ethyl acetate (50 mL*3). The combined organic layer was dried over Na_2SO_4 , concentrated *in vacuo* to afford 6-bromo-2-chloro-3-fluoropyridine (Intermediate O-1). LC-MS: $[\text{M}+\text{H}]^+ = 176.0$.


Intermediates E-O were prepared following procedures analogous to the preparation of Intermediate A, from the reaction of methyl 2-bromo-5-fluoroisonicotinate and corresponding boronic acid or ester.

Intermediate		Boronic acid/ ester	LC-MS and/or ^1H NMR
E			^1H NMR (400 MHz, CDCl_3) δ ppm 8.70 (s, 1H), 8.31-8.29 (d, $J = 5.6$ Hz, 1H), 7.79-7.90 (m, 1H), 7.11-7.02 (m, 1H), 4.03 (s, 3H). LC-MS: $[\text{M}+\text{H}]^+ = 286.1$.
F			LC-MS: $[\text{M}+\text{H}]^+ = 300.1$

Intermediate		Boronic acid/ ester	LC-MS and/or ^1H NMR
G			LC-MS: $[\text{M}+\text{H}]^+ = 298.1.1$
H			LC-MS: $[\text{M}+\text{H}]^+ = 312.1$
I			LC-MS: $[\text{M}+\text{H}]^+ = 298.1$
J			LC-MS: $[\text{M}+\text{H}]^+ = 330.1$
K			LC-MS: $[\text{M}+\text{H}]^+ = 296.1$
L			^1H NMR (CDCl_3 , 400MHz): δ 8.69-8.68 (d, $J = 1.6$ Hz, 1H), 7.97-7.95 (d, $J = 6.4$ Hz, 1H), 7.68-7.63 (m, 1H), 7.47-7.37 (m, 1H), 7.21-7.97 (m, 1H), 4.02 (s, 3H). LC-MS: $[\text{M}+\text{H}]^+ = 318.2$.
M			LC-MS: $[\text{M}+\text{H}]^+ = 286.2$.
N			^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.84 (d, $J = 2.1$ Hz, 1H), 8.24 (d, $J = 5.9$ Hz, 1H), 7.80 (dd, $J = 8.7, 7.1$ Hz, 1H), 7.12 (dd, $J = 11.5, 2.5$ Hz, 1H), 6.93 (td, $J = 8.4, 2.5$ Hz, 1H), 3.93 (s, 3H), 3.89 (s, 3H). LC-MS: $[\text{M}+\text{H}]^+ = 280.0$.


Intermediate		Boronic acid/ ester	LC-MS and/or ^1H NMR
O			^1H NMR (400 MHz, DMSO- d_6) δ = 8.79 (d, J =5.9 Hz, 1H), 8.61 (d, J =1.8 Hz, 1H), 8.34 (dd, J =3.5, 8.4 Hz, 1H), 7.63 - 7.57 (m, 1H), 4.03 (s, 3H). LC-MS: $[\text{M}+\text{H}]^+ = 285.1$

Intermediate 1-1: 5-Fluoro-2-(3-fluoro-4-methoxyphenyl)isonicotinaldehyde



A suspension of 2-bromo-5-fluoroisonicotinaldehyde (8 g, 27.5 mmol), (3-fluoro-4-methoxyphenyl)boronic acid (4.67 g, 27.5 mmol), $\text{PdCl}_2(\text{dppf}) \cdot \text{CH}_2\text{Cl}_2$ adduct (1.121 g, 1.373 mmol) and cesium carbonate (13.42 g, 41.2 mmol) in dioxane (50 mL) was stirred at 100°C for 3 hr under nitrogen atmosphere. LCMS indicated the reaction was complete. The reaction mixture was filtered and the filtrate was concentrated in vacuum to afford a black residue. The residue was redissolved in DCM (60 mL), washed with water (20 mL), brine (20 mL), dried over anhydrous magnesium sulfate, filtered and concentrated in vacuum. The residue was purified by silica gel column chromatography (EtOAc in hexane and DCM, EtOAc/DCM/Hexane=8/20/100) to give 5-fluoro-2-(3-fluoro-4-methoxyphenyl)isonicotinaldehyde (Intermediate 1-1) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 10.51 (d, J = 2.1 Hz, 1H), 8.77 (d, J = 1.9 Hz, 1H), 8.07 (dd, J = 5.3, 2.1 Hz, 1H), 7.85 (dd, J = 12.5, 2.4 Hz, 1H), 7.78 (d, J = 8.6 Hz, 1H), 7.11 (td, J = 8.6, 2.2 Hz, 1H), 4.01 (d, J = 2.2 Hz, 3H). LC-MS: $[\text{M}+\text{H}]^+ = 249.9$.

Intermediate 22-7 : tert-Butyl (3-(cyclopropoxymethyl)piperidin-3-yl)carbamate



To a solution of 1-(tert-butyl) 3-ethyl piperidine-1,3-dicarboxylate (70.0 g, 272 mmol, 1.0 eq.) in THF (1.4 L) was added dropwise LiHMDS (435 mL, 435 mmol, 1.6 eq., 1M in THF) at -70°C under N_2 atmosphere. After stirred at -78°C for 1 hr, ((chloromethoxy)methyl)benzene (56.0 g, 354 mmol, 1.3 eq.) was added at -78°C . The resulting mixture was allowed to warm to $15-20^\circ\text{C}$.

and stirred for 16 hr. The reaction was quenched with water (800 mL), and extracted with EtOAc (800 mLx3). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated in *vacuo*. The residue was purified by Combi Flash (10% EtOAc in PE) to give 1-(tert-butyl) 3-ethyl 3-((benzyloxy)methyl)piperidine-1,3-dicarboxylate (22-1) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.20-7.40 (5H, m), 4.50 (2H, q, *J* = 12.8 Hz), 4.10-4.20 (2H, m), 3.65-3.85 (2H, m), 3.45-3.60 (2H, m), 3.30-3.45 (2H, m), 1.90-2.10 (1H, m), 1.65-1.75 (1H, m), 1.50-1.60 (2H, m), 1.45 (9H, s), 1.20-1.30 (3H, m). LC-MS: [M+H-100]⁺ = 278.1.

A mixture of 1-(tert-butyl) 3-ethyl 3-((benzyloxy)methyl)piperidine-1,3-dicarboxylate (22-1) (50.0 g, 132 mmol, 1.0 eq.) and Pd/C (5.00 g, 10% wet) in dioxane/2N HCl (1L, v/v = 1/1) was stirred under H₂ balloon at 20 °C for 16 hr. Then the mixture was filtered and the filtrate was concentrated in *vacuo*. The pH of the residue was adjusted to 8-9 with NaHCO₃ aqueous. Then THF (500 mL) and CbzCl (45.0 g, 265 mmol, 2.0 eq.) were added. The resulting mixture was stirred at 5-10 °C for 24 hr. The mixture was extracted with EtOAc (500 mLx3). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated in *vacuo*. The residue was purified by Combi Flash (30% EtOAc in PE) to give 1-benzyl 3-ethyl 3-(hydroxymethyl)piperidine-1,3-dicarboxylate (22-2) as colorless oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.30-7.40 (5H, m), 5.05-5.20 (2H, s), 4.05-4.20 (2H, m), 2.60-4.05 (7H, m), 1.55-1.95 (4H, m), 1.15-1.30 (3H, m).

To a solution of 1-benzyl 3-ethyl 3-(hydroxymethyl)piperidine-1,3-dicarboxylate (22-2) (31.0 g, 96.5 mmol, 1.0 eq.) and Py (15.3 g, 193 mmol, 2.0 eq.) in DCM (300 mL) was added dropwise Tf₂O (57.0 g, 193 mmol, 2.0 eq.) at -70 °C under N₂. Then the mixture was allowed to warm to 10-15 °C, and stirred for 1 hr. The reaction was quenched with water (500 mL), and extracted with DCM (500 mLx2). The combined organic layer was washed with water (500 mLx3), dried over anhydrous Na₂SO₄ and concentrated in *vacuo*. The residue was purified by Combi Flash (10% EtOAc in PE) to give 1-benzyl 3-ethyl 3-(((trifluoromethyl)sulfonyl)oxy)methyl)piperidine-1,3-dicarboxylate (22-3) as yellow oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.30-7.45 (5H, m), 5.05-5.25 (2H, s), 4.45-4.75 (2H, m), 4.05-4.25 (2H, m), 3.60-3.85 (2H, m), 3.20-3.40 (3H, m), 1.95-2.10 (1H, m), 1.75-1.90 (1H, m), 1.60-1.75 (2H, m), 1.15-1.30 (3H, m).

To a solution of compound cyclopropanol (3.20 g, 55.1 mmol, 1.0 eq.) in THF (100 mL) was added NaH (60% in mineral oil, 2.70 g, 66.1 mmol, 1.2 eq.) at 0 °C. After stirred at 10-15 °C for 30 min, a solution of 1-benzyl 3-ethyl 3-(((trifluoromethyl)sulfonyl)oxy)methyl)piperidine-1,3-dicarboxylate (22-3) (27.0 g, 60.6 mmol, 1.1 eq.) in THF (100 mL) was added at 0 °C. The resulting mixture was stirred at 10-15 °C for 3 hr. The reaction was quenched with water (500 mL), and extracted with EtOAc (500 mLx2). The combined organic layers were washed with water (500 mLx3), dried over anhydrous Na₂SO₄ and concentrated in *vacuo*. The residue was purified by Combi Flash (20% EtOAc in PE) to 1-benzyl 3-ethyl 3-(cyclopropoxymethyl)piperidine-1,3-dicarboxylate (22-4) as colorless oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.25-7.45


(5H, m), 5.05-5.25 (2H, s), 4.05-4.20 (2H, m), 3.86 (1H, d, $J = 13.2$ Hz), 3.30-3.60 (5H, m), 3.10-3.25 (1H, m), 1.90-2.05 (1H, m), 1.50-1.70 (3H, m), 1.95 (3H, t, $J = 6.8$ Hz), 0.30-0.55 (4H, m).

A mixture of 1-benzyl 3-ethyl 3-(cyclopropoxymethyl)piperidine-1,3-dicarboxylate (22-4) (10.0 g, 27.6 mmol, 1.0 eq.) and LiOH.H₂O (11.6 g, 276 mmol, 10.0 eq.) in MeOH/THF/H₂O (120 mL, v/v/v = 1/1/1) was stirred at 20 °C for 16 hr. Then the mixture was concentrated in *vacuo* to remove THF and MeOH. The residue was diluted with water (300 mL), and extracted with EtOAc (200 mL). The pH of the aqueous layer was adjusted to 5 by 1N HCl, then the aqueous layer was extracted with EtOAc (300 mLx3). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated in *vacuo* to give 1-((benzyloxy)carbonyl)-3-(cyclopropoxymethyl)piperidine-3-carboxylic acid (22-5) as yellow oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.25-7.45 (5H, m), 5.14 (2H, s), 3.79 (1H, d, $J = 13.6$ Hz), 3.15-3.65 (6H, m), 1.90-2.00 (1H, m), 1.50-1.80 (3H, m), 0.30-0.60 (4H, m).

A solution of 1-((benzyloxy)carbonyl)-3-(cyclopropoxymethyl)piperidine-3-carboxylic acid (22-5) (6.00 g, 18 mmol, 1.0 eq), DPPA (5.50 g, 19.8 mmol, 1.1 eq) and Et₃N (3.60 g, 36 mmol, 2.0 eq.) in toluene (100 mL) was stirred at 80 °C under N₂ for 2 hr. Then the reaction was concentrated in *vacuo*. The residue was dissolved in THF (100 mL). Then KOH (3.03 g, 54 mmol, 3.0 eq) and water (10 mL) were added. The mixture was stirred at 15-20 °C for 4 hr. Then Boc₂O (5.90 g, 27 mmol, 1.5 eq) and K₂CO₃ (10.0 g, 72 mmol, 4.0 eq) were added. The resulting mixture was stirred at 15-20 °C for 16hr. The mixture was extracted with EtOAc (200 mLx3). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated in *vacuo*. The residue was purified by Combi Flash (15% EtOAc in PE) to give benzyl 3-((tert-butoxycarbonyl)amino)-3-(cyclopropoxymethyl)piperidine-1-carboxylate (22-6) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.25-7.45 (5H, m), 5.05-5.25 (2H, m), 4.40-4.80 (1H, brs), 3.50-4.05 (4H, m), 3.00-3.35 (3H, m), 2.15-2.55 (1H, m), 1.60-1.75 (1H, m), 1.35-1.55 (11H, m), 0.30-0.60 (4H, m).

A mixture of benzyl 3-((tert-butoxycarbonyl)amino)-3-(cyclopropoxymethyl)piperidine-1-carboxylate (22-6) (4.90 g, 12.1 mmol) and Pd/C (500 mg, 10% wet) in MeOH (100 mL) was stirred under H₂ balloon at 15-20 °C for 1 hr. Then the Pd/C was filtered off and the filtrate was concentrated in *vacuo* to give tert-butyl (3-(cyclopropoxymethyl)piperidin-3-yl)carbamate (Intermediate 22-7) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 4.82 (1H, brs), 3.80 (1H, d, $J = 10.0$ Hz), 3.53 (1H, d, $J = 9.6$ Hz), 3.20-3.30 (1H, m), 3.01 (1H, d, $J = 12.4$ Hz), 2.85-2.95 (1H, m), 2.55-2.65 (2H, m), 2.05-2.20 (1H, brs), 1.30-1.70 (13H, m), 0.35-0.60 (4H, m).

Intermediate 47-6: tert-Butyl (3-(2,2-difluoroethyl)piperidin-3-yl)carbamate



To a solution of 1-benzyl 3-methyl piperidine-1,3-dicarboxylate (5g, 18.03 mmol) in THF (70 mL) was added 1M LHMDs in THF (19.83 mL, 19.83 mmol) dropwise at -78 °C in 30 min. The mixture was stirred at -78 °C for another 30 min. Then 1,1-difluoro-2-iodoethane (6.92 g, 36.1 mmol) was added. The mixture was stirred at -78 °C for another 2 hr. Then the temperature was allowed to increase to RT slowly, and the mixture was allowed to stir at RT for overnight. TLC (PE/EA = 3/1, ninhydrin) monitored the reaction and indicated the reaction was complete. The reaction was quenched by addition of water (10 mL). The most THF was removed under reduced pressure. The residue was extracted with ethyl acetate (30 mL*2), the combined organic phase washed with water (20 mL), brine (20 mL), dried over anhydrous magnesium sulfate, filtered and concentrated. The crude product was purified by flash chromatography (elution gradient: 5% to 20% EtOAc in hexane in 40 mins) to afford 1-benzyl 3-methyl 3-(2,2-difluoroethyl)piperidine-1,3-dicarboxylate (47-1). LC-MS: $[M+H]^+ = 341.9$.

To a solution of 1-benzyl 3-methyl 3-(2,2-difluoroethyl)piperidine-1,3-dicarboxylate (47-1) (6 g, 17.58 mmol) in methanol (50 mL) was added lithium hydroxide (4.21 g, 176 mmol) in Water (30 mL). The mixture was stirred at RT for overnight. TLC (MeOH/DCM = 20/1, ninhydrin) monitored the reaction and indicated the reaction was complete. Remove the most methanol under reduced pressure. The residue was diluted with water (20 mL), then the mixture was washed with ethyl acetate (5 mL), then the aqueous layer was acidified by HCl to pH=3. Then the mixture was extracted with DCM (20 mL*3). The combined organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo to afford crude 1-((benzyloxy)carbonyl)-3-(2,2-difluoroethyl)piperidine-3-carboxylic acid (47-2). LC-MS: $[M+H]^+ = 328.1$.


To a solution of 1-((benzyloxy)carbonyl)-3-(2,2-difluoroethyl)piperidine-3-carboxylic acid (47-2) (5 g, 15.28 mmol) in Toluene (70 mL) was added TEA (4.26 mL, 30.6 mmol) and DPPA (3.70 mL, 16.80 mmol). The mixture was stirred at 100 °C under nitrogen protection for 2 hr. LCMS monitored the reaction and indicated the reaction was complete. The mixture was diluted with ethyl acetate (60 mL), washed with water (20 mL), brine (60 mL). The organic phase was dried over anhydrous magnesium sulfate, filtered and concentrated to give crude benzyl 3-(2,2-difluoroethyl)-3-isocyanatopiperidine-1-carboxylate (47-3). LC-MS: $[M+H]^+ = 325.1$.

To a solution of benzyl 3-(2,2-difluoroethyl)-3-isocyanatopiperidine-1-carboxylate (47-3) (5.7 g, 12.30 mmol) in 1,4-dioxane (25 mL) was added 6M HCl (25 mL, 150 mmol). The mixture was stirred at 45 °C for 30 hr. LCMS monitored the reaction and indicated the reaction was complete. The mixture was cooled to rt and diluted with 20 mL of water. Then it was washed with ethyl acetate (5 mL). The aqueous phase was basified with sodium hydroxide to adjust the pH value to 9. Then the mixture was extracted with DCM (30 mL*3). The organic layer was combined and dried over anhydrous magnesium sulfate, filtered and concentrated to afford crude benzyl 3-amino-3-(2,2-difluoroethyl)piperidine-1-carboxylate (47-4). LC-MS: $[M+H]^+ = 299.2$.

To a solution of benzyl 3-amino-3-(2,2-difluoroethyl)piperidine-1-carboxylate (intermediate 47-4) (4 g, 13.41 mmol) in DCM (50 mL) was added Boc-anhydride (4.67 mL, 20.11 mmol) and DIPEA (7.03 mL, 40.2 mmol) at RT under N₂ atmosphere. The mixture was stirred at 40 °C for 20h. The mixture was cooled to RT and diluted with DCM (30 mL), washed with water (20 mL),
 5 brine(20 mL), dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo to afford the crude product. The crude product was purified by flash chromatography (elution gradient: 5% to 20% EtOAc in hexane in 30mins) to afford benzyl 3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoroethyl)piperidine-1-carboxylate (47-5). LC-MS: [M+H]⁺ = 399.0.

10 To a solution of benzyl 3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoroethyl)piperidine-1-carboxylate (47-5) (4 g, 10.04 mmol) in methanol (50 mL) was added 10% Pd(OH)₂ on carbon, wet (1.410 g, 0.502 mmol), the mixture was stirred at rt for 3 hr under a hydrogen balloon. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was filtered and concentrated to afford the crude tert-butyl (3-(2,2-difluoroethyl)piperidin-3-yl)carbamate (Intermediate 47-6). LC-MS: [M+H]⁺ = 265.0.

Intermediate 78-5: Methyl tert-butyl 3-(methylcarbamoyl)piperidin-3-ylcarbamate



To a solution of (NH₄)₂CO₃ (2.13 g, 22 mmol) in H₂O (8 mL) was added another solution of 1-benzylpiperidin-3-one (500 mg, 2 mmol) in EtOH (8 mL). Then trimethylsilyl cyanide (TMSCN) (0.74 mL, 5.5 mmol) was added to the mixture dropwise at RT. The resulting mixture was stirred
 20 at 70 °C for 16h. LCMS monitored the reaction and indicated the reaction was complete. The EtOH was removed in vacuo. The resulting mixture was extracted with EtOAc (20 mL*3). The organic layer was washed with H₂O (20 mL), brine (20 mL), dried over Na₂SO₄ and concentrated in vacuo. The residue obtained was recrystallized from EtOAc: PE (1: 5) to give 7-benzyl-1,3,7-triazaspiro[4.5]decane-2,4-dione (78-1) as white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.46 – 7.17 (m, 5H), 3.54 (dd, J = 29.8, 13.2 Hz, 2H), 2.90 (d, J = 10.8 Hz, 1H), 2.69 (d, J = 11.2 Hz, 1H), 2.32 (d, J = 11.2 Hz, 1H), 2.08 (t, J = 10.6 Hz, 1H), 1.88 – 1.59 (m, 4H). LC-MS (UV 214): (M+H)⁺ = 260.1

A mixture of 7-benzyl-1,3,7-triazaspiro[4.5]decane-2,4-dione (78-1) (1 g, 3.86 mmol) in 10 M
 30 of 2.0 M KOH aqueous solution was heated at 120 °C for 16h. LCMS monitored the reaction and indicated the reaction was complete. The mixture was cooled to RT. Con. HCl solution (12.0 M in H₂O) was added to the mixture to adjust pH = 4~5. The H₂O was removed in vacuo. The residue was washed with a solution of MeOH: DCM (10%, 30 mL) and filtered. The filtrate


was dried over Na_2SO_4 and concentrated to give crude 3-amino-1-benzylpiperidine-3-carboxylic acid (78-2) as a brown oil. LC-MS $[\text{M}+\text{H}]^+ = 235.3$.

A mixture of 3-amino-1-benzylpiperidine-3-carboxylic acid (78-2) (5.7g, 24.33 mmol), K_2CO_3 (13.45g, 97.31 mmol), Boc_2O (8.2 mL, 36.49 mmol), THF (100 mL) and H_2O (100 mL) was stirred at RT for 16h. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was extracted with EtOAc, the combined organic phase was washed with water, brine, dried over anhydrous sodium sulfate, concentrated to give a residue. The residue was purified by combi-flash (silica gel, KMnO_4 , $\text{NH}_3\cdot\text{H}_2\text{O}$: MeOH: DCM, 20: 100: 1000) to give 1-benzyl-3-(tert-butoxycarbonylamino)piperidine-3-carboxylic acid (78-3) as brown solid. LC-MS: $[\text{M}+\text{H}]^+ = 335.3$.

To a solution of 1-benzyl-3-(tert-butoxycarbonylamino)piperidine-3-carboxylic acid (78-3) (670 mg, 2.00 mmol), HATU (1.5 g, 4.00 mmol) and DIPEA (778 mg, 6.00 mmol) in DCM (20 mL), was added CH_3NH_2 (35% in MeOH, 2 mL). The mixture was stirred at RT for 1 h, LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with water, extracted with EtOAc, the combined organic phase was washed with sat. aq. NaHCO_3 (20 mL), brine (20 mL), dried over anhydrous sodium sulfate, concentrated to give a residue. The residue was purified by flash chromatography (elution gradient: 10% to 50% EtOAc in PE in 30mins) to afford tert-butyl 1-benzyl-3-(methylcarbamoyl)piperidin-3-ylcarbamate (78-4). LC-MS: $[\text{M}+\text{H}]^+ = 348.3$.

To a solution of tert-butyl 1-benzyl-3-(methylcarbamoyl)piperidin-3-ylcarbamate (78-4) (290 mg, 0.836 mmol) in EtOH (10 mL) was added $\text{Pd}(\text{OH})_2$ (87 mg). The resulting mixture was stirred at RT for 4h under H_2 atmosphere. LC-MS monitored the reaction and indicated the reaction was complete. The mixture was filtered and the filtrate was concentrated to give crude methyl tert-butyl 3-(methylcarbamoyl)piperidin-3-ylcarbamate (Intermediate 78-5) as yellow oil. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 7.87 (s, 1H), 7.29 (s, 1H), 3.62-3.59 (m, 1H), 3.04-2.87 (m, 3H), 2.61-2.60 (m, 3H), 1.83-1.76 (m, 3H), 1.53-1.51 (m, 1H), 1.38 (s, 9 H), 1.27-1.25 (m, 1 H). LC-MS (UV 214): $[\text{M}+\text{H}]^+ = 258.4$.

Intermediate 89-6: Methyl (3-(2,3-dimethylbutanoyl)piperidin-3-yl)carbamate



To a solution of tert-butyl 3-cyanopiperidine-1-carboxylate (10 g, 47.6 mmol, 1.0 eq.) in dry THF (100 mL) was added 1M LiHMDS (71.4 mL, 71.4 mmol, 1.5 eq) dropwise at -78°C under nitrogen. The mixture was stirred at -78°C for 40 min. Then 3-methylbutanal (6.1 g, 71.4 mmol, 1.5 eq.) was added in one portion at -78°C . Then the mixture was stirred at RT for 4 hours.

TLC (PE/EA = 2/1) indicated the reaction was complete. The mixture was quenched with water (200 mL), extracted with EA (100 mL*2), washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered, concentrated. The residue was purified by flash chromatography (PE/EA = 92/8 to 90/10 to 70/30) to give tert-butyl 3-cyano-3-(1-hydroxy-3-

5 methylbutyl)piperidine-1-carboxylate (89-1) as yellow oil. ¹H NMR (400 MHz, CD₃OD) δ ppm 4.57 (d, *J* = 13.6 Hz, 0.5H), 4.24-3.93 (m, 1.5H), 3.56 (dd, *J* = 1.6, 10.8 Hz, 0.5H), 3.52-3.42 (m, 0.5H), 3.09-2.56 (m, 2H), 2.22-2.09 (m, 0.5H), 2.01-1.82 (m, 1.5H), 1.78-1.53 (m, 4H), 1.48 (s, 9H), 1.41-1.29 (m, 1H), 0.99 (dd, *J* = 1.6, 6.8 Hz, 3H), 0.95-0.89 (m, 3H). LC-MS: [M+H]⁺ = 297.2

10 To a solution of tert-butyl 3-cyano-3-(1-hydroxy-3-methylbutyl)piperidine-1-carboxylate (89-1) (5.5 g, 18.5 mmol, 1.0 eq.) in CH₂Cl₂ (100 mL) was added DMP (11.8 g, 27.8 mmol, 1.5 eq.). The mixture was stirred at RT for 30 min. TLC (PE/EA = 3/1, ninhydrin) indicated the reaction was complete. The mixture was diluted with H₂O (100 mL) and extracted with CH₂Cl₂ (100 mL*2). The organic layers were washed with brine (200 mL), dried over sodium sulfate, filtered,
15 concentrated and purified by combi-flash (PE/EA = 80/20) to afford tert-butyl 3-cyano-3-(3-methylbutanoyl)piperidine-1-carboxylate (89-2) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 4.59-3.90 (m, 2H), 3.22-2.92 (m, 1H), 2.87-2.58 (m, 3H), 2.29-2.03 (m, 2H), 1.98-1.69 (m, 3H), 1.50 (s, 9H), 1.03-0.89 (m, 6H). LC-MS: [M+H]⁺ = 295.1.

To a solution of tert-butyl 3-cyano-3-(3-methylbutanoyl)piperidine-1-carboxylate (89-2) (3.3 g, 11.2 mmol, 1.0 eq.) in THF (40 mL) was added LiHMDS (12.3 mL, 12.3 mmol, 1.1 eq. 1M in THF) dropwise at -78°C under N₂. The mixture was stirred at -78°C for 20 min. Then MeI (1.8 g, 12.3 mmol, 1.1 eq.) was added to the mixture. The mixture was stirred at RT for another 4 hours. TLC (PE/EA = 10/1, ninhydrin) monitored the reaction and indicated the reaction was complete. The reaction was quenched with H₂O (40 mL) and extracted with EtOAc (40 mL*2). The organic
25 layers were combined and washed with brine (100 mL), dried over sodium sulfate, filtered, concentrated and purified by combi-flash (5% EtOAc in hexane) to give tert-butyl 3-cyano-3-(2,3-dimethylbutanoyl)piperidine-1-carboxylate (89-3) as yellow oil. ¹H NMR (400 MHz, CD₃OD) δ ppm 4.50-4.02 (m, 2H), 3.23-2.64 (m, 3H), 2.27-1.72 (m, 5H), 1.49 (s, 9H), 1.16-1.06 (m, 3H), 1.01-0.88 (m, 6H). LC-MS: [M+H]⁺ = 310.2.


30 To a mixture of tert-butyl 3-cyano-3-(2,3-dimethylbutanoyl)piperidine-1-carboxylate (89-3) (3.3 g, 11 mmol, 1.0 eq.) in MeOH (40 mL) was added NaOH (21 mL, 21 mmol, 1M/L) and H₂O₂ (17 mL, 30% aq. solution). The mixture was stirred at RT for 16 hours. TLC (PE/EA=3:1, ninhydrin) indicated the reaction was completed. The mixture was quenched with saturated aqueous Na₂SO₃ (100 mL), extracted with EtOAc (100 mL*2). The combined organic layers
35 were washed with brine (150 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (15%-30% EtOAc in PE) to give tert-butyl 3-carbamoyl-3-(2,3-dimethylbutanoyl)piperidine-1-carboxylate (89-4) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.15 (brs, 1H), 5.35 (brs, 1H), 4.78-2.28 (m, 5H), 1.94-

1.57 (m, 5H), 1.47 (s, 9H), 1.00 (dd, $J = 7.2, 20.0$ Hz, 3H), 0.90-0.80 (m, 6H). LC-MS: $[M+H]^+ = 327.0$.

To a solution of tert-butyl 3-carbamoyl-3-(2,3-dimethylbutanoyl)piperidine-1-carboxylate (89-4) (1.37 g, 4.2 mmol, 1.0 eq.) in MeOH (30 mL) was added $\text{PhI}(\text{OAc})_2$ (1.6 g, 5.04 mmol, 1.2 eq.) and KOH (589 mg, 10.5 mmol, 2.5 eq.). The mixture was stirred at 0°C for 15 minutes. The mixture was stirred at RT for another 2 hours. TLC (PE/EA=3:1, ninhydrin) indicated the reaction was completed. The mixture was diluted with H_2O (40 mL), extracted with EtOAc (40 mL*2). The combined organic layers were washed with brine (40 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (20% EtOAc in PE) to give tert-butyl 3-(2,3-dimethylbutanoyl)-3-((methoxycarbonyl)amino)piperidine-1-carboxylate (89-5) as a yellow oil. ^1H NMR (400MHz, CD_3OD): δ 4.74-4.42 (m, 1H), 4.14-3.91 (m, 1H), 3.80-3.48 (m, 3H), 3.29-3.12 (m, 1H), 2.96-2.64 (m, 2H), 1.98-1.50 (m, 5H), 1.43 (s, 9H), 1.01-0.85 (m, 9H). LC-MS: $[M+H]^+ = 357.1$.

To a solution of tert-butyl 3-(2,3-dimethylbutanoyl)-3-((methoxycarbonyl)amino)piperidine-1-carboxylate (89-5) (500 mg, 1.40 mmol, 1.0 eq.) in DCM (10 mL) was added TFA (10 mL) at RT. The mixture was stirred at RT for 30 minutes. TLC (PE/EA=3:1, ninhydrin) indicated the reaction was complete. The mixture was concentrated in vacuo and diluted with H_2O (15 mL), basified by $\text{NH}_3 \cdot \text{H}_2\text{O}$ to pH = 11, extracted with $\text{CHCl}_3/\text{i-PrOH}$ (3:1, 20 mL*3). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated to give methyl (3-(2,3-dimethylbutanoyl)piperidin-3-yl)carbamate (Intermediate 89-6) as a yellow oil. ^1H NMR (400 MHz, CD_3OD) δ ppm 3.63 (s, 3H), 3.27-3.20 (m, 1H), 3.07-2.95 (m, 1H), 2.92-2.81 (m, 2H), 2.66-2.55 (m, 1H), 2.10-2.00 (m, 1H), 1.94-1.76 (m, 2H), 1.72-1.57 (m, 1H), 1.54-1.44 (m, 1H), 1.00-0.95 (m, 3H), 0.91-0.74 (m, 6H). LC-MS: $[M+H]^+ = 257.1$.

Intermediate 113-5: tert-Butyl (3-(2,2-difluoro-1-hydroxyethyl)piperidin-3-yl)carbamate



To a solution of 1-benzyl 3-ethyl 3-((tert-butoxycarbonyl)amino)piperidine-1,3-dicarboxylate (5.0 g, 12.30 mmol) in THF (80 mL) and methanol (80 mL), was added lithium chloride (10.43 g, 246 mmol) and sodium tetrahydroborate (9.31 g, 246 mmol) at rt under N_2 atmosphere, the reaction mixture was stirred at RT for 18 hours under N_2 atmosphere. LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with water, extracted with EtOAc (50 mL*3), the combined organic phase was washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate, concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 10% to 50% EtOAc in PE

in 30mins) to give benzyl 3-((tert-butoxycarbonyl)amino)-3-(hydroxymethyl)piperidine-1-carboxylate (113-1). LC-MS: $[M+H]^+ = 365.2$.

To a solution of benzyl 3-((tert-butoxycarbonyl)amino)-3-(hydroxymethyl)piperidine-1-carboxylate (113-1) (6.2 g, 17.01 mmol) in DCM (50 mL) was added Dess-Martin Periodinane (14.43 g, 34.0 mmol) at 0 °C under N₂ atmosphere, the reaction mixture was stirred at RT for 2h under N₂ atmosphere. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with 30ml of sat. NaHCO₃ aqueous solution, extracted with DCM (40 mL*3), the combined organic phase was washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate, concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 10% to 40% EtOAc in PE in 30mins) to afford benzyl 3-((tert-butoxycarbonyl)amino)-3-formylpiperidine-1-carboxylate (113-2). LC-MS: $[M+H]^+ = 362.1$.


To a solution of benzyl 3-((tert-butoxycarbonyl)amino)-3-formylpiperidine-1-carboxylate (113-2) (3 g, 8.28 mmol) and (difluoro(phenylsulfonyl)methyl)trimethylsilane (4.38 g, 16.56 mmol) in anhydrous THF (50 mL) was added a solution of TBAT (0.447 g, 0.828 mmol) in 15 mL anhydrous THF dropwise at -78 °C under N₂ atmosphere. After addition, the reaction mixture was slowly warmed to rt and stirred at rt for 18h under N₂ atmosphere. And then TBAF (10.76 mL, 10.76 mmol) was added and the reaction mixture was stirred at rt for another 30min. LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted sat. NaCl solution, extracted with EtOAc (50 mL*3), the combined organic phase was washed with water (40 mL), brine (40 mL), dried over anhydrous sodium sulfate, and concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 10% to 50% EtOAc in hexane in 40mins) to afford benzyl 3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxy-2-(phenylsulfonyl)ethyl) piperidine-1-carboxylate (113-3). LC-MS: $[M+H]^+ = 555.2$.

To a solution of benzyl 3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxy-2-(phenylsulfonyl)ethyl) piperidine-1-carboxylate (113-3) (2.4 g, 4.33 mmol) in DMF (50 mL), was added 40 mL of HOAc/NaOAc (1:1) buffer solution (4 mol/L). Magnesium turnings (1.578 g, 64.9 mmol) were added in portions. The reaction mixture was stirred at room temperature for 4h. LCMS monitored the reaction and indicated the reaction was complete. The reaction was quenched with water and extracted with EtOAc (30 mL*3). The combined organic layers were washed with water (30 mL), brine (30 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to give a residue. The residue was purified by flash chromatography (elution gradient: 0% to 40% EtOAc in PE in 40mins) to afford benzyl 3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidine-1-carboxylate (113-4). LC-MS: $[M+H]^+ = 415.2$.

To a solution of benzyl 3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidine-1-carboxylate (113-4) (1.0g, 2.413 mmol) in MeOH (50 mL) was added Pd(OH)₂ (0.068 g, 0.483 mmol) at RT, the reaction mixture was stirred at RT for 0.5 h under H₂

atmosphere. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was filtered and concentrated to give tert-butyl (3-(2,2-difluoro-1-hydroxyethyl)piperidin-3-yl)carbamate (Intermediate 113-5). LC-MS: $[M+H]^+ = 281$.

Intermediate 156-2: 1-(3-amino-1-(4-(hydroxymethyl)-6-(2,4,5-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol




To a mixture of methyl 5-fluoro-2-(2,4,5-trifluorophenyl)isonicotinate (Intermediate **E**) (2.5 g, 8.77 mmol) and 1-(3-aminopiperidin-3-yl)-2,2-difluoroethan-1-ol (Intermediate **113-5A**) (3.58 g, 8.77 mmol) in DMSO (40 ml) was added DIPEA (40 ml, 229 mmol). The mixture was heated to 100°C for 3 hrs. LC-MS indicated the reaction was complete. The mixture was cooled to room temperature and was treated with EtOAc (50 ml) and H₂O (50 ml). The layers were separated and the aqueous layer was extracted with EtOAc (50 ml*3). The combined organic layers were washed with brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated. The residue was purified via biotage, eluting with EtOAc in n-hexane (0 to 50%) to give methyl 5-(3-amino-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2,4,5-trifluorophenyl)isonicotinate (Intermediate **156-1**) as a light yellow solid, which was used for the next stage. ¹H NMR (400 MHz, CDCl₃) δ 8.52 (s, 1H), 8.09 - 7.98 (m, 1H), 7.92 (ddd, J = 11.3, 9.1, 7.2 Hz, 1H), 7.04 (td, J = 10.2, 6.4 Hz, 1H), 5.92 (td, J = 55.2, 3.5 Hz, 1H), 3.98 (s, 3H), 3.65 (td, J = 12.9, 3.5 Hz, 1H), 3.36 - 3.21 (m, 2H), 3.11 (d, J = 11.8 Hz, 1H), 2.99 (ddd, J = 12.2, 10.2, 3.2 Hz, 1H), 2.02 (tdd, J = 15.2, 9.7, 4.6 Hz, 1H), 1.88 - 1.65 (m, 3H). LC-MS: $[M+H]^+ = 446.1$.

To a mixture of methyl 5-(3-amino-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2,4,5-trifluorophenyl)isonicotinate (Intermediate **156-1**) (3.2 g, 7.18 mmol) and LiCl (6.09 g, 144 mmol) in MeOH (100 ml) and THF (100 ml) was added NaBH₄ (5.44 g, 144 mmol) at 0 °C. The mixture was stirred at room temperature for 4 hrs. LC-MS indicated most of sm was consumed. The mixture was quenched with H₂O (50 ml) and was extracted with EtOAc (50 ml*4). The combined organic layers were washed with brine, dried over Na₂SO₄ and filtered. The filtrate was concentrated. The filtrate was concentrated and purified via biotage, eluting with MeOH in DCM (0 to 10%) to give 1-(3-amino-1-(4-(hydroxymethyl)-6-(2,4,5-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol (Intermediate **156-2**) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.47 (s, 1H), 7.89 (ddd, J = 11.2, 9.1, 7.2 Hz, 1H), 7.81 (d, J = 2.0 Hz, 1H), 7.04 (td, J = 10.2, 6.5 Hz, 1H), 5.92 (td, J = 55.2, 3.6 Hz, 1H), 5.12 - 4.62 (m, 2H), 3.68 (td, J = 12.5, 3.6

Hz, 1H), 3.09 (dd, $J = 25.6, 10.6$ Hz, 3H), 2.97 - 2.89 (m, 1H), 2.09 - 1.72 (m, 4H). LC-MS: $[M+H]^+ = 418.2, 419.1$.

Intermediate 158-3: tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2-(difluoromethyl)-4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate




To a solution of tert-butyl (3-(2,2-difluoro-1-hydroxyethyl)piperidin-3-yl)carbamate (Intermediate 113-5) (1.828 g, 4.48 mmol) and methyl 2-(2-(difluoromethyl)-4-fluorophenyl)-5-fluoroisonicotinate (Intermediate F) (1.34 g, 4.48 mmol) in DMSO (15 mL) was added DIPEA (15.64 mL, 90 mmol) at RT, the reaction mixture was stirred at 80°C for 8 hr under N₂ atmosphere. LC-MS monitored the reaction. The reaction mixture was diluted with water (40 mL), extracted with EtOAc (30 mL*3). The combined organic layers were washed with water (20 mL*3), brine (20 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to give a residue. The residue was purified by flash chromatography (elution gradient: 0% to 10% MeOH in DCM in 40 mins) to afford methyl 5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2-(difluoromethyl)-4-fluorophenyl)isonicotinate (Intermediate 158-1). LC-MS: $[M+H]^+ = 460.1$.

To a solution of methyl 5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2-(difluoromethyl)-4-fluorophenyl)isonicotinate (Intermediate 158-

1) (1.5g, 3.27 mmol) in THF (30 mL) and MeOH (30 mL), was added NaBH₄ (2.471 g, 65.3 mmol) and LiCl (2.77 g, 65.3 mmol). The reaction mixture was stirred at 20 °C for 2 hr under N₂ atmosphere. LC-MS monitored the reaction. The reaction mixture was diluted with 30ml of water, extracted with EtOAc (20 mL*3). The combined organic layers were washed with water (20 mL), brine (20 mL), concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 0% to 10% MeOH DCM in 30 mins) to afford tert-butyl (3-(2,2-difluoro-1-hydroxyethyl)-1-(6-(2-(difluoromethyl)-4-fluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-3-yl)carbamate (Intermediate **158-2**). LC-MS: [M+H]⁺ =432.

To a solution of tert-butyl (3-(2,2-difluoro-1-hydroxyethyl)-1-(6-(2-(difluoromethyl)-4-fluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-3-yl)carbamate (Intermediate **158-2**) (500 mg, 1.159 mmol), Intermediate **B** (389 mg, 1.159 mmol) and PPh₃ (912 mg, 3.48 mmol) in THF (50 mL), was added DEAD (0.550 mL, 3.48 mmol), the reaction mixture was stirred at 0 °C for 30min under N₂ atmosphere. LC-MS monitored the reaction. The reaction mixture was diluted with 20 ml of water, extracted with EtOAc (20 mL*3). The combined organic layers were washed with water (20 mL), brine (20 mL), concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 0% to 10% MeOH in DCM in 30mins) to afford tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2-(difluoromethyl)-4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (Intermediate **158-3**). LC-MS: [M+H]⁺ =749.

Intermediate 160-3: tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2,5-difluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate









To a solution of methyl 2-(2,5-difluoro-4-methoxyphenyl)-5-fluoroisonicotinate (Intermediate **G**) (2.0 g, 6.73 mmol) and tert-butyl (3-(2,2-difluoro-1-hydroxyethyl)piperidin-3-yl)carbamate (Intermediate **113-5**) (2.263 g, 8.07 mmol) in DMSO (10 mL) was added DIPEA (23.50 mL, 135 mmol) under N₂ atmosphere, and the reaction mixture was stirred at 120 °C for 6 hrs. LC-MS monitored the reaction. The reaction mixture was diluted with water, extracted with EtOAc, the combined organic phase was washed with water, brine, dried over Na₂SO₄, concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 10% to 50% EtOAc in n-hexane in 30mins) to afford methyl 5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2-(difluoromethyl)-4-fluorophenyl)isonicotinate (Intermediate **160-1**). LC-MS: [M+H]⁺ = 558.1.

To a solution of methyl 5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2-(difluoromethyl)-4-fluorophenyl)isonicotinate (Intermediate **160-1**) (1.9 g, 3.41 mmol) in THF (30 mL) and methanol (30 mL) was added LiCl (0.068 g, 3.41 mmol) and NaBH₄ (0.068 g, 3.41 mmol) at 0°C. The reaction mixture was stirred at rt for 2 hours under N₂. LC-MS monitored the reaction. The reaction mixture was diluted with water, extracted with EtOAc, the combined organic phase was washed with water, brine, dried over sodium sulfate, concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 10% to 60% EtOAc in n-hexane in 40mins) to afford tert-butyl (3-(2,2-difluoro-1-hydroxyethyl)-1-(6-(2,5-difluoro-4-methoxyphenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-3-yl)carbamate (Intermediate **160-2**). LC-MS: [M+H]⁺ = 530.2.


To a solution of tert-butyl (3-(2,2-difluoro-1-hydroxyethyl)-1-(6-(2,5-difluoro-4-methoxyphenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-3-yl)carbamate (Intermediate **160-2**) (1.2 g, 2.3 mmol), Intermediate **B** (0.76 g, 2.3 mmol) and PPh₃ (1.783 g, 6.80 mmol) in THF (20 mL) was added DEAD (1.1 mL, 6.8 mmol) dropwise at 0 °C under N₂ atmosphere, the reaction mixture was stirred at 0 °C for 0.5 hr under N₂ atmosphere. LC-MS monitored the reaction. The reaction mixture was quenched with water and extracted with EtOAc, the combined organic phase was washed with water, brine, dried over Na₂SO₄, concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 10% to 50% EtOAc in n-hexane in 50 mins) to afford tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2,5-difluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (Intermediate **160-3**). LC-MS: [M+H]⁺ = 847.3.

The following intermediates were prepared following procedures analogous to the preparation of tert-butyl (3-(2,2-difluoro-1-hydroxyethyl)-1-(6-(2,5-difluoro-4-methoxyphenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-3-yl)carbamate (Intermediate **160-2**), from reacting the corresponding fluoroisonicotinate with 1-(3-aminopiperidin-3-yl)-2,2-difluoroethan-1-ol (Intermediate **113-5A**) (Intermediate Nos. 162-2, 164-2 and 166-2) or tert-butyl (3-(2,2-difluoro-1-hydroxyethyl)piperidin-3-yl)carbamate (Intermediate **113-5**) (Intermediate Nos. 168-2, 170-2, 172-2).

Intermediate No.			LC-MS
162-2		 (Intermediate H)	[M+H] ⁺ = 444.2, 445.2
164-2		 (Intermediate I)	[M+H] ⁺ = 430.1
166-2		 (Intermediate J)	[M+H] ⁺ = 462.1


Intermediate No.			LC-MS
168-2			$[M+H]^+ = 528.2$
170-2			$[M+H]^+ = 550.2$
172-2			$[M+H]^+ = 518.2$
174-2			$[M+H]^+ = 512.0$
175-2			$[M+H]^+ = 517.1$

Intermediate 168-3: tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2-chloro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate



To a solution of tert-butyl (1-(6-(2-chloro-4-methoxyphenyl)-4-(hydroxymethyl)pyridin-3-yl)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-3-yl)carbamate (Intermediate **168-2**) (0.5 g, 0.947 mmol, 1.0 eq), Intermediate B (0.318 g, 0.947 mmol, 1.1 eq) and n-PPh₃ (0.745 g, 2.84 mmol, 3 eq) in THF (20 mL), was added DIAD (0.552 mL, 2.84 mmol, 3 eq) dropwise at 0 °C under N₂ over 20 min, after addition the reaction mixture was stirred at RT for 1 hr under N₂ atmosphere. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with 20 mL of water, extracted with EtOAc (20 mL*3). The combined organic layers were washed with water (20 mL), brine (20 mL), concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 20% to 70% EtOAc in n-hexane in 50 mins) to afford tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2-chloro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (Intermediate **168-3**). LC-MS: [M+H]⁺ = 845.4.

Intermediate 170-4: tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2-(difluoromethyl)-4,5-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate




Step 1. To a solution of tert-butyl (3-(2,2-difluoro-1-hydroxyethyl)-1-(6-(2-(difluoromethyl)-4,5-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-3-yl)carbamate (Intermediate **170-2**) (0.22 g, 0.40 mmol, 1.0 eq) in dry DCM (5 mL) was added dropwise thionyl chloride (0.146 mL,

2.02mmol) at 0°C. The reaction mixture diluted with sat. K₂CO₃ solution, extracted with DCM, washed with water (10 mL), brine (10 mL × 2) and dried over Na₂SO₄, concentrated under reduced pressure to afford tert-butyl (1-(4-(chloromethyl)-6-(2-(difluoromethyl)-4,5-difluorophenyl)pyridin-3-yl)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-3-yl)carbamate (Intermediate 170-3) as yellow solid. LC-MS: [M+H]⁺ = 568.1.


Step 2. A suspension of tert-butyl (1-(4-(chloromethyl)-6-(2-(difluoromethyl)-4,5-difluorophenyl)pyridin-3-yl)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-3-yl)carbamate (Intermediate 170-3) (0.24 g, 0.42 mmol, 1.0 eq), intermediate B (0.14 g, 0.42 mmol) and K₂CO₃ (0.175 g, 1.27 mmol, 3.0 eq) in dry DMF (5 mL) was stirred at RT for 16 hours and quenched with water. The mixture was extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with water (10 mL × 3), brine (10 mL) and dried over Na₂SO₄, filtered and concentration. The crude product was purified by flash chromatography (elution gradient: 10% to 70% EtOAc in m-hexane 50mins) to afford tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2-(difluoromethyl)-4,5-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (Intermediate 170-4) as a white solid. LC-MS: [M+H]⁺ = 867.3.

Intermediate 172-4: tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2,3,4-trifluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate




tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2,3,4-trifluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (Intermediate 172-4) was obtained as a white solid following analogous procedures described in Intermediate 170-4 from tert-butyl (3-(2,2-difluoro-1-hydroxyethyl)-1-(4-(hydroxymethyl)-6-(2,3,4-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)carbamate (Intermediate 172-2). LC-MS: [M+H]⁺ = 835.2.

Intermediate 174-3: tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(4-fluoro-2-

methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate

To a solution of tert-butyl (3-(2,2-difluoro-1-hydroxyethyl)-1-(6-(4-fluoro-2-methoxyphenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-3-yl)carbamate (**Intermediate 174-2**) (310 mg, 0.61 mmol),
 5 **Intermediate B** (203 mg, 0.61 mmol) and PPh₃ (477 mg, 1.82 mmol) in THF (10 mL), was added DEAD (0.288 mL, 1.82 mmol) dropwise at 0 °C, after addition the reaction mixture was stirred at RT for 0.5 hr under N₂ atmosphere. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with 20 mL of water, extracted with EtOAc (20 mL*3). The combined organic layers were washed with water (20 mL), brine (20 mL),
 10 concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 10% to 70% EtOAc in PE in 50 mins) to afford tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(4-fluoro-2-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (**Intermediate 174-3**). LC-MS: [M+H]⁺ = 829.2.

Intermediate 175-3: tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-6'-chloro-5'-fluoro-[2,2'-bipyridin]-4-yl)methyl)-9H-purin-6-yl)carbamate



Tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-6'-chloro-5'-fluoro-[2,2'-bipyridin]-4-yl)methyl)-9H-purin-6-yl)carbamate


yl)carbamate (Intermediate 175-3) was obtained following procedures analogous to Intermediate 174-3. LC-MS: $[M+H]^+ = 834.1$.

Intermediate 177-4: Methyl (3-(6-methylpyridin-2-yl)piperidin-3-yl)carbamate hydrochloride

Intermediates 177-5: Methyl 2-(3,4-difluorophenyl)-5-(3-((methoxycarbonyl)amino)-3-(6-methylpyridin-2-yl)piperidin-1-yl)isonicotinate

Intermediate 177-6: Methyl (1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)-3-(6-methylpyridin-2-yl)piperidin-3-yl)carbamate

Intermediate 177-7: tert-butyl (tert-butoxycarbonyl)(9-((2-(3,4-difluorophenyl)-5-(3-((methoxycarbonyl)amino)-3-(6-methylpyridin-2-yl)piperidin-1-yl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate



To a solution of tert-butyl 3-cyanopiperidine-1-carboxylate (3.00 g, 14.3 mmol, 1.0 eq.) and 2-fluoro-6-methylpyridine (1.66 g, 14.9 mmol, 1.05 eq.) in THF (30 mL) was added dropwise KHMDS (17 mL, 17 mmol, 1.2 eq., 1M in THF) at -70 °C under N₂ atmosphere. The resulting mixture was allowed to warm to 25°C and stirred for 12 hours. LCMS showed the starting material was consumed completely. The reaction was quenched with water (50 mL), and extracted with EtOAc (30 mLx3). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo*. The residue was purified by combi flash (20% EtOAc in PE) to give tert-butyl 3-cyano-3-(6-methylpyridin-2-yl)piperidine-1-carboxylate (177-1) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.64 (t, *J* = 7.6 Hz, 1H), 7.48 (d, *J* = 7.6 Hz, 1H), 7.12 (d, *J* = 8.0 Hz, 1H), 4.61-4.14 (m, 2H), 3.54-3.21 (m, 1H), 2.94-2.73 (m, 1H), 2.55 (s, 3H), 2.40-2.24 (m, 1H), 2.23-2.12 (m, 1H), 2.06-1.92 (m, 1H), 1.84-1.75 (m, 1H), 1.51 (s, 9H). LC-MS: $[M+H]^+ = 302.0$.

To a solution of tert-butyl 3-cyano-3-(6-methylpyridin-2-yl)piperidine-1-carboxylate (177-1) (2.70 g, 8.97 mmol, 1.0 eq.) in MeOH (30 mL) was added NaOH (10 mL, 1M) and H₂O₂ (5 mL, 30%). Then the reaction mixture was stirred at 25 °C for 12 hours. LCMS showed that most of the starting material was consumed completely. Then the mixture was quenched with sat. Na₂SO₃ (100 mL) and stirred at 25 °C for 1 hour. The resulting mixture was concentrated in *vacuo* to remove MeOH. The aqueous was extracted with EtOAc (1000 mLx3). The combined

organic layers were dried over anhydrous Na_2SO_4 , filtered and concentrated in *vacuo*. The residue was purified by silica gel (PE/EtOAc 5/1 to 1/1) to give tert-butyl 3-carbamoyl-3-(6-methylpyridin-2-yl)piperidine-1-carboxylate (177-2) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ ppm 7.54 (t, $J = 7.6$ Hz, 1H), 7.34 (d, $J = 7.6$ Hz, 1H), 7.03 (d, $J = 7.6$ Hz, 1H), 5.48 (brs, 1H), 4.67-4.24 (m, 1H), 3.91-3.43 (m, 2H), 3.21-2.95 (m, 1H), 2.72-2.55 (m, 1H), 2.53 (s, 3H), 2.32-2.02 (m, 1H), 1.68-1.54 (m, 2H), 1.48 (s, 9H). LC-MS: $[\text{M}+\text{H}]^+ = 320.1$.

To a solution of tert-butyl 3-carbamoyl-3-(6-methylpyridin-2-yl)piperidine-1-carboxylate (177-2) (2.40 g, 7.51 mmol, 1.0 eq.) and KOH (1.05 g, 18.8 mmol, 2.5 eq.) in MeOH (30 mL) was added $\text{PhI}(\text{OAc})_2$ (2.42 g, 7.51 mmol, 1.0 eq.) at 0°C . The resulting mixture was stirred at 25°C for 16 hours. LCMS showed the starting material was consumed completely. The reaction was concentrated in *vacuo*. The residue was purified by silica gel column (PE/EtOAc 10/1 to 3/1) to give tert-butyl 3-((methoxycarbonyl)amino)-3-(6-methylpyridin-2-yl)piperidine-1-carboxylate (177-3) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ ppm 7.55 (t, $J = 8.0$ Hz, 1H), 7.26 (d, $J = 8.0$ Hz, 1H), 7.01 (d, $J = 7.6$ Hz, 1H), 4.31-3.98 (m, 2H), 3.62 (s, 3H), 3.14-2.82 (m, 1H), 2.53 (s, 3H), 2.48-2.09 (m, 1H), 1.82-1.67 (m, 2H), 1.66-1.57 (m, 1H), 1.50 (s, 9H). LC-MS: $[\text{M}+\text{H}]^+ = 350.3$.


To a mixture of tert-butyl 3-((methoxycarbonyl)amino)-3-(6-methylpyridin-2-yl)piperidine-1-carboxylate (177-3) (1.5 g, 4.30 mmol, 1.0 eq.) in DCM (10 mL) was added HCl/dioxane (10 mL, 4M), and the resulting mixture was stirred at 25°C for 1 hour. TLC showed the starting material was consumed completely. The mixture was concentrated in *vacuo* to give methyl (3-(6-methylpyridin-2-yl)piperidin-3-yl)carbamate hydrochloride (Intermediate 177-4) as a white solid. ^1H NMR (400 MHz, CD_3OD) δ ppm 8.48-8.39 (m, 1H), 7.92-7.78 (m, 2H), 4.33-4.25 (m, 1H), 4.09-4.01 (m, 1H), 3.68 (s, 3H), 3.50-3.39 (m, 1H), 3.30-3.17 (m, 1H), 2.91 (s, 3H), 2.44-2.31 (m, 1H), 2.30-2.14 (m, 2H), 2.06-1.94 (m, 1H). LC-MS: $[\text{M}+\text{H}]^+ = 250.0$.

To a solution of methyl (3-(6-methylpyridin-2-yl)piperidin-3-yl)carbamate hydrochloride (Intermediate 177-4) (1.22 g, 4.27 mmol, 1.0 eq.) in DMSO (10 mL) was added DIEA (3.86 g, 29.9 mmol, 7.0 eq.) and methyl 2-(3,4-difluorophenyl)-5-fluoroisonicotinate (Intermediate A) (1.14 g, 4.27 mmol, 1.0 eq.). The reaction mixture was stirred at 120°C for 3 hours. LCMS showed that the starting material was consumed completely. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (20 mL $\times$ 3). The combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in *vacuo*. The residue was purified by silica gel column chromatography (PE/EA 10/1 to 3/1) to give methyl 2-(3,4-difluorophenyl)-5-(3-((methoxycarbonyl)amino)-3-(6-methylpyridin-2-yl)piperidin-1-yl)isonicotinate (177-5) as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ ppm 8.52 (s, 1H), 7.94 (s, 1H), 7.87-7.78 (m, 1H), 7.71-7.65 (m, 1H), 7.57 (t, $J = 7.6$ Hz, 1H), 7.35 (d, $J = 8.0$ Hz, 1H), 7.26 (d, $J = 7.6$ Hz, 1H), 7.02 (d, $J = 7.6$ Hz, 1H), 6.75 (brs, 1H), 4.09 (s, 3H), 3.67 (s, 3H), 3.49-3.34 (m, 2H), 3.12-2.95 (m, 2H), 2.86-2.74 (m, 1H), 2.54 (s, 3H), 2.40-2.28 (m, 1H), 2.16-1.98 (m, 1H), 1.86-1.81 (m, 1H). LC-MS: $[\text{M}+\text{H}]^+ = 497.3$.

To a mixture of methyl 2-(3,4-difluorophenyl)-5-(3-((methoxycarbonyl)amino)-3-(6-methylpyridin-2-yl)piperidin-1-yl)isonicotinate (177-5) (600 mg, 1.21 mmol, 1.0 eq.) and LiCl (512 mg, 12.1 mmol, 10 eq.) in MeOH/THF (20 mL, v/v = 1/1) was added NaBH₄ (914 mg, 24.2 mmol, 20 eq.). The mixture was stirred at 25°C for 1 hour. TLC showed that the starting material was consumed completely. The reaction was quenched with water (50 mL), and extracted with EtOAc (20 mLx3). The combined organic layers were dried over Na₂SO₄ and concentrated in vacuo to give methyl (1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)-3-(6-methylpyridin-2-yl)piperidin-3-yl)carbamate (177-6) as a white solid. LC-MS: [M+H]⁺ = 469.1.

To a solution of methyl (1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)-3-(6-methylpyridin-2-yl)piperidin-3-yl)carbamate (177-6) (500 mg, 1.07 mmol, 1.0 eq.), Intermediate B (537 mg, 1.60 mmol, 1.5 eq.) and Bu₃P (324 mg, 1.60 mmol, 1.5 eq.) in THF (10 mL) was added DIAD (324 mg, 1.60 mmol, 1.5 eq.). The mixture was stirred at 25 °C for 3 hours. LC-MS showed that the starting material was consumed completely. The reaction was concentrated in *vacuo* and the residue was purified by silica gel column chromatography (Eluents: PE/EA 10/1 to 3:1) to give tert-butyl (tert-butoxycarbonyl)(9-((2-(3,4-difluorophenyl)-5-(3-((methoxycarbonyl)amino)-3-(6-methylpyridin-2-yl)piperidin-1-yl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (177-7) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.96 (s, 1H), 8.53 (s, 1H), 8.25 (s, 1H), 7.70-7.57 (m, 2H), 7.50-7.43 (m, 1H), 7.36 (d, *J* = 8.0 Hz, 1H), 7.20-7.11 (m, 1H), 7.06 (d, *J* = 8.4 Hz, 1H), 6.51 (s, 1H), 5.84 (d, *J* = 15.6 Hz, 1H), 5.45 (d, *J* = 15.2 Hz, 1H), 3.64-3.56 (m, 1H), 3.55 (s, 3H), 3.53-3.46 (m, 1H), 3.17-3.09 (m, 1H), 3.02-2.94 (m, 1H), 2.66-2.58 (m, 1H), 2.57 (s, 3H), 2.48-2.37 (m, 1H), 2.19-2.05 (m, 1H), 1.94-1.84 (m, 1H), 1.47 (s, 18H). LC-MS: [M+H]⁺ = 786.3.

Intermediate 269-4 : 3-(1-methyl-1H-pyrazol-4-yl)piperidin-3-amine



269-4

To a solution of 4-bromo-1H-pyrazole (10.0 g, 68 mmol, 1.0 eq) in DMF (100 mL) was added NaH (5.44 g, 136 mmol, 1.5 eq) at 10 °C. After 30 min, MeI (15.0 g, 102 mmol, 2.0 eq) was added. The mixture was stirred at 30-35 °C for 2hr, quenched with water (200 mL) and extracted with EtOAc (200 mLx3). The combined organic layer was dried over Na₂SO₄ and concentrated in vacuo to give 4-bromo-1-methyl-1H-pyrazole (269-1) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.43 (s, 1H), 7.37 (s, 1H), 3.88 (s, 3H).


To a solution of 4-bromo-1-methyl-1H-pyrazole (269-1) (10.6 g, 66.1 mmol, 1.1 eq) in THF (140 mL) was added n-BuLi (29.4 mL, 72.1 mmol, 1.2 eq, 2.5 M in THF) at -70 °C under N₂. After 30 min, a solution of benzyl 3-oxopiperidine-1-carboxylate (14.0 g, 60.1 mmol, 1.0 eq) in THF (10 mL) was added. The reaction was stirred at -70 °C for 2hr. The reaction was quenched

with water (200 mL), extracted with EtOAc (200 mLx3). The combined organic layer was dried over anhydrous Na_2SO_4 and concentrated in vacuo. The residue was purified by combi flash (70-90% EtOAc in PE) to give benzyl 3-hydroxy-3-(1-methyl-1H-pyrazol-4-yl)piperidine-1-carboxylate (269-2) as a yellow oil. LC-MS: $[\text{M}+\text{H}]^+ = 316.1$.

5 To a mixture of NaN_3 (1.3 g, 19 mmol, 2.0 eq.) in DCM (30 mL) was added TFA (6.00 g, 47.6 mmol, 5.0 eq) at 0 °C. After 10 min, a solution of benzyl 3-hydroxy-3-(1-methyl-1H-pyrazol-4-yl)piperidine-1-carboxylate (intermediate 269-2) (3.00 g, 9.52 mmol, 1.0 eq.) in DCM (10 mL) was added. The resulting mixture was stirred at 30-35 °C for 16hr. The reaction was quenched with $\text{NH}_3\cdot\text{H}_2\text{O}$ (3 mL), diluted with water (20 mL) and extracted with DCM (300 mLx3). The
10 combined organic layers were dried over anhydrous Na_2SO_4 and concentrated in vacuo. The residue was purified by Combi Flash (40% EtOAc in PE) to give benzyl 3-azido-3-(1-methyl-1H-pyrazol-4-yl)piperidine-1-carboxylate (269-3) as a yellow oil. LC-MS: $[\text{M}+\text{H}]^+ = 341.1$.

A mixture of benzyl 3-azido-3-(1-methyl-1H-pyrazol-4-yl)piperidine-1-carboxylate (269-3) (1.00 g, 2.9 mmol, 1.0 eq.) and Pd/C (100 mg, 10% wet) in EtOAc (10 mL) was stirred with H_2
15 balloon at 30-35 °C for 16 hr. TLC indicated the reaction was complete. Then Pd/C was filtered off and the filtrate was concentrated in vacuo to give 3-(1-methyl-1H-pyrazol-4-yl)piperidin-3-amine (Intermediate 269-4) as a colorless oil.

Intermediate 269-6 : methyl 2-(3,4-difluorophenyl)-5-(3-((methoxycarbonyl)amino)-3-(1-methyl-1H-pyrazol-4-yl)piperidin-1-yl)isonicotinate




Methyl 5-(3-amino-3-(1-methyl-1H-pyrazol-4-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)isonicotinate (Intermediate 269-5) was prepared following procedures analogous to the preparation of Intermediate 177-5 and corresponding intermediates. ^1H NMR (400 MHz, CDCl_3) δ ppm 8.46 (s, 1H), 7.88 (s, 1H), 7.75-7.85 (m, 1H), 7.65-7.70 (m, 1H), 7.53 (s, 1H), 7.50
25 (s, 1H), 7.15-7.25 (m, 1H), 3.97 (s, 3H), 3.89 (s, 3H), 3.10-3.30 (m, 3H), 2.90-3.00 (m, 1H), 2.05-2.15 (m, 1H), 1.65-1.90 (m, 3H).

To a solution of Intermediate 269-5 (500 mg, 1.17 mmol, 1.0 eq) and Et_3N (400 mg, 3.51 mmol, 3.0 eq) in THF (10 mL) was added methyl carbonochloridate (200 mg, 1.75 mmol, 1.5 eq) at 0 °C. The reaction was stirred at 25-30 °C for 1hr. The reaction was quenched with water (50
30 mL), extracted with EtOAc (50 mLx3). The combined organic layer was dried over Na_2SO_4 and concentrated in vacuo. The residue was purified by combi flash (60% EtOAc in PE) to give Intermediate 269-6 as a yellow solid. ^1H NMR (400 MHz, CDCl_3) δ ppm 8.51 (s, 1H), 7.95 (s, 1H), 7.80-7.90 (m, 1H), 7.60-7.70 (m, 1H), 7.40 (s, 1H), 7.35 (s, 1H), 7.15-7.25 (m, 1H), 6.66 (brs,

1H), 4.03 (s, 3H), 3.85 (s, 3H), 3.64 (s, 3H), 3.30-3.40 (m, 2H), 2.85-3.10 (m, 2H), 2.80 (d, $J = 12.0$ Hz, 1H), 1.95-2.05 (m, 1H), 1.60-1.85 (m, 2H). LC-MS: $[M+H]^+ = 486.3$.


Intermediate 269-8: tert-butyl (tert-butoxycarbonyl)(1-((2-(3,4-difluorophenyl)-5-(3-((methoxycarbonyl)amino)-3-(1-methyl-1H-pyrazol-4-yl)piperidin-1-yl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-yl)carbamate



Methyl (1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)-3-(1-methyl-1H-pyrazol-4-yl)piperidin-3-yl)carbamate (Intermediate 269-7) was prepared following procedures analogous to the preparation of Intermediate 177-6 and corresponding intermediates. LC-MS: $[M+H]^+ = 458.2$.

Intermediate 269-8 was prepared by using a procedure similar to that of intermediate 177-7 in example 177 by replacing intermediate 177-6 with intermediate 269-7. LC-MS: $[M+H]^+ = 717.4$.

Intermediate 271-7: 3-(pyridin-3-yl)piperidin-3-amine



To a solution of nicotinaldehyde (17.85 g, 166.7 mmol, 1.0 eq.) in THF (250 mL) at -78°C under N_2 atmosphere was added a solution of 3-butenylmagnesium bromide (400 mL, 200 mmol, 0.5M, 1.2 eq.) dropwise. The reaction mixture was stirred at -78°C for 2h as monitored by TLC ($R_f = 0.2$, PE/EA = 1/1). The reaction was quenched with saturated ammonium chloride solution (300 mL) and separated. The aqueous layer was extracted with ethyl acetate (100 mL*2). The combined organic layer was washed with brine (200 mL), dried over anhydrous sodium sulfate and concentrated *in vacuo*. The residue was purified by Combi-flash (EA in PE: 30~50%) to give 1-(pyridin-3-yl)pent-4-en-1-ol (271-1) as yellow oil. ^1H NMR (CDCl_3 400MHz): δ 8.55 (d, $J = 1.6$ Hz, 1H), 8.51 (dd, $J = 1.6$ Hz and 4.8 Hz, 1H), 7.71 (dt, $J = 8.0$ Hz and 2.0 Hz, 1H), 7.29 (dd,

$J = 4.8$ Hz and 8.0 Hz, 1H), 5.90-5.79 (m, 1H), 5.06 (dd, $J = 1.6$ Hz and 17.2 Hz, 1H), 5.02 (dd, $J = 1.2$ Hz and 10.4 Hz, 1H), 4.77 (dd, $J = 5.6$ Hz and 8.0 Hz), 2.34 (brs, 1H), 2.24-2.10 (m, 2H), 1.98-1.88 (m, 1H), 1.86-1.77 (m, 1H).

To a solution of 1-(pyridin-3-yl)pent-4-en-1-ol (271-1) (10 g, 61.27 mmol, 1 eq) in CH_2Cl_2 (200 mL) was added Dess-Martin periodinane (38.98 g, 91.9 mmol, 1.5 eq) portionwise at 16-24°C, the suspension was stirred for 30min at 16-24°C as monitored by TLC ($R_f = 0.8$, PE/EA = 1/1). The mixture was poured into a saturated sodium bicarbonate solution (300 mL) slowed and stirred for 30min. The mixture was filtered and aqueous layer was extracted with CH_2Cl_2 (100 mL*2). The combined organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate and concentrated *in vacuo*. The residue was purified by Combi-flash (EA in PE: 20~30%) to give 1-(pyridin-3-yl)pent-4-en-1-one (271-2) as a yellow oil. ^1H NMR (CDCl_3 400MHz): δ 9.18 (d, $J = 1.6$ Hz, 1H), 8.78 (dd, $J = 1.6$ Hz and 4.8 Hz, 1H), 8.23 (dt, $J = 8.0$ Hz and 2.0 Hz, 1H), 7.43 (dd, $J = 4.8$ Hz and 8.0 Hz, 1H), 5.94-5.84 (m, 1H), 5.12-5.06 (m, 1H), 5.05-5.01 (m, 1H), 2.10 (t, $J = 7.2$ Hz, 2H), 2.55-2.48 (m, 2H).

To a mixture of 1-(pyridin-3-yl)pent-4-en-1-one (271-2) (8.64 g, 53.6 mmol, 1eq) and 2-methylpropane-2-sulfinamide (12.99 g, 107.2 mmol, 2.0 eq) in anhydrous THF (120 ml) was added titanium ethoxide (30.57 g, 134.0 mmol, 2.5 eq), the reaction mixture was refluxed for 16h at 80°C as monitored by TLC ($R_f = 0.6$, PE/EA = 1/1). The mixture was cooled to room temperature, poured into brine (300 ml) and stirred for 30min. The mixture was filtered through a celite pad and the aqueous layer was extracted with ethyl acetate (200 mL*2). The combined organic layer was washed with brine (200 mL), dried over anhydrous sodium sulfate and concentrated. The residue was purified by Combi-flash (EA in PE: 20~30%) to give (E)-2-methyl-N-(1-(pyridin-3-yl)pent-4-en-1-ylidene)propane-2-sulfinamide (271-3) as a yellow oil. ^1H NMR (CDCl_3 400MHz): δ 9.05 (s, 1H), 8.70 (dd, $J = 1.6$ Hz and 4.8 Hz, 1H), 8.10 (d, $J = 7.6$ Hz, 1H), 7.38 (dd, $J = 4.8$ Hz and 8.0 Hz, 1H), 5.93-5.81 (m, 1H), 5.09-5.01 (m, 2H), 3.45-3.37 (m, 1H), 3.32-3.25 (m, 1H), 2.55-2.35 (m, 2H).


To a solution of (E)-2-methyl-N-(1-(pyridin-3-yl)pent-4-en-1-ylidene)propane-2-sulfinamide (271-3) (9.85 g, 37.3 mmol, 1eq) in anhydrous THF (120 mL) at -78°C was added a solution of vinylmagnesium bromide (90 mL, 90 mmol, 2.4eq, 1M in Et_2O) dropwise, the resulting mixture was stirred for 2h at -78°C as monitored by TLC ($R_f = 0.1$, PE/EA = 1/1). The reaction was quenched with saturated ammonium chloride (200 mL). The mixture was extracted with ethyl acetate (100 mL*3), the combined organic layer was washed with brine (100 ml), dried over anhydrous sodium sulfate and concentrated *in vacuo*. The residue was purified by Combi-flash (EA in PE: 30~70%) to give 2-methyl-N-(3-(pyridin-3-yl)hepta-1,6-dien-3-yl)propane-2-sulfinamide (271-4) as a red oil. ^1H NMR (CDCl_3 400MHz): δ 8.89 (d, $J = 1.6$ Hz, 1H), 8.53 (dd, $J = 1.6$ Hz and 4.8 Hz, 1H), 7.82-7.78 (m, 1H), 7.29 (dd, $J = 4.8$ Hz and 8.0 Hz, 1H), 6.03 (dd, $J = 10.8$ Hz and 17.2 Hz, 1H), 5.87-5.78 (m, 1H), 5.37 (d, $J = 10.8$ Hz, 1H), 5.30 (d, $J = 17.2$ Hz,

1H), 5.05-4.96 (m, 2H), 3.75 (s, 1H), 2.43-2.35 (m, 1H), 2.26-2.18 (m, 1H), 2.07-1.97 (m, 2H), 1.24 (s, 9H).

To a solution of 2-methyl-N-(3-(pyridin-3-yl)hepta-1,6-dien-3-yl)propane-2-sulfonamide (271-4) (6.90 g, 23.6 mmol, 1.0 eq) in methanol (400 ml) at -78°C was bubbled O₃ until the solution was blue color. The excess O₃ was removed by N₂. The mixture was concentrated *in vacuo* to remove about 200 mL of methanol. Diphenylmethanamine (6.48 g, 35.4 mmol, 1.5 eq), sodium cyanoborohydride (3.72 g, 59.0 mmol, 2.5 eq) and acetic acid (1.42 g, 23.6 mmol, 1.0 eq) were added to the above solution and the reaction mixture was stirred for 16h at 11-17 °C. The mixture was concentrated *in vacuo*, the residue was diluted with water (100 mL) and extracted with dichloromethane (100 mL*3). The combined organic layer was concentrated *in vacuo*, the residue was purified by Combi-flash (EA in PE: 30~100%) to give N-(1-benzhydryl-3-(pyridin-3-yl)piperidin-3-yl)-2-methylpropane-2-sulfonamide (271-6) as a yellow solid. ¹H NMR (CDCl₃ 400MHz): δ 8.57 (d, *J* = 2.0 Hz, 1H), 8.47 (dd, *J* = 1.6 Hz and 4.8 Hz, 1H), 7.64 (dt, *J* = 8.0 Hz and 1.6 Hz, 1H), 7.40-7.37 (m, 4H), 7.33-7.28 (m, 4H), 7.25-7.20 (m, 3H), 5.53 (brs, 1H), 4.39 (s, 1H), 3.06-2.99 (m, 2H), 2.58 (d, *J* = 12.8 Hz, 1H), 2.33-2.25 (m, 1H), 2.09-2.01 (m, 1H), 1.96-1.89 (m, 2H), 1.77-1.73 (m, 1H), 1.28 (s, 9H). LC-MS: *M*+*H*⁺=448.2.

To a solution of N-(1-benzhydryl-3-(pyridin-3-yl)piperidin-3-yl)-2-methylpropane-2-sulfonamide (271-6) (2.34 g, 5.23 mmol, 1.0 eq.) in TFA (24 mL) was added Et₃SiH (4.68 mL), the reaction mixture was stirred for 16h at 80°C as monitored by LC-MS. The mixture was concentrated *in vacuo*, the residue was diluted with water (50 mL) and extracted with ethyl acetate (30 mL*2) to remove impurities. The aqueous layer was neutralized with sodium hydroxide solid and concentrated *in vacuo* to give crude 3-(pyridin-3-yl)piperidin-3-amine (Intermediate 217-7) as a yellow oil. LC-MS: *[M+H]*⁺=177.9.

Intermediate 271-9: (5-(3-amino-3-(pyridin-3-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methanol




Methyl 5-(3-amino-3-(pyridin-3-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)isonicotinate (Intermediate 271-8) was prepared following procedures analogous to the preparation of Intermediate 177-5 and corresponding intermediates. ¹H NMR (CDCl₃ 400MHz): δ 8.90 (d, *J* = 2.0 Hz, 1H), 8.54 (dd, *J* = 1.6 Hz and 4.8 Hz, 1H), 8.46 (s, 1H), 7.98 (dt, *J* = 8.0 Hz and 1.6 Hz, 1H), 7.88 (s, 1H), 7.85-7.79 (m, 1H), 7.69-7.66 (m, 1H), 7.30 (dd, *J* = 4.8 Hz and 8.0 Hz, 1H), 7.24-7.19 (m, 1H), 3.97 (s, 3H), 3.34-3.23 (m, 3H), 2.97 (td, *J* = 12 Hz and 2.4 Hz, 1H), 2.21-

2.15 (m, 1H), 2.08 (dt, $J = 12.8$ Hz and 4.4 Hz, 1H), 1.88-1.84 (m, 1H), 1.82-1.76 (m, 1H). LC-MS: $[M+H]^+ = 425.2$,

Intermediate 271-9 was prepared by using a procedure similar to that of intermediate 177-6 in Example 177 by replacing intermediate 177-5 with intermediate 271-8. ^1H NMR (CDCl_3


400MHz): δ 8.81 (d, $J = 2.0$ Hz, 1H), 8.52 (dd, $J = 1.6$ Hz and 4.8 Hz, 1H), 8.41 (s, 1H), 7.88 (dt, $J = 8.0$ Hz and 1.6 Hz, 1H), 7.85-7.79 (m, 1H), 7.71 (s, 1H), 7.69-7.66 (m, 1H), 7.30 (dd, $J = 4.8$ Hz and 8.0 Hz, 1H), 7.25-7.18 (m, 1H), 4.92 (d, $J = 14$ Hz, 1H), 4.73 (d, $J = 14$ Hz, 1H), 3.20 (t, $J = 11.6$ Hz, 2H), 3.09 (d, $J = 11.6$ Hz, 1H), 3.01-2.94 (m, 1H), 2.14-2.08 (m, 2H), 1.92-1.87 (m, 2H). LC-MS: $[M+H]^+ = 397.3$.

Intermediate 272-2: 1-Benzyl 3-methyl 2-oxopiperidine-1,3-dicarboxylate




To a solution of piperidin-2-one (10 g, 100 mmol, 1.0 eq) in dry THF (200 mL) was added portions NaH (6g, 60 % wt, 150 mmol, 1.5 eq) below 0°C . The resulting mixture was stirred at 0° for 0.5 h and 30°C for 1 h. Then a solution of benzyl carbonochloridate (26 g, 151.31 mmol, 1.5 eq) in dry THF (50 mL) was added into the suspension below 0°C over 30 min. The resulting mixture was stirred at 30°C for 3 h. TLC showed the reaction was completed. The reaction was quenched by Sat. NH_4Cl (50 mL), extracted with EtOAc (50 mL $\times$ 2). The combined organic layers were washed with brine (50 mL) and dried over Na_2SO_4 . After filtration and concentration, the residue was purified by silica gel chromatography to give benzyl 2-oxopiperidine-1-carboxylate (272-1) as a yellow oil. ^1H NMR (CDCl_3 , 400MHz): δ ppm 7.45-7.32 (m, 5H), 5.28 (s, 2H), 3.78-3.70 (m, 2H), 2.56-2.50 (m, 2H), 1.86-1.80 (m, 4H).

To a solution of benzyl 2-oxopiperidine-1-carboxylate (272-1) (9.1 g, 39.1 mmol, 1.0 eq) in dry THF (200 mL) was added LDA (30 mL, 2M, 60 mmol, 1.54 eq) below -70°C over 30 min under N_2 . After stirring for 1 h at -70° , methyl carbonochloridate (6.23 g, 65.93 mmol, 1.69 eq) was added into the mixture below -70°C over 30 min. The resulting mixture was stirred at -70°C for 1 h. The reaction mixture was quenched by Sat. NH_4Cl (50 mL) below -70°C . The mixture was extracted with EtOAc (100 mL $\times$ 3). The combined organic layers were washed with brine (100 mL) and dried over Na_2SO_4 . After filtration and concentration, the residue was purified by inversed phase chromatography to give 1-benzyl 3-methyl 2-oxopiperidine-1,3-dicarboxylate (Intermediate 272-2) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ ppm 7.45-7.32 (m, 2H), 5.29 (s, 2H), 3.80-3.79 (d, $J = 5.2$ Hz, 1H), 3.77 (s, 3H), 3.76-3.74 (d, $J = 7.6$ Hz, 1H), 3.58-3.54 (dd, $J = 6.8$ Hz, $J = 8.0$ Hz, 1H), 2.30-2.16 (m, 1H), 2.14-2.06 (m, 2H), 2.02-1.93 (m, 1H).

Intermediate 272-3 : (2-methoxypyridin-3-yl)boronic acid

A suspension 3-bromo-2-methoxypyridine (9 g, 47.87 mmol, 1.0 eq), Mg (2.33 g, 95.73 mmol, 2.0 eq) and LiCl (2.54 g, 59.83 mmol, 1.25 eq) in dry THF (200 mL) was stirred at 35 °C for 2 hours under N₂. Then B(OMe)₃ (10 g, 96.23 mmol, 2.01 eq) was added into the reaction mixture below 0 °C. Then resulting mixture was allowed to warm to 35 °C with stirring for 2 hours. TLC showed 3-bromo-2-methoxypyridine was consumed. The reaction was quenched with HCl (0.1M, 200 mL) to pH = 6. The mixture was extracted with EtOAc (100 mL × 3). The combined organic layers were washed with brine (100 mL) and dried over Na₂SO₄. After filtration and concentration, the residue was washed with chloroform (10 mL) to give (2-methoxypyridin-3-yl)boronic acid (Intermediate 272-3) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.19-8.17 (dd, *J*₁ = 2.0 Hz, *J*₂ = 4.8 Hz, 1H), 7.89-7.88 (d, *J* = 2.0 Hz, 1H), 3.98-6.95 (dd, *J*₁ = 4.8 Hz, *J*₂ = 6.8 Hz, 1H), 3.87 (s, 3H).


Intermediate 272-5: 1-Benzyl 3-methyl 3-(2-methoxypyridin-3-yl)-2-oxopiperidine-1,3-dicarboxylate



To a suspension of Pb(OAc)₄ (6.38 g, 14.39 mmol, 1.0 eq) and Hg(OAc)₂ (1.17 g, 3.67 mmol, 0.26 eq) in chloroform (20 mL) was added (2-methoxypyridin-3-yl)boronic acid (272-3) (2.2 g, 14.38 mmol, 1.0 eq) at 30 °C under N₂. The suspension was stirred at 40 °C for 1 hour and 30 °C for 16 hours under N₂. The reaction mixture of (2-methoxypyridin-3-yl)plumbanetriyl triacetate (272-4) was used in the next step directly. Then a solution of 1-benzyl 3-methyl-2-oxopiperidine-1,3-dicarboxylate (272-2) (3.9 g, 13.23 mmol, 0.93 eq) in chloroform (20 mL) and pyridine (3 mL) was added into the suspension. The resulting mixture was stirred at 40 °C for 12 hours under N₂. LC-MS showed intermediate 272-4 was consumed. The reaction mixture was cooled to room temperature and filtrated. The filtrate was washed with H₂SO₄ (1M, 20 mL × 4), water (20 mL × 2) and dried over Na₂SO₄. After filtration and concentration, the residue was purified by Prep-HPLC (FA) to give 1-benzyl 3-methyl 3-(2-methoxypyridin-3-yl)-2-

oxopiperidine-1,3-dicarboxylate (Intermediate 272-5) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ ppm 8.12-8.11 (m, 1H), 7.45-7.44 (m, 2H), 7.40-7.31 (m, 4H), 6.88-6.85 (m, 1H), 5.33 (s, 2H), 3.91 (s, 3H), 3.88-3.85 (m, 1H), 3.79 (s, 3H), 3.76-3.69 (m, 1H), 2.66-2.60 (m, 1H), 2.56-2.50 (m, 1H), 1.90-1.82 (m, 1H), 1.77-1.68 (m, 1H). LC-MS: $[\text{M}+\text{H}]^+ = 398.9$.

5 **Intermediate 272-10: Methyl (3-(2-methoxypyridin-3-yl)piperidin-3-yl)carbamate**



To a solution of 1-benzyl 3-methyl 3-(2-methoxypyridin-3-yl)-2-oxopiperidine-1,3-dicarboxylate (Intermediate 272-5) (1.7 g, 4.27 mmol, 1.0 eq) in dry THF (50 mL) and dry THF (50 mL) was added NaBH_4 (0.3 g, 7.93 mmol, 1.86 eq) below 0°C . After addition, the reaction mixture was allowed to stir at 30°C for 2 hours. Then Pd/C (0.45 g, 0.427 mmol, 0.1 eq) was added into the mixture, the resulting mixture was stirred at 30°C under H_2 (15 Psi) for 12 hours. TLC (showed the reaction was completed. The mixture was filtered, the filtrate was concentrated under reduced pressure to afford methyl 3-(2-methoxypyridin-3-yl)piperidine-3-carboxylate (272-6) as a yellow oil.

15 To a solution of methyl 3-(2-methoxypyridin-3-yl)piperidine-3-carboxylate (272-6) (2.2 g, 8.79 mmol, 1.0 eq) and Boc_2O (5.75 g, 26.37 mmol, 3.0 eq) in MeOH (10 mL) was stirred at 30°C for 16 hours. TLC showed the reaction was completed, the reaction mixture was concentrated. The residue was purified by silica gel chromatography to give 1-(tert-butyl) 3-methyl 3-(2-methoxypyridin-3-yl)piperidine-1,3-dicarboxylate (272-7) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ ppm 8.08-8.07 (d, $J = 4.0$ Hz, 1H), 7.63-7.61 (dd, $J_1 = 1.6$ Hz, $J_2 = 8.6$ Hz, 1H), 6.90-6.86 (dd, $J_1 = 5.2$ Hz, $J_2 = 7.6$ Hz, 1H), 4.15-4.10 (m, 1H), 3.92 (s, 3H), 3.82-3.66 (m, 2H), 3.61 (s, 3H), 3.22 (m, 1H), 2.23-2.19 (m, 2H), 1.71 (m, 4H), 1.32 (s, 9H). LC-MS: $[\text{M}+\text{H}]^+ = 351.0$.


25 A solution of 1-(tert-butyl) 3-methyl 3-(2-methoxypyridin-3-yl)piperidine-1,3-dicarboxylate (272-7) (0.85 g, 2.43 mmol, 1.0 eq) and LiOH (0.233g, 9.70 mmol, 4.0 eq) in MeOH (10 mL) and H_2O (2 mL) was heated to 40°C with stirring for 2 hours and 80°C for 4 hours. TLC showed the reaction was completed, the reaction mixture was concentrated, the residue was acidified with HCl (2N) to pH = 3-4. The mixture was extracted with chloroform / *i*-PrOH (v/v = 3:1, 10 mL $\times$ 4). The combined organic layers were washed with water (10 mL) and dried over Na_2SO_4 .
30 The mixture was filtered and the filtrate was concentrated to give 1-(tert-butoxycarbonyl)-3-(2-methoxypyridin-3-yl)piperidine-3-carboxylic acid (272-8) was obtained as a yellow solid. ^1H NMR (400 MHz, CD_3OD) δ ppm 8.05-8.04 (d, $J = 3.2$ Hz, 1H), 7.75-7.73 (dd, $J_1 = 1.6$ Hz, $J_2 = 7.2$

Hz, 1H), 6.96 (s, 1H), 4.14-4.10 (m, 1H), 4.10-3.89 (m, 4H), 3.62-3.58 (m, 1H), 3.30-3.28 (m, 1H), 2.33-2.28 (m, 2H), 1.83-1.79 (m, 2H), 1.27 (s, 9H).


To a solution of 1-(tert-butoxycarbonyl)-3-(2-methoxypyridin-3-yl)piperidine-3-carboxylic acid (272-8) (0.8 g, 2.38 mmol, 1.0 eq) in dry toluene (20 mL) was added DPPA (1.31 g, 4.76 mmol, 2.0 eq) and TEA (0.963 g, 9.51 mmol, 4.0 eq) in turns at 28 °C under N₂. The mixture was stirred at 80 °C for 12 hours. Then MeOH (20 mL) was added into the mixture and the mixture was stirred at 80 °C for 12 hours. TLC showed the reaction was completed. The mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography to tert-butyl 3-((methoxycarbonyl)amino)-3-(2-methoxypyridin-3-yl)piperidine-1-carboxylate (272-9) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.098.074 (dd, J₁= 2.0 Hz, J₂= 5.2 Hz, 1H), 7.67-7.64 (dd, J₁= 1.6 Hz, J₂= 7.6 Hz, 1H), 6.92-6.88 (dd, J₁= 4.8 Hz, J₂= 7.6 Hz, 1H), 5.78-5.49 (m, 1H), 4.72-4.68 (d, 13.6 Hz, 1H), 3.99 (s, 3H), 3.53 (s, 3H), 2.98-2.80 (m, 3H), 1.91-1.71 (m, 4H), 1.83 (s, 9H).

To a solution of tert-butyl 3-((methoxycarbonyl)amino)-3-(2-methoxypyridin-3-yl)piperidine-1-carboxylate (272-9) (0.6 g, 1.64 mmol, 1.0 eq) in dry DCM (5 mL) was added TFA (1 mL) below 0 °C. After addition, the mixture was allowed to warm to 30 °C with stirring for 3 hours. LCMS showed the reaction was completed, the mixture was concentrated under reduced pressure to methyl (3-(2-methoxypyridin-3-yl)piperidin-3-yl)carbamate (Intermediate 272-10) as a yellow oil. LC-MS: [M+H]⁺ =266.2.

Intermediate 272-13: tert-butyl (tert-butoxycarbonyl)(9-((2-(3,4-difluorophenyl)-5-(3-((methoxycarbonyl)amino)-3-(2-methoxypyridin-3-yl)piperidin-1-yl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate



Intermediate 272-13 was prepared following procedures analogous to the preparation of Intermediate 177-7 and corresponding intermediates. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.93 (s, 1H), 8.50 (s, 1H), 8.27 (s, 1H), 8.14-8.12 (dd, J₁=1.6 Hz, J₂= 5.2 Hz, 1H), 7.77-7.75 (dd, J₁=1.6 Hz, J₂= 7.6 Hz, 1H), 7.70-7.64 (m, 1H), 7.48-7.46 (m, 1H), 7.20-7.13 (dd, J₁=5.2 Hz, J₂= 7.6 Hz, 1H), 6.60 (s, 1H), 5.89-5.85 (d, J=15.6 Hz, 1H), 5.43-5.39 (d, J=15.6 Hz, 1H), 4.04-4.01 (m, 1H), 3.98 (s, 3H), 3.49 (s, 3H), 3.36-3.34 (m, 1H), 3.14-3.11 (m, 1H), 2.94-2.84 (m, 2H), 2.21-2.18 (m, 2H), 1.88-1.85 (m, 1H), 1.47 (s, 18 H). LC-MS: [M+H]⁺ =802.5.

Intermediate 273-5a : tert-Butyl 3-cyano-3-(1-(difluoromethyl)-1H-pyrazol-3-yl)piperidine-1-carboxylate**Intermediate 273-5b: tert-Butyl 3-cyano-3-(1-(difluoromethyl)-1H-pyrazol-5-yl)piperidine-1-carboxylate**

To a solution of tert-butyl 3-cyanopiperidine-1-carboxylate (25 g, 119.0 mmol, 1.0 eq.) in THF (300 mL) at -70°C under N₂ atmosphere was added LiHMDS (178 mL, 178.57 mmol, 1.5 eq.) dropwise. The reaction mixture was stirred at -70°C for 30 min, then CH₃CHO (7.85 g, 178.57 mmol, 3 eq.) was added. TLC indicate the reaction was complete. The reaction was quenched with aq. NH₄Cl (200 mL), extracted with EtOAc (100 mL*3). The combined organic layer was washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Combi-flash (EtOAc in PE, 10~50%) to give tert-butyl 3-cyano-3-(1-hydroxyethyl)piperidine-1-carboxylate (273-1) as a colorless oil. ¹H NMR (CDCl₃, 400MHz): δ ppm 4.39-4.05 (m, 2H), 3.75-3.68 (m, 2H), 2.94-2.76 (m, 2H), 2.39-2.20 (m, 1H), 1.94-1.70 (m, 4H), 1.47 (s, 9H), 1.39 (t, J = 6.4 Hz, 3H).

To a solution of tert-butyl 3-cyano-3-(1-hydroxyethyl)piperidine-1-carboxylate (273-1) (9 g, 35.43 mmol, 1.0 eq.) in DCM (150 mL) was added DMP (22.5 g, 53.15 mmol, 1.5 eq.). The mixture was stirred at 20°C for 1 hour. TLC showed that the starting material was consumed completely. The reaction was quenched with aq. NaHCO₃ (150 mL) and aq. Na₂SO₃ (150 mL), extracted with EtOAc (150 mL*3). The combined organic layers were washed with aq. NaHCO₃ (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give crude tert-butyl 3-acetyl-3-cyanopiperidine-1-carboxylate (273-2) as a yellow oil. ¹H NMR (CDCl₃, 400MHz): δ 4.50-3.85 (m, 2H), 3.20-3.05 (m, 1H), 2.95-2.60 (m, 1H), 2.46 (s, 3H), 2.25-1.70 (m, 4H), 1.48 (s, 9H).


To a solution of tert-butyl 3-acetyl-3-cyanopiperidine-1-carboxylate (273-2) (12 g, 47.62 mmol, 1.0 eq.) in toluene (100 mL) was added DMF-DMA (28.3g, 238.1 mmol, 5.0 eq.). The reaction was heated to 100°C and stirred for 2h. LC-MS showed a main product. The reaction was concentrated to give tert-butyl (E)-3-cyano-3-(3-(dimethylamino)acryloyl)piperidine-1-carboxylate (273-3) as a brown oil. LCMS: [M+H]⁺ = 308.0.

A mixture of tert-butyl (E)-3-cyano-3-(3-(dimethylamino)acryloyl)piperidine-1-carboxylate (273-3) (5.6 g, 18.22 mmol) in EtOH (30 mL), was added hydrazine hydrate (8.85 mL, 182 mmol), then the mixture was stirred at 70 °C for 8 hr under Ar atmosphere. LC-MS monitored the reaction. 50ml of water was added, the mixture was extracted with EtOAc, the combined organic phase was washed with water, brine, dried over Na₂SO₄, filtered and concentrated in

vacuo. The residue was purified by flash chromatography (PE/EA, EA: 40% for 30mins) to give tert-butyl 3-cyano-3-(1H-pyrazol-3-yl)piperidine-1-carboxylate (273-4) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.63 (d, *J* = 2.0 Hz, 1H), 6.39 (d, *J* = 2.8 Hz, 1H), 4.56-4.46 (m, 1H), 4.25-4.07 (m, 1H), 3.20 (d, *J* = 12.0 Hz, 1H), 2.80-2.90 (m, 1H), 2.37 (d, *J* = 13.2 Hz, 1H), 2.10-1.91 (m, 2H), 1.77 (d, *J* = 11.0 Hz, 1H), 1.48 (s, 9H).


To a solution of tert-butyl 3-cyano-3-(1H-pyrazol-3-yl)piperidine-1-carboxylate (273-4) (500 mg, 1.809 mmol) and Cs₂CO₃ (2948 mg, 9.05 mmol) in DMF (10 mL), was added methyl 2-chloro-2,2-difluoroacetate (523 mg, 3.62 mmol) dropwise, and the reaction mixture was stirred at 60 °C for 24 hr. LC-MS monitored the reaction. The reaction mixture was diluted with ammonium chloride solution, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and concentrated in vacuum, the residue was purified by flash chromatography (PE/EA, EA: 40% for 30mins) to give tert-butyl 3-cyano-3-(1-(difluoromethyl)-1H-pyrazol-3-yl)piperidine-1-carboxylate (Intermediate 273-5a) and tert-butyl 3-cyano-3-(1-(difluoromethyl)-1H-pyrazol-5-yl)piperidine-1-carboxylate (Intermediate 273-5b). LC-MS: [M-100]⁺ = 227.1.

Intermediate 273-11: tert-Butyl tert-butoxycarbonyl(9-((5-(3-(1-(difluoromethyl)-1H-pyrazol-3-yl)-3-((methoxycarbonyl)amino)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate



Intermediate 273-11 was prepared following procedures analogous to the preparation of Intermediate 177-7 and corresponding intermediates. LC-MS: [M+H]⁺ = 792.3.

Intermediate 281-7: Benzyl 3-carbamoyl-3-(2-chlorothiazol-4-yl)piperidine-1-carboxylate



A solution of 1-benzyl 3-methyl piperidine-1,3-dicarboxylate (20 g, 72.12 mmol, 1.0 eq) in THF (120 mL) was cooled to -78°C and a solution of LiHMDS (108.18 mL, 108.18 mmol, 1.5 eq) was added dropwise over 20 minutes, and then stirred at -78°C for 30 minutes, followed by the addition of CH₃CHO (3.81 g, 86.54 mmol, 1.2 eq). The resulting mixture was then stirred at 32°C for 1 hour. TLC showed the starting material was consumed. The mixture was quenched with saturated NH₄Cl solution (150 mL), extracted with EtOAc (200 mL*3). The combined organic phase was washed with brine (400 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude was purified by flash column (Petroleum ether: EtOAc = 9:1~5:1) to give 1-benzyl 3-methyl 3-(1-hydroxyethyl)piperidine-1,3-dicarboxylate (281-1) as a yellow oil. ¹H NMR (CDCl₃ 400MHz): δ 7.36-7.28 (m, 5H), 5.12 (s, 2H), 4.04-3.92 (m, 1H), 3.84-3.77 (m, 1H), 3.66-3.46 (m, 4H), 3.29-3.20 (m, 1H), 3.11-2.92 (m, 1H), 2.09-1.99 (m, 1H), 1.84-1.79 (m, 1H), 1.70-1.63 (m, 1H), 1.54-1.36 (m, 1H), 1.16 (d, J = 6.4 Hz, 3H).

To a mixture of 1-benzyl 3-methyl 3-(1-hydroxyethyl)piperidine-1,3-dicarboxylate (281-1) (17 g, 52.9 mmol, 1.0 eq.) in CH₂Cl₂ (300 mL) was added Dess-Martin reagent (29.2 g, 68.8 mmol, 1.3 eq) in portions over 10 minutes at 0°C. Then, the mixture was stirred at 32°C for 2 hours. TLC showed the starting material was consumed completely. The mixture was quenched with saturated NaHCO₃ solution (300 mL) and stirred for 30 minutes until pH to 8, diluted with CH₂Cl₂ (300 mL), continued to stirred for 30 minutes, filtered, separated and concentrated the organic phase. The crude was purified by flash column (Petroleum ether: EtOAc = 10: 1) to give 1-benzyl 3-methyl 3-acetylpiperidine-1,3-dicarboxylate (281-2) as a yellow oil. ¹H NMR (CDCl₃ 400MHz): δ 7.34-7.28 (m, 5H), 5.11 (s, 2H), 4.20-3.16 (m, 7H), 2.28-1.84 (m, 5H), 1.76-1.59 (m, 2H).

To a solution of 1-benzyl 3-methyl 3-acetylpiperidine-1,3-dicarboxylate (intermediate 281-2) (15.0 g, 46.9 mmol, 1.0 eq.) in MeOH (200 mL) was added Br₂ (2.6 mL, 51.67 mmol, 1.1 eq) in portions over 5 minutes. The resulting mixture was stirred at 60°C for 1.5 hours. LCMS showed the starting material was consumed completely. The mixture was concentrated and the crude was diluted with EtOAc (300 mL), washed with saturated Na₂SO₃ solution (300 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 1-benzyl 3-methyl 3-(2-bromoacetyl)piperidine-1,3-dicarboxylate (281-3) as a yellow oil. LCMS: [M+H]⁺=399.9.

To a mixture of 1-benzyl 3-methyl 3-(2-bromoacetyl)piperidine-1,3-dicarboxylate (281-3) (16 g, 32.14 mmol, 1.0 eq) and thiourea (4.89 g, 64.28 mmol, 2.0 eq) in EtOH (200 mL) was added NaHCO₃ (5.40 g, 64.28 mmol, 2.0 eq). The resulting mixture was heated at 90°C for 1.5 hours with stirring. TLC showed the starting material was consumed completely, and the mixture was concentrated in vacuum. The residue was dissolved in EtOAc (300 mL), washed with saturated brine (300 mL*3), dried over anhydrous sodium sulfate, filtered and concentrated. The crude was purified by flash column (petroleum ether: EtOAc = 8:1~1:1) to give 1-benzyl 3-methyl 3-(2-aminothiazol-4-yl)piperidine-1,3-dicarboxylate (281-4) as an off-white solid. ¹H NMR (CDCl₃ 400MHz): δ 7.41-7.30 (m, 5H), 6.41-6.23 (m, 1H), 5.53-5.47 (m, 2H), 5.16 (s, 2H), 4.36-4.09 (m,


2H), 3.77-3.68 (m, 1H), 3.62-3.59 (m, 3H), 3.54-3.48 (m, 1H), 3.37-3.18 (m, 1H), 2.40-2.25 (m, 2H), 2.12-2.01 (m, 1H), 1.61-1.55 (m, 2H).

To a solution of 1-benzyl 3-methyl 3-(2-aminothiazol-4-yl)piperidine-1,3-dicarboxylate (281-4) (5 g, 13.32 mmol, 1.0 eq) in CH₃CN (50 mL) was added CuCl (3.30 g, 33.29 mmol, 2.5 eq) and heated to 60°C, followed by the addition of t-BuONO (3.43 g, 33.29 mmol, 2.5 eq) in portions over 5 minutes. The resulting mixture was then stirred at 80°C under nitrogen for 1 hour. TLC showed the reaction complete. The mixture was cooled to 30°C, diluted with water (50 mL), extracted with EtOAc (60 mL*3), and the organic phase was washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered and concentrated. Two batches with same scale was carried out and combined. The crude was purified by flash column (Petroleum ether: EtOAc = 15: 1 ~ 5: 1) to give 1-benzyl 3-methyl 3-(2-chlorothiazol-4-yl)piperidine-1,3-dicarboxylate (281-5) as a yellow oil. ¹H NMR (DMSO-d₆ 400MHz): δ. 7.57 (s, 1H), 7.37-7.31 (m, 5H), 5.07 (s, 2H), 4.28-4.13 (m, 1H), 3.69-3.63 (m, 1H), 3.55 (s, 3H), 3.58-3.51 (m, 1H), 3.28-3.18 (m, 1H), 2.32-2.27 (m, 1H), 2.12-2.02 (m, 1H), 1.61-1.42 (m, 2H).

To a solution of 1-benzyl 3-methyl 3-(2-chlorothiazol-4-yl)piperidine-1,3-dicarboxylate (281-5) (7.0 g, 17.73 mmol, 1.0 eq) in MeOH/H₂O (80 mL/10 mL) was added LiOH.H₂O (7.4 g, 177.27 mmol, 10.0 eq) and the resulting mixture was stirred at 30°C for 2.0 hours. TLC showed the starting material was consumed. The mixture was acidified with 2N HCl to pH 5~6, diluted with water (40 mL), extracted with EtOAc (80 mL*3). The combined organic phase was washed with brine (250 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 1-((benzyloxy)carbonyl)-3-(2-chlorothiazol-4-yl)piperidine-3-carboxylic acid (281-6) as a light-yellow oil. LCMS: [M+Na]⁺=403.0.

To a solution of 1-((benzyloxy)carbonyl)-3-(2-chlorothiazol-4-yl)piperidine-3-carboxylic acid (281-6) (5.6 g, 14.70 mmol, 1.0 eq) and NH₄Cl (1.57 g, 29.41 mmol, 2.0 eq) in DMF (60 mL) was added DIEA (7.60 g, 58.82 mmol, 4.0 eq) and HATU (11.18 g, 29.41 mmol, 2.0 eq). The resulting mixture was stirred at 30°C for 1 hour and the desired MS was observed by LC-MS. The mixture was diluted with water (40 mL), extracted with EtOAc (80 mL*3). The combined organic phase was washed with brine (200 mL*5), dried over anhydrous sodium sulfate, filtered and concentrated. The crude was purified by flash column (Petroleum ether: EtOAc = 5:1 ~ 1: 1) to give benzyl 3-carbamoyl-3-(2-chlorothiazol-4-yl)piperidine-1-carboxylate (Intermediate 281-7) as a yellow syrup. ¹H NMR (DMSO-d₆ 400MHz): δ. 7.44-7.31 (m, 6H), 7.13 (s, 1H), 7.01 (s, 1H), 5.06 (s, 2H), 4.07-4.03 (m, 1H), 3.78-3.63 (m, 1H), 3.58-3.46 (m, 1H), 3.18 (br s, 1H), 2.33-2.25 (m, 1H), 2.13-2.08 (m, 1H), 1.61-1.46 (m, 1H), 1.40-1.29 (m, 1H).

Intermediate 281-10: Methyl 5-(3-(2-chlorothiazol-4-yl)-3-((methoxycarbonyl)amino)piperidin-1-yl)-2-(4-fluorophenyl)isonicotinate




Benzy 3-(2-chlorothiazol-4-yl)-3-((methoxycarbonyl)amino)piperidine-1-carboxylate (Intermediate 281-8) was prepared following procedures analogous to the preparation of Intermediate 177-3 and corresponding intermediates. ¹H NMR (CDCl₃ 400MHz): δ. 7.37-7.30 (m, 5H), 7.18-7.07 (m, 1H), 5.44-5.11 (m, 3H), 4.23-4.08 (m, 1H), 3.92-3.89 (m, 1H), 3.74-3.56 (m, 4H), 3.14 (t, *J* = 10.4 Hz, 1H), 2.71-2.50 (m, 1H), 2.25-2.12 (m, 1H), 1.71-1.65 (m, 1H), 1.60-1.49 (m, 1H).

A solution of benzy 3-(2-chlorothiazol-4-yl)-3-((methoxycarbonyl)amino)piperidine-1-carboxylate (Intermediate 281-8) (1.5 g, 3.66 mmol, 1.0 eq) in TFA (12.0 mL) was stirred at 66°C for 4.0 hours. TLC showed the starting material was consumed completely. The mixture was concentrated in vacuo and the residue was dissolved in EtOAc (20 mL), washed with saturated NaHCO₃ solution (40 mL*3), dried over anhydrous sodium sulfate, filtered and concentrated to give methyl 3-(2-chlorothiazol-4-yl)piperidin-3-yl)carbamate (281-9) as a brown oil.

To a solution of methyl 3-(2-chlorothiazol-4-yl)piperidin-3-yl)carbamate (281-9) (1.3 g, 3.63 mmol, 1.0 eq) and Intermediate C (903.7 mg, 3.63 mmol, 1.0 eq) in DMSO (20 mL) was added DIEPA (1.87 g, 14.51 mmol, 4.0 eq). The reaction mixture was stirred at 120°C for 12 hours. The desired MS was observed by LCMS. The mixture was cooled to 30°C, diluted with water (20 mL), extracted with EtOAc (30 mL*3). The organic phase was washed with brine (60 mL*3), dried over anhydrous sodium sulfate, filtered and concentrated. The crude was purified by flash column (Petroleum ether: EtOAc = 15:1 ~ 6:1) to give methyl 5-(3-(2-chlorothiazol-4-yl)-3-((methoxycarbonyl)amino)piperidin-1-yl)-2-(4-fluorophenyl)isonicotinate (Intermediate 281-10) as a yellow solid. ¹H NMR (CDCl₃ 400MHz): δ. 8.53 (s, 1H), 7.97 (s, 1H), 7.96-7.92 (m, 2H), 7.18-7.12 (m, 3H), 6.82 (brs, 1H), 4.04 (s, 3H), 3.66 (s, 3H), 3.50 (d, *J* = 12.4 Hz, 1H), 3.32 (d, *J* = 10.0 Hz, 1H), 3.10-2.98 (m, 2H), 2.93-2.84 (m, 1H), 2.06-1.95 (m, 2H), 1.87-1.76 (m, 1H).


Intermediate 281-12: tert-Butyl (tert-butoxycarbonyl)(9-((5-(3-(2-chlorothiazol-4-yl)-3-((methoxycarbonyl)amino)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate



Methyl (3-(2-chlorothiazol-4-yl)-1-(6-(4-fluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-3-yl)carbamate (Intermediate 281-11) was prepared following procedures analogous to the preparation of Intermediate 177-6. ¹H NMR (CDCl₃ 400MHz): δ. 8.45 (s, 1H), 7.94-7.90 (m, 2H), 7.64 (s, 1H), 7.15-7.11 (m, 3H), 7.15-7.10 (m, 2H), 5.75 (brs, 1H), 4.89-4.78 (m, 2H), 3.63 (s, 3H), 3.60-3.56 (m, 1H), 3.30-3.26 (m, 1H), 3.15-3.11 (m, 1H), 2.99-2.92 (m, 1H), 2.60-2.57 (m, 1H), 2.14-2.07 (m, 1H), 2.00-1.93 (m, 1H), 1.85-1.79 (m, 1H).

Intermediate 281-12 was prepared following procedures analogous to the preparation of Intermediate 177-7 and corresponding intermediates. LCMS: [M+H]⁺=794.4

Intermediate 282-4: 1-Benzyl 3-methyl 3-(2H-1,2,3-triazol-4-yl)piperidine-1,3-dicarboxylate



282-4

To a solution of 1-benzyl 3-methyl piperidine-1,3-dicarboxylate (30 g, 108 mmol, 1.0 eq) in THF (350 mL) was added LiHMDS (163 mL, 163 mmol, 1.5 eq) dropwise at -65°C under N₂ atmosphere. After stirred for 30 min, paraformaldehyde (9.72 g, 324 mmol, 3.0 eq) was added. The reaction suspension was stirred at 13-23°C for 1 hour. TLC showed compound 1 was consumed completely. The reaction was quenched with water (300 mL), extracted with EtOAc (300 mL*3), washed with brine (500 mL*2). The combined organic layer was dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by CombiFlash (20~40% EtOAc in PE) to give 1-benzyl 3-methyl 3-(hydroxymethyl)piperidine-1,3-dicarboxylate (282-1) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.40-7.26 (m, 5H), 5.15 (s, 2H), 4.06-3.80 (m,

1H), 3.75-3.60 (m, 6H), 3.50-3.25 (m, 1H), 3.15-2.85 (m, 1H), 1.84-1.71 (m, 1H), 1.70-1.62 (m, 1H), 1.61-1.50 (m, 2H). LC-MS: $[M+H]^+ = 308.0$.


To a solution of 1-benzyl 3-methyl 3-(hydroxymethyl)piperidine-1,3-dicarboxylate (282-1) (13.4 g, 43.6 mmol, 1.0 eq.) in dry DCM (150 mL) was added DMP (36.97 g, 87.21 mmol, 2.0 eq.) portion-wise at 0°C. The resulting mixture was stirred at 11-20°C for 2 hours. TLC showed the reaction was completed. The mixture was poured into saturated NaHCO₃ solution (300 mL) and extracted with DCM (300 mL*3), washed with NaHCO₃ aq. (400 mL*2), dried over Na₂SO₄, concentrated. The residue was purified by flash chromatography (PE/EA = 80/20) to give 1-benzyl 3-methyl 3-formylpiperidine-1,3-dicarboxylate (282-2) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 9.69-9.53 (m, 1H), 7.43-7.28 (m, 5H), 5.14 (s, 2H), 4.42-4.04 (m, 1H), 3.86-3.55 (m, 5H), 3.35-3.11 (m, 1H), 2.28-1.90 (m, 2H), 1.73-1.54 (m, 2H).

To a solution of 1-benzyl 3-methyl 3-formylpiperidine-1,3-dicarboxylate (282-2) (6.5 g, 21.29 mmol, 1.0 eq.) and comp dimethyl (1-diazo-2-oxopropyl)phosphonate (8.17 g, 42.58 mmol, 2.0 eq.) in dry methanol (120 mL) was added K₂CO₃ (8.8 g, 63.87 mmol, 3.0 eq.). The mixture was stirred at 15-22°C for 16 hours. TLC showed the reaction was completed. The mixture was concentrated. The residue was purified by flash chromatography (PE/EA = 60/40) to give 1-benzyl 3-methyl 3-ethynylpiperidine-1,3-dicarboxylate (282-3) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.41-7.29 (m, 5H), 5.15 (s, 2H), 4.21-4.07 (m, 1H), 4.00-3.82 (m, 1H), 3.75 (s, 3H), 3.54-3.41 (m, 1H), 3.14-2.99 (m, 1H), 2.26-2.17 (m, 1H), 2.10-1.82 (m, 3H), 1.92-1.83 (m, 1H), 1.68-1.58 (m, 1H).

To a solution of 1-benzyl 3-methyl 3-ethynylpiperidine-1,3-dicarboxylate (intermediate 282-3) (4 g, 13.27 mmol, 1.0 eq.) in DMF/MeOH (40 mL/4 mL), TMSN₃ (2.3 g, 19.91 mmol, 1.5 eq.) was added. The mixture was stirred at 100-110°C for 16 hours. LCMS () showed the desired MS by LCMS. The mixture was diluted with water (100 mL), extracted with EA (100 mL*4), washed with brine (100 mL*3), dried over Na₂SO₄, filtered and concentrated to give crude compound, which was purified by CombiFlash (DCM/ MeOH = 10 / 1) to give 1-benzyl 3-methyl 3-(2H-1,2,3-triazol-4-yl)piperidine-1,3-dicarboxylate (Intermediate 282-4) as a purple oil. LC-MS: $[M+H]^+ = 345.0$.

Intermediate 282-5a: 1-benzyl 3-methyl 3-(2-methyl-2H-1,2,3-triazol-4-yl)piperidine-1,3-dicarboxylate

Intermediate 282-5b: 1-benzyl 3-methyl 3-(1-methyl-1H-1,2,3-triazol-4-yl)piperidine-1,3-dicarboxylate




To a solution of 1-benzyl 3-methyl 3-(2H-1,2,3-triazol-4-yl)piperidine-1,3-dicarboxylate (intermediate 282-4) (3.3 g, 9.58 mmol, 1.0 eq.) in DMF (40 mL), Cs_2CO_3 (15.6 g, 47.9 mmol, 5 eq.) and MeI (9.3 g, 28.74 mmol, 3eq.) were added. The mixture was stirred at 13-18°C for 16 hours. LCMS showed compound 5 was consumed completely. The mixture was filtered and the filtrate was concentrated to give crude compound, which was purified by pre-HPLC to give 1-benzyl 3-methyl 3-(2-methyl-2H-1,2,3-triazol-4-yl)piperidine-1,3-dicarboxylate (Intermediate 282-5a) and 1-benzyl 3-methyl 3-(1-methyl-1H-1,2,3-triazol-4-yl)piperidine-1,3-dicarboxylate (Intermediate 282-5b) as a yellow oil.

Intermediate 282-5a: ^1H NMR (400 MHz, CD_3OD) δ ppm 7.63-7.47 (m, 1H), 7.44-7.27 (m, 5H), 5.15-5.07 (m, 2H), 4.40-4.15 (m, 1H), 4.09 (s, 3H), 3.90-3.70 (m, 1H), 3.60 (brs, 4H), 3.48-3.32 (m, 1H), 2.38 (brs, 1H), 2.26-2.10 (m, 1H), 1.70-1.55 (m, 2H). LC-MS: $[\text{M}+\text{H}]^+ = 359.3$.


Intermediate 282-5b: ^1H NMR (400 MHz, CD_3OD) δ ppm 7.81 (s, 1H), 7.44-7.27 (m, 5H), 5.12 (s, 2H), 4.48-4.04 (m, 1H), 4.00 (s, 3H), 3.94-3.82 (m, 0.6H), 3.73-3.43 (m, 2H), 3.60 (s, 3H), 3.28-3.17 (m, 0.4H), 2.48-2.10 (m, 2H), 1.82-1.47 (m, 2H).

Intermediate 282-6: 1-((Benzyloxy)carbonyl)-3-(1-methyl-1H-1,2,3-triazol-4-yl)piperidine-3-carboxylic acid




Intermediate 282-6 was prepared by using a procedure similar to that of intermediate 281-6 in Example 281 by replacing intermediate 281-5 with intermediate 282-5a. LC-MS: $[\text{M}+\text{H}]^+ = 345.4$.

Intermediate 282-7: Benzyl 3-carbamoyl-3-(1-methyl-1H-1,2,3-triazol-4-yl)piperidine-1-carboxylate




Intermediate 282-7 was prepared by using a procedure similar to that of intermediate 281-7 in Example 281 by replacing intermediate 281-6 with intermediate 282-6. LC-MS: $[M+H]^+$ = 344.1.

5 **Intermediate 282-8: Benzyl 3-((methoxycarbonyl)amino)-3-(1-methyl-1H-1,2,3-triazol-4-yl)piperidine-1-carboxylate**




Intermediate 282-8 was prepared by using a procedure similar to that of intermediate 177-3 in Example 177 by replacing intermediate 177-3 with intermediate 281-7. ^1H NMR (400 MHz, CDCl_3) δ ppm 7.64-7.30 (m, 6H), 5.29-5.10 (m, 2H), 4.09-3.71 (m, 6H), 3.57 (s, 3H), 3.30 (brs, 1H), 2.69-2.45 (m, 1H), 2.37-2.15 (m, 1H), 1.82-1.65 (m, 1H), 1.55-1.45 (m, 1H). LC-MS: $[M+H]^+$ = 374.1.

Intermediate 282-9: Methyl (3-(1-methyl-1H-1,2,3-triazol-4-yl)piperidin-3-yl)carbamate




15 Intermediate 282-9 was prepared by using a procedure similar to that of intermediate 269-4 in Example 269 by replacing intermediate 269-3 with intermediate 281-8. ^1H NMR (400 MHz, CD_3OD) δ ppm 7.81 (s, 1H), 4.06 (s, 3H), 3.56 (s, 3H), 3.40-3.32 (m, 1H), 3.13-2.89 (m, 2H), 2.71-2.62 (m, 1H), 2.39 (d, $J = 13.6$ Hz, 1H), 2.08-1.99 (m, 1H), 1.79-1.66 (m, 1H), 1.57-1.47 (m, 1H).

20 **Intermediate 282-10: Methyl 2-(3,4-difluorophenyl)-5-(3-((methoxycarbonyl)amino)-3-**

(1-methyl-1H-1,2,3-triazol-4-yl)piperidin-1-yl)isonicotinate


Intermediate 282-10 was prepared by using a procedure similar to that of intermediate 177-5 in example 177 by replacing intermediate 177-4 with intermediate 282-9. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.56 (s, 1H), 7.98 (s, 1H), 7.87-7.81 (m, 12 Hz, 1H), 7.72-7.67 (m, 1H), 7.64 (s, 1H), 7.27-7.20 (m, 1H), 6.87 (brs, 1H), 4.07 (s, 3H), 4.03 (s, 3H), 3.72-3.68 (m, 0.5H), 3.66 (s, 3H), 3.60-3.50 (m, 0.5H), 3.35 (d, *J* = 11.2 Hz, 1H), 3.18 (d, *J* = 12.4 Hz, 1H), 3.10 (td, *J* = 11.6 Hz, 2.8 Hz, 1H), 2.94 (d, *J* = 11.2 Hz, 1H), 2.09-1.70 (m, 3H). LC-MS: [M+H]⁺ = 487.5.

Intermediate 282-11 : methyl (1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)-3-(1-methyl-1H-1,2,3-triazol-4-yl)piperidin-3-yl)carbamate




Intermediate 282-11 was prepared by using a procedure similar to that of intermediate 177-6 in example 177 by replacing intermediate 177-5 with intermediate 282-10. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.46 (s, 1H), 7.86-7.80 (m, 1H), 7.70-7.66 (m, 1H), 7.65 (s, 1H), 7.57 (s, 1H), 7.25-7.19 (m, 1H), 5.75 (brs, 1H), 4.85-4.77 (m, 2H), 4.08 (s, 3H), 3.95 (brs, 1H), 3.62 (s, 3H), 3.69-3.52 (m, 1H), 3.42 (d, *J* = 11.2 Hz, 1H), 3.13 (d, *J* = 11.6 Hz, 1H), 3.03-2.94 (m, 1H), 2.64-2.52 (m, 1H), 2.25-2.10 (m, 1H), 2.02-1.94 (m, 1H), 1.85-1.77 (m, 1H). LC-MS: [M+H]⁺ = 459.1.

Intermediate 282-12: tert-Butyl (tert-butoxycarbonyl)(9-((2-(3,4-difluorophenyl)-5-(3-((methoxycarbonyl)amino)-3-(1-methyl-1H-1,2,3-triazol-4-yl)piperidin-1-yl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate



Intermediate 282-12 was prepared by using a procedure similar to that of intermediate 177-7 in example 177 by replacing intermediate 177-6 with intermediate 282-11. LC-MS: $[M+H]^+ = 776.3$.

5 **Intermediate:284-4: 3-(5-methylisoxazol-3-yl)piperidin-3-amine**



A mixture of benzyl 3-((tert-butoxycarbonyl)amino)-3-formylpiperidine-1-carboxylate (238 mg, 0.656 mmol) and hydroxylamine HCl (38 mg, 0.547 mmol) and K_2CO_3 (91 mg, 0.656 mmol) in EtOH /H₂O (1:1, 20 mL) was stirred at rt overnight. LC-MS indicated the reaction was complete. Then the mixture was treated with EA (20 mL) and H₂O (10 mL). The layers were separated and the aqueous layers were extracted with EA (10 mL*2). The combined organic layer were washed with brine, dried over Na_2SO_4 and filtered. The filtrate was concentrated to give benzyl (E)-3-((tert-butoxycarbonyl)amino)-3-((hydroxyimino)methyl)piperidine-1-carboxylate (284-1) as a white solid, it was used for the next step directly. LC-MS: $[M+H-100]^+ = 277.9$.


15 A mixture of benzyl (E)-3-((tert-butoxycarbonyl)amino)-3-((hydroxyimino)methyl)piperidine-1-carboxylate (284-1) (2 g, 5.3 mmol) in DMF (20 mL) was added NCS (1.061 g, 7.95 mmol). The mixture was stirred at 40°C for 2 hrs. Then the mixture was treated with EA (20 mL) and H₂O (20 mL). The layers were separated and the aqueous layers were extracted with EA (20 mL*2). The combined organic layer were washed with brine, dried over Na_2SO_4 and filtered. The filtrate was concentrated to give crude benzyl (Z)-3-((tert-butoxycarbonyl)amino)-3-(chloro(hydroxyimino)methyl)piperidine-1-carboxylate (284-2) as a light yellow syrup.

20 To a mixture of crude benzyl (Z)-3-((tert-butoxycarbonyl)amino)-3-(chloro(hydroxyimino)methyl)piperidine-1-carboxylate (284-2) (2 g, 4.86 mmol) in DCM (50 mL) was added 2-chloroprop-1-ene (7.43 g, 97 mmol) and TEA (3.41 mL, 24.28 mmol). The mixture was heated to

40 °C for overnight. Then the mixture was concentrated. The residue was purified via biotage, eluting with EA in n-hexane (0 to 50%) to give benzyl 3-((tert-butoxycarbonyl)amino)-3-(5-methylisoxazol-3-yl)piperidine-1-carboxylate (284-3) as a light yellow syrup, which was used for the next step directly. LC-MS: $[M+H]^+ = 415.9$.

- 5 A mixture of benzyl 3-((tert-butoxycarbonyl)amino)-3-(5-methylisoxazol-3-yl)piperidine-1-carboxylate (284-3) (700 mg, 1.685 mmol) in HBr in HOAc (10 mL) was stirred at rt for 8 hrs. LC-MS indicated the reaction was complete. The mixture was concentrated and the residue was adjusted pH=10~12 with 1 M of aq. NaOH. The mixture was then extracted with i-PrOH/DCM (1:3 20 mL*3). The combined organic layers were dried over Na₂SO₄ and filtered. The filtrate
- 10 was concentrated to 3-(5-methylisoxazol-3-yl)piperidin-3-amine (Intermediate 284-4) as a light brown syrup, it was used for the next stage directly. LC-MS: $[M+H]^+ = 182.0$.


Intermediate 284-6: (5-(3-amino-3-(5-methylisoxazol-3-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methanol



- 15 Methyl 5-(3-amino-3-(5-methylisoxazol-3-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)isonicotinate (Intermediate 284-5) was prepared following procedures analogous to those described in Example 177-5 and from corresponding intermediates. LC-MS: $[M+H]^+ = 428.9, 429.8$.

- 20 Intermediate 284-6 was prepared by using a procedure similar to that of intermediate 177-6 in example 177 by replacing intermediate 177-5 with intermediate 284-5. LC-MS: $[M+H]^+ = 400.9, 401.9$.

Intermediate 285-4: 3-(2-(benzyloxy)-1-fluoroethyl)piperidin-3-amine



- 25 To a solution of 2-(benzyloxy)acetaldehyde (0.652 g, 4.34 mmol) in 0.025 M NaOH aqueous solution (15 mL, 0.375 mmol) was added 2-(benzyloxy)acetaldehyde (0.652 g, 4.34 mmol) and N,N,N-trimethylhexadecan-1-aminium chloride (0.139 g, 0.434 mmol) at rt, the mixture was


stirred at rt for 3h under N₂ atmosphere. LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with water, extracted with EtOAc (20ml*3), the combined organic phase was washed with water (20ml), brine (20ml), dried over anhydrous sodium sulfate, concentrated in vacuum to give a residue. The residue was purified by flash chromatography (elution gradient: 0% to 30% EtOAc in PE in 30mins) to afford the tert-butyl 3-(2-(benzyloxy)-1-hydroxyethyl)-3-nitropiperidine-1-carboxylate (285-1). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm. 4.0 - 7.24 (m, 6H), 5.84 (dd, J = 28.5, 6.2 Hz, 1H), 4.79 - 4.56 (m, 1H), 4.54 - 4.44 (m, 2H), 4.07 - 3.91 (m, 1H), 3.85 (s, 1H), 3.59 (ddd, J = 27.8, 10.5, 4.9 Hz, 1H), 3.39 (ddd, J = 12.0, 10.4, 6.3 Hz, 1H), 3.18 (dd, J = 22.8, 13.2 Hz, 1H), 2.72 (s, 1H), 2.41 (t, J = 15.6 Hz, 1H), 1.95 - 1.77 (m, 1H), 1.61 (dt, J = 14.0, 3.9 Hz, 1H), 1.37 (d, J = 2.5 Hz, 9H). LC-MS: [M+H-100]⁺ = 281.2.

To a solution of tert-butyl 3-(2-(benzyloxy)-1-hydroxyethyl)-3-nitropiperidine-1-carboxylate (285-1) (0.93 g, 2.445 mmol) in DCM (20 mL), was added DAST (0.646 mL, 4.89 mmol) at 0 °C, the mixture was stirred at 0 °C for 3h under N₂ atmosphere. LCMS monitored the reaction and indicated the reaction was complete. Then the reaction mixture was diluted with water, extracted with EtOAc (20ml*3), the combined organic phase was washed with water (20ml), brine (20ml), dried over anhydrous sodium sulfate, concentrated in vacuum to give a residue. The residue was purified by flash chromatography (elution gradient: 0% to 40% EtOAc in PE in 30mins) to afford tert-butyl 3-(2-(benzyloxy)-1-fluoroethyl)-3-nitropiperidine-1-carboxylate (285-2) as a colorless oil. LC-MS: [M+H-100]⁺ = 383.1.

To a solution of tert-butyl 3-(2-(benzyloxy)-1-fluoroethyl)-3-nitropiperidine-1-carboxylate (285-2) (200 mg, 0.684 mmol) in EtOH (10 mL), was added Zn dust (44.7 mg, 0.684 mmol) at RT, then 4M HCl (2.281 mL, 6.84 mmol) was added dropwise at 0 °C, after addition the mixture was stirred at 0 °C for 3h under N₂ atmosphere. LC-MS monitored the reaction. The reaction mixture was filtered and concentrated to give a residue. The residue was purified by flash chromatography (elution gradient: 0% to 40% EtOAc in PE in 30mins) to afford tert-butyl 3-amino-3-(2-(benzyloxy)-1-fluoroethyl)piperidine-1-carboxylate (285-3). LC-MS: [M+H]⁺ = 263.2.

To a solution of tert-butyl 3-amino-3-(2-(benzyloxy)-1-fluoroethyl)piperidine-1-carboxylate (285-3) (180 mg, 0.511 mmol) in DCM (15 mL), was added TFA (5 mL, 64.9 mmol) at rt, the mixture was stirred at rt for 1h under N₂ atmosphere. Then the mixture was concentrated in vacuum to afford 3-(2-(benzyloxy)-1-fluoroethyl)piperidin-3-amine (Intermediate 285-4) as TFA salt. LC-MS: [M+H]⁺ = 253.2.

Intermediate 287-6: 2,2,2-trifluoroacetaldehyde compound with N-benzyl-3-(1,2-difluoroethyl)piperidin-3-amine (1:1)



AlLiH₄ (13.42 g, 353.45 mmol) in THF (200 mL) was stirred at 80 °C for 2 h. Then the mixture was added to ethyl 2-fluoroacetate (150 g, 1.41 mol) in THF (100 mL) at -60 °C and stirred at -60 °C for 1 h. The mixture was quenched by EtOH (20 mL) at -60 °C, poured into a solution of ice-water (500 mL) and H₂SO₄ (50 mL), extracted with MTBE (150 mL*3). The organic layers were concentrated in vacuo (25 °C) to give residue. The residue was purified by distillation (-0.095 MPa, 25~50 °C) to give 1-ethoxy-2-fluoroethan-1-ol (287-1) as an oil. ¹H NMR (400MHz, CD₃OD) δ = 4.30 - 4.16 (m, 2H), 3.61 (q, J=7.1 Hz, 2H), 1.20 - 1.18 (m, 3H).

To a solution of tert-butyl 3-nitropiperidine-1-carboxylate (40 g, 173.72 mmol) in THF (40 mL) was added 1-ethoxy-2-fluoroethan-1-ol (287-1) (93.90 g, 868.58 mmol), K₂CO₃ (12.00 g, 86.86 mmol) and stirred at 40 °C for 4h. TLC (PE: EA=2:1, R_f=0.4) indicated tert-butyl 3-nitropiperidine-1-carboxylate was consumed. The mixture was concentrated in vacuo to give a residue. The residue was purified by column chromatography (PE/EA = 50:1~10:1) to give tert-butyl 3-(2-fluoro-1-hydroxyethyl)-3-nitropiperidine-1-carboxylate (287-2) as a syrup. ¹H NMR (400MHz, CDCl₃) δ = 4.78 - 4.62 (m, 1H), 4.60 - 4.50 (m, 1H), 4.50 - 4.41 (m, 1H), 4.22 - 4.02 (m, 1H), 3.99 - 3.60 (m, 1H), 3.48 - 2.92 (m, 2H), 2.57 - 2.37 (m, 1H), 2.34 - 2.10 (m, 1H), 1.74 - 1.64 (m, 2H), 1.47 (m, 9H). LCMS: [M+H-56]⁺=237.3.

To a solution of tert-butyl 3-(2-fluoro-1-hydroxyethyl)-3-nitropiperidine-1-carboxylate (287-2) (25 g, 85.53 mmol) in DCM (100 mL) was added BAST (85.15 g, 384.87 mmol) and stirred at 50 °C for 4 h. TLC (PE: EA=2:1, R_f=0.50) showed tert-butyl 3-(2-fluoro-1-hydroxyethyl)-3-nitropiperidine-1-carboxylate (intermediate 287-2) was consumed. The mixture was quenched with aq.NaHCO₃ (1.0 L), extracted with EA (200 mL*3). The organic layer was concentrated in vacuo to give a residue. The residue was purified by column chromatography (PE: EA = 100:1~20:1) to give tert-butyl 3-(1,2-difluoroethyl)-3-nitropiperidine-1-carboxylate (287-3). LCMS: [M+H-56]⁺=239.3.


To a solution of tert-butyl 3-(1,2-difluoroethyl)-3-nitropiperidine-1-carboxylate (287-3) (10.0 g, 33.98 mmol) in MeOH (100 mL) was added Pd/C (5.0 g, 10% purity) and stirred under H₂ (15 Psi) at 40 °C for 16 h. TLC (PE: EA=1:1, R_f=0.2) indicated intermediate 287-3 was consumed. The mixture was filtered and concentrated in vacuo to give crude tert-butyl 3-amino-3-(1,2-difluoroethyl)piperidine-1-carboxylate (287-4). LCMS: [M+H-56]⁺=209.3.

To a solution of tert-butyl 3-amino-3-(1,2-difluoroethyl)piperidine-1-carboxylate (287-4) (8.1 g, 30.65 mmol) and benzaldehyde (4.88 g, 45.97 mmol) in EtOH (100 mL) was stirred at 40 °C for 1h. Then NaBH₄ (5.8 g, 153.23 mmol) was added to the mixture and stirred at 40 °C for 16 h. LCMS detected the reaction. The mixture was quenched by aq.NH₄Cl (100 mL), diluted with

H₂O (200 mL), extracted with EA (50 mL*3). The organic layer was concentrated in vacuo to give tert-butyl 3-(benzylamino)-3-(1,2-difluoroethyl)piperidine-1-carboxylate (287-5). LCMS: [M+H]⁺=355.4.

To a solution of tert-butyl 3-(benzylamino)-3-(1,2-difluoroethyl)piperidine-1-carboxylate (287-5) (7.0 g, 19.75 mmol) in DCM (20 mL) was added TFA (10 mL) and stirred at 40 °C for 3 h. TLC (EA: EA= 2: 1, R_f=0.1) showed intermediate 287-5 was consumed. The mixture was quenched by aq.NaHCO₃ (200 mL), extracted with DCM (50 mL*3). The organic layer was concentrated in vacuo to give 2,2,2-trifluoroacetaldehyde compound with N-benzyl-3-(1,2-difluoroethyl)piperidin-3-amine (1:1) (Intermediate 287-6). LCMS: [M+H]⁺=254.9.

10 **Intermediate 288-9: 3-(6-methyl-1,4-dioxan-2-yl)piperidin-3-amine**



To a stirred solution of NaH (7.7g, 180 mmol, 1.0 eq) in anhydrous THF (120ml) at 0°C was added prop-2-en-1-ol (10.4 g, 180 mmol, 1.0 eq) dropwise. The reaction mixture was stirred for 15 min at 0 °C, and stirred at 15 °C for another 15 min. Besides, to another suspension of NaH (7.7 g, 180 mmol, 1.0 eq) and THF (60mL) was added 2-chloroacetic acid in anhydrous at 0°C, after stirred at 0°C for 15mins, the previously prepared solution was added and the reaction mixture was stirred at 15 °C for 12 hours. LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was quenched by water (100 mL), the aqueous layer was acidified with 2N HCl to PH=3~4 and extracted with EA (200 mL*3), dried over anhydrous Na₂SO₄, filtered and concentrated to give 2-(allyloxy)acetic acid (288-1) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 5.98 - 5.85 (m, 1H), 5.39 - 5.22 (m, 2H), 4.15 (s, 2H), 4.13 (m, 2H). LC-MS: [M+Na]⁺ =161.1.

To a solution of 2-(allyloxy)acetic acid (288-1) (9.2 g, 79.23 mmol, 1.0 eq) in anhydrous DCM (60 mL) was added DMF (115 mg, 1.58 mmol, 0.02 eq) and (COCl)₂ (12.1 g, 95.07 mmol, 1.2 eq) dropwise at 15°C. The reaction mixture was stirred at 15°C for 2 hours. LCMS (quenched by benzylamine) showed 2-(allyloxy)acetyl chloride (intermediate 288-2) was in main peak. The reaction mixture was concentrated in vacuum to give crude 2-(allyloxy)acetyl chloride (288-2). LC-MS: [M+C₇H₉N-HCl+H]⁺ =206.2.

To a solution of 1-benzyl 3-methyl piperidine-1,3-dicarboxylate (16.9 g, 60.94 mmol, 1.0 eq) in anhydrous THF (170 mL) was added a solution of LiHMDS (61 mL, 60.94 mmol, 1.0 eq) dropwise at -78°C. The reaction mixture was stirred at -78°C for 1 hour, 2-(allyloxy)acetyl chloride (288-2) (8.2 g, 60.94 mmol, 1.0 eq) was added dropwise at -78 °C, the reaction was stirred at -78°C for 1 hour and at 15°C for another 1 hour. LC-MS showed 2-(allyloxy)acetyl

chloride (288-2) was partly remained and the reaction mixture was quenched with sat. NH_4Cl (200 mL), extracted with EA (100 mL*3), dried over Na_2SO_4 , filtered, concentrated to give crude 1-benzyl 3-methyl 3-(2-(allyloxy)acetyl)piperidine-1,3-dicarboxylate (288-3). LC-MS: $[\text{M}+\text{H}]^+ = 376.2$.

5 To a solution of 1-benzyl 3-methyl 3-(2-(allyloxy)acetyl)piperidine-1,3-dicarboxylate (288-3) (20.4 g, 53.34 mmol, 1.0 eq) in MeOH (100 mL) was added NaBH_4 (2.0 g, 53.34 mmol, 1.0 eq) portionwise at 15°C . The reaction was stirred at 15°C for 3 hours. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was quenched with Sat. NH_4Cl (100 mL), acidified with 2N HCl to $\text{pH}=4\sim 5$, extracted with EtOAc (100 mL*3), the combined
10 organic phase was washed with water (100 mL), brine (100 mL), dried over anhydrous sodium sulfate, concentrated in vacuum to give a residue. The residue was purified by column chromatography (SiO_2 , PE/EA=20:1 to 1:1) to give 1-benzyl 3-methyl 3-(2-(allyloxy)-1-hydroxyethyl)piperidine-1,3-dicarboxylate (288-4). LC-MS: $[\text{M}+\text{H}]^+ = 378.3$.

To a solution of 1-benzyl 3-methyl 3-(2-(allyloxy)-1-hydroxyethyl)piperidine-1,3-dicarboxylate
15 (288-4) (10.4 g, 27.55 mmol, 1.0 eq) in dry MeCN (100 mL) was added NIS (10.6 g, 4.684 mmol, 1.7 eq). The reaction mixture was stirred at 90°C for 3 hours. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was quenched with Sat. Na_2SO_3 (50 mL), extracted with EA (100 mL*3), dried over anhydrous Na_2SO_4 , concentrated. The residue was purified by column chromatography (SiO_2 , PE/EA=20/1 to 2/1) to give 1-benzyl 3-methyl 3-(6-(iodomethyl)-1,4-dioxan-2-yl)piperidine-1,3-dicarboxylate (288-5) as a light oil,. LC-MS:
20 $[\text{M}+\text{H}]^+ = 504.2$.

To a solution of 1-benzyl 3-methyl 3-(6-(iodomethyl)-1,4-dioxan-2-yl)piperidine-1,3-dicarboxylate (288-5) (4.3 g, 8.54 mmol, 1.0 eq) and $n\text{-Bu}_3\text{SnH}$ (2.5 g, 8.54 mmol, 1.0 eq) and in anhydrous toluene (200 mL) was added AIBN (140 mg, 0.85 mmol, 0.1 eq), the reaction mixture
25 was stirred under N_2 for 16 hours. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was quenched by a solution of KF (0.5 g, 8.54 mmol, 1.0 eq) in H_2O (50 mL), diluted with water (100 mL), extracted with EA (100 mL*3), dried over anhydrous Na_2SO_4 , concentrated in vacuo to give residue. The residue was purified by column chromatography (SiO_2 , PE/EA=20/1 to 1/1) to give 1-benzyl 3-methyl 3-(6-methyl-1,4-dioxan-2-yl)piperidine-1,3-dicarboxylate (288-6) as a colorless oil. LC-MS: $[\text{M}+\text{H}]^+ = 378.3$.
30


To a solution of 1-benzyl 3-methyl 3-(6-methyl-1,4-dioxan-2-yl)piperidine-1,3-dicarboxylate (288-6) (3.6 g, 9.54 mmol, 1.0 eq) in MeOH (50 mL) was added a solution of $\text{LiOH}\cdot\text{H}_2\text{O}$ (4.0 g, 95.38 mmol, 10.0 eq) in H_2O (50 mL) at RT. The reaction was stirred at RT for 16 hours. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was
35 concentrated in vacuum to remove most of MeOH, diluted with 20 mL of water, the aqueous phase was washed with EA (10 mL*3). Then the aqueous phase was acidified with 2N HCl to $\text{pH}=3\sim 4$, extracted with EA (50 mL*3), dried over anhydrous Na_2SO_4 , concentrated in vacuo to

give 1-((benzyloxy)carbonyl)-3-(6-methyl-1,4-dioxan-2-yl)piperidine-3-carboxylic acid (288-7) as a colorless oil. LC-MS: $[M+H]^+ = 364.3$.

To a solution of 1-((benzyloxy)carbonyl)-3-(6-methyl-1,4-dioxan-2-yl)piperidine-3-carboxylic acid (288-7) (2.1 g, 5.78 mmol, 1.0 eq) in anhydrous THF (800 mL) was added TEA (1.7 g, 17.34 mmol, 3.0 eq) and DPPA (2.2 g, 8.09 mmol, 1.4 eq) at 20°C, the reaction mixture was stirred at 70°C for 2 hours and cooled to 20°C then a solution of KOH (1.0 g, 17.34 mmol, 3.0 eq) in H₂O (10 mL) was added. The reaction mixture was stirred at 20°C for 2 hours. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was concentrated, extracted with EA (50 mL*3), washed with water (50 mL), brine (50 mL). The organic layer was dried over Na₂SO₄, concentrated in vacuo. The crude was purified by column chromatography (SiO₂, PE/EA=20/1 to EA) to give a not pure product, which was further purified by Prep-HPLC to give benzyl 3-amino-3-(6-methyl-1,4-dioxan-2-yl)piperidine-1-carboxylate (288-8) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.39 - 7.21 (m, 5H), 5.06 (m, 2H), 3.96 - 2.86 (m, 10H), 1.82 - 1.61 (m, 2H), 1.52 - 1.31 (m, 2H), 1.30 - 0.96 (m, 3H). LC-MS: $[M+H]^+ = 335.3$.

To a solution of benzyl 3-amino-3-(6-methyl-1,4-dioxan-2-yl)piperidine-1-carboxylate (288-8) (1.0 g, 2.99 mmol, 1.0 eq) in MeOH (10 mL) was added Pd(OH)₂ (104 mg, 10% wt), the reaction mixture was stirred at 20°C under H₂ atmosphere (16 Psi) for 8 hours. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was filtered and concentrated in vacuum to give crude 3-(6-methyl-1,4-dioxan-2-yl)piperidin-3-amine (Intermediate 288-9).

Intermediate 292-3: 3-oxa-1,7-diazaspiro[4.5]decan-2-one




292-3

To a solution of 1-benzyl 3-ethyl 3-(hydroxymethyl)piperidine-1,3-dicarboxylate (intermediate 22-2) (2.0 g, 6.97 mmol, 1.0 eq.) in THF/MeOH/H₂O (1:1:1, 30 mL) was added LiOH·H₂O (0.87 g, 20.9 mmol, 3.0 eq.) at 20°C. The mixture was stirred at 20°C for 8 h. TLC showed that the starting material was consumed completely. Water (50 mL) was added and the mixture was extracted with EtOAc (100 mL*3). The aqueous phase was acidified by 1M HCl to pH=2-3 and then extracted with EtOAc (100 mL*3). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to give 1-(tert-butoxycarbonyl)-3-(hydroxymethyl)piperidine-3-carboxylic acid (292-1) as a colorless oil. ¹H NMR (CDCl₃ 400MHz): δ 4.05-3.85 (m, 1H), 3.85-3.65 (m, 3H), 3.45-3.20 (m, 1H), 3.14-2.95 (m, 1H), 1.97-1.85 (m, 1H), 1.80-1.70 (m, 1H), 1.62-1.52 (m, 2H), 1.44 (s, 9H).

To a solution of 1-(tert-butoxycarbonyl)-3-(hydroxymethyl)piperidine-3-carboxylic acid (292-1) (1.8 g, 6.94 mmol, 1.0 eq.) in Toluene (40 mL) was added TEA (1.4 g, 13.9 mmol, 2.0 eq.) and DPPA (2.7 g, 10.4 mmol, 1.5 eq.) under N₂ at 20°C. Then the reaction mixture was stirred at 110°C for 8 h. TLC showed that the starting material was consumed completely. H₂O (100 mL) was added and the mixture was extracted with EtOAc (100 mL*3). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (PE:EA=1:1) to give tert-butyl 2-oxo-3-oxa-1,7-diazaspiro[4.5]decane-7-carboxylate (292-2) as a yellow oil. ¹H NMR (CDCl₃ 400MHz): δ 5.87 (brs, 1H), 4.22 (d, J = 8.8Hz, 1H), 4.07 (d, J = 8.8Hz, 1H), 3.66-3.42 (m, 2H), 3.38-3.18 (m, 2H), 1.85-1.78 (m, 2H), 1.75-1.65 (m, 1H), 1.60-1.52 (m, 1H), 1.48 (s, 9H).

A solution of tert-butyl 2-oxo-3-oxa-1,7-diazaspiro[4.5]decane-7-carboxylate (292-2) (0.6 g, 2.34 mmol, 1.0 eq.) in HCl/dioxane (5 mL, 4N) was stirred at 20 °C for 2 h. TLC showed that the starting material was consumed completely. The mixture was concentrated to give crude 3-oxa-1,7-diazaspiro[4.5]decan-2-one (Intermediate 292-3) as a yellow solid.

Intermediate 293-8: 3-(1,1-difluoroprop-1-en-2-yl)piperidin-3-amine



293-8

To a solution of tert-butyl 3-cyanopiperidine-1-carboxylate (25 g, 119.0 mmol, 1.0 eq.) in THF (300 mL) at -70 °C under N₂ atmosphere was added LiHMDS (178 mL, 178.57 mmol, 1.5 eq.) dropwise. The reaction mixture was stirred at -70°C for 30 min, then CH₃CHO (7.85 g, 178.57 mmol, 3 eq.) was added. TLC monitored the reaction and indicated the reaction was complete. The reaction was quenched with aq. NH₄Cl (200 mL), extracted with EtOAc (100 mL*3). The combined organic layer was washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by Combi-flash (EtOAc in PE, 10%~50%) to afford tert-butyl 3-(1-hydroxyethyl)-3-methylpiperidine-1-carboxylate (293-1) as a colorless oil.

To a solution of tert-butyl 3-(1-hydroxyethyl)-3-methylpiperidine-1-carboxylate (intermediate 293-1) (9 g, 35.43 mmol, 1.0 eq.) in DCM (150 mL) was added DMP (22.5 g, 53.15 mmol, 1.5 eq.). The mixture was stirred at 20°C for 1 hour. TLC monitored the reaction and indicated the reaction was complete. The reaction was quenched with aq. NaHCO₃ (150 mL) and aq. Na₂SO₃ (150 mL), extracted with EtOAc (150 mL x 3). The combined organic layers were washed with aq. NaHCO₃ (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated to afford tert-butyl 3-acetyl-3-cyanopiperidine-1-carboxylate (293-2) as a yellow oil. ¹H NMR (400 MHz,

CDCl₃) δ ppm 4.50-3.85 (m, 2H), 3.20-3.05 (m, 1H), 2.95-2.60 (m, 1H), 2.46 (s, 3H), 2.25-1.70 (m, 4H), 1.48 (s, 9H).

To a solution of tert-butyl 3-acetyl-3-cyanopiperidine-1-carboxylate (293-2) (5 g, 19.84 mmol, 1.0 eq.) in DCM (100 mL) was added TFA (15 mL). The mixture was stirred at 20°C for 2 hours.

5 The reaction mixture was then concentrated. The residue was diluted with EtOAc (150 mL), and aq. NaHCO₃ (150 mL) was added. Then CbzCl (4.0 g, 23.81 mmol, 1.2 eq) was added. The reaction mixture was stirred at 20°C for another 1h. TLC monitored the reaction and indicated the reaction was complete. The product was extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na₂SO₄, filtered and
10 concentrated. The residue was purified by combi-flash (EtOAc in PE, 0%-30%) to afford benzyl 3-acetyl-3-cyanopiperidine-1-carboxylate (293-3) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.45-7.30 (m, 5H), 5.25-5.10 (m, 2H), 4.50-4.05 (m, 2H), 3.20 (d, J=13.6 MHz, 1H), 2.95-2.75 (m, 1H), 2.47 (d, J=16.8 MHz, 3H), 2.25-1.60 (m, 4H).

To a solution of benzyl 3-acetyl-3-cyanopiperidine-1-carboxylate (293-3) (5 g, 17.46 mmol, 1.0 eq.) and 2-((difluoromethyl)sulfonyl)pyridine (5 g, 26.19 mmol, 1.5 eq.) in THF (50 mL) was
15 added KHMDS (26 mL, 26.19 mmol, 1.5 eq.) dropwise at -70 °C under N₂ atmosphere. The mixture was stirred at -70°C for 2 hours. LCMS monitored the reaction and indicated the reaction was complete. The reaction was quenched with aq. NH₄Cl (50 mL) and extracted with EtOAc (50 mL x 3). The organic layers were washed with brine (100 mL), dried over anhydrous
20 Na₂SO₄, filtered and concentrated to afford benzyl 3-cyano-3-(1,1-difluoro-2-hydroxy-1-(pyridin-2-ylsulfonyl)propan-2-yl)piperidine-1-carboxylate (293-4) as a yellow oil. LC-MS: [M+H]⁺ =480.0.

To a solution of benzyl 3-cyano-3-(1,1-difluoro-2-hydroxy-1-(pyridin-2-ylsulfonyl)propan-2-yl)piperidine-1-carboxylate (293-4) (12 g, crude) in DMF (30 mL) was added sat. NH₄Cl (30 mL) and aq. HCl (30 mL, 6M). The reaction mixture was stirred at 80°C for 48 hours. LCMS
25 monitored the reaction and showed 23% desired product. The reaction was cooled and diluted with H₂O (50 mL). The product was extracted with EtOAc (50 mL x 3). The organic layers were washed with brine (100 mL), dried over Na₂SO₄, filtered and concentrated. The residue was purified by combi-flash (EtOAc in PE, 0%-20%) to afford benzyl 3-cyano-3-(1,1-difluoroprop-1-en-2-yl)piperidine-1-carboxylate (293-5) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.45-
30 7.30 (m, 5H), 5.30-5.15 (m, 2H), 4.65-4.15 (m, 2H), 3.10-2.70 (m, 2H), 2.25 (d, J=11.2 MHz, 1H), 2.10-1.60 (m, 6H). LC-MS: [M+H]⁺ =320.9.

To a mixture of benzyl 3-cyano-3-(1,1-difluoroprop-1-en-2-yl)piperidine-1-carboxylate (293-5) (2.7 g, 8.44 mmol, 1.0 eq), 1 M NaOH solution (12.6 mL, 1.5 eq) in MeOH (100 mL) was added
35 H₂O₂ (30%, 6.68 g, 59 mmol, 7.0 eq). The reaction was stirred at 18°C for 36 hrs. TLC showed a new spot was detected. The reaction was quenched with saturated Na₂S₂O₃ (50 mL). The aqueous layer was extracted with EtOAc (50 mL x 3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated into dryness. The residue was purified by combi-flash (EtOAc in PE, 0-40%) to afford benzyl 3-carbamoyl-3-(1,1-difluoroprop-1-en-2-yl)piperidine-1-

carboxylate (293-6) as a colorless oil. ^1H NMR (CDCl_3 400MHz): δ ppm 7.42-7.30 (m, 5H), 5.22-5.08 (m, 2H), 4.48 (brs, 1H), 3.99 (brs, 1H), 3.17-2.88 (m, 2H), 2.53 (brs, 1H), 1.76-1.46 (m, 7H).

To a solution of benzyl 3-carbamoyl-3-(1,1-difluoroprop-1-en-2-yl)piperidine-1-carboxylate (293-6) (1.34 g, 4 mmol, 1.0 eq) and KOH (560 mg, 10 mmol, 2.5 eq) in MeOH (30 mL) was added PhI(OAc) $_2$ (1.53 g, 4.8 mmol, 1.2 eq) at 0°C. The resulting mixture was stirred at 15°C for 3hr. TLC showed a new spot was detected. The reaction was quenched with sat. NH_4Cl solution (50 mL). The aqueous layer was extracted with EtOAc (50 mL x 3). The combined organic layers were dried over Na_2SO_4 , filtered and concentrated. The residue was purified by combi-

flash (EtOAc in PE, 0-30%) to afford benzyl 3-(1,1-difluoroprop-1-en-2-yl)-3-((methoxycarbonyl)amino)piperidine-1-carboxylate (293-7) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ ppm 7.42-7.30 (m, 5H), 5.24-5.08 (m, 2H), 4.30 (d, $J=14.2$ Hz, 1 H), 4.18-4.04 (m, 1H), 3.60 (s, 3H), 2.82 (brs, 2H), 1.73-1.60 (m, 4H), 1.57 (s, 3H). LC-MS: $[\text{M}+\text{H}]^+ = 369.0$.

To a solution of benzyl 3-(1,1-difluoroprop-1-en-2-yl)-3-((methoxycarbonyl)amino)piperidine-1-carboxylate (293-7) (600 mg, 1.63 mmol, 1.0 eq) in DCM (15 mL) was added TMSI (977 mg, 4.89 mmol, 3.0 eq). The reaction was stirred at 16°C for 18hr. LCMS showed a main product. The reaction was quenched with water (10 mL). The aqueous layer was adjusted to pH=4-5 by 1 M HCl solution. The mixture was partitioned between DCM and water. The aqueous layer was lyophilized to afford 3-(1,1-difluoroprop-1-en-2-yl)piperidin-3-amine HCl salt (Intermediate 293-8) as a dark yellow solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 3.73 (d, $J=13.4$ Hz, 1 H), 3.17 (d, $J=12.8$ Hz, 2 H), 2.98 (t, $J=10.2$ Hz, 1 H), 2.27 (d, $J=13.6$ Hz, 1 H), 2.01-1.78 (m, 2 H), 1.71 (t, $J=3.4$ Hz, 3 H), 1.65-1.50 (m, 1 H). LC-MS: $[\text{M}+\text{H}]^+ = 177.1$

Intermediate 295-6: 3-(1-fluoroethyl)piperidin-3-amine



295-6

To solution of 1-benzyl 3-methyl 3-((tert-butoxycarbonyl)amino)piperidine-1,3-dicarboxylate (160 mg, 0.41 mmol) in MeOH (10 ml) was added LiCl (510mg, 12.3 mmol) and NaBH_4 (462 mg, 12.3 mmol) at room temperature. The reaction mixture was stirred at this temperature until no starting material left. The reaction mixture was diluted with EA, washed with 1 N HCl and brine. The organic layer was dried over Na_2SO_4 and concentrated under vacuum to give the crude alcohol as a white solid. LC-MS: $[\text{M}+\text{H}-100]^+ = 265.0$.

To a solution of the alcohol (560 mg, 1.537 mmol) in DCM (15 ml) was added Dess-Martin reagent (782 mg, 1.844 mmol). The mixture was stirred at rt for 2 hrs. TLC indicated the reaction was complete. The mixture was treated with aq. NaHCO_3 (10 ml) and the layers were separated. The aqueous layer was extracted with DCM (10 ml*2). The combined organic layers were washed with brine, dried over Na_2SO_4 and filtered. The filtrate was concentrated. The

residue was purified via biotage, eluting with EA in n-hexane (0 to 50%) to give benzyl 3-((tert-butoxycarbonyl)amino)-3-formylpiperidine-1-carboxylate (295-1) as a white solid, which was used for the next stage. LC-MS: $[M+H-100]^+ = 624.8$.

To a solution of benzyl 3-((tert-butoxycarbonyl)amino)-3-formylpiperidine-1-carboxylate (295-1) (100 mg, 0.276 mmol) in THF (10 ml) was added dropwise aq. CH_3MgBr in 2-Me THF (3M, 0.138 ml, 0.414 mmol) at $-78^\circ C$. The mixture was stirred at $-78^\circ C$ for another 1 hr and was allowed to warm to $0^\circ C$ for another 2 hr. TLC indicated the reaction was complete. The mixture was quenched with aq. NH_4Cl (10 ml) and was extracted with EA (20 ml*3). The combined organic layers were washed with brine, dried over Na_2SO_4 and filtered. The filtrate was concentrated. The residue was purified via biotage, eluting with EA in n-hexane (0 to 50%) to give the alcohol as a white solid. LC-MS: $[M+H-100]^+ = 279.0$. To a solution of the alcohol (100 mg, 0.264 mmol) in DCM (3 ml) was added TFA (0.5 ml). The resulting mixture was stirred at rt for 2hrs. LC-MS indicated the reaction was complete. The mixture was concentrated under vacuum (below $40^\circ C$) to give benzyl 3-amino-3-(1-hydroxyethyl)piperidine-1-carboxylate (295-2) as a light yellow syrup. LC-MS $[M+H]^+ = 279.0$.

To a solution of benzyl 3-amino-3-(1-hydroxyethyl)piperidine-1-carboxylate (295-2) (330 mg, 1.186 mmol), DMAP (14.48 mg, 0.119 mmol) and DIPEA (0.958 mL, 5.34mmol) in DCM (20 mL) was added $NaCl$ (657 mg, 2.96 mmol) in portions. The mixture was stirred at rt under N_2 overnight. LC-MS indicated the reaction was complete. The reaction was treated with aq. $NaHCO_3$ (20 mL). The layers were separated. The aqueous layer was extracted with DCM (20 mL*2). The combined organic layers were washed with brine, dried over Na_2SO_4 and filtered. The filtrate was concentrated. The residue was purified via biotage, eluting with n-hexane in EA (0 to 30%) to give benzyl 2-methyl-1-((4-nitrophenyl)sulfonyl)-1,5-diazaspiro[2.5]octane-5-carboxylate (295-3) as a light yellow syrup. LC-MS: $[M+H]^+ = 445.8$.


To a solution of benzyl 2-methyl-1-((4-nitrophenyl)sulfonyl)-1,5-diazaspiro[2.5]octane-5-carboxylate (295-3) (420 mg, 0.943 mmol) in THF (10 mL) was added 1 M TBAF in THF (0.606 ml, 0.606 mmol) under N_2 . The mixture was heated to $45^\circ C$ overnight. LC-MS indicated the reaction was complete. The mixture was cooled to rt and was treated with EA (15 mL) and H_2O (10 mL). The layers were separated and the aqueous layer was extracted with EA (15 mL *3). The combined organic layers were washed with brine, dried over Na_2SO_4 and filtered. The filtrate was concentrated and was purified via prep. HPLC to give benzyl 3-(1-fluoroethyl)-3-((4-nitrophenyl)sulfonamido)piperidine-1-carboxylate (295-4) as a light yellow solid. LC-MS: $[M+H]^+ = 465.8$.

A mixture of thioglycolic acid (71.2 mg, 0.773mmol) and DBU 235(98 mg, 1.547 mmol) in CH_3CN (10 mL) was stirred under N_2 for 5 min. Then benzyl 3-(1-fluoroethyl)-3-((4-nitrophenyl)sulfonamido)piperidine-1-carboxylate (295-4) (120 mg, 0.258mmol) in CH_3CN (2 mL) was added. The mixture was stirred at rt overnight. LC-MS indicated the reaction was complete. The mixture was concentrated. The residue was treated with EA (10 ml) and was

washed with aq. NaHCO_3 (5 mL *2), H_2O (10 mL) and brine, dried over Na_2SO_4 and filtered. The filtrate was concentrated and the residue purified via prep. HPLC to give benzyl 3-amino-3-(1-fluoroethyl)piperidine-1-carboxylate (295-5) as a light yellow syrup. LC-MS: $[\text{M}+\text{H}]^+ = 281.1$.

To a solution of benzyl 3-amino-3-(1-fluoroethyl)piperidine-1-carboxylate (295-5) (120 mg, 0.428 mmol) in MeOH (15 mL) was added $\text{Pd}(\text{OH})_2$ (60 mg) under N_2 . The mixture was then stirred under H_2 balloon for 3 hr. LC-MS indicated the SM was consumed. The mixture was filtered and the filtrate was concentrated to give 3-(1-fluoroethyl)piperidine-3-amine (Intermediate 295-6) as a colorless oil. LC-MS: $[\text{M}+\text{H}]^+ = 147.1$

Intermediate 297-6: 3-((methylthio)methyl)piperidine-3-amine



297-6

To a solution of 1-benzyl 3-ethyl 3-(((trifluoromethyl)sulfonyl)oxy)methyl)piperidine-1,3-dicarboxylate (22-3) (18.0 g, 39.7 mmol, 1.0 eq.) in THF (200 mL) was added MeSNa (11.0 g, 159 mmol, 4.0 eq) at 0 °C. The resulting mixture was stirred at 15-20 °C for 16 hr. The reaction was quenched with water (300 mL), and extracted with EtOAc (300 mLx3). The combined organic layers were dried over anhydrous Na_2SO_4 and concentrated in *vacuo*. The residue was purified by Combi Flash (30% EtOAc in PE) to give 1-benzyl 3-ethyl 3-((methylthio)methyl)piperidine-1,3-dicarboxylate (297-1) as a yellow oil. ^1H NMR (400 MHz, CDCl_3) δ ppm 7.25-7.45 (5H, m), 5.13 (2H, s), 4.05-4.25 (2H, m), 3.80-4.00 (1H, m), 3.25-3.60 (3H, m), 2.60-2.85 (2H, m), 2.00-2.15 (4H, m), 1.55-1.75 (3H, m), 1.10-1.30 (3H, m).


A mixture of 1-benzyl 3-ethyl 3-((methylthio)methyl)piperidine-1,3-dicarboxylate (297-1) (10.0 g, 28.5 mmol, 1.0 eq.) and $\text{LiOH}\cdot\text{H}_2\text{O}$ (12.0 g, 285 mmol, 10.0 eq.) in MeOH/THF/ H_2O (120 mL, v/v/v = 1/1/1) was stirred at 20 °C for 16 hr. The reaction was concentrated in *vacuo*. The residue was diluted with water (200 mL), and extracted with MTBE (100 mL). Then the pH of the aqueous layer was adjusted to 5 by 1N HCl, and extracted with EtOAc (200 mLx3). The combined organic layers were dried over anhydrous Na_2SO_4 and concentrated in *vacuo* to give crude 1-((benzyloxy)carbonyl)-3-((methylthio)methyl)piperidine-3-carboxylic acid (297-2) as a yellow oil. LC-MS: $[\text{M}+\text{H}]^+ = 324.1$.

A mixture of 1-((benzyloxy)carbonyl)-3-((methylthio)methyl)piperidine-3-carboxylic acid (297-2) (8.00 g, 24.7 mmol, 1.0 eq.), DPPA (7.50 g, 27.2 mmol, 1.1 eq.) and Et_3N (5.00 g, 48.5 mmol, 2.0 eq.) in toluene (100 mL) was stirred at 80 °C under N_2 for 1 hr. Then the reaction was concentrated in *vacuo*. The residue was dissolved in dioxane (50 mL) and 6N HCl (50 mL), and the mixture was stirred for 16 hr at 25-30 °C. The reaction was concentrated in *vacuo*. The pH of the aqueous layer was adjusted to 9 by 1N NaOH. Then the mixture was extracted with

EtOAc (200 mLx3). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated in *vacuo*. The residue was dissolved in DCM (100 mL), DIPEA (10.0 g, 74.2 mmol, 3.0 eq) and Boc₂O (11.0 g, 48.4 mmol) were added. The resulting mixture was stirred at 25-30 °C for 16 hr. The reaction was concentrated in *vacuo*. The residue was purified by Combi Flash (20% EtOAc in PE) to give benzyl 3-((tert-butoxycarbonyl)amino)-3-((methylthio)methyl)piperidine-1-carboxylate (297-5) as a white solid. LC-MS: [M+H-100]⁺=295.1.

To a solution of benzyl 3-((tert-butoxycarbonyl)amino)-3-((methylthio)methyl)piperidine-1-carboxylate (297-5) (2.37 g, 6.00 mmol, 1 eq.) in CH₃CN (50 mL) was added dropwise TMSI (3.60 g, 18 mmol, 3 eq.) at about 0 °C. After addition, the reaction mixture was stirred at the same temperature for 2 h. TLC showed most starting material was consumed. The reaction mixture was carefully quenched with MeOH (20 mL) and HCl/dioxane (5 mL, 4M). The reaction mixture was concentrated to dryness. Water (20 mL) was added and the mixture was extracted with MTBE (40 mL*4). The aqueous layer was lyophilized to give crude 3-((methylthio)methyl)piperidin-3-amine (Intermediate 297-6) as a yellow solid.

Intermediate 299-3: 2,2,2-Trifluoroacetaldehyde compound with 1-(3-aminopiperidin-3-yl)-2,2,2-trifluoroethan-1-ol (1:1)




To a mixture of tert-butyl 3-nitropiperidine-1-carboxylate (5.0 g, 21.71 mmol, 1.0 eq) and 2,2,2-trifluoroethane-1,1-diol (10.08 g, 86.86 mmol, 4.0 eq) in THF (50 mL) was added K₂CO₃ (1.8 g, 13.03 mmol, 0.6 eq) at 60 °C for 16 hours. TLC (PE: EA =2:1, R_f= 0.4) showed the reaction was complete. 1N HCl (10 mL) was added to the mixture, and extracted with EA(40 mL*3).The combined organic layer was washed with brine (30 mL), dried over Na₂SO₄, filtered and concentrated in *vacuo* to give tert-butyl 3-nitro-3-(2,2,2-trifluoro-1-hydroxyethyl)piperidine-1-carboxylate (299-1) was obtained as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 5.01 - 4.71 (m, 2H), 4.67 - 4.34 (m, 1H), 4.07 - 3.35 (m, 2H), 2.88 - 2.13 (m, 2H), 1.95 - 1.52 (m, 2H), 1.50 - 1.36 (m, 9H). LCMS: [M+H-56]⁺=273.3.

To a solution of tert-butyl 3-nitro-3-(2,2,2-trifluoro-1-hydroxyethyl)piperidine-1-carboxylate (299-1) (4.0 g, 12.89 mmol, 1.0 eq) and NH₄Cl (3.45 g, 64.45 mmol, 5.0 eq) in EtOH/H₂O (40 mL, v/v =4:1) was added Zn (8.43 g, 128.91 mmol, 10.0 eq) at 25°C under N₂. The mixture was stirred at 80°C for 16 h. TLC (PE: EA =1:1, R_f= 0.3). aq. NaHCO₃ (20 mL) was added to the mixture, and it was filtrated, the filter liquor was extracted with EA(40 mL*3).The combined organic layer was washed with brine (20 mL), dried over Na₂SO₄, filtered and concentrated in *vacuo*. The crude was purified by column chromatography (PE: EA=10:1) to give tert-butyl 3-amino-3-(2,2,2-trifluoro-1-hydroxyethyl)piperidine-1-carboxylate (299-2) was obtained as a

yellow oil. ^1H NMR (400 MHz, CDCl_3) δ ppm 4.05 - 3.93 (m, 1H), 3.69 - 3.50 (m, 2H), 3.22 - 2.74 (m, 2H), 1.90 - 1.70 (m, 2H), 1.68 - 1.60 (m, 2H), 1.47 (s, 9H).

To a solution of tert-butyl 3-amino-3-(2,2,2-trifluoro-1-hydroxyethyl)piperidine-1-carboxylate (299-2) (1.2 g, crude) in DCM (10 mL) was added TFA (2 mL) drop-wise under the protection of nitrogen and the mixture was stirred at 25 °C for 2 hours. TLC (DCM:MeOH = 10:1, R_f = 0.2) showed the reaction was complete. The mixture was concentrated to give 2,2,2-trifluoroacetaldehyde compound with 1-(3-aminopiperidin-3-yl)-2,2,2-trifluoroethan-1-ol (1:1) (Intermediate 299-3) as a red oil.

Intermediate 300-6: (5-(3-amino-3-(1,2,2-trifluoroethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methanol



To a solution of tert-butyl 3-nitropiperidine-1-carboxylate (3 g, 13.03 mmol) in THF (30 mL), was added K_2CO_3 (0.540 g, 3.91 mmol) and 1-ethoxy-2,2-difluoroethanol (4.93 g, 39.1 mmol), the reaction mixture was stirred at 55 °C for 18 h under N_2 atmosphere. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with water, extracted with EtOAc (20 mL*3), the combined organic phase was washed with water (20 mL), brine (20 mL), dried over anhydrous sodium sulfate, concentrated in vacuum to give a residue. The residue was purified by flash chromatography (elution gradient: 0% to 40% EtOAc in PE in 30 mins) to afford tert-butyl 3-(2,2-difluoro-1-hydroxyethyl)-3-nitropiperidine-1-carboxylate (300-1). LC-MS: $[\text{M}+\text{H}]^+ = 311.1$

A solution of tert-butyl 3-(2,2-difluoro-1-hydroxyethyl)-3-nitropiperidine-1-carboxylate (300-1) (2.0 g, 6.45 mmol) in BAST (20 mL) was stirred at 60 °C for 4 hours under N_2 atmosphere. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with water, extracted with EtOAc, the combined organic phase was washed with water, sat. NaHCO_3 solution, brine, dried over sodium sulfate, concentrated to give a crude product. The reaction mixture was diluted with water, extracted with EtOAc (20 mL*3), the combined organic phase was washed with water (20 mL), brine (20 mL), dried over anhydrous sodium sulfate, concentrated in vacuum to give a residue. The crude product was purified by flash chromatography (elution gradient: 0% to 30% EtOAc in PE in 30 mins) to afford tert-butyl 3-nitro-3-(1,2,2-trifluoroethyl)piperidine-1-carboxylate (300-2). LC-MS: $[\text{M}+\text{H}]^+ = 313.1$


To a solution of tert-butyl 3-nitro-3-(1,2,2-trifluoroethyl)piperidine-1-carboxylate (300-2) (1.36g, 4.35 mmol) in EtOH (30 mL) and water (15 mL), was added Fe (2.432 g, 43.5 mmol) and NH₄Cl (1.165 g, 21.77 mmol), the reaction mixture was stirred at 60 °C for 18 h under N₂ atmosphere. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was filtered and the filtrate was diluted with water, extracted with EtOAc (30ml*3), the combined organic phase was washed with water (20ml), brine (20ml), dried over anhydrous sodium sulfate, concentrated in vacuum to give a residue. The crude product was purified by flash chromatography (elution gradient: 0% to 50% EtOAc in PE in 30 mins) to afford tert-butyl 3-amino-3-(1,2,2-trifluoroethyl)piperidine-1-carboxylate (300-3). LC-MS: [M+H]⁺ = 283.2.

To a solution of tert-butyl 3-amino-3-(1,2,2-trifluoroethyl)piperidine-1-carboxylate (300-3) (700 mg, 2.480 mmol) in DCM (12 mL), was added TFA (4 mL), the reaction mixture was stirred at rt for 1h under N₂ atmosphere. LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was concentrated to give 860mg of 3-(1,2,2-trifluoroethyl)piperidin-3-amine (300-4) as crude product. LC-MS: [M+H]⁺ = 183.2.

To a solution of methyl 2-(3,4-difluorophenyl)-5-fluoroisonicotinate (Intermediate A) (0.847 g, 3.17 mmol) and 3-(1,2,2-trifluoroethyl)piperidin-3-amine (300-4) (1.3g, 3.17 mmol) in DMSO (30 mL) was added DIPEA (15 mL) at RT, the reaction mixture was stirred at 80 °C for 8 hr under N₂ atmosphere. LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with water, extracted with EtOAc (20ml*3), the combined organic phase was washed with water (20ml*3), brine (20ml), dried over anhydrous sodium sulfate, concentrated in vacuum to give a residue. The crude product was purified by flash chromatography (elution gradient: 0% to 30% EtOAc in PE in 30mins) to afford methyl 5-(3-amino-3-(1,2,2-trifluoroethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)isonicotinate (300-5). LC-MS: [M+H]⁺ = 430.1.


To a solution of methyl 5-(3-amino-3-(1,2,2-trifluoroethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)isonicotinate (300-5) (0.65 g, 1.514 mmol) in THF (20 mL) and Methanol (20 mL), was added lithium chloride (1.284 g, 30.3 mmol) and sodium tetrahydroborate (1.145 g, 30.3 mmol) at RT, the reaction mixture was stirred at rt for 3h under N₂ atmosphere. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with water, extracted with EtOAc (20ml*3), the combined organic phase was washed with water (20 mL), brine (20 mL), dried over anhydrous sodium sulfate, concentrated in vacuum to give a residue. The crude product was purified by flash chromatography (elution gradient: 10% to 40% EtOAc in PE in 30mins) to afford (5-(3-amino-3-(1,2,2-trifluoroethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methanol (Intermediate 300-6). LC-MS: [M+H]⁺ = 402.2.

Intermediate 300-7



To a solution of (5-(3-amino-3-(1,2,2-trifluoroethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methanol (Intermediate 300-6) (500 mg, 1.246 mmol), Intermediate B (501 mg, 1.495 mmol) and triphenylphosphine (980 mg, 3.74 mmol) in THF (90 mL), was added DEAD (0.592 mL, 3.74 mmol) dropwise at 0 °C, the reaction mixture was stirred at 0 °C for 0.5 hr under N₂ atmosphere. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with water, extracted with EtOAc (20 mL*3), the combined organic phase was washed with water (20 mL), brine (20 mL), dried over anhydrous sodium sulfate, concentrated in vacuum to give a residue. The crude product was purified by flash chromatography (elution gradient: 0% to 10% MeOH in DCM in 50 mins) to afford Intermediate 300-7. LC-MS: [M+H]⁺ = 719.2.

Intermediate 301-8: 3-amino-1-(4-(chloromethyl)-6-(3,4-difluorophenyl)pyridin-3-yl)-3-(2,2-difluoroethyl)piperidin-4-ol



301-8

To a solution of LDA (6.94 mL, 13.88 mmol) in THF (9 mL) was added a solution of 1-(tert-butyl) 3-methyl 4-hydroxypiperidine-1,3-dicarboxylate (1.5g, 5.78 mmol) in THF at -78 °C under N₂ atmosphere, after stirred for 10 min at this temperature, a solution of 1,1-difluoro-2-iodoethane (1.443 g, 7.52 mmol) in HMPA (5 mL, 28.7 mmol) was added -15 °C, the reaction mixture was stirred at RT for 30 mins under N₂ atmosphere. LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with water, extracted with EtOAc (20 mL*3), the combined organic phase was washed with water (20 mL), brine (20 mL), dried over anhydrous sodium sulfate, concentrated in vacuum to give a residue. The residue was purified by flash chromatography (elution gradient: 0% to 30% EtOAc in PE in 30 mins) to afford 1-(tert-butyl) 3-methyl 3-(2,2-difluoroethyl)-4-hydroxypiperidine-1,3-dicarboxylate (301-1). LC-MS: [M+H]⁺ = 324.1.

To a solution of 1-(tert-butyl) 3-methyl 3-(2,2-difluoroethyl)-4-hydroxypiperidine-1,3-dicarboxylate (301-1) (0.6g, 1.856 mmol) in methanol (5 mL) was added a solution of LiOH (700 mg, 29.2 mmol) in Water (5 mL) at RT under N₂ atmosphere, the reaction was stirred at RT

for 5 hr. LCMS monitored the reaction and indicated the reaction was complete. The pH of the reaction mixture was adjusted to 4 by addition of 3M HCl solution, extracted with EtOAc (20ml*3), the combined organic phase was washed with water (20ml), brine (20ml), dried over anhydrous sodium sulfate, concentrated in vacuum to give crude 1-(tert-butoxycarbonyl)-3-(2,2-difluoroethyl)-4-hydroxypiperidine-3-carboxylic acid (301-2). LC-MS: $[M+H]^+ = 310.1$.

To a solution of 1-(tert-butoxycarbonyl)-3-(2,2-difluoroethyl)-4-hydroxypiperidine-3-carboxylic acid (301-2) (0.4 g, 1.293 mmol) in Toluene (10 mL) was added DPPA (0.534 g, 1.940 mmol) and TEA (0.721 mL, 5.17 mmol) at RT under N₂ atmosphere, the reaction was stirred at 100 °C for 18 hr. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with water, extracted with EtOAc (20ml*3), the combined organic phase was washed with water (20ml), brine (20ml), dried over anhydrous sodium sulfate, concentrated in vacuum to give a residue. The residue was purified by flash chromatography (elution gradient: 0% to 50% EtOAc in PE in 30mins) to afford tert-butyl 3a-(2,2-difluoroethyl)-2-oxohexahydrooxazolo[4,5-c]pyridine-5(4H)-carboxylate (303-3). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.12 (s, 1H), 6.43 - 5.89 (m, 1H), 4.41 - 4.15 (m, 2H), 4.13 (dt, *J* = 12.9, 2.5 Hz, 1H), 3.03 - 2.75 (m, 2H), 2.03 - 1.74 (m, 4H), 1.39 (s, 9H). LC-MS: $[M+H]^+ = 307.1$.

To a solution of tert-butyl 3a-(2,2-difluoroethyl)-2-oxohexahydrooxazolo[4,5-c]pyridine-5(4H)-carboxylate (301-3) (400 mg, 1.306 mmol) in DCM (9 mL) was added TFA (3 mL, 38.9 mmol) at RT under N₂ atmosphere, the reaction was stirred at RT for 1 hr. LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was concentrated in vacuum to give crude 3a-(2,2-difluoroethyl)hexahydrooxazolo[4,5-c]pyridin-2(3H)-one (301-4). LC-MS: $[M+H]^+ = 207.1$.

To a solution of methyl 2-(3,4-difluorophenyl)-5-fluoroisonicotinate (Intermediate A) (259 mg, 0.970 mmol) and 3a-(2,2-difluoroethyl)hexahydrooxazolo[4,5-c]pyridin-2(3H)-one (301-4) in DMSO (10 mL) was added DIPEA (10 mL, 57.3 mmol) at RT under N₂ atmosphere, the reaction was stirred at 120 °C for 18 hr. LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with water, extracted with EtOAc (20ml*3), the combined organic phase was washed with water (20ml*3), brine (20ml), dried over anhydrous sodium sulfate, concentrated in vacuum to give a residue. The residue was purified by flash chromatography (elution gradient: 0% to 10% MeOH in DCM in 30mins) to afford methyl 5-(3a-(2,2-difluoroethyl)-2-oxohexahydrooxazolo[4,5-c]pyridin-5(4H)-yl)-2-(3,4-difluorophenyl)isonicotinate (301-5). LC-MS: $[M+H]^+ = 454.1$.


To a solution of methyl 5-(3a-(2,2-difluoroethyl)-2-oxohexahydrooxazolo[4,5-c]pyridin-5(4H)-yl)-2-(3,4-difluorophenyl)isonicotinate (301-5) (40 mg, 0.088 mmol) in THF (5ml) and Methanol (5ml) was added LiCl (74.8 mg, 1.764 mmol) and NaBH₄ (33.4 mg, 0.882 mmol) at RT under N₂ atmosphere, the reaction was stirred at RT for 5 hr. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with water, extracted with EtOAc (20ml*3), the combined organic phase was washed with water (20ml), brine (20ml), dried over

anhydrous sodium sulfate, concentrated in vacuum to give a residue. The residue was purified by flash chromatography (elution gradient: 0% to 10% MeOH in DCM in 30mins) to afford 3a-(2,2-difluoroethyl)-5-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)hexahydrooxazolo[4,5-c]pyridin-2(3H)-one (301-6). LC-MS: $[M+H]^+ = 426.2$.

5 To a solution of 3a-(2,2-difluoroethyl)-5-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)hexahydrooxazolo[4,5-c]pyridin-2(3H)-one (301-6) (100 mg, 0.235 mmol) in MeOH (10 mL) and Water (10 mL) was added KOH (132 mg, 2.351 mmol) at RT under N_2 atmosphere, the reaction was stirred at 100 °C for 18 hr. LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with water, extracted with EtOAc (20ml*3), the combined organic phase was washed with water (20ml), brine (20ml), dried over anhydrous sodium sulfate, concentrated in vacuum to give a residue. The residue was purified by flash chromatography (elution gradient 0% to 10% MeOH in DCM in 30mins) to afford 3-amino-3-(2,2-difluoroethyl)-1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-4-ol (301-7). LC-MS: $[M+H]^+ = 400.1$.

15 To a solution of 3-amino-3-(2,2-difluoroethyl)-1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-4-ol (301-7) (130 mg, 0.325 mmol) in DCM (10 mL) was added thionyl chloride (0.119 mL, 1.627 mmol) at 0 °C under N_2 atmosphere, the reaction was stirred at RT for 5 hr. LCMS monitored the reaction and indicated the reaction was complete. The reaction was quenched with 5ml of sat. K_2CO_3 aqueous solution at 0 °C. The reaction mixture was extracted with DCM (20ml*3), the combined organic phase was washed with water (20 mL), brine (20 mL), dried over anhydrous sodium sulfate, concentrated in vacuum to give crude 3-amino-1-(4-(chloromethyl)-6-(3,4-difluorophenyl)pyridin-3-yl)-3-(2,2-difluoroethyl)piperidin-4-ol (Intermediate 301-8). LC-MS: $[M+H]^+ = 418.1$.

25 **Intermediate 302-9: 3-amino-3-(6-chloropyridin-2-yl)-1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-4-ol**



To a solution of m-CPBA (23.17 g, 94 mmol) and 2-chloro-6-iodopyridine (15g, 62.6 mmol) in DCM (450 mL) was added TfOH (22.25 mL, 251 mmol) dropwise at 0 °C. And then the reaction mixture was stirred at RT for 2 hr, mesitylene (9.54 mL, 68.9 mmol) was added dropwise at 0 °C, the reaction mixture was stirred at RT for 18 hr under N_2 atmosphere. LC-MS monitored the reaction. The solvent was removed in vacuo to give a crude product. The

crude product was recrystallized in Et₂O at -20 °C to afford (6-chloropyridin-2-yl)(mesityl)iodonium trifluoromethanesulfonate (302-1). LC-MS: [M+H]⁺ =358.

To a solution of 1-tert-butyl 3-methyl 4-oxopiperidine-1,3-dicarboxylate (1.3 g, 5.05 mmol) in DMF (30 mL) was added potassium tert-butoxide (0.680 g, 6.06 mmol) at RT, after the reaction mixture was stirred at RT for 10mins, (6-chloropyridin-2-yl)(mesityl)iodonium trifluoromethanesulfonate (intermediate 302-1) (3.52 g, 5.56 mmol) was added at rt, the reaction mixture was stirred at rt for 18 hr under N₂ atmosphere. LC-MS monitored the reaction. The reaction mixture was diluted with water, extracted with EtOAc, the combined organic phase was washed with water, brine, dried over sodium sulfate, concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 0% to 30% EtOAc in Hexane in 30mins) to afford 1-(tert-butyl) 3-methyl 3-(6-chloropyridin-2-yl)-4-oxopiperidine-1,3-dicarboxylate (302-2). LC-MS: [M+H]⁺ =369.0

To a solution of 1-(tert-butyl) 3-methyl 3-(6-chloropyridin-2-yl)-4-oxopiperidine-1,3-dicarboxylate (intermediate 302-2) (1.0g, 2.71 mmol) in MeOH (30 mL) was added sodium tetrahydroborate (0.205 g, 5.42 mmol) at 0 °C, the reaction mixture was stirred at 0 °C for 30mins, LC-MS monitored the reaction. The reaction mixture was diluted with water, extracted with EtOAc, the combined organic phase was washed with water, brine, dried over sodium sulfate, concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 0% to 30% EtOAc in Hexane in 30mins) to afford 1-(tert-butyl) 3-methyl 3-(6-chloropyridin-2-yl)-4-hydroxypiperidine-1,3-dicarboxylate (302-3). LC-MS: [M+H]⁺ =371.0

To a solution of 1-(tert-butyl) 3-methyl 3-(6-chloropyridin-2-yl)-4-hydroxypiperidine-1,3-dicarboxylate (302-3) (0.9g, 2.427 mmol) in methanol (5 mL) and water (5 mL) was added LiOH (0.581 g, 24.27 mmol) at RT, the reaction mixture was stirred at RT for 5 hr under N₂ atmosphere. LC-MS monitored the reaction. The pH of reaction mixture was adjusted to 4 by addition of 5M HCl aqueous solution, extracted with EtOAc, the combined organic phase was washed with water, brine, dried over sodium sulfate, concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 0% to 10% MeOH in DCM in 30mins) to afford 1-(tert-butoxycarbonyl)-3-(6-chloropyridin-2-yl)-4-hydroxypiperidine-3-carboxylic acid (302-4). LC-MS: [M+H]⁺ =357.1.

To a solution of 1-(tert-butoxycarbonyl)-3-(6-chloropyridin-2-yl)-4-hydroxypiperidine-3-carboxylic acid (302-4) (0.8g, 2.242 mmol) in toluene (20 mL) and was added DPPA (0.926 g, 3.36 mmol) and TEA (1.250 mL, 8.97 mmol) at RT, after the reaction mixture was stirred at 100 °C for 3h under N₂ atmosphere, methanol (0.091 mL, 2.242 mmol) was added, the reaction mixture was stirred at 100 °C for 18 hr under N₂ atmosphere. LC-MS monitored the reaction. The reaction mixture was diluted with water, extracted with EtOAc, the combined organic phase was washed with water, brine, dried over sodium sulfate, concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 0% to 10% MeOH in

DCM in 30mins) to afford tert-butyl 3a-(6-chloropyridin-2-yl)-2-oxohexahydrooxazolo[4,5-c]pyridine-5(4H)-carboxylate (302-5). LC-MS: $[M+H]^+ = 354.1$.


To a solution of tert-butyl 3a-(6-chloropyridin-2-yl)-2-oxohexahydrooxazolo[4,5-c]pyridine-5(4H)-carboxylate (302-5) (400 mg, 0.113 mmol) in DCM (9 mL) and was added TFA (3 ml) at rt, the reaction mixture was stirred at rt for 3h. LC-MS monitored the reaction. The reaction mixture was concentrated to give crude 3a-(6-chloropyridin-2-yl)hexahydrooxazolo[4,5-c]pyridin-2(3H)-one (302-6). LC-MS: $[M+H]^+ = 254.1$

To a solution of methyl 2-(3,4-difluorophenyl)-5-fluoroisonicotinate (Intermediate A) (87 mg, 0.326 mmol) and 3a-(6-chloropyridin-2-yl)hexahydrooxazolo[4,5-c]pyridin-2(3H)-one (302-6) (120mg, 0.326 mmol) in DMSO (5 mL), was added DIPEA (5 mL), the reaction mixture was stirred at 100 °C for 5 hr under N₂ atmosphere. LC-MS monitored the reaction. The reaction mixture was diluted with water, extracted with EtOAc, the combined organic phase was washed with water, brine, dried over sodium sulfate, concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 0% to 10% MeOH in DCM in 30mins) to afford methyl 5-(3a-(6-chloropyridin-2-yl)-2-oxohexahydrooxazolo[4,5-c]pyridin-5(4H)-yl)-2-(3,4-difluorophenyl)isonicotinate (302-7). LC-MS: $[M+H]^+ = 501.1$

To a solution of methyl 5-(3a-(6-chloropyridin-2-yl)-2-oxohexahydrooxazolo[4,5-c]pyridin-5(4H)-yl)-2-(3,4-difluorophenyl)isonicotinate (302-7) (70 mg, 0.140 mmol) in methanol (5 mL) and THF (5 mL), was added lithium chloride (59.2 mg, 1.398 mmol) and sodium tetrahydroborate (52.9 mg, 1.398 mmol), the reaction mixture was stirred at rt for 5 hr under N₂ atmosphere. LC-MS monitored the reaction. The reaction mixture was diluted with water, extracted with EtOAc, the combined organic phase was washed with water, brine, dried over sodium sulfate, concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 0% to 10% MeOH in DCM in 30mins) to afford 3a-(6-chloropyridin-2-yl)-5-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)hexahydrooxazolo[4,5-c]pyridin-2(3H)-one (302-8). LC-MS: $[M+H]^+ = 473.1$.

To a solution of 3a-(6-chloropyridin-2-yl)-5-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)hexahydrooxazolo[4,5-c]pyridin-2(3H)-one (302-8) (50 mg, 0.106 mmol) in methanol (5 mL) and was added a solution of KOH (59.3 mg, 1.057 mmol) in Water (5ml) at rt, the reaction mixture was stirred at 100 °C for 8 hr under N₂ atmosphere. LC-MS monitored the reaction. The reaction mixture was diluted with water, extracted with EtOAc, the combined organic phase was washed with water, brine, dried over sodium sulfate, concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 0% to 10% MeOH in DCM in 30mins) to afford 3-amino-3-(6-chloropyridin-2-yl)-1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-4-ol (Intermediate 302-9). LC-MS: $[M+H]^+ = 447.1$

Intermediate 303-3: 3-(2,2,2-trifluoroethyl)piperidin-3-amine




Togni reagent (6.42 g, 19.46 mmol) and tetrakis(acetonitrile)copper(I) hexafluorophosphate (483 mg, 1.297 mmol) were dissolved in DMA (50 ml) under N₂. Then reagent 1 (3 g, 12.97 mmol) and TMSN₃ (2.99 g, 25.9 mmol) was added. The mixture was stirred at rt overnight. LC-MS indicated the reaction was complete. The mixture was treated with EA (50 ml) and H₂O (50 ml). The layers were separated and the aqueous layer was extracted with EA (30 ml *3). The combined organic layers were washed with brine (20 ml), dried over Na₂SO₄ and filtered. The filtrate was concentrated and the residue was purified via biotage, eluting with EA in n-hexane (0 to 20%) to give benzyl 3-azido-3-(2,2,2-trifluoroethyl)piperidine-1-carboxylate (303-1) as a light yellow oil. ¹H NMR (400 MHz, CDCl₃) δ: 7.31 - 7.51 (m, 1 H), 5.03 - 5.34 (m, 1 H), 3.86 (d, J=12.80 Hz, 1 H), 3.20 (d, J=13.55 Hz, 1 H), 2.39 (br. s., 1 H), 1.92 - 2.01 (m, 1 H), 1.81 (d, J=9.54 Hz, 2 H), 1.54 - 1.72 (m, 1 H).

To a solution of benzyl 3-azido-3-(2,2,2-trifluoroethyl)piperidine-1-carboxylate (303-1) (1.3 g, 0.146 mmol) in MeOH (20 ml) was added indium powder (1.308 g, 11.39 mmol) and NH₄Cl (0.609 g, 11.38 mmol). The mixture was heated to reflux under a sealed tube for 2 hrs. LC-MS indicated the reaction was completed. The mixture was cooled to rt and filtered. The filtrate was concentrated. The residue was purified via prep. HPLC to give benzyl 3-amino-3-(2,2,2-trifluoroethyl)piperidine-1-carboxylate TFA salt (303-2) as a white solid. LC-MS: [M+H]⁺ = 316.9.

To a solution of benzyl 3-amino-3-(2,2,2-trifluoroethyl)piperidine-1-carboxylate (303-2) (500 mg, 1.58 mmol) in MeOH (40 ml) was added Pd(OH)₂ (222 mg, 1.581 mmol) under N₂. The mixture was then stirred under H₂ balloon for 3 hr. LC-MS indicated the SM was consumed. The mixture was filtered and the filtrate was concentrated to 3-(2,2,2-trifluoroethyl)piperidin-3-amine (Intermediate 303-3) as a colorless oil. ¹H NMR (CDCl₃) δ: 3.57 - 3.35 (m, 4H), 3.02 - 2.84 (m, 2H), 2.43 (q, J = 11.1 Hz, 2H), 2.25 (dddd, J = 17.3, 13.2, 8.6, 4.2 Hz, 1H), 1.96 (d, J = 13.1 Hz, 1H), 1.84 - 1.59 (m, 2H) LC-MS: [M+H]⁺ = 183.0.

Intermediate 304-7: Methyl (1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)-3-ethynylpiperidin-3-yl)carbamate



To a solution of 1-benzyl 3-ethyl 3-formylpiperidine-1,3-dicarboxylate (6.5 g, 20.4 mmol, 1.0 eq.) and dimethyl (1-diazo-2-oxopropyl)phosphonate (7.8 g, 40.8 mmol, 2.0 eq.) in dry methanol (120 mL) was added K_2CO_3 (8.5 g, 61.2 mmol, 3.0 eq.). The mixture was stirred at 1~7°C for 18h. TLC (PE/EA = 1/1) showed the reaction was completed. The mixture was filtered. The filtrate was concentrated. The residue was purified by flash chromatography (PE/EA = 70/30) to give 1-benzyl 3-methyl 3-ethynylpiperidine-1,3-dicarboxylate (304-1) as a colorless oil. 1H NMR ($CDCl_3$ 400MHz): δ 7.48-7.28 (m, 5H), 5.14 (s, 2H), 4.25-4.09 (m, 1H), 4.00-3.84 (m, 1H), 3.73 (s, 3H), 3.48 (d, J = 12.8 Hz, 1H), 3.14-2.97 (m, 1H), 2.20 (s, 1H), 2.06-1.80 (m, 3H), 1.64-1.60 (m, 1H).

To a solution of 1-benzyl 3-methyl 3-ethynylpiperidine-1,3-dicarboxylate (intermediate 304-1) (3.1 g, 10.3 mmol, 1.0 eq.) in THF (50 mL) and water (15 mL) was added $LiOH \cdot H_2O$ (1.7 g, 41.1 mmol, 4.0 eq.). The mixture was stirred at 50°C for 2h. TLC (PE/EA = 1/1) showed the SM was all consumed. The mixture was diluted with water (100 mL), extracted with EA (80 mL). The aqueous layer was acidified to pH = 2 with 1N HCl (aq.). The suspension was extracted with DCM (80 mL*2), dried over Na_2SO_4 , concentrated to give crude 1-((benzyloxy)carbonyl)-3-ethynylpiperidine-3-carboxylic acid (304-2) as a colorless oil. 1H NMR ($CDCl_3$ 400MHz): δ 10.03 (brs, 1H), 7.40-7.31 (m, 5H), 5.17 (s, 2H), 4.29-4.16 (m, 1H), 4.02-3.88 (m, 1H), 3.49 (d, J = 12 Hz, 1H), 3.15-2.98 (m, 1H), 2.24 (s, 1H), 2.12-2.06 (m, 1H), 2.04-1.92 (m, 2H), 1.67-1.64 (m, 1H).

To a solution of 1-((benzyloxy)carbonyl)-3-ethynylpiperidine-3-carboxylic acid (304-2) (2.7 g, 9.4 mmol, 1.0 eq.) in DCM (125 mL) was added NH_4Cl (1 g, 18.8 mmol, 2.0 eq.), HATU (7.1 g, 18.8 mmol, 2.0 eq.) and DIEA (4.9 g, 37.6 mmol, 4 eq.). The resulting mixture was stirred at 25°C for 16h. The mixture was washed with water (100 mL) and brine (150 mL), dried over Na_2SO_4 , concentrated. The residue was purified by flash chromatography (PE/EA = 50/50) to give benzyl 3-carbamoyl-3-ethynylpiperidine-1-carboxylate (304-3) as a colorless oil. 1H NMR (400MHz, $CDCl_3$): δ 7.35-7.21 (m, 5H), 6.68-6.59 (d, J = 36.8 Hz, 1H), 5.87 (s, 1H), 5.11-5.01 (m, 2H), 4.25-4.02 (m, 2H), 3.20-3.14 (m, 1H), 2.89-2.64 (m, 1H), 2.26 (d, J = 20.8 Hz, 1H), 2.12-1.71 (m, 3H), 1.57 (d, J = 10 Hz, 1H).


To a solution of benzyl 3-carbamoyl-3-ethynylpiperidine-1-carboxylate (304-3) (2.5 g, 8.7 mmol, 1.0 eq.) in methanol (100 mL) was added KOH (1.2 g, 21.8 mmol, 2.5 eq.). Then $PhI(OAc)_2$ (2.8 g, 8.7 mmol, 1.0 eq.) was added. The resulting mixture was stirred at 3~10°C for 30min. The color turned from colorless to yellow. TLC (PE/EA = 1/1) showed the reaction was completed. The reaction was concentrated, diluted with water (150 mL), extracted with EA (100 mL*2), dried over Na_2SO_4 and concentrated. The residue was purified by flash chromatography (PE/EA = 70/30) to give benzyl 3-ethynyl-3-((methoxycarbonyl)amino) piperidine-1-carboxylate (304-4) as a white solid. 1H NMR (400MHz, CD_3OD): δ 7.48-7.30 (m, 5H), 5.20-4.86 (m, 3H), 4.13-3.83 (m, 2H), 3.65 (s, 3H), 3.51-3.22 (m, 2H), 2.69-2.30 (m, 2H), 1.95-1.64 (m, 3H).

A mixture of benzyl 3-ethynyl-3-((methoxycarbonyl)amino)piperidine-1-carboxylate (304-4) (800 mg, 2.53 mmol, 1.0 eq.) and TFA (10 mL) in DCM (10 mL) was stirred at 75°C for 12h. LCMS showed the reaction was almost completed. The mixture was concentrated and diluted with DCM (20 mL), poured into saturated NaHCO₃ solution (50 mL), extracted with CHCl₃/i-PrOH = 3/1 (50 mL*4), dried over Na₂SO₄, concentrated to give crude methyl (3-ethynylpiperidin-3-yl)carbamate (304-5). LCMS: [M+H]⁺=182.9.

To a mixture of methyl (3-ethynylpiperidin-3-yl)carbamate (304-5) (600 mg, 2.53 mmol, 1.0 eq.) and methyl 2-(3,4-difluorophenyl)-5-fluoroisonicotinate (Intermediate A) (670 mg, 2.53 mmol, 1.0 eq.) in DMSO (10 mL) was added DIEA (2.3 g, 7.0 eq.). Then the mixture was stirred at 120°C for 2.5h. LCMS showed there was desired MS value. The mixture was cooled and diluted with water (100 mL), extracted with EA (50 mL*2), washed with brine (100 mL), dried over Na₂SO₄, concentrated. The residue was purified by flash chromatography (PE/EA = 10/1 to 70/30) to give methyl 2-(3,4-difluorophenyl)-5-(3-ethynyl-3-((methoxycarbonyl)amino)piperidin-1-yl)isonicotinate (304-6) as yellow gum. LCMS: [M+H]⁺=430.2.

To a solution of methyl 2-(3,4-difluorophenyl)-5-(3-ethynyl-3-((methoxycarbonyl)amino)piperidin-1-yl)isonicotinate (intermediate 304-6) (280 mg, 0.652 mmol, 1.0 eq.) in dry THF (12 mL) was added L-selectride (3.9 mL) dropwise at 0°C under N₂. The solution was stirred at 0°C for 30min. LCMS showed the reaction was completed. The mixture was quenched with saturated NH₄Cl solution (30 mL) and diluted with water (100 mL), extracted with EA (50 mL*2), dried over Na₂SO₄, concentrated. The residue was purified by flash chromatography (PE/EA = 1/1) to give methyl (1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)-3-ethynylpiperidin-3-yl)carbamate (Intermediate 304-7) as a colorless oil. LCMS: 402.1 [M+H]⁺=402.1.

Intermediate 305-5: 3-(difluoromethyl)piperidin-3-amine



305-5

To a solution of 1-benzyl 3-ethyl 3-formylpiperidine-1,3-dicarboxylate (7.0 g, 21.9 mmol, 1.0 eq.) in DCM (100 mL) at 0 °C under N₂ atmosphere was added DAST (14.1 g, 87.8 mmol, 4.0 eq.) dropwise. The reaction was allowed to warm to 10 °C and stirred for 16 h. TLC showed the reaction was complete. The reaction was cooled to 0 °C and quenched with aq.NaHCO₃ (100 mL) carefully. The mixture was extracted with DCM (50 mLx3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column (PE/EA=10/1) to afford 4.0 g crude product, which was further purified by *prep*-HPLC (0.1% TFA as additive) to give 1-benzyl 3-ethyl 3-(difluoromethyl)piperidine-1,3-dicarboxylate (305-1) as light yellow oil. ¹H NMR (400MHz, CDCl₃): δ 7.45-7.28 (m, 5H), 5.89 (t,

$J = 15.2$ Hz, 1H), 5.16 (s, 2H), 4.55-4.37 (m, 1H), 4.27-4.05 (m, 2H), 4.04-3.87 (m, 1H), 3.28-3.10 (m, 1H), 3.05-2.90 (m, 1H), 2.25-2.10 (m, 1H), 1.80-1.60 (m, 3H), 1.30-1.12 (m, 3H).


To a mixture of 1-benzyl 3-ethyl 3-(difluoromethyl)piperidine-1,3-dicarboxylate (305-1) (2.6 g, 7.62 mmol, 1 eq.) in THF (10 mL), MeOH (10 mL) and H₂O (10 mL) was added LiOH.H₂O (3.2 g, 76.2 mmol, 10 eq.). The reaction was stirred at 40 °C for 16 h. LC-MS showed the reaction was complete. The reaction mixture was cooled and acidified to pH = 3 with 6M HCl, then extracted with DCM (30 mLx3). The combined organic layers were washed with brine (50 mL), dried over Na₂SO₄, filtered and concentrated to give 1-((benzyloxy)carbonyl)-3-(difluoromethyl)piperidine-3-carboxylic acid (305-2) as a white solid. ¹H NMR(400MHz, CDCl₃): δ 7.45-7.25 (m, 5H), 5.93 (t, $J = 15.6$ Hz, 1H), 5.17 (s, 2H), 4.55-4.42 (m, 1H), 4.05-3.95 (m, 1H), 3.25-3.15 (m, 1H), 3.05-2.95 (m, 1H), 2.28-2.15 (m, 1H), 1.85-1.68 (m, 3H). LCMS: [M+H]⁺=314.

To a mixture of 1-((benzyloxy)carbonyl)-3-(difluoromethyl)piperidine-3-carboxylic acid (305-2) (3.4 g, 10.9 mmol, 1.0 eq.) and Et₃N (2.2 g, 21.72 mmol, 2.0 eq.) in toluene (50 mL) under N₂ atmosphere was added DPPA (3.3 g, 11.9 mmol, 1.1 eq.). The reaction was heated and stirred at 60 °C for 3 h. TLC showed the reaction was complete. The reaction mixture was cooled and diluted with EtOAc (100 mL), then washed with H₂O (50 mLx2). The organic layer was dried over Na₂SO₄, filtered and concentrated to give the crude benzyl 3-(difluoromethyl)-3-isocyanatopiperidine-1-carboxylate (305-3) as a yellow oil.

To a solution of benzyl 3-(difluoromethyl)-3-isocyanatopiperidine-1-carboxylate (305-3) (3.4 g, 10.9 mmol, 1.0 eq.) in dioxane (10 mL) was added 6M HCl (10 mL). The reaction was stirred at 40°C for 16 h. TLC showed the reaction was complete. The reaction mixture was concentrated to remove dioxane, then diluted with H₂O (20 mL) and extracted with EtOAc(20 mL). The aqueous phase was basified to pH = 10 with aq.NaOH. The mixture was extracted with DCM (50 mLx3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated to give benzyl 3-amino-3-(difluoromethyl)piperidine-1-carboxylate (305-4) as a yellow oil. ¹H NMR (400MHz, CDCl₃): δ 7.45-7.28 (m, 5H), 5.56 (t, $J = 16.0$ Hz, 1H), 5.15 (s, 2H), 3.88-3.80 (m, 1H), 3.65-3.50 (m, 1H), 3.35-3.00 (m, 2H), 1.87-1.65 (m, 4H), 1.30-1.15 (m, 2H). LCMS: [M+H]⁺=285.

A mixture of benzyl 3-amino-3-(difluoromethyl)piperidine-1-carboxylate (intermediate 305-4) (1.8 g, 6.33 mmol, 1 eq.) and Pd/C (10%, 1.5 g) in EtOH (36 mL) was hydrogenated under H₂ balloon for 3 h. The reaction mixture was filtered and the filtrate was concentrated to dryness to give 3-(difluoromethyl)piperidin-3-amine (Intermediate 305-5) as a yellow oil. ¹H NMR (400MHz, CD₃OD): δ 5.68 (t, $J = 16.4$ Hz, 1H), 5.15 (s, 2H), 2.88-2.75 (m, 1H), 2.80-2.65 (m, 1H), 2.63-2.52 (m, 2H), 1.80-1.65 (m, 2H), 1.62-1.51 (m, 2H).

Intermediate 306-9: tert-butyl (tert-butoxycarbonyl)(9-((5-((3R,5R)-3-((tert-butoxycarbonyl)amino)-5-(fluoromethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate



A mixture of ethyl 5-bromonicotinate (20.0 g, 86.9 mmol, 1 eq.), NH_2Boc (12.2 g, 104 mmol, 1.2 eq.), Xant-Phos (1.60 g, 2.77 mmol, 0.03 eq.), $\text{Pd}_2(\text{dba})_3$ (1.60 g, 1.75 mmol, 0.02 eq.) and Cs_2CO_3 (40.0 g, 123 mmol, 1.4 eq.) and dioxane (300 mL) was stirred at 110 °C under N_2 atmosphere for 16 h. TLC showed that most starting material was consumed. Then the reaction mixture was concentrated to dryness. Water (800 mL) was added and the reaction mixture was extracted with EtOAc (300 mL*2). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in *vacuo*. The residue was purified by combi flash (EtOAc/PE=0-40%) to give ethyl 5-((tert-butoxycarbonyl)amino)nicotinate (306-1) as a yellow solid. ^1H NMR (400MHz, CDCl_3): δ 8.89 (d, J = 2.0 Hz, 1H), 8.72 (d, J = 2.8 Hz, 1H), 8.47 (s, 1H), 6.99 (brs, 1H), 4.41 (q, J = 7.6 Hz, 2H), 1.54 (s, 9H), 1.40 (t, J = 7.2 Hz, 3H).

To a solution of LAH (3.05 g, 80.3 mmol, 1.6 eq.) in THF (200 mL) was added dropwise a solution of ethyl 5-((tert-butoxycarbonyl)amino)nicotinate (306-1) (13.5 g, 50.7 mmol, 1 eq.) in THF (200 mL) at 0 °C. After addition, the reaction mixture was stirred at about 0 °C for 2 h. TLC showed that most starting material was consumed. The reaction mixture was carefully quenched with water (3 mL), 10% NaOH (3 mL) and water (10 mL). The reaction mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by combi flash (EtOAc/PE=0-100%) to give tert-butyl (5-(hydroxymethyl)pyridin-3-yl)carbamate (306-2) as a colorless oil. ^1H NMR (400MHz, CDCl_3): δ 8.33 (d, J = 2.4 Hz, 1H), 8.22 (d, J = 1.6 Hz, 1H), 8.01 (s, 1H), 7.23 (brs, 1H), 4.69 (s, 2H), 1.53 (s, 9H).

A mixture of tert-butyl (5-(hydroxymethyl)pyridin-3-yl)carbamate (intermediate 306-2) (10.0 g, 44.6 mmol, 1 eq.) and PtO_2 (3.0 g) in AcOH (3 mL) and EtOH (300 mL) was hydrogenated under H_2 atmosphere (50 psi) at 50 °C for 7 days. TLC (EtOAc) showed most starting material was consumed. The reaction mixture was filtered and the filtrate was concentrated to dryness to give tert-butyl (5-(hydroxymethyl)piperidin-3-yl)carbamate (306-3) as a yellow oil. LC-MS: $[\text{M}+\text{H}]^+ = 230.1$

To a suspension of tert-butyl (5-(hydroxymethyl)piperidin-3-yl)carbamate (306-3) (10.0 g, impure, 1 eq.) and NaHCO_3 (10.9 g, 130 mmol, 3 eq.) in THF (100 mL) and H_2O (100 mL) was added dropwise CbzCl (8.20 g, 47.4 mmol, 1.1 eq.) at about 0 °C. After addition, the reaction mixture was stirred at about 20 °C for 16 h. LC-MS showed that most starting material was

consumed. The reaction mixture was poured into water (400 mL) and extracted with EtOAc (200 mL*3). The combined organic layers were dried over Na₂SO₄, and concentrated to dryness. The residue was purified by combi flash (EtOAc/PE=0-70%) to give benzyl 3-((tert-butoxycarbonyl)amino)-5-(hydroxymethyl)piperidine-1-carboxylate (306-4) as a yellow oil. ¹H NMR (400MHz, CDCl₃): δ 7.40-7.25 (m, 5H), 5.25-5.05 (m, 2H), 4.80-4.10 (m, 3H), 3.65-3.40 (m, 4H), 2.60-2.45 (m, 1H), 2.15-2.00 (m, 1H), 1.98-1.65 (m, 2H), 1.43 (s, 9H), 1.15-1.00 (m, 1H). LC-MS: [M+Na]⁺ = 387.1.

To a mixture of benzyl 3-((tert-butoxycarbonyl)amino)-5-(hydroxymethyl)piperidine-1-carboxylate (306-4) (3.50 g, 9.60 mmol, 1.0 eq.) in THF (60 mL) was added Et₃N (13.6 g, 134 mmol, 14.0 eq.), FSO₂(CF₂)₃CF₃ (5.80 g, 19.2 mmol, 2.0 eq.) and TEA.3HF (6.19 g, 38.4 mmol, 4.0 eq.). The reaction mixture was stirred at 25°C for 12 hours. TLC showed the starting material was consumed completely. The reaction mixture was concentrated in *vacuo*. The residue was purified by silica gel column chromatography (Eluents: PE/EA 10/1 to 3/1) to give benzyl 3-((tert-butoxycarbonyl)amino)-5-(fluoromethyl)piperidine-1-carboxylate (306-5) as a yellow oil. LC-MS: [M+Na]⁺ = 389.1.

To a solution of benzyl 3-((tert-butoxycarbonyl)amino)-5-(fluoromethyl)piperidine-1-carboxylate (306-5) (2.50 g, 6.83 mmol, 1.0 eq.) in MeOH (30 mL) was added Pd(OH)₂/C (250 mg, 10%wt). The reaction mixture was stirred at 25°C for 1 hour. TLC showed that the starting material was consumed completely. The mixture was filtered and the filtrate was concentrated in *vacuo* to give tert-butyl (5-(fluoromethyl)piperidin-3-yl)carbamate (305-6) as a white solid. LC-MS: [M+H]⁺ = 233.1.


To a solution of tert-butyl (5-(fluoromethyl)piperidin-3-yl)carbamate (305-6) (1.50 g, 6.51 mmol, 1.0 eq.) in DMSO (15 mL) was added DIEA (5.89 g, 45.6 mmol, 7.0 eq.) and methyl 5-fluoro-2-(3-fluoro-4-methoxyphenyl)isonicotinate (Intermediate D) (1.82 g, 6.51 mmol, 1.0 eq.). The reaction mixture was stirred at 120°C under N₂ for 3 hours. LC-MS showed that the starting material was consumed completely. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (20 mL*3). The combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in *vacuo*. The residue was purified by silica gel column chromatography (PE/EA 10/1 to 2/1) and further purified by prep-HPLC (0.05% NH₃.H₂O as additive) to afford methyl 5-((3R,5R)-3-((tert-butoxycarbonyl)amino)-5-(fluoromethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)isonicotinate (306-7) as a yellow solid. ¹H NMR (400MHz, CD₃OD): δ 8.45 (s, 1H), 7.93 (s, 1H), 7.76-7.67 (m, 2H), 7.19 (t, J = 8.4 Hz, 1H), 4.51 (d, J = 6.0 Hz, 1H), 4.39 (d, J = 6.0 Hz, 1H), 4.02 (s, 3H), 3.94 (s, 3H), 3.92-3.86 (m, 1H), 3.35-3.24 (m, 1H), 3.20-3.08 (m, 2H), 3.01-2.92 (m, 1H), 2.46-2.31 (m, 1H), 1.84-1.76 (m, 1H), 1.64-1.54 (m, 1H), 1.42-1.41 (m, 10H). LC-MS: [M+H]⁺ = 492.2

To a mixture of methyl 5-((3R,5R)-3-((tert-butoxycarbonyl)amino)-5-(fluoromethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)isonicotinate (306-7) (120 mg, 0.24 mmol, 1.0 eq.) and LiCl (102 mg, 2.44 mmol, 10 eq.) in THF (2 mL) and MeOH (2 mL) was added NaBH₄ (181 mg, 4.88

mmol, 20 eq.) in small portions. After addition, the mixture was stirred at 25°C for 1 hour. LCMS showed that the starting material was consumed completely. Then water (20 mL) was added, and the mixture was extracted with EtOAc (10 mLx3). The combined organic phase were washed with brine (10 mLx2), dried over anhydrous Na₂SO₄, filtered and concentrated in *vacuo* to give tert-butyl ((3R,5R)-1-(6-(3-fluoro-4-methoxyphenyl)-4-(hydroxymethyl)pyridin-3-yl)-5-(fluoromethyl)piperidin-3-yl)carbamate (306-8) as a white solid. LC-MS: [M+H]⁺ = 464.3

To a mixture of tert-butyl ((3R,5R)-1-(6-(3-fluoro-4-methoxyphenyl)-4-(hydroxymethyl)pyridin-3-yl)-5-(fluoromethyl)piperidin-3-yl)carbamate (intermediate 306-8) (100 mg, 0.22 mmol, 1.0 eq.), Intermediate B (109 mg, 0.32 mmol, 1.5 eq.), n-Bu₃P (66.0 mg, 0.32 mmol, 1.5 eq.) and THF (10 mL) was added DIAD (66.0 mg, 0.32 mmol, 1.5 eq.) dropwise. After addition, the mixture was stirred at 25°C for 12 hours under N₂. LCMS showed that the starting material was consumed completely. The mixture was concentrated in *vacuo*. The residue was purified by silica gel column (PE/EA = 5:1 to 1:1) to give tert-butyl (tert-butoxycarbonyl(9-((5-((3R,5R)-3-((tert-butoxycarbonyl)amino)-5-(fluoromethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (Intermediate 306-9) as a pale yellow solid. LC-MS: [M+Na]⁺ = 803.4

Intermediate 311-11: Methyl 5-(3-(benzyl(methoxycarbonyl)amino)-2-((difluoromethoxy)methyl)piperidin-1-yl)-2-(3,4-difluorophenyl)isonicotinate



To a solution of 3-aminopicolinic acid (50 g, 360 mmol, 1.0 eq) in anhydrous MeOH (500 mL) was added conc.H₂SO₄ (106 g, 1090 mmol, 3.0 eq) dropwise. The reaction was stirred at 80 °C for 48 h. SOCl₂ (130 g, 1090mmol, 3.0 eq) was added to the reaction and stirred at 80 °C for another 48 h. TLC showed one main spot formed. The reaction was concentrated and diluted with water (500 mL), basified with K₂CO₃(s) to PH=9, extracted with EA (500 mLx3), washed with brine (500 mL), dried over Na₂SO₄, concentrated to give methyl 3-aminopicolinate (311-1) as a brown solid. ¹H NMR (400MHz, CDCl₃) δ = 8.04 (d, J=4.3 Hz, 1H), 7.20 (dd, J=4.3, 8.4 Hz, 1H), 7.04 (dd, J=1.3, 8.4 Hz, 1H), 5.76 (br s, 2H), 3.98 - 3.92 (m, 3H).

To a solution of methyl 3-aminopicolinate (311-1) (27 g, 180 mmol, 1.0 eq) and K₂CO₃ (48 g, 350 mmol, 2.0 eq) in MeCN (500 mL) was added methyl carbonochloridate (33 g, 350mmol, 2.0 eq) at 20 °C for 18 h. TLC showed one main spot formed. The reaction mixture was diluted with water (500 mL), concentrated. The residue was acidified with 1N HCl to PH=3, extracted with EA (500 mLx3), washed with sat.NaHCO₃ (500 mL) and brine (300 mL), dried over Na₂SO₄,

concentrated to give methyl 3-((methoxycarbonyl)amino)picolinate (311-2) as a brown solid. ¹H NMR (400MHz, CDCl₃) δ = 10.39 (br s, 1H), 8.82 (dd, J=1.4, 8.7 Hz, 1H), 8.34 (dd, J=1.5, 4.4 Hz, 1H), 7.51 - 7.40 (m, 1H), 3.99 (s, 3H), 3.78 (s, 3H).

A solution of methyl 3-((methoxycarbonyl)amino)picolinate (intermediate 311-2) (22 g, 105 mmol, 1.0 eq) and PtO₂ (5 g, 23% wt) in AcOH (220 mL) was stirred at 25 °C and 5MPa under H₂ for 144 h. Upon reaction completion as indicated by TLC, the reaction mixture was filtered and concentrated to give methyl (2S,3R)-3-((methoxycarbonyl)amino)piperidine-2-carboxylate (311-3) as a colorless oil, which was use into next step directly.

To a solution of methyl (2S,3R)-3-((methoxycarbonyl)amino)piperidine-2-carboxylate (311-3) (30 g, about 105 mmol, 1.0 eq) in THF (300 mL) was added TEA (53 g, 525mmol, 5.0 eq) and Boc₂O (69 g, 315 mmol, 3.0 eq) at 20 °C for 18 h. Upon reaction completion as indicated by TLC, the reaction mixture was concentrated and diluted with water (100 mL), acidified with 1 N HCl to PH=3, extracted with EA (100 mL×3), washed with brine (100 mL), dried over Na₂SO₄, concentrated. The residue was purified by combi-flash (EA%=0%~50%) to give 1-(tert-butyl) 2-methyl (2S,3R)-3-((methoxycarbonyl)amino)piperidine-1,2-dicarboxylate (311-4) as a colorless oil.

To a solution of 1-(tert-butyl) 2-methyl (2S,3R)-3-((methoxycarbonyl)amino)piperidine-1,2-dicarboxylate (311-4) (33 g, 104 mmol, 1.0 eq) in anhydrous THF (660 mL) was added LiAlH₄ (5.15 g, 136 mmol, 1.3 eq) at -78 °C~ -10 °C for 2 h. Upon reaction completed as indicated by TLC, the reaction mixture was poured into sat.NH₄Cl (700 mL), acidified with 1 N HCl to PH=5, extracted with EA (500 mL×3), washed with brine (500 mL), dried over Na₂SO₄, concentrated. The residue was purified by combi-flash (EA%=0%~70%) to give tert-butyl (2S,3R)-2-(hydroxymethyl)-3-((methoxycarbonyl)amino)piperidine-1-carboxylate (311-5) as a colorless oil. ¹H NMR (400MHz, CDCl₃) δ: 5.70 (br s, 1H), 4.44 (br d, J=5.5 Hz, 1H), 3.92 (br d, J=10.9 Hz, 2H), 3.86 - 3.71 (m, 2H), 3.64 (br s, 3H), 2.98 - 2.64 (m, 2H), 1.92-1.80 (m, 1H), 1.73 - 1.63 (m, 1H), 1.61 - 1.50 (m, 2H), 1.44 (s, 9H) . LC-MS: [M+H]⁺ =289.2.

To a mixture of tert-butyl (2S,3R)-2-(hydroxymethyl)-3-((methoxycarbonyl)amino)piperidine-1-carboxylate (311-5) (5 g, 17 mmol, 1.0 eq), BnBr (12 g, 69 mmol, 1.0 eq) and TBAI (3.1 g, 9 mmol, 0.5 eq) in anhydrous THF (50 mL) was added NaH (2.6 g, 65 mmol, 3.8 eq) at 20 °C. After the addition, the reaction was stirred at 60 °C for 2 h. TLC showed one main spot formed. The reaction mixture was poured into a solution of sat.NH₄Cl (200 mL), extracted with EA (100 mL×3), washed with brine (50 mL), dried over Na₂SO₄, concentrated. The residue was purified by combi-flash (EA%=0%~50%) to give tert-butyl (2S,3R)-3-(benzyl(methoxycarbonyl)amino)-2-((benzyloxy)methyl)piperidine-1-carboxylate (311-6) as a colorless oil. ¹H NMR (400MHz, CDCl₃) δ: 7.53 - 6.90 (m, 10H), 4.90 - 3.31 (m, 12H), 3.08 - 2.74 (m, 1H), 1.97 - 1.79 (m, 1H), 1.62-1.50 (m, 1H), 1.50 - 1.42 (m, 1H), 1.41 - 1.28 (m, 9H). LC-MS: [M+H]⁺ =469.4.

A solution of tert-butyl (2S,3R)-3-(benzyl(methoxycarbonyl)amino)-2-((benzyloxy)methyl)piperidine-1-carboxylate (intermediate 311-6) (7.2 g, 15 mmol, 1.0 eq) in

DCM (40 mL) and TFA (20 mL) was stirred at 20 °C for 20 h. After completion of reaction by TLC, the reaction mixture was diluted with H₂O (100 mL), basified with K₂CO₃(s) to PH=9, extracted with EA (100 mL×3), washed with brine, dried over Na₂SO₄, concentrated to give methyl benzyl((2S,3R)-2-((benzyloxy)methyl)piperidin-3-yl)carbamate (311-7) as colorless oil.

5 LC-MS: [M+H]⁺ =369.5.

A mixture of methyl 2-(3,4-difluorophenyl)-5-fluoroisonicotinate (Intermediate A) (30 g, 0.112 mmol, 1.0 eq) and m-CPBA(30 g, 0.174 mmol, 1.55 eq) inCDCl₃ (500 mL) was stirred at 65 °C for 20 h. More m-CPBA (30 g, 0.174 mmol, 1.55 eq) was added to the reaction mixture and the reaction was stirred at 65 °C for 72 h. TLC showed one main spot formed. The reaction mixture
10 was diluted with water (300 mL), basified with K₂CO₃(s) to PH=8, extracted with EA (300 mL×3),washed with brine (300 mL, dried over Na₂SO₄, and concentrated. The crude was purified by trituration with PE/MTBE=1/1 (100 mL) to give 2-(3,4-difluorophenyl)-5-fluoro-4-(methoxycarbonyl)pyridine 1-oxide (311-7A) as grey solid. LC-MS: [M+H]⁺ =284.2.

To a mixture of methyl benzyl((2S,3R)-2-((benzyloxy)methyl)piperidin-3-yl)carbamate (311-7)
15 (17 g, 0.06 mol, 4.0 eq) and 2-(3,4-difluorophenyl)-5-fluoro-4-(methoxycarbonyl)pyridine 1-oxide (311-7A) (6 g, about 15 mmol, 1.0 eq) in DIPEA (40 mL) and DMSO (40 mL) was stirred at 120 °C for 5 h. TLC showed one main spot formed. The reaction mixture was diluted with H₂O (100 mL), extracted with EA (50 mL×3), washed with brine (20 mL), dried over Na₂SO₄, concentrated. The residue was purified by combi-flash (EA%=10%~100%) to give 5-(3-(benzyl(methoxycarbonyl)amino)-2-((benzyloxy)methyl)piperidin-1-yl)-2-(3,4-difluorophenyl)-4-(methoxycarbonyl)pyridine 1-oxide (311-8) as a yellow oil. LCMS: [M+H]⁺ =632.5.

To a mixture of 5-(3-(benzyl(methoxycarbonyl)amino)-2-((benzyloxy)methyl)piperidin-1-yl)-2-(3,4-difluorophenyl)-4-(methoxycarbonyl)pyridine 1-oxide (311-8) (5200 mg, about 4.69 mmol, 1.0 eq) and Pd(OH)₂ (2000 mg, 38% wt) in MeOH(25 mL) and EA (25 mL) was stirred at 60 °C
25 and 50 Psi for 20 h. LCMS showed desired MS was detected as main peak. The reaction mixture was filtered and concentrated. The residue was purified by combi-flash (EA%=0%~60%) to give methyl 5-(3-(benzyl(methoxycarbonyl)amino)-2-((benzyloxy)methyl) piperidin-1-yl)-2-(3,4-difluorophenyl)isonicotinate (311-9) as yellow solid.LCMS: [M+H]⁺ =616.7.


To a mixture of methyl 5-(3-(benzyl(methoxycarbonyl)amino)-2-((benzyloxy)methyl)piperidin-1-yl)-2-(3,4-difluorophenyl)isonicotinate (311-9) (1500 mg, 2.44 mmol, 1.0 eq) and Pd(OH)₂ (1500 mg, 100% wt) in EA (45 mL) was stirred at 60 °C and 50 Psi for 18 h. LCMS showed desired MS was detected as main peak. The reaction mixture was filtered and concentrated. The residue was purified by combi-flash (EA%=0%~50%) to give methyl 5-(3-(benzyl(methoxycarbonyl)amino)-2-(hydroxymethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)isonicotinate (311-10) as a yellow oil. LCMS: [M+H]⁺ =526.5.
35

To a solution of methyl 5-(3-(benzyl(methoxycarbonyl)amino)-2-(hydroxymethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)isonicotinate (311-10) (300 mg, 0.571 mmol) and CuI (21.74 mg, 0.114 mmol) in MeCN (10 mL) , was added 2,2-difluoro-2-(fluorosulfonyl)acetic acid (0.113 mL, 1.142

mmol) dropwise at 55 °C, the reaction mixture was stirred at 55 °C for 2 hr. LC-MS monitored the reaction. 2 hr later, the reaction mixture was diluted with EA, washed with water and brine. The organic layer was dried over Na₂SO₄ and concentrated under vacuum to give the crude product. The crude product was purified by flash chromatography (elution gradient: 0% to 40% EtOAc in PE in 30 mins) to give methyl 5-(3-(benzyl(methoxycarbonyl)amino)-2-((difluoromethoxy)methyl)piperidin-1-yl)-2-(3,4-difluorophenyl)isonicotinate (Intermediate 311-11). LCMS: [M+H]⁺ = 576.3.

EXAMPLES

Example 1: (R)-9-((5-(3-(benzyl(methoxycarbonyl)amino)-2-((3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine



A suspension of 5-fluoro-2-(3-fluoro-4-methoxyphenyl)isonicotinaldehyde (intermediate 1-1) (800 mg, 3.21 mmol), (R)-tert-butyl piperidin-3-ylcarbamate (643 mg, 3.21 mmol), and potassium carbonate (887 mg, 6.42 mmol) in DMF (15 mL) was stirred at 100 °C for 20 hr.

LCMS indicated the reaction was complete. The mixture was diluted with H₂O (30 mL), extracted with EtOAc (20 mL*3). The combined organic layers were washed with H₂O (20 mL*2), brine (20 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (0-30% EtOAc in PE in 30mins) to give tert-butyl (R)-((5-(3-(benzyl(methoxycarbonyl)amino)-2-((3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-ylideneamino)carbamate (1-2) as a yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.24 (s, 1H), 8.63 (s, 1H), 8.01 (s, 1H), 7.93 – 7.83 (m, 2H), 7.27 (t, J = 8.8 Hz, 1H), 7.04 (d, J = 7.5 Hz, 1H), 3.90 (s, 3H), 3.63 (s, 1H), 3.42 –

3.37 (m, 1H), 3.30 – 3.23 (m, 1H), 3.06 – 2.94 (m, 1H), 2.84 (dd, $J = 11.7, 9.0$ Hz, 1H), 1.85 (d, $J = 11.2$ Hz, 2H), 1.70 (d, $J = 10.5$ Hz, 1H), 1.40 (s, 10H). LC-MS: $[M+H]^+ = 429.9$.

To a suspension of tert-butyl (R)-(1-(6-(3-fluoro-4-methoxyphenyl)-4-formylpyridin-3-yl)piperidin-3-yl)carbamate (1-2) (260 mg, 0.605 mmol) in MeOH (15 mL) was added sodium borohydride (22.9 mg, 0.605 mmol). The mixture was stirred at RT for 30 min. LCMS monitored the reaction and indicated the reaction was complete. Most of methanol was removed in reduced pressure, the residue was redissolved in DCM (30 mL), washed with water (10 mL), brine (10 mL), dried over anhydrous magnesium sulfate, filtered and concentrated to afford a residue. The residue was purified by flash chromatography (10-50% EtOAc in PE in 30mins) to afford tert-butyl (R)-(1-(6-(3-fluoro-4-methoxyphenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-3-yl)carbamate (1-3) as a light yellow solid. ^1H NMR (400 MHz, CD_3OD) δ 8.26 (s, 1H), 7.93 (s, 1H), 7.75 – 7.62 (m, 2H), 7.21 (t, $J = 8.5$ Hz, 1H), 5.52 (s, 1H), 4.88 – 4.72 (m, 2H), 3.95 (s, 3H), 3.71 (dt, $J = 9.5, 4.8$ Hz, 1H), 3.21 (dd, $J = 11.2, 3.7$ Hz, 1H), 3.07 (d, $J = 11.6$ Hz, 1H), 2.83 (t, $J = 10.7$ Hz, 1H), 2.66 (t, $J = 10.0$ Hz, 1H), 2.06 – 1.86 (m, 2H), 1.78 (q, $J = 13.1, 11.6$ Hz, 1H), 1.47 (s, 9H). LC-MS: $[M+H]^+ = 431.9$.





To a solution of tert-butyl (R)-(1-(6-(3-fluoro-4-methoxyphenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-3-yl)carbamate (1-3) (370 mg, 0.857 mmol), Intermediate B (300 mg, 0.895 mmol) and PPh_3 (704 mg, 2.68 mmol) in THF (15 mL) was added DEAD (0.425 mL, 2.68 mmol) dropwise at 0°C . The mixture was stirred at rt for 1hr. LCMS indicated the reaction was complete. The mixture was diluted with H_2O (20 mL), extracted with EtOAc (20 mL*3). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (10-50% EtOAc in hexane in 40mins) to give tert-butyl (R)-(tert-butoxycarbonyl)(9-((5-(3-(tert-butoxycarbonyl)amino)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (1-4) as a white solid. ^1H NMR (400 MHz, CD_3OD) δ 8.88 (s, 1H), 8.76 (s, 1H), 8.45 (s, 1H), 7.54 – 7.44 (m, 2H), 7.26 (s, 1H), 7.13 (t, $J = 8.6$ Hz, 1H), 5.90 – 5.72 (m, 2H), 3.90 (s, 3H), 3.85 (d, $J = 4.6$ Hz, 1H), 3.42 – 3.37 (m, 1H), 3.18 – 3.09 (m, 1H), 2.99 (t, $J = 10.1$ Hz, 1H), 2.88 (d, $J = 10.1$ Hz, 1H), 1.97 (d, $J = 10.2$ Hz, 2H), 1.82 (d, $J = 6.8$ Hz, 1H), 1.64 – 1.54 (m, 1H), 1.44 (s, 9H), 1.36 (s, 18H). LC-MS: $[M+H]^+ = 749.0$.

To a solution of tert-butyl (R)-(tert-butoxycarbonyl)(9-((5-(3-(tert-butoxycarbonyl)amino)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (1-4) (360 mg, 0.481 mmol) in DCM (9 mL) was added TFA (3 mL). The mixture was stirred at RT for 1 hr. LCMS monitored the reaction and indicated the reaction was complete. The mixture was concentrated in vacuum. The residue was purified by Prep-HPLC (Basic condition, $\text{NH}_3\text{H}_2\text{O}\% = 0.05\%$, $\text{MECN}/\text{H}_2\text{O} = 0-95\%$ in 12 mins) to give (R)-9-((5-(3-aminopiperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine (Example 1) as a white solid. ^1H NMR (400 MHz, CD_3OD) δ 8.59 – 8.32 (m, 3H), 7.69 – 7.53 (m, 2H), 7.37 (s, 1H), 7.17 (td, $J = 8.6, 1.7$ Hz, 1H), 5.85 – 5.63 (m, 2H), 3.93 (d, $J = 1.8$ Hz, 3H),






3.62 (s, 1H), 3.56 – 3.44 (m, 1H), 3.19 – 3.07 (m, 2H), 3.04 (d, $J = 9.5$ Hz, 1H), 2.22 – 2.12 (m, 1H), 2.04 (s, 1H), 1.89 (dd, $J = 9.0, 4.2$ Hz, 1H), 1.76 (d, $J = 10.1$ Hz, 1H). LC-MS: $[M+H]^+ = 449.1$.






Example 2-21 can be prepared following procedures analogous to those described in

5 Example 1.

Examp e #	Structure	^1H NMR & MS
2		^1H NMR (400 MHz, CD_3OD) δ ppm 8.56 (s, 1 H) 8.26 (s, 1 H) 8.11 (s, 1 H) 7.85 (td, $J = 8.03, 1.76$ Hz, 1 H) 7.35 - 7.43 (m, 1 H) 7.32 (s, 2 H) 7.17 - 7.29 (m, 2 H) 6.97 (s, 1 H) 5.42 - 5.68 (m, 2 H) 4.66 - 4.94 (m, 1 H) 2.86 - 3.19 (m, 4 H) 1.87 - 2.23 (m, 2 H) 1.73 (br. s., 1 H). LC-MS: $[M+H]^+ = 436.9, 437.9$.
3		^1H NMR (400 MHz, CD_3OD) δ ppm 8.49 (s, 1H), 8.22 (d, $J = 4.7$ Hz, 2H), 7.73 (ddd, $J = 12.1, 7.8, 2.2$ Hz, 1H), 7.52 (ddt, $J = 8.2, 3.8, 1.6$ Hz, 1H), 7.28 (d, $J = 11.2$ Hz, 2H), 5.63 (d, $J = 1.4$ Hz, 2H), 3.90 (dt, $J = 7.4, 3.5$ Hz, 1H), 3.25 - 2.98 (m, 4H), 2.89 (ddd, $J = 11.5, 7.4, 3.8$ Hz, 1H), 1.90 (dddd, $J = 33.5, 13.2, 6.7, 3.6$ Hz, 2H). LC-MS: $[M+H]^+ = 453.2, 454.2$.
4		^1H NMR (400 MHz, CD_3OD) δ 8.57 (d, $J = 6.2$ Hz, 1H), 8.47 (d, $J = 6.0$ Hz, 1H), 8.37 (d, $J = 5.8$ Hz, 1H), 7.68 – 7.56 (m, 2H), 7.50 – 7.39 (m, 2H), 7.15 (td, $J = 8.2, 7.7, 2.3$ Hz, 1H), 5.85 – 5.67 (m, 2H), 3.62 (tt, $J = 8.1, 3.7$ Hz, 1H), 3.51 (dd, $J = 11.4, 3.7$ Hz, 1H), 3.14 (dq, $J = 10.5, 6.5, 4.5$ Hz, 2H), 3.05 (td, $J = 8.5, 4.2$ Hz, 1H), 2.24 – 2.11 (m, 1H), 2.05 (dtt, $J = 9.5, 6.1, 3.1$ Hz, 1H), 1.90 (ddq, $J = 13.2, 8.8, 4.0$ Hz, 1H), 1.82 – 1.69 (m, 1H). LC-MS: $[M+H]^+ = 418.9$.
5		^1H NMR (400 MHz, CD_3OD) δ ppm 8.49 (s, 1H), 8.24 (d, $J = 1.5$ Hz, 2H), 7.58 (dd, $J = 12.6, 2.2$ Hz, 1H), 7.48 (ddd, $J = 8.5, 2.3, 1.2$ Hz, 1H), 7.25 (s, 1H), 7.13 (t, $J = 8.6$ Hz, 1H), 5.64 (s, 2H), 4.79 (dd, $J = 5.4, 2.6$ Hz, 1H), 3.91 (s, 3H), 3.22 – 3.02 (m, 4H), 3.02 – 2.88 (m, 1H), 2.20 (ddd, $J = 15.0, 9.6, 4.9$ Hz, 1H), 2.03 (ddd, $J = 36.1, 14.0, 10.3$ Hz, 1H). LC-MS: $[M+H]^+ = 466.9, 467.9$.


Example #	Structure	¹ H NMR & MS
6		¹ H NMR (400 MHz, CD ₃ OD) δ 8.55 (s, 1H), 8.41 (s, 1H), 8.34 (s, 1H), 7.71 (t, <i>J</i> = 9.0 Hz, 1H), 7.17 (d, <i>J</i> = 1.6 Hz, 1H), 6.86 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 6.75 (dd, <i>J</i> = 13.3, 2.5 Hz, 1H), 5.84 – 5.67 (m, 2H), 3.84 (s, 3H), 3.63 (dt, <i>J</i> = 8.3, 4.5 Hz, 1H), 3.55 – 3.48 (m, 1H), 3.19 – 3.11 (m, 2H), 3.05 (t, <i>J</i> = 8.8 Hz, 1H), 2.23 – 2.13 (m, 1H), 2.11 – 2.02 (m, 1H), 1.91 (ddq, <i>J</i> = 13.2, 8.6, 4.3 Hz, 1H), 1.77 (d, <i>J</i> = 9.2 Hz, 1H). LC-MS: [M+H] ⁺ = 448.9.
7		¹ H NMR (400MHz, CDCl ₃) : 8.61 (s, 1H), 8.43 (s, 1H), 8.33 (s, 1H), 8.17 (d, <i>J</i> = 1.8 Hz, 1H), 7.92 (dd, <i>J</i> = 8.3, 1.7 Hz, 1H), 7.81 (d, <i>J</i> = 8.1 Hz, 1H), 7.50 (s, 1H), 5.92 – 5.49 (m, 2H), 3.60 (tt, <i>J</i> = 7.7, 3.5 Hz, 1H), 3.50 (dd, <i>J</i> = 11.5, 3.4 Hz, 1H), 3.23 – 2.97 (m, 3H), 2.09 (dddd, <i>J</i> = 41.4, 10.0, 7.1, 3.5 Hz, 2H), 1.92 – 1.62 (m, 2H). LC-MS: [M+H] ⁺ = 459.8
8		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.54 (s, 1H), 8.24 (d, <i>J</i> = 3.3 Hz, 2H), 7.60 – 7.50 (m, 2H), 7.43 (td, <i>J</i> = 8.3, 6.1 Hz, 1H), 7.31 (s, 1H), 7.12 (tt, <i>J</i> = 7.7, 1.5 Hz, 1H), 5.66 (s, 2H), 4.80 – 4.57 (m, 1H), 3.25 – 3.06 (m, 4H), 3.06 – 2.91 (m, 1H), 2.21 (td, <i>J</i> = 11.0, 10.3, 5.7 Hz, 1H), 2.04 (ddd, <i>J</i> = 36.2, 14.1, 10.4 Hz, 1H). LC-MS: [M+H] ⁺ = 436.9, 437.9.
9		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.80 (s, 1H), 8.35 (s, 1H), 8.28 (s, 1H), 8.07 (dd, <i>J</i> = 10.8, 1.5 Hz, 1H), 8.01 (dd, <i>J</i> = 8.2, 1.6 Hz, 1H), 7.96 (s, 1H), 7.88 (dd, <i>J</i> = 8.2, 6.7 Hz, 1H), 6.03 (d, <i>J</i> = 15.3 Hz, 1H), 5.43 (d, <i>J</i> = 15.3 Hz, 1H), 3.88 (d, <i>J</i> = 4.0 Hz, 1H), 3.64 – 3.50 (m, 2H), 3.42 – 3.34 (m, 1H), 3.16 (s, 3H), 3.11 – 2.95 (m, 2H), 2.15 – 1.97 (m, 2H), 1.69 – 1.57 (m, 1H), 1.57 – 1.39 (m, 1H). LC-MS: [M+H] ⁺ = 487.9, 488.9.
10		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.52 (s, 1H), 8.26 (s, 1H), 8.11 (s, 1H), 7.81 (t, <i>J</i> = 9.3 Hz, 1H), 7.32 (s, 2H), 6.91 – 6.71 (m, 3H), 5.54 (s, 2H), 4.81 (ddt, <i>J</i> = 49.4, 5.4, 2.5 Hz, 1H), 3.77 (s, 3H), 3.18 – 2.83 (m, 5H), 2.20 – 1.88 (m, 2H), 1.85 – 1.58 (m, 2H). LC-MS: [M+H] ⁺ = 466.9, 470.9.

Example #	Structure	¹ H NMR & MS
11		¹ H NMR (400 MHz, CD ₃ OD) δ: 8.50 (d, J = 26.4 Hz, 2H), 8.36 (s, 1H), 7.73 (d, J = 8.9 Hz, 2H), 7.40 (s, 1H), 7.14 – 6.93 (m, 2H), 5.93 – 5.62 (m, 2H), 3.85 (s, 3H), 3.57 (ddd, J = 44.7, 9.9, 3.8 Hz, 2H), 3.22 – 3.01 (m, 3H), 2.22 – 1.99 (m, 2H), 1.94 – 1.69 (m, 2H). LC-MS: [M+H] ⁺ = 430.9
12		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.57 (d, J = 2.3 Hz, 1H), 8.32 – 8.17 (m, 2H), 7.87 (p, J = 1.6 Hz, 1H), 7.67 (ddt, J = 5.1, 3.2, 1.8 Hz, 1H), 7.47 – 7.30 (m, 3H), 5.65 (s, 2H), 5.15 – 4.95 (m, 1H), 3.63 (dd, J = 39.0, 22.1 Hz, 1H), 3.38 (d, J = 6.0 Hz, 1H), 3.26 (s, 1H), 3.22 – 3.13 (m, 1H), 3.04 (dq, J = 12.6, 4.5 Hz, 1H), 2.32 – 2.04 (m, 2H). LC-MS: [M+H] ⁺ = 452.9, 453.9.
13		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.6 (s, 1H), 8.23 (d, 2H), 7.9 (d, 1H), 7.79 (m, 2H), 7.45 (s, 1H), 5.6 (s, 2H), 4.9 4.81 (m, 1H), 3.83 (s, 3H), 3.21 – 3.12 (m, 4H), 3.05 – 3.01 (m, 1H), 2.19 (m, 1H), 2.14 – 1.88 (m, 1H). LC-MS: [M+H] ⁺ = 461.9, 462.9.
14		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.45 (s, 1H), 8.23 (d, J = 1.3 Hz, 2H), 7.61 (d, J = 1.8 Hz, 1H), 7.46 (dd, J = 8.3, 1.9 Hz, 1H), 7.18 (s, 1H), 6.76 (d, J = 8.4 Hz, 1H), 5.64 (s, 2H), 4.65 (s, 1H), 4.58 (t, J = 8.7 Hz, 2H), 3.23 (t, J = 8.7 Hz, 2H), 3.20 – 3.04 (m, 4H), 3.00 – 2.92 (m, 1H), 2.26 – 2.13 (m, 1H), 2.12 – 1.93 (m, 1H). LC-MS: [M+H] ⁺ = 460.9, 461.9.
15		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.44 (s, 1H), 8.23 (d, J = 1.3 Hz, 2H), 7.56 (dd, J = 12.7, 2.2 Hz, 1H), 7.45 (ddd, J = 8.5, 2.3, 1.1 Hz, 1H), 7.24 (s, 1H), 7.09 (t, J = 8.7 Hz, 1H), 5.62 (s, 2H), 3.48 (dt, J = 7.1, 3.3 Hz, 1H), 3.44 (s, 3H), 3.22 – 2.95 (m, 4H), 2.85 (ddd, J = 11.4, 7.4, 3.6 Hz, 1H), 2.06 (ddt, J = 18.0, 7.4, 3.0 Hz, 1H), 1.87 – 1.73 (m, 1H). LC-MS: [M+H] ⁺ = 478.9, 479.9.

Example #	Structure	¹ H NMR & MS
16		¹ H NMR (400MHz, DMSO-d ₆) δ: 8.52 (s, 1H), 8.25 (s, 1H), 8.12 (s, 1H), 7.67 (dd, J = 13.0, 2.1 Hz, 1H), 7.52 (s, 1H), 7.31 (s, 1H), 7.27 – 7.07 (m, 2H), 5.50 (d, J = 2.7 Hz, 2H), 3.85 (s, 3H), 3.32 – 3.09 (m, 3H), 2.71 (t, J = 10.2 Hz, 1H), 2.36 (d, J = 12.1 Hz, 1H), 2.09 – 1.54 (m, 3H), 1.06 (t, J = 7.0 Hz, 1H) LC-MS: [M+H] ⁺ = 485.1
17		¹ H NMR (400MHz, CD ₃ OD) δ: 8.64 (s, 1H), 8.47 (s, 1H), 8.36 (s, 1H), 7.67 – 7.55 (m, 2H), 7.52 – 7.35 (m, 2H), 7.22 – 7.02 (m, 1H), 5.87 – 5.64 (m, 2H), 4.10 (ddt, J = 18.1, 9.6, 4.6 Hz, 1H), 3.63 (d, J = 11.8 Hz, 1H), 3.46 – 3.37 (m, 1H), 3.32 – 3.26 (m, 2H), 2.57 – 2.37 (m, 2H) LC-MS: [M+H] ⁺ = 454.9
18		¹ H NMR (400MHz, DMSO-d ₆) δ: 8.51 (s, 1H), 8.48 (s, 1H), 8.24 (s, 1H), 7.95-7.85 (m, 1H), 7.67-7.57 (m, 1H), 7.49 (q, J = 8.8 Hz, 1H), 7.38 (s, 1H), 7.28 (s, 2H), 5.49 (s, 2H), 3.27-3.15 (m, 1H), 3.14-3.05 (m, 1H), 3.04-2.97 (m, 1H), 2.86-2.77 (m, 1H), 2.70-2.55 (m, 2H), 2.20-2.02 (m, 3H), 1.95-1.80 (m, 1H). LC-MS: [M+H] ⁺ = 462.3
19		¹ H NMR (400MHz, CD ₃ OD) δ: 8.54 (s, 1H), 8.48 (s, 1H), 7.79 – 7.45 (m, 3H), 7.23 (s, 1H), 7.14 (t, J = 8.6 Hz, 1H), 7.00 (d, J = 7.1 Hz, 1H), 5.92 – 5.61 (m, 2H), 3.91 (s, 3H), 3.62 – 3.51 (m, 1H), 3.47 (dd, J = 11.4, 3.5 Hz, 1H), 3.12 (dq, J = 14.0, 4.9, 4.0 Hz, 2H), 3.04 – 2.94 (m, 1H), 2.17 (dt, J = 10.4, 5.0 Hz, 1H), 2.10 – 1.98 (m, 1H), 1.97 – 1.81 (m, 1H), 1.72 (d, J = 10.5 Hz, 1H) LC-MS: [M+H] ⁺ = 447.8
20		¹ H NMR (400 MHz, CD ₃ OD) δ 8.55 (s, 1H), 8.46 (s, 1H), 8.34 (s, 1H), 7.61 (dd, J = 12.6, 2.2 Hz, 1H), 7.55 (dt, J = 8.8, 1.6 Hz, 1H), 7.28 (s, 1H), 7.14 (t, J = 8.6 Hz, 1H), 5.76 (q, J = 16.4 Hz, 2H), 3.91 (s, 3H), 3.26 (s, 2H), 3.20 – 3.13 (m, 1H), 2.96 (t, J = 10.9 Hz, 1H), 1.98 (t, J = 10.9 Hz, 3H), 1.89 – 1.80 (m, 1H), 1.52 (s, 3H). LC-MS: [M+H] ⁺ = 462.9.

Examp e #	Structure	¹ H NMR & MS
21		¹ H NMR (400MHz, CD ₃ OD) δ: 8.54 (s, 1H), 8.48 (s, 1H), 7.66 – 7.41 (m, 3H), 7.23 (s, 1H), 7.14 (t, J = 8.6 Hz, 1H), 7.00 (d, J = 7.1 Hz, 1H), 5.89 – 5.68 (m, 2H), 3.91 (s, 3H), 3.58 (tt, J = 8.3, 4.0 Hz, 1H), 3.47 (dd, J = 11.3, 3.5 Hz, 1H), 3.20 – 3.08 (m, 2H), 3.04 (d, J = 3.2 Hz, 1H), 2.17 (dt, J = 10.4, 5.0 Hz, 1H), 2.10 – 1.99 (m, 1H), 1.90 (qt, J = 9.4, 4.2 Hz, 1H), 1.80 – 1.62 (m, 1H). LC-MS: [M+H] ⁺ = 447.8

Example 22: (R)-9-((5-(3-amino-3-(cyclopropoxymethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine



5

A mixture of tert-butyl (3-(cyclopropoxymethyl)piperidin-3-yl)carbamate (Intermediate 22-7) (300 mg, 1.11 mmol, 1.0 eq), methyl 2-(3,4-difluorophenyl)-5-fluoroisonicotinate (intermediate A) (296 mg, 1.11 mmol, 1.0 eq) and DIPEA (1.00 g, 7.77 mmol, 7.0 eq) in DMSO (3 mL) was stirred at 120 °C under N₂ for 3 hr. The mixture was quenched with water (200 mL) at 10 °C, and extracted with EtOAc (100 mLx3). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated in *vacuo*. The residue was purified by Combi Flash (20% EtOAc in

10

PE) to give methyl 5-(3-((tert-butoxycarbonyl)amino)-3-(cyclopropoxymethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)isonicotinate (22-8) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.48 (1H, s), 7.86 (1H, s), 7.83 (1H, dd, *J* = 10.0, 2.0 Hz), 7.67 (1H, d, *J* = 8.4 Hz), 7.23 (1H, dd, *J* = 8.4, 1.6 Hz), 5.63 (1H, brs), 3.80-4.05 (4H, m), 3.57 (1H, d, *J* = 9.6 Hz), 3.15-3.35 (3H, m), 2.80-2.95 (2H, m), 2.30-2.45 (1H, m), 1.85-2.00 (1H, m), 1.65-1.75 (1H, m), 1.46 (9H, s), 1.25-1.40 (1H, m), 0.40-0.60 (4H, m).

To a solution of methyl 5-(3-((tert-butoxycarbonyl)amino)-3-(cyclopropoxymethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)isonicotinate (22-8) (330 mg, 0.638 mmol, 1.0 eq) in THF/MeOH (10 mL, v/v = 1/1) was added LiCl (270 mg, 6.38 mmol, 10.0 eq) followed by NaBH₄ (480 mg, 12.75 mmol, 20.0 eq) at 15-20 °C. The resulting mixture was stirred at 30 °C for 2 hr. TLC (PE/EtOAc = 5/1) indicated the reaction was complete. The reaction was quenched with water (100 mL), and extracted with EtOAc (100 mLx3). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated in *vacuo* to give crude tert-butyl (3-(cyclopropoxymethyl)-1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-3-yl)carbamate (22-9) as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.43 (1H, s), 7.75-7.85 (1H, m), 7.60-7.70 (2H, m), 7.15-7.25 (1H, m), 4.79 (2H, s), 4.76 (1H, brs), 3.65-3.85 (3H, m), 3.35-3.45 (1H, m), 3.25-3.35 (1H, m), 3.05-3.15 (1H, m), 2.80-2.95 (2H, m), 2.05-2.15 (1H, m), 1.85-1.95 (1H, m), 1.65-1.75 (1H, m), 1.55-1.60 (1H, m), 1.44 (9H, s), 0.40-0.60 (4H, m).





To a solution of tert-butyl (3-(cyclopropoxymethyl)-1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-3-yl)carbamate (22-9) (300 mg, 0.613 mmol, 1.0 eq.), Intermediate B (310 mg, 0.919 mmol, 1.5 eq.) and Bu₃P (372 mg, 1.84 mmol, 3.0 eq.) in THF (10 mL) was added DIAD (372 mg, 1.84 mmol, 3.0 eq.) at 0 °C. The mixture was stirred at 20-30 °C for 2 hr. The reaction was concentrated in *vacuo*. The residue was purified by Combi Flash (30-40% EtOAc in PE) to give tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(cyclopropoxymethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (22-10) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.88 (1H, s), 8.52 (1H, s), 8.25 (1H, s), 7.60-7.70 (1H, m), 7.35-7.45 (1H, m), 7.10-7.25 (2H, m), 5.70 (1H, d, *J* = 15.6 Hz), 5.53 (1H, d, *J* = 15.6 Hz), 5.19 (1H, brs), 3.75-3.90 (2H, m), 3.40-3.50 (1H, m), 3.25-3.35 (1H, m), 2.90-3.10 (3H, m), 2.15-2.30 (1H, m), 1.90-2.00 (1H, m), 1.70-1.80 (1H, m), 1.55-1.65 (1H, m), 1.45 (18H, s), 1.35 (9H, s), 0.40-0.60 (4H, m).

A solution of tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(cyclopropoxymethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (22-10) (270 mg, 0.335 mmol) in 20% TFA in DCM (7.5 mL) was stirred at 15-20 °C for 2 hr. Then the pH of the reaction was adjusted to 8-9 by NH₃·H₂O, and extracted with DCM (100 mLx3). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated in *vacuo*. The residue was purified by Prep-HPLC (0.1% NH₃·H₂O as additive) and SFC to give (R)-9-((5-(3-amino-3-(cyclopropoxymethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine (Example 22) as a white solid. ¹H NMR

(400 MHz, CD₃OD) δ ppm 8.51 (1H, s), 8.25 (1H, d, J = 4.0 Hz), 7.70-7.80 (1H, m), 7.50-7.60 (1H, m), 7.25-7.40 (2H, m), 5.66 (2H, s), 3.60-3.80 (1H, m), 3.45-3.55 (1H, d, J = 9.6 Hz), 2.90-3.15 (4H, m), 1.55-2.00 (4H, m), 1.25-1.40 (1H, m), 0.35-0.65 (4H, m). LC-MS: $[M+H]^+ = 506.8$.

Example 23-46 can be prepared following procedures analogous to those described in

5 Example 22.

Example #	Structure	¹ H NMR & MS
23		¹ H NMR (400 MHz, CDCl ₃) δ ppm 8.50 (s, 1H), 8.36 (br s, 1H), 8.16 (br s, 1H), 7.76-7.91 (m, 2H), 7.65 (br d, J =7.0 Hz, 1H), 7.20-7.27 (m, 1H), 5.71 (br d, J =12.8 Hz, 1H), 5.47 (br s, 1H), 3.58-3.70 (m, 2H), 3.54 (br d, J =12.0 Hz, 1H), 3.45 (s, 3H), 2.93-3.06 (m, 1H), 2.86 (br s, 2H), 2.28 (br d, J =14.3 Hz, 1H), 2.05 (br s, 1H), 1.75 (br d, J =13.8 Hz, 1H), 1.56-1.68 (m, 1H), 1.18-1.39 (m, 3H), 0.80-0.95 (m, 1H). LC-MS: $[M+H]^+ = 480.9$.
24		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 1.40-1.82 (4H, m), 2.68-3.05 (4H, m), 3.20 (1H, t), 3.26 (3H, s), 3.42 (1H, d), 5.56 (3H, t), 7.01 (1H, t), 7.15 (1H, s), 7.25-7.44 (2H, m), 8.12 (2H, d), 8.38 (1H, s). LC-MS: $[M+H]^+ = 463.1$.
25		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.45 (s, 1H), 8.24 (d, J = 6.4 Hz, 2H), 7.56 (dd, J = 12.8, 2.2 Hz, 1H), 7.45 (dt, J = 8.6, 1.6 Hz, 1H), 7.18 (s, 1H), 7.11 (t, J = 8.6 Hz, 1H), 5.67 (s, 2H), 3.90 (s, 3H), 3.74 – 3.53 (m, 2H), 3.14 (d, J = 11.3 Hz, 1H), 3.10 – 2.93 (m, 2H), 2.87 (d, J = 11.4 Hz, 1H), 2.00 – 1.74 (m, 2H), 1.73 – 1.48 (m, 2H), 1.17 (d, J = 6.0 Hz, 3H), 1.12 (d, J = 6.1 Hz, 3H). LC-MS: $[M+H]^+ = 520.8, 521.8$.
26		¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ ppm 8.53 (s, 1H), 8.29 (s, 1H), 8.11 (s, 1H), 7.88 (dd, J = 6.8, 2.8 Hz, 1H), 7.45 (ddd, J = 8.7, 4.1, 2.8 Hz, 1H), 7.40 – 7.22 (m, 3H), 7.00 (d, J = 1.5 Hz, 1H), 5.63 – 5.47 (m, 2H), 3.46 (d, J = 8.8 Hz, 1H), 3.28 (s, 3H), 3.23 (d, J = 8.8 Hz, 1H), 3.08 – 2.93 (m, 3H), 2.75 (d, J = 11.3 Hz, 1H), 1.88 (d, J = 13.0 Hz, 1H), 1.72 (s, 3H), 1.61 (td, J = 8.7, 4.5 Hz, 1H), 1.40 (dt, J = 12.6, 5.2 Hz, 1H). LC-MS: $[M+H]^+ = 496.8, 497.8$.


Example #	Structure	¹ H NMR & MS
27		¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ ppm 8.50 (s, 1H), 8.33 (s, 1H), 8.13 (s, 1H), 7.89 (t, <i>J</i> = 1.9 Hz, 1H), 7.71 (dt, <i>J</i> = 7.2, 1.8 Hz, 1H), 7.51 – 7.38 (m, 2H), 7.32 (d, <i>J</i> = 13.0 Hz, 3H), 5.61 – 5.42 (m, 2H), 3.41 (d, <i>J</i> = 8.8 Hz, 1H), 3.26 (s, 3H), 3.21 (d, <i>J</i> = 8.8 Hz, 1H), 3.04 – 2.86 (m, 3H), 2.73 (d, <i>J</i> = 11.2 Hz, 1H), 1.92 – 1.52 (m, 5H), 1.37 (ddt, <i>J</i> = 10.6, 8.0, 3.9 Hz, 1H). LC-MS: [M+H] ⁺ = 478.9, 479.9.
28		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.50 (s, 1H), 8.22-8.27 (m, 2H), 7.96 (d, <i>J</i> =6.7 Hz, 1H), 7.64-7.71 (m, 2H), 7.28 (s, 1H), 5.67 (s, 2H), 3.57 (br d, <i>J</i> =9.3 Hz, 1H), 3.36-3.39 (m, 4H), 3.04-3.16 (m, 2H), 2.86-3.04 (m, 2H), 1.75-1.93 (m, 2H), 1.50-1.73 (m, 2H). LC-MS: [M+H] ⁺ = 496.8.
29		¹ H NMR (400 MHz, CDCl ₃) δ ppm 8.55 (s, 1H), 8.42 (s, 1H), 7.92 (s, 1H), 7.88 (td, <i>J</i> =8.8, 6.7 Hz, 1H), 6.96 (td, <i>J</i> =8.3, 2.0 Hz, 1H), 6.84 (ddd, <i>J</i> =11.3, 8.8, 2.5 Hz, 1H), 5.48-5.65 (m, 2H), 3.53-3.61 (m, 1H), 3.38 (s, 3H), 3.29-3.35 (m, 1H), 2.91-3.09 (m, 4H), 1.88-2.01 (m, 2H), 1.63 (br s, 2H). LC-MS: [M+H] ⁺ = 480.9.
30		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.51 (s, 1H), 8.24 (s, 1H), 8.24 (s, 1H), 7.78-7.72 (m, 1H), 7.54-7.52 (m, 2H), 7.33-7.26 (m, 2H), 5.67 (s, 1H), 3.98-3.94 (m, 1H), 3.56-3.54 (m, 1H), 3.32 (d, <i>J</i> = 6. Hz, 1H), 3.12 – 2.94 (m, 3H), 1.93 – 1.50 (m, 8H). LC-MS: [M+H] ⁺ = 520.7.
31		¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ ppm 8.44 (1H, s), 8.31 (1H, s), 8.12 (1H, s), 7.66 (1H, dd, <i>J</i> = 13.2, 2.0 Hz), 7.50 (1H, d, <i>J</i> = 8.4 Hz), 7.30 (2H, brs), 7.15-7.25 (2H, m), 5.45-5.60 (2H, m), 3.84 (3H, s), 3.53 (1H, d, <i>J</i> = 8.8 Hz), 3.20-3.35 (2H, m), 2.85-2.95 (3H, m), 2.68 (1H, d, <i>J</i> = 11.2 Hz), 1.25-1.85 (6H, m), 0.25-0.50 (4H, m). LC-MS: [M+H] ⁺ = 519.1.

Example #	Structure	¹ H NMR & MS
32		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.33 (s, 1H), 8.13 (s, 1H), 8.12 (s, 1H), 7.43 (dd, <i>J</i> = 2.0, 12.8 Hz, 1H), 7.32 (d, <i>J</i> = 8.4 Hz, 1H), 7.06 (s, 1H), 7.00-6.97 (m, 1H), 5.59-5.50 (m, 2H), 3.86-3.79 (m, 1H), 3.77 (s, 3H), 3.44 (d, <i>J</i> = 8.0 Hz, 1H), 3.12 (d, <i>J</i> = 8.8 Hz), 3.04-3.01 (m, 1H), 2.95-2.86 (m, 2H), 2.75-2.72 (m, 1H), 2.09-2.00 (m, 2H), 1.84-1.74 (m, 3H), 1.68-1.16 (m, 5H). LC-MS: [M+H] ⁺ = 533.2.
33		¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ ppm 8.48 (s, 1H), 8.29 (s, 1H), 8.11 (s, 1H), 7.80 (t, <i>J</i> = 9.3 Hz, 1H), 7.32 (s, 2H), 6.90 – 6.75 (m, 3H), 5.61 – 5.43 (m, 2H), 3.77 (s, 3H), 3.47 (d, <i>J</i> = 8.8 Hz, 1H), 3.28 (s, 3H), 3.24 (d, <i>J</i> = 8.8 Hz, 1H), 2.98 (t, <i>J</i> = 11.8 Hz, 3H), 2.75 – 2.66 (m, 1H), 1.94 – 1.77 (m, 1H), 1.72 (s, 3H), 1.60 (ddd, <i>J</i> = 13.0, 8.6, 4.3 Hz, 1H), 1.39 (ddd, <i>J</i> = 12.3, 7.4, 4.4 Hz, 1H). LC-MS: [M+H] ⁺ = 492.9, 493.9.
34		¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ ppm 8.49 (s, 1H), 8.31 (s, 1H), 8.12 (s, 1H), 7.87 (ddd, <i>J</i> = 12.2, 8.0, 2.2 Hz, 1H), 7.60 (d, <i>J</i> = 8.8 Hz, 1H), 7.48 (dt, <i>J</i> = 10.8, 8.5 Hz, 1H), 7.29 (d, <i>J</i> = 5.8 Hz, 3H), 5.64 – 5.38 (m, 2H), 3.60 – 3.41 (m, 2H), 3.21 (d, <i>J</i> = 8.8 Hz, 1H), 3.08 – 2.85 (m, 3H), 2.70 (d, <i>J</i> = 11.5 Hz, 1H), 1.83 (s, 1H), 1.68 (s, 3H), 1.58 (ddd, <i>J</i> = 13.0, 8.7, 4.2 Hz, 1H), 1.46 – 1.31 (m, 1H), 1.07 (d, <i>J</i> = 6.0 Hz, 3H), 1.02 (d, <i>J</i> = 6.0 Hz, 3H). LC-MS: [M+H] ⁺ = 508.9, 509.9.
35		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 1.73-2.05 (7H, m), 2.84-2.90 (1H, m), 3.03-3.07 (2H, m), 3.84 (3H, s), 3.88 (3H, s), 5.49-5.59 (2H, m), 7.01 (1H, t, <i>J</i> = 8.4 Hz), 7.21 (1H, s), 7.38 (1H, d, <i>J</i> = 8.4 Hz), 7.48 (1H, dd, <i>J</i> = 8.8 Hz, 2.4 Hz), 8.14 (1H, d, <i>J</i> = 7.2 Hz), 8.38 (1H, s). LC-MS: [M+H] ⁺ = 503.3.
36		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.49 (s, 1H), 8.25 (s, 1H), 8.24 (s, 1H), 7.19 (s, 1H), 7.15 (t, <i>J</i> = 6.8 Hz, 2H), 5.69 (dd, <i>J</i> ₁ = 13.2 Hz, <i>J</i> ₂ = 15.2 Hz, 2H), 4.00 – 3.91 (m, 1H), 3.58 (br, 1H), 3.25 (d, <i>J</i> = 7.2 Hz, 1H), 3.22 – 3.15 (m, 1H), 3.13-2.97 (m, 2H), 2.93-2.83 (m, 1H), 2.26 – 2.17 (m, 1H), 2.16 – 2.07 (m, 1H), 1.97 – 1.75 (m, 4H), 1.72 – 1.45 (m, 4H). LC-MS: [M+H] ⁺ = 503.2.

Example #	Structure	¹ H NMR & MS
37		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.50 (s, 1H), 8.25 (d, <i>J</i> = 7.2 Hz, 2H), 7.86 – 7.70 (m, 2H), 7.25 (s, 1H), 7.21 – 7.08 (m, 2H), 5.68 (s, 2H), 3.78 – 3.55 (m, 2H), 3.41 (d, <i>J</i> = 9.3 Hz, 1H), 3.24 – 3.15 (m, 1H), 3.11 – 2.86 (m, 3H), 2.01 – 1.77 (m, 2H), 1.71 (dd, <i>J</i> = 9.0, 5.0 Hz, 2H), 1.17 (dd, <i>J</i> = 18.3, 6.0 Hz, 6H). LC-MS: [M+H] ⁺ = 490.9, 491.9.
38		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 1.46-1.85 (4H, m), 2.80-3.00 (4H, m), 3.20 (1H, t), 3.26 (3H, s), 3.46 (1H, d), 3.78 (3H, s), 5.53 (3H, s), 7.00 (1H, t), 7.09 (1H, s), 7.33-7.46 (2H, m), 8.12 (2H, d), 8.34 (1H, s). LC-MS: [M+H] ⁺ = 493.1.
39		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.46 (s, 1H), 8.24 (d, <i>J</i> = 2.7 Hz, 2H), 7.57 (dd, <i>J</i> = 12.8, 2.2 Hz, 1H), 7.52 – 7.39 (m, 1H), 7.19 (s, 1H), 7.12 (t, <i>J</i> = 8.6 Hz, 1H), 5.66 (s, 2H), 4.02 (q, <i>J</i> = 9.0 Hz, 2H), 3.59 (d, <i>J</i> = 9.0 Hz, 1H), 3.15 (d, <i>J</i> = 11.3 Hz, 1H), 3.10 – 2.86 (m, 3H), 1.97 – 1.85 (m, 1H), 1.85 – 1.50 (m, 3H). LC-MS: [M+H] ⁺ = 560.8, 561.8.
40		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 1.60-1.92 (4H, m), 2.94-3.14 (4H, m), 3.84-4.04 (2H, dd), 5.66 (2H, s), 6.46 (1H, t), 7.07-7.11 (1H, m), 7.25 (1H, s), 7.37-7.54 (3H, m), 8.23 (2H, d), 8.50 (1H, s). LC-MS: [M+H] ⁺ = 499.1.
41		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.40 (s, 1H), 8.12 (d, <i>J</i> = 2.4 Hz, 2H), 7.65-7.60 (m, 1H), 7.43-7.41 (m, 1H), 7.20-7.13 (m, 1H), 6.54-6.17 (m, 1H), 5.54 (s, 2H), 3.93 (d, <i>J</i> = 9.6 Hz, 1H), 3.75 (d, <i>J</i> = 10.0 Hz, 1H), 3.02 (d, <i>J</i> = 11.6 Hz, 1H), 2.90-2.84 (m, 3H), 1.80-1.48 (m, 4H). LC-MS: [M+H] ⁺ = 517.2.

Example #	Structure	¹ H NMR & MS
42		¹ H NMR (400 MHz, CD ₃ OD) δ 1.58-1.90 (4H, m), 2.98-3.14 (4H, m), 3.84-4.05(5H, m), 5.65 (2H, s), 6.46 (1H, t), 7.11 (1H, m), 7.19 (1H, s), 7.55 (2H, q), 8.23(2H, d), 8.46 (1H, s). LC-MS: [M+H] ⁺ = 529.1.
43		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.51 (s, 1H), 8.24 (d, J = 1.4 Hz, 2H), 7.75 (ddd, J = 12.0, 7.8, 2.2 Hz, 1H), 7.53 (ddt, J = 8.2, 4.0, 1.7 Hz, 1H), 7.37 – 7.23 (m, 2H), 5.66 (s, 2H), 4.02 (q, J = 9.0 Hz, 2H), 3.86 (d, J = 9.0 Hz, 1H), 3.58 (d, J = 9.1 Hz, 1H), 3.16 (d, J = 11.2 Hz, 1H), 3.11 – 2.83 (m, 3H), 1.92 (s, 1H), 1.86 – 1.66 (m, 2H), 1.66 – 1.51 (m, 1H). LC-MS: [M+H] ⁺ = 548.8, 549.8.
44		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 1.59-1.94 (4H, m), 2.95-3.15 (4H, m), 3.85-4.05(2H, dd), 5.66 (2H, s), 6.46 (1H, t), 7.10-7.15 (2H, m), 7.20 (1H, s), 7.73-7.76 (2H, m), 8.23(2H, d), 8.49 (1H, s). LC-MS: [M+H] ⁺ = 499.1.
45		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.49 (s, 1H), 8.24 (s, 2H), 7.82 – 7.70 (m, 2H), 7.23 – 7.09 (m, 3H), 5.67 (s, 2H), 4.03 (q, J = 9.0 Hz, 2H), 3.86 (d, J = 8.9 Hz, 1H), 3.59 (d, J = 9.0 Hz, 1H), 3.16 (d, J = 11.3 Hz, 1H), 3.09 – 2.85 (m, 3H), 1.92 (s, 1H), 1.86 – 1.51 (m, 3H). LC-MS: [M+H] ⁺ = 530.8, 531.8.
46		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.34 (s, 1H), 8.12 (d, 2H), 7.46 -7.33 (m, 2H), 7.09 (s, 1H), 7.00 (t, 1H), 5.53 (s, 3H), 3.78 (s, 3H), 3.46 (d, 1H), 3.26 (s, 3H), 3.20 (t, 1H), 3.00 - 2.80 (m, 4H), 1.85 - 1.46 (m, 4H). LC-MS: [M+H] ⁺ = 493.1.

Example 47: (S)-9-((5-(3-amino-3-(2,2-difluoroethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine



To a solution of methyl 2-(3,4-difluorophenyl)-5-fluoroisonicotinate (Intermediate A) (1.35g, 5.05 mmol) and tert-butyl (3-(2,2-difluoroethyl)piperidin-3-yl)carbamate (Intermediate 47-6) (1.3 g, 5.05 mmol) in DMSO (30 mL) was added DIPEA (20 mL) at rt, the reaction mixture was stirred at 120 °C for 8 hr under N₂ atmosphere. LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with water, extracted with EtOAc (20 mL*3), the combined organic phase was washed with water (20 mL), brine (20 mL), dried over anhydrous sodium sulfate, concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 0% to 30% EtOAc in PE in 30mins) to afford methyl 5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoroethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)isonicotinate (47-7). LC-MS: [M+H]⁺ = 512.0.


To a solution of methyl 5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoroethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)isonicotinate (47-7) (1.2 g, 2.346 mmol) in THF (30 mL) and Methanol (30 mL), was added lithium chloride (1.97 g, 46.9 mmol) and sodium tetrahydroborate (1.78 g, 46.9 mmol) at rt, the reaction mixture was stirred at rt for 5h under N₂ atmosphere. LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with water (20 mL), extracted with EtOAc (20 mL*3), the combined organic phase was washed with water (20 mL), brine (20 mL), dried over anhydrous sodium sulfate, concentrated to give a residue. The residue was purified by flash chromatography (elution gradient: 10% to 50% EtOAc

in hexane in 30mins) to afford tert-butyl (3-(2,2-difluoroethyl)-1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-3-yl)carbamate (47-8). LC-MS: $[M+H]^+ = 484.2$.







To a solution of tert-butyl (3-(2,2-difluoroethyl)-1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-3-yl)carbamate (47-8) (865 mg, 1.789 mmol), Intermediate B (600 mg, 1.789 mmol) and triphenylphosphine (939 mg, 3.58 mmol) and in THF (20 mL), was added DEAD (0.567 mL, 3.58 mmol) dropwise at 0 °C, the reaction mixture was stirred at 0 °C for 0.5 hr under N₂ atmosphere. LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with water (20 mL), extracted with EtOAc (20 mL*3), the combined organic phase was washed with water (10 mL), brine (20 mL), dried over sodium sulfate, concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 0% to 10% MeOH in DCM in 30mins) to afford tert-butyl (tert-butoxycarbonyl(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoroethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (47-9). LC-MS: $[M+H]^+ = 801.1$.






To a solution of tert-butyl (tert-butoxycarbonyl(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoroethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (47-9) (700mg, 0.875 mmol) in DCM (18 mL) was added TFA (6 mL), the reaction mixture was stirred at RT for 2 hr under N₂ atmosphere. LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was concentrated in vacuo to give the crude product. The crude product was purified by Pre-HPLC (Basic condition, NH₃H₂O%=0.05%, MECHN/H₂O=0-95% in 12 mins) to afford the pure racemic product. The racemic product was isolated by SFC to afford (S)-9-((5-(3-amino-3-(2,2-difluoroethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine (Example 47). ¹H NMR (400 MHz, CD₃OD) δ 8.49 (s, 1H), 8.23 (d, J = 3.9 Hz, 2H), 7.75 (ddd, J = 12.2, 7.8, 2.2 Hz, 1H), 7.53 (s, 1H), 7.34 – 7.22 (m, 2H), 6.38 – 6.02 (m, 1H), 5.73 – 5.52 (m, 2H), 3.00 (d, J = 9.4 Hz, 3H), 2.92 (d, J = 10.5 Hz, 1H), 2.11 (q, J = 18.5, 18.0 Hz, 2H), 1.92 (s, 1H), 1.73 (d, J = 28.9 Hz, 3H). LC-MS: $[M+H]^+ = 501.3$.

Example 48-77 can be prepared following procedures analogous to those described in Example 47, from corresponding intermediates.






Exempl e #	Structure	¹ H NMR & MS
48		¹ H NMR (400MHz, CD ₃ OD) δ : 8.47-8.58 (m, 1H), 8.26 (s, 1H), 7.76 (d, J=3.5 Hz, 1H), 7.68 (d, J=6.0 Hz, 2H), 7.48 (d, J=3.5 Hz, 1H), 7.38-7.46 (m, 1H), 7.24 (dt, J=10.3, 8.5 Hz, 1H), 6.69 (d, J=6.0 Hz, 1H), 5.64-5.77 (m, 2H), 3.25-3.42 (m, 4H), 3.13 (br d, J=11.0 Hz, 1H), 2.93-3.05 (m, 3H), 1.86-1.99 (m, 2H), 1.65-1.77 (m, 1H), 1.52-1.64 (m, 1H). LC-MS: $[M+H]^+ = 533.1$.


Example #	Structure	¹ H NMR & MS
49		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.49 (s, 1H), 8.25 (s, 1H), 7.69 (q, J = 4.1, 2.3 Hz, 3H), 7.50 (d, J = 2.1 Hz, 1H), 7.21 – 6.94 (m, 3H), 6.69 (d, J = 6.1 Hz, 1H), 6.16 (d, J = 2.2 Hz, 1H), 5.70 (s, 2H), 3.85 (s, 3H), 3.07 (dd, J = 11.7, 6.3 Hz, 2H), 2.91 (d, J = 21.9 Hz, 4H), 1.92 (dtq, J = 29.4, 10.3, 5.0, 4.6 Hz, 2H), 1.63 (dtd, J = 29.5, 13.2, 4.8 Hz, 2H). LC-MS: [M+H] ⁺ = 512.1, 513.0.
50		¹ H NMR (400 MHz, DMSO-d ₆) δ ppm 8.51 (d, J = 4.4 Hz, 1H), 8.44 (s, 1H), 8.23 (s, 1H), 7.76 (t, J = 7.6 Hz, 1H), 7.68 (d, J = 6.0 Hz, 1H), 7.49 (dd, J = 12.4 Hz, 2.0 Hz, 1H), 7.35 (d, J = 7.2 Hz, 1H), 7.29 (t, J = 8.0 Hz, 1H), 7.06 (t, J = 8.4 Hz, 1H), 7.00 (s, 1H), 6.68 (d, J = 6.0 Hz, 1H), 5.68 (s, 2H), 3.86 (s, 3H), 3.13-3.00 (m, 4H), 2.97-2.85 (m, 2H), 2.00-1.80 (m, 2H), 1.72-1.52 (m, 2H). LC-MS: [M+H] ⁺ = 539.3.
51		¹ H NMR (400 MHz, DMSO-d ₆) δ ppm 8.55-8.46 (m, 2H), 8.24 (s, 1H), 7.76 (t, J = 7.6 Hz, 1H), 7.71-7.63 (m, 2H), 7.47-7.40 (m, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.31-7.21 (m, 2H), 7.07 (s, 1H), 6.67 (d, J = 6.0 Hz, 1H), 5.69 (s, 2H), 3.16-3.02 (m, 4H), 2.95-2.88 (m, 2H), 2.02-1.81 (m, 2H), 1.71-1.54 (m, 2H). LC-MS: [M+H] ⁺ = 527.2 [M+H] ⁺ .
52		¹ H NMR (400 MHz, DMSO-d ₆) δ ppm 8.48 (s, 1H), 8.29 (s, 1H), 8.11 (s, 1H), 8.01 (s, 1H), 7.97 – 7.80 (m, 1H), 7.61 (d, J = 8.1 Hz, 1H), 7.56 – 7.43 (m, 1H), 7.31 (d, J = 14.8 Hz, 3H), 7.13 (s, 1H), 5.71 – 5.44 (m, 2H), 3.13 – 2.82 (m, 6H), 2.06 – 1.63 (m, 4H), 1.65 – 1.40 (m, 2H). LC-MS: [M+H] ⁺ = 518.2, 519.2.
53		¹ H NMR (400 MHz, DMSO-d ₆) δ ppm 8.46 (s, 1H), 8.29 (s, 1H), 8.12 (s, 1H), 7.90-7.84 (m, 1H), 7.71 (d, J = 3.2 Hz, 1H), 7.63-7.55 (m, 2H), 7.51-7.44 (m, 1H), 7.30 (d, J = 10.8 Hz, 2H), 5.61-5.59 (m, 2H), 3.31 (m, 2H), 3.18 (d, J = 14.4 Hz, 1H), 2.95-2.82 (m, 4H), 1.85-1.70 (m, 2H), 1.58-1.48 (m, 1H), 1.46-1.39 (m, 1H). LC-MS: [M+H] ⁺ = 534.1.

Example #	Structure	¹ H NMR & MS
54		¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ ppm 8.47 (d, <i>J</i> = 3.6 Hz, 1H), 8.43 (s, 1H), 8.29 (s, 1H), 8.09 (s, 1H), 7.88-7.81 (m, 1H), 7.66 (dt, <i>J</i> = 2.0 Hz, 7.6 Hz, 1H), 7.61-7.55 (m, 1H), 7.50-7.41 (m, 1H), 7.33 (d, <i>J</i> = 7.6 Hz, 1H), 7.30-7.22 (m, 2H), 7.21-7.16 (m, 2H), 5.55 (q, <i>J</i> = 16.4 Hz, 2H), 3.01-2.75 (m, 6H), 2.05 (brs, 2H), 1.85-1.70 (m, 2H), 1.55-1.43 (m, 1H), 1.42-1.30 (m, 1H). LC-MS: [M+H] ⁺ = 528.2.
55		¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ ppm 8.51 (s, 1H), 8.23 (s, 1H), 7.81-7.74 (m, 2H), 7.61 (t, <i>J</i> = 7.6 Hz, 1H), 7.59 (d, <i>J</i> = 6.0 Hz, 1H), 7.54 (d, <i>J</i> = 7.6 Hz, 1H), 7.25-7.16 (m, 2H), 7.13-7.05 (m, 2H), 6.54 (d, <i>J</i> = 6.0 Hz, 1H), 6.19 (s, 2H), 5.54 (s, 2H), 3.53-3.45 (m, 1H), 3.18-3.09 (m, 1H), 3.04-2.99 (m, 1H), 2.98-2.89 (m, 1H), 2.48 (s, 3H), 2.34-2.16 (m, 3H), 2.15-2.04 (m, 1H), 1.81-1.72 (m, 1H), 1.70-1.63 (m, 1H). LC-MS: [M+H] ⁺ = 509.3.
56		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.49 (s, 1H), 8.23 (d, <i>J</i> = 3.8 Hz, 2H), 7.74 (ddd, <i>J</i> = 12.1, 7.7, 2.2 Hz, 1H), 7.51 (dd, <i>J</i> = 14.3, 4.2 Hz, 2H), 7.29 (d, <i>J</i> = 10.3 Hz, 2H), 6.17 (d, <i>J</i> = 2.2 Hz, 1H), 5.74 – 5.56 (m, 2H), 3.86 (s, 3H), 3.03 (d, <i>J</i> = 11.2 Hz, 2H), 2.88 (d, <i>J</i> = 26.8 Hz, 4H), 2.00 – 1.74 (m, 2H), 1.62 (q, <i>J</i> = 5.8, 5.4 Hz, 2H). LC-MS: [M+H] ⁺ = 531.0, 532.0.
57		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.39 (s, 1H), 8.21 (s, 1H), 7.72 (d, <i>J</i> = 3.2 Hz, 1H), 7.66 (d, <i>J</i> = 6 Hz, 1H), 7.50-7.49 (m, 2H), 7.31 (d, <i>J</i> = 8.8 Hz, 1H), 6.96 (t, <i>J</i> = 7.6 Hz, 2H), 6.67 (d, <i>J</i> = 6.0 Hz, 1H), 5.72-5.59 (m, 2H), 3.79 (s, 3H), 3.40-3.20 (m, 2H), 3.05 (d, <i>J</i> = 11.2 Hz, 1H), 2.95-2.85 (m, 3H), 1.95-1.76 (m, 2H), 1.70-1.60 (m, 1H), 1.55-1.45 (m, 1H). LC-MS: [M+H] ⁺ = 545.2
58		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.50 (s, 1H), 8.32 (s, 1H), 8.23 (s, 1H), 7.52-7.47 (m, 2H), 7.42-7.36 (m, 1H), 7.20 (s, 1H), 7.11-7.07 (m, 1H), 5.72-5.63 (m, 2H), 3.15-2.94 (m, 4H), 2.56-2.47 (m, 2H), 1.96-1.64 (m, 4H). LC-MS: [M+H] ⁺ = 477.1.
60		¹ H NMR (400MHz, CD ₃ OD) δ: 8.51 (s, 1H), 8.24 (d, <i>J</i> = 4.0 Hz, 2H), 7.76 (ddd, <i>J</i> = 12.1, 7.8, 2.2 Hz, 1H), 7.60 – 7.47 (m, 1H), 7.39 – 7.16 (m, 2H), 5.89 – 5.55 (m, 2H), 3.60 (td, <i>J</i> = 6.4, 2.3 Hz, 2H), 3.35 (s, 3H), 2.97 (dp, <i>J</i> = 24.6, 11.2 Hz, 4H), 2.04 – 1.71 (m, 4H), 1.65 (d, <i>J</i> = 7.3 Hz, 2H). LC-MS: [M+H] ⁺ = 495.2


Examp e #	Structure	¹ H NMR & MS
61		¹ H NMR (400 MHz, CD ₃ OD) δ 8.46 (d, <i>J</i> = 2.5 Hz, 1H), 8.32 – 8.16 (m, 2H), 7.58 (dt, <i>J</i> = 12.7, 1.8 Hz, 1H), 7.53 – 7.42 (m, 1H), 7.25 (s, 1H), 7.20 – 6.97 (m, 1H), 6.41 – 6.00 (m, 1H), 5.83 – 5.51 (m, 2H), 3.90 (d, <i>J</i> = 1.4 Hz, 3H), 3.07 – 2.80 (m, 4H), 2.33 – 1.99 (m, 2H), 1.93 (s, 1H), 1.82 – 1.55 (m, 3H). LC-MS: [M+H] ⁺ = 512.8, 513.8.
62		¹ H NMR (400 MHz, CDCl ₃) δ ppm 8.52 (s, 1H), 8.39 (s, 1H), 7.92 (s, 1H), 7.66-7.77 (m, 2H), 7.48 (br d, <i>J</i> =8.0 Hz, 1H), 7.19 (s, 1H), 5.76 (br s, 2H), 5.47-5.58 (m, 2H), 2.92-3.12 (m, 4H), 2.42-2.49 (m, 1H), 2.15 (d, <i>J</i> =4.3 Hz, 1H), 1.59-1.79 (m, 4H). LC-MS: [M+H] ⁺ = 493.8.
63		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.52 (s, 1H), 8.27 (s, 1H), 7.87 (s, 1H), 7.74 – 7.64 (m, 2H), 7.45 (ddt, <i>J</i> = 8.3, 4.0, 1.7 Hz, 1H), 7.27 (dt, <i>J</i> = 10.6, 8.4 Hz, 1H), 7.15 (s, 1H), 7.07 (s, 1H), 6.70 (d, <i>J</i> = 6.0 Hz, 1H), 5.80 – 5.60 (m, 2H), 3.24 – 3.04 (m, 4H), 3.04 – 2.99 (m, 2H), 2.01 – 1.88 (m, 2H), 1.68 (dp, <i>J</i> = 28.2, 7.3, 6.5 Hz, 2H). LC-MS: [M+H] ⁺ = 517.2, 518.2.
64		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.55-8.61 (m, 1H), 8.52 (s, 1H), 8.38 (s, 1H), 7.74-7.80 (m, 2H), 7.66-7.73 (m, 2H), 7.39 (s, 1H), 6.21-6.53 (m, 1H), 5.85 (br d, <i>J</i> =12.5 Hz, 2H), 3.73 (t, <i>J</i> =6.4 Hz, 2H), 3.42 (s, 2H), 3.01 (t, <i>J</i> =6.4 Hz, 2H), 2.42-2.62 (m, 2H), 1.94-2.18 (m, 4H), 1.35-1.41 (m, 2H). LC-MS: [M+H] ⁺ = 613.9.
65		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.62 – 8.40 (m, 2H), 8.25 (s, 2H), 7.77 (q, <i>J</i> = 7.7 Hz, 2H), 7.56 (q, <i>J</i> = 3.4 Hz, 1H), 7.44 – 7.14 (m, 4H), 5.82 – 5.55 (m, 2H), 3.18 – 3.08 (m, 2H), 3.00 (dd, <i>J</i> = 11.9, 6.2 Hz, 2H), 2.87 (t, <i>J</i> = 10.4 Hz, 1H), 1.88 (t, <i>J</i> = 9.8 Hz, 1H), 1.80 – 1.65 (m, 1H), 1.55 (td, <i>J</i> = 12.3, 10.9, 4.5 Hz, 1H), 1.34 (t, <i>J</i> = 11.2 Hz, 4H). LC-MS: [M+H] ⁺ = 542.0, 543.0.

Examp e #	Structure	¹ H NMR & MS
66		¹ H NMR (400 MHz, CD ₃ OD) δ 8.49 (s, 1H), 8.27 (s, 1H), 8.23 (s, 1H), 7.54-7.49 (m, 2H), 7.43-7.37 (m, 1H), 7.24 (s, 1H), 7.11-7.07 (m, 1H), 5.72-5.63 (m, 2H), 3.10-2.94 (m, 4H), 2.72 (s, 3H), 2.49 (s, 2H), 1.90-1.66 (m, 4H). LC-MS: [M+H] ⁺ = 490.2
67		¹ H NMR (400MHz, CD ₃ OD) δ: 8.49 (s, 1H), 8.32 (s, 1H), 7.73 – 7.55 (m, 2H), 7.38 (d, J = 8.7 Hz, 1H), 7.26 (dt, J = 10.4, 8.4 Hz, 1H), 6.79 (s, 1H), 5.95 (s, 2H), 3.19 – 2.99 (m, 4H), 2.74 (s, 3H), 2.55 (q, J = 14.9 Hz, 2H), 1.93 (d, J = 39.7 Hz, 2H), 1.70 (s, 2H) . LC-MS: [M+H] ⁺ = 540.8
68		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.48 (d, J = 6.1 Hz, 1H), 8.32 (d, J = 6.1 Hz, 1H), 7.63 (h, J = 6.6 Hz, 2H), 7.37 (s, 1H), 7.26 (q, J = 8.4 Hz, 1H), 6.79 (d, J = 6.2 Hz, 1H), 5.90 (d, J = 6.5 Hz, 2H), 3.07 (dd, J = 14.0, 7.4 Hz, 7H), 2.96 – 2.75 (m, 4H), 2.61 (dd, J = 16.5, 6.4 Hz, 1H), 1.94 (d, J = 25.0 Hz, 2H), 1.74 (s, 2H). LC-MS: [M+H] ⁺ = 554.8, 556.7.
69		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.45 (s, 1H), 8.22 (s, 1H), 8.21 (s, 1H), 7.86 (q, J = 8.0 Hz, 1H), 7.76-7.65 (m, 1H), 7.54-7.46 (m, 1H), 7.30-7.20 (m, 3H), 6.90 (dd, J = 2.4, 8.0 Hz, 1H), 5.76-5.58 (m, 2H), 3.09-2.86 (m, 6H), 1.96-1.76 (m, 2H), 1.72-1.51 (m, 2H). LC-MS: [M+H] ⁺ = 546.4.
70		¹ H NMR (400 MHz, CD ₃ OD) δ 8.38 (s, 1H), 8.14 (s, 1H), 8.12 (s, 1H), 7.43-7.38 (m, 2H), 7.31-7.26 (m, 1H), 7.14 (s, 1H), 7.00-6.96 (m, 1H), 5.54-5.51 (m, 2H), 3.09-2.92 (m, 6H), 2.88-2.78 (m, 4H), 2.67-2.60 (m, 1H), 2.52-2.48 (m, 1H), 1.88-1.57 (m, 4H). LC-MS: [M+H] ⁺ = 504.2.
71		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.49 (s, 1H), 8.24 (t, J = 3.0 Hz, 2H), 7.78 (dt, J = 8.4, 4.3 Hz, 2H), 7.25 (s, 1H), 7.15 (t, J = 8.5 Hz, 2H), 6.22 (tt, J = 56.3, 4.7 Hz, 1H), 5.93 – 5.53 (m, 2H), 3.13 – 2.79 (m, 4H), 2.34 – 1.86 (m, 3H), 1.86 – 1.54 (m, 3H). LC-MS: [M+H] ⁺ = 482.9, 483.9.

Examp e #	Structure	¹ H NMR & MS
72		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.52 (s, 1H), 8.28 (s, 1H), 7.76 – 7.63 (m, 2H), 7.44 (ddt, J = 8.3, 3.9, 1.6 Hz, 1H), 7.27 (dt, J = 10.5, 8.5 Hz, 1H), 7.04 (s, 1H), 6.66 (d, J = 6.0 Hz, 1H), 5.71 (s, 2H), 3.21 – 2.91 (m, 4H), 2.74 (s, 3H), 2.55 (s, 2H), 1.97 (d, J = 11.2 Hz, 1H), 1.88 (d, J = 5.2 Hz, 1H), 1.72 (d, J = 4.7 Hz, 2H). LC-MS: [M+H] ⁺ = 506.9, 507.9.
73		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.37 (s, 1H), 8.13 (s, 1H), 8.10 (s, 1H), 7.44-7.39 (m, 2H), 7.31-7.26 (m, 1H), 7.18 (s, 1H), 7.00-6.96 (m, 1H), 5.60-5.49 (m, 2H), 3.57 (s, 3H), 2.98-2.86 (m, 4H), 2.56-2.45 (m, 2H), 1.82-1.56 (m, 4H). LC-MS: [M+H] ⁺ = 491.2.
74		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.68 – 8.56 (m, 2H), 8.56 – 8.43 (m, 2H), 8.24 (d, J = 3.5 Hz, 2H), 7.76 (ddd, J = 12.0, 7.8, 2.2 Hz, 1H), 7.54 (ddt, J = 8.2, 3.8, 1.7 Hz, 1H), 7.38 – 7.17 (m, 2H), 5.82 – 5.51 (m, 2H), 3.21 – 3.05 (m, 3H), 2.97 (t, J = 8.5 Hz, 3H), 1.88 (d, J = 9.1 Hz, 2H), 1.70 (dt, J = 13.8, 6.5 Hz, 1H), 1.61 (q, J = 7.6, 6.4 Hz, 1H). LC-MS: [M+H] ⁺ = 529.2, 530.2.
75		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.55 (s, 1H), 8.35 (s, 1H), 8.25 (s, 1H), 7.79 (br d, J=8.0 Hz, 2H), 7.47 (s, 1H), 7.39 (br d, J=8.0 Hz, 2H), 6.20-6.53 (m, 1H), 5.65 (br d, J=3.0 Hz, 2H), 4.46 (s, 2H), 4.11 (s, 2H), 3.06 (br s, 2H), 2.98 (br s, 2H), 2.40-2.54 (m, 2H), 1.87-2.03 (m, 4H). LC-MS: [M+H] ⁺ = 570.0.
76		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.55-8.59 (m, 1H), 8.47-8.51 (m, 1H), 8.36 (s, 1H), 7.73-7.81 (m, 4H), 7.37 (s, 1H), 6.42-6.48 (m, 1H), 6.41 (d, J=2.5 Hz, 1H), 6.21-6.39 (m, 1H), 5.77-5.84 (m, 3H), 3.40 (br d, J=4.3 Hz, 2H), 3.12-3.22 (m, 1H), 3.01-3.09 (m, 1H), 2.43-2.60 (m, 2H), 2.04 (br d, J=11.0 Hz, 4H). LC-MS: [M+H] ⁺ = 534.0.

Examp e #	Structure	¹ H NMR & MS
77		¹ H NMR (CD ₃ OD) δ: 8.55 (s, 1H), 8.28 (d, J = 20.9 Hz, 2H), 7.80 (t, J = 10.0 Hz, 1H), 7.59 (s, 1H), 7.45 – 7.23 (m, 2H), 5.66 (s, 2H), 3.22 (t, J = 9.4 Hz, 2H), 3.08 – 2.86 (m, 4H), 2.23 (s, 2H), 1.90 (d, J = 8.8 Hz, 4H) LC-MS: [M+H] ⁺ = 475.8

Example 78: (R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-fluorophenyl)pyridin-3-yl)-N-methylpiperidine-3-carboxamide



5 To a solution of methyl tert-butyl 3-(methylcarbamoyl)piperidin-3-ylcarbamate (Intermediate 78-5) (200 mg, 0.777 mmol), methyl 5-fluoro-2-(3-fluorophenyl)isonicotinate (Intermediate C) (161 mg, 0.648 mmol) in DMSO (4 mL) was added DIPEA (4 mL) at RT, the reaction mixture was stirred at 120 °C overnight. The reaction mixture was dilluted with water, extracted with EtOAc, the combined organic phase was washed with water (20 mL), brine (20 mL), dried over
10 anhydrous sodium sulfate, concentrated to give a residue. The residue was purified by flash chromatography (elution gradient: 0% to 30% EtOAc in PE in 30mins) to afford methyl 5-(3-(tert-butoxycarbonylamino)-3-(methylcarbamoyl)piperidin-1-yl)-2-(3-fluorophenyl) isonicotinate (78-6) as a light yellow oil. LC-MS: [M+H]⁺ = 487.3.

To a mixture of methyl 5-(3-(tert-butoxycarbonylamino)-3-(methylcarbamoyl)piperidin-1-yl)-
15 2-(3-fluorophenyl) isonicotinate (78-6) (150 mg, 0.308 mmol), LiCl (130 mg, 3.08 mmol), THF (5






mL) and MeOH (5 mL) was added NaBH₄ (232 mg, 6.16 mmol) portionwise. After addition, the mixture was stirred at RT for 3 h. LC-MS monitored the reaction and indicated the reaction was complete. Then water (10 mL) was added to quench the reaction, extracted with EtOAc, the combined organic phase was washed with water (20 mL), brine, dried over anhydrous sodium sulfate, concentrated to give a residue. The residue was purified by flash chromatography (elution gradient: 10% to 50% EtOAc in PE in 30mins) to give tert-butyl 1-(6-(3-fluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)-3-(methylcarbamoyl)piperidin-3-ylcarbamate (78-7) as a white solid. LC-MS: [M+H]⁺ = 459.2.






To a solution of tert-butyl 1-(6-(3-fluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)-3-(methylcarbamoyl)piperidin-3-ylcarbamate (78-7) (129 mg, 0.282 mmol), Intermediate B (142 mg, 0.423 mmol), n-Bu₃P (171 mg, 0.845 mmol) in THF (5 mL) was added DIAD (171 mg, 0.845 mmol) dropwise at RT under N₂ atmosphere, after addition, the mixture was stirred at RT for 1h under N₂. LC-MS monitored the reaction and indicated the reaction was complete. Then water (10 mL) was added to quench the reaction, extracted with EtOAc, the combined organic phase was washed with water (20 mL), brine, dried over anhydrous sodium sulfate, concentrated to give a residue. The residue was purified by flash chromatography (elution gradient: 10% to 70% EtOAc in PE in 30mins) to afford tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(methylcarbamoyl) piperidin-1-yl)-2-(3-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (78-8) as a colorless oil. LC-MS: [M+H]⁺ = 776.3

To a solution of tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(methylcarbamoyl) piperidin-1-yl)-2-(3-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (78-8) (100 mg, 0.232 mmol) in DCM (9 mL), was added TFA (3 mL) at RT. The reaction mixture was stirred at RT for 1h. LCMS monitored the reaction and indicated the reaction was complete. The mixture was concentrated in vacuo to give a residue. The residue was purified by Pre-HPLC (Basic condition, NH₃H₂O%=0.05%, MeOH/H₂O=0-95% in 12mins) to afford 40mg of pure racemic product. The racemic product was isolated by SFC to give (R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-fluorophenyl)pyridin-3-yl)-N-methylpiperidine-3-carboxamide (Example 78) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 8.39 (s, 1H), 8.17 (s, 1H), 8.11 (s, 1H), 7.44-7.39 (m, 2H), 7.32-7.27 (m, 1H), 7.18 (s, 1H), 7.01-6.97 (m, 1H), 5.62-5.51 (m, 2H), 3.32-3.29 (m, 1H), 3.02-2.99 (m, 1H), 2.91-2.78 (m, 2H), 2.69 (s, 3H), 2.09-2.01 (m, 1H), 1.97-1.87 (m, 1H), 1.70-1.67 (m, 1H), 1.55-1.51 (m, 1H). LC-MS: [M+H]⁺ = 476.2


Example 79-88 can be prepared following procedures analogous to those described in Example 78.

Example #	Structure	¹ H NMR & MS
-----------	-----------	-------------------------

Example #	Structure	¹ H NMR & MS
79		¹ H NMR (400 MHz, CDCl ₃) δ ppm 8.54 (s, 1H), 8.41 (s, 1H), 7.94 (s, 1H), 7.59 – 7.47 (m, 2H), 7.40 – 7.30 (m, 2H), 7.04 (td, <i>J</i> = 8.2, 2.1 Hz, 1H), 5.67 (s, 2H), 5.60 – 5.46 (m, 2H), 3.79 (s, 3H), 3.48 (d, <i>J</i> = 11.4 Hz, 1H), 3.01 (dd, <i>J</i> = 13.7, 8.4 Hz, 3H), 2.21 (d, <i>J</i> = 5.4 Hz, 1H), 2.04 – 1.86 (m, 2H), 1.67 – 1.59 (m, 1H). LC-MS: [M+H] ⁺ = 477.1.
80		¹ H NMR (400 MHz, CD ₃ OD) δ 8.37(1H, s), 8.17 (1H, s), 8.12 (1H, s), 7.45 (1H, dd, <i>J</i> = 8.4 Hz, 2.0 Hz), 7.35 (1H, d, <i>J</i> = 8.8 Hz), 7.12 (1H, s), 6.99 (1H, t, <i>J</i> = 8.8 Hz), 5.48-5.62 (2H, m), 3.78 (3H, s), 3.34-3.37 (1H, m), 2.98-3.20 (8H, m), 2.68-2.74 (1H, m), 1.86-1.96 (2H, m), 1.67-1.82 (2H, m). LC-MS: [M+H] ⁺ = 520.2.
81		¹ H NMR (400 MHz, CD ₃ OD) δ 8.36 (s, 1H), 8.13 (s, 2H), 7.47-7.43 (m, 1H), 7.35-7.33 (m, 1H), 7.13 (s, 1H), 7.01-6.97 (m, 1H), 5.56-5.47 (m, 2H), 4.98-4.92 (m, 1H), 3.77 (s, 3H), 3.38 (d, <i>J</i> = 11.2 Hz, 1H), 2.89-2.86 (m, 3H), 2.08-2.04 (m, 1H), 1.83-1.77 (m, 2H), 1.59-1.57 (m, 1H), 1.19-1.16 (m, 6H). LC-MS: [M+H] ⁺ = 535.2.
82		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.48 (s, 1H), 8.23 (d, <i>J</i> = 15.0 Hz, 2H), 7.74 (ddd, <i>J</i> = 12.1, 7.8, 2.2 Hz, 1H), 7.52 (ddt, <i>J</i> = 7.5, 3.5, 1.7 Hz, 1H), 7.39 – 7.21 (m, 2H), 6.05 – 5.41 (m, 2H), 3.90 (tdd, <i>J</i> = 15.3, 7.9, 4.1 Hz, 3H), 3.62 – 3.33 (m, 3H), 3.15 – 3.04 (m, 1H), 3.00 – 2.79 (m, 2H), 2.27 – 1.91 (m, 2H), 1.90 – 1.73 (m, 3H), 1.57 (dddd, <i>J</i> = 17.4, 15.8, 8.9, 5.2 Hz, 3H). LC-MS: [M+H] ⁺ = 564.2, 565.2.
83		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.48 (s, 1H), 8.24 (d, <i>J</i> = 5.3 Hz, 2H), 7.56 (dd, <i>J</i> = 12.7, 2.1 Hz, 1H), 7.45 (d, <i>J</i> = 8.6 Hz, 1H), 7.21 (s, 1H), 7.11 (t, <i>J</i> = 8.7 Hz, 1H), 5.73 – 5.52 (m, 2H), 3.89 (s, 3H), 3.46 (d, <i>J</i> = 11.3 Hz, 1H), 3.08 – 2.88 (m, 3H), 2.14 (s, 1H), 1.91 (d, <i>J</i> = 17.6 Hz, 2H), 1.67 (s, 1H), 1.51 (s, 9H). LC-MS: [M+H] ⁺ = 549.1.

Example #	Structure	¹ H NMR & MS
84		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.52 (s, 1H), 8.39 – 8.14 (m, 2H), 7.64 (d, J = 86.3 Hz, 2H), 7.30 (s, 2H), 5.65 (q, J = 15.9 Hz, 2H), 3.84 (d, J = 55.4 Hz, 2H), 3.50 (d, J = 12.3 Hz, 3H), 3.11 (d, J = 11.1 Hz, 2H), 2.86 (s, 1H), 1.89 (d, J = 47.7 Hz, 8H). LC-MS: [M+H] ⁺ = 534.3, 535.3.
85		¹ H NMR (400MHz, CD ₃ OD) δ 8.48 (s, 1H), 8.25 (s, 1H), 8.22 (s, 1H), 7.81-7.63 (m, 1H), 7.55-7.44 (m, 1H), 7.36-7.19 (m, 2H), 5.77-5.57 (m, 2H), 4.44-4.32 (m, 1H), 3.97-3.74 (m, 3H), 3.68-3.62 (m, 1H), 3.39 (d, J = 11.2 Hz, 1H), 3.13-2.81 (m, 3H), 2.31-1.54 (m, 6H). LC-MS: [M+Na] ⁺ = 572.1
86		¹ H NMR (400MHz, CD ₃ OD): δ 8.52 (s, 1H), 8.27 (s, 1H), 8.21 (s, 1H), 7.78-7.69 (m, 1H), 7.56-7.49 (m, 1H), 7.34-7.22 (m, 2H), 5.75-5.56 (m, 2H), 3.81 (br s, 4H), 3.46 (d, J = 12.0 Hz, 1H), 3.20-3.06 (m, 2H), 2.92-2.74 (m, 1H), 2.10-1.54 (m, 10H). LC-MS: [M+H] ⁺ = 548.1.
87		¹ H NMR (400MHz, CD ₃ OD): δ 8.52 (s, 1H), 8.26 (d, J = 2.0 Hz, 1H), 8.21 (s, 1H), 7.80-7.67 (m, 1H), 7.58-7.45 (m, 1H), 7.34-7.21 (m, 2H), 5.77-5.55 (m, 2H), 5.47-4.90(m, 1H), 4.83-4.22 (m, 1H), 3.53-3.35 (m, 1H), 3.19-2.68 (m, 4H), 2.10-1.17 (m, 13H). LC-MS: [M+H] ⁺ = 562.2
88		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.79 – 8.49 (m, 1H), 8.27 (dd, J = 31.2, 5.8 Hz, 2H), 7.86 – 7.50 (m, 2H), 7.34 (s, 2H), 5.65 (q, J = 16.2 Hz, 2H), 4.23 (s, 1H), 4.03 (s, 1H), 3.90 – 3.73 (m, 1H), 3.57 (d, J = 11.7 Hz, 1H), 3.23 – 3.04 (m, 2H), 2.92 (d, J = 10.1 Hz, 1H), 2.11 – 1.80 (m, 7H), 1.55 (s, 1H), 1.21 (d, J = 6.4 Hz, 3H). LC-MS: [M+H] ⁺ = 548.3, 549.3.

Example 89: 1-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,3-dimethylbutan-1-one



To a solution of methyl (3-(2,3-dimethylbutanoyl)piperidin-3-yl)carbamate (Intermediate 89-6) (367 mg, 1.4 mmol, 1.0 eq.) and methyl 2-(3,4-difluorophenyl)-5-fluoroisonicotinate (Intermediate A) (383 mg, 1.4 mmol, 1.0 eq.) in DMSO (10 mL) was added DIPEA (724 mg, 5.6 mmol, 4.0 eq.). The mixture was stirred at 120°C for 5 hours under N₂ atmosphere. LCMS indicated the reaction was complete. The mixture was diluted with H₂O (20 mL), extracted with EtOAc (20 mL*2). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (30% EtOAc in PE) to give methyl 2-(3,4-difluorophenyl)-5-(3-(2,3-dimethylbutanoyl)-3-((methoxycarbonyl)amino) piperidin-1-yl)isonicotinate (89-7) as a yellow solid. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.52 (s, 0.5H), 8.50 (s, 0.5H), 8.02 (s, 0.5H), 7.98 (s, 0.5H), 7.94-7.86 (m, 1H), 7.80-7.73 (m, 1H), 7.39-7.30 (m, 1H), 4.00 (s, 1.5H), 3.99 (s, 1.5H), 3.75 (d, *J* = 12.4 Hz, 0.5H), 3.67 (d, *J* = 12.0 Hz, 0.5H), 3.59 (s, 1.5H), 3.54 (s, 1.5H), 3.42-3.34 (m, 1H), 3.23 (d, *J* = 12.4 Hz, 0.5H), 3.13-3.00 (m, 1.5H), 2.97-2.88 (m, 1H), 2.30-2.20 (m, 1H), 2.01-1.82 (m, 3H), 1.78-1.66 (m, 1H), 0.99-0.94 (m, 3H), 0.90-0.84 (m, 6H). LC-MS: [M+H]⁺ = 504.2.

To a mixture of methyl 2-(3,4-difluorophenyl)-5-(3-(2,3-dimethylbutanoyl)-3-((methoxycarbonyl)amino) piperidin-1-yl)isonicotinate (89-7) (416 mg, 0.82 mmol, 1.0 eq.) in CH₃OH (10 mL) was added NaBH₄ (312 mg, 8.2 mmol, 10 eq.) at RT. The mixture was stirred at RT for 20 minutes. LCMS indicated the reaction was not completed. Another NaBH₄ (312 mg, 8.2 mmol, 10 eq.) was added and the mixture was stirred at RT for another 20 minutes. LCMS indicated the reaction was complete. The mixture was diluted with H₂O (20 mL),

extracted with EtOAc (20 mL*2). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (30% EtOAc in hexane) to give methyl (1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)-3-(1-hydroxy-2,3-dimethylbutyl)piperidin-3-yl)carbamate (89-8) as white solid. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.34 (s, 0.4H), 8.33 (s, 0.6H), 7.91 (s, 0.4H), 7.90 (s, 0.6H), 7.88-7.81 (m, 1H), 7.76-7.70 (m, 1H), 7.39-7.32 (m, 1H), 4.84-4.69 (m, 1H), 3.90-3.64 (m, 1H), 3.63-3.55 (m, 3H), 3.49-3.43 (m, 0.3H), 3.28-3.23 (m, 0.6H), 3.18-3.02 (m, 2H), 2.86-2.76 (m, 1H), 2.31-2.15 (m, 1H), 2.00-1.86 (m, 1H), 1.82-1.54 (m, 3H), 1.21-1.20 (m, 1H), 0.95-0.78 (m, 9H). LC-MS: [M+H]⁺ = 478.2.

To a solution of methyl (1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)-3-(1-hydroxy-2,3-dimethylbutyl)piperidin-3-yl)carbamate (intermediate 89-8) (273 mg, 0.57 mmol, 1.0 eq.), Intermediate B (192 mg 0.57 mmol 1.0 eq.) and Bu₃P (578 mg, 2.86 mmol, 5.0 eq.) in THF (15 mL) was added DIEA (578 mg, 2.86 mmol, 5.0 eq.) dropwise at 0°C under N₂. Then the reaction mixture was stirred at RT for 1 hour under N₂. LC-MS showed that the starting material was consumed completely. The mixture was diluted with H₂O (20 mL), extracted with EtOAc (20 mL*2). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (50% EtOAc in PE) to give tert-butyl (tert-butoxycarbonyl)(9-((2-(3,4-difluorophenyl)-5-(3-(1-hydroxy-2,3-dimethylbutyl)-3-((methoxycarbonyl)amino)piperidin-1-yl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (89-9) as a yellow solid. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.91-8.81 (m, 1H), 8.80-8.70 (m, 1H), 8.56-8.50 (m, 1H), 7.76-7.67 (m, 1H), 7.59-7.51 (m, 1H), 7.36-7.23 (m, 2H), 5.92-5.64 (m, 2H), 4.04-3.65 (m, 2H), 3.60-3.48 (m, 3H), 3.30-2.75 (m, 3H), 2.33-2.13 (m, 2H), 1.88-1.70 (m, 4H), 1.36 (s, 18H), 0.98-0.93 (m, 9H). LC-MS: [M+H]⁺ = 795.3.

A mixture of tert-butyl (tert-butoxycarbonyl)(9-((2-(3,4-difluorophenyl)-5-(3-(1-hydroxy-2,3-dimethylbutyl)-3-((methoxycarbonyl)amino)piperidin-1-yl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (89-9) (279 mg, 0.37 mmol, 1.0 eq.) and DMP (237 mg 0.56 mmol, 1.5eq.) in DCM (10 ml) was stirred at RT for 4 hours. TLC (PE/EA=1:1, UV) and LCMS indicated the reaction was completed. The mixture was quenched with sat. aq. NaHCO₃ (30 mL), extracted with DCM (30 mL*2). The combined organic layers were washed with sat. aq. NaHCO₃ (20 mL*2), brine (30 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (50% EtOAc in PE) to give tert-butyl (tert-butoxycarbonyl)(9-((2-(3,4-difluorophenyl)-5-(3-(2,3-dimethylbutanoyl)-3-((methoxycarbonyl)amino)piperidin-1-yl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (89-10) as a yellow solid. LC-MS: [M+H]⁺ = 793.5.





A mixture of tert-butyl (tert-butoxycarbonyl)(9-((2-(3,4-difluorophenyl)-5-(3-(2,3-dimethylbutanoyl)-3-((methoxycarbonyl)amino)piperidin-1-yl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (89-10) (280 mg, crude, 0.34 mmol, 1 eq.) and 10 ml of 35% HBr in acetic acid was

stirred at RT for 20 hours. LC-MS showed most of starting material was consumed. The reaction mixture was concentrated in vacuo and diluted with H₂O (30 mL), washed with EtOAc (30 mL*3) to remove impurities. The aqueous layer was basified by NH₃.H₂O to pH = 11, extracted with EtOAc (30 mL*2), The organic layers were dried over Na₂SO₄, filtered and

- 5 concentrated to give the crude product, which was purified by prep-HPLC to give 1-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,3-dimethylbutan-1-one (Example 89) as a white solid. ¹H NMR (400MHz, CD₃OD) δ 8.52 (d, J = 4.0 Hz, 1H), 8.32-8.17 (m, 2H), 7.83-7.65 (m, 1H), 7.60-7.48 (m, 1H), 7.37-7.15 (m, 2H), 5.67 (d, J = 3.6 Hz, 2H), 3.41 (t, J = 12.0 Hz, 1H), 3.14-2.87 (m, 4H), 2.08-1.61 (m, 5H), 1.06 (t, J = 8.0
- 10 Hz, 3H), 0.95 (d, J = 6.8 Hz, 3H), 0.90 (d, J = 6.8 Hz, 3H). LC-MS: [M+H]⁺ = 535.3.






Example 90-112 can be prepared following procedures analogous to those described in Example 89.

Example #	Structure	¹ H NMR & MS
90		¹ H NMR (400 MHz, CD ₃ OD) δ 8.48 (dd, J = 13.4, 7.8 Hz, 1H), 8.36 – 8.15 (m, 2H), 7.66 – 7.36 (m, 2H), 7.27 (dd, J = 13.5, 7.9 Hz, 1H), 7.14 (dd, J = 14.3, 7.0 Hz, 1H), 5.77 – 5.51 (m, 2H), 4.02 – 3.82 (m, 3H), 3.70 (d, J = 14.0 Hz, 1H), 3.21 – 3.00 (m, 2H), 3.00 – 2.75 (m, 2H), 1.96 (s, 1H), 1.73 (d, J = 37.1 Hz, 3H), 1.25 (p, J = 7.4, 6.2 Hz, 3H). LC-MS: [M+H] ⁺ = 493.0
91		¹ H NMR (400 MHz, CD ₃ OD) δ 8.57 – 8.51 (m, 1H), 8.45 (s, 1H), 8.25 (s, 1H), 8.21 (s, 1H), 7.86 (td, J = 7.8, 1.8 Hz, 1H), 7.73 (ddd, J = 12.0, 7.7, 2.2 Hz, 1H), 7.59 (dd, J = 8.0, 1.2 Hz, 1H), 7.51 (dddd, J = 8.5, 3.9, 2.2, 1.3 Hz, 1H), 7.37 (ddd, J = 7.7, 4.9, 1.1 Hz, 1H), 7.32 – 7.22 (m, 2H), 5.77 – 5.56 (m, 3H), 3.18 (d, J = 11.4 Hz, 1H), 2.96 (tq, J = 18.3, 9.1, 8.2 Hz, 3H), 2.02 – 1.82 (m, 3H), 1.71 (dd, J = 11.0, 6.0 Hz, 1H). LC-MS: [M+H] ⁺ = 546.3
92		¹ H NMR (400 MHz, CD ₃ OD) δ 8.47 (s, 1H), 8.27 (d, J = 13.6 Hz, 2H), 7.57 (dd, J = 12.6, 2.3 Hz, 1H), 7.53 – 7.42 (m, 1H), 7.21 (s, 1H), 7.13 (t, J = 8.7 Hz, 1H), 5.69 (d, J = 2.7 Hz, 2H), 3.90 (s, 4H), 3.06 (d, J = 16.7 Hz, 3H), 2.92 (d, J = 10.5 Hz, 1H), 1.93 (d, J = 21.6 Hz, 1H), 1.79 (d, J = 4.6 Hz, 1H), 1.62 (s, 2H), 1.25 (d, J = 6.5 Hz, 3H). LC-MS: [M+H] ⁺ = 493.0

Example #	Structure	¹ H NMR & MS
93		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.46 (s, 1H), 8.25 (d, <i>J</i> = 3.4 Hz, 2H), 7.58 (d, <i>J</i> = 12.7 Hz, 1H), 7.47 (d, <i>J</i> = 8.6 Hz, 1H), 7.24 (s, 1H), 7.13 (t, <i>J</i> = 8.6 Hz, 1H), 5.83 – 5.52 (m, 2H), 3.90 (s, 3H), 3.41 (s, 2H), 3.04 (d, <i>J</i> = 9.6 Hz, 3H), 2.91 (t, <i>J</i> = 11.3 Hz, 1H), 2.07 – 1.83 (m, 1H), 1.75 (d, <i>J</i> = 15.2 Hz, 1H), 1.59 (t, <i>J</i> = 5.2 Hz, 2H), 1.20 (d, <i>J</i> = 6.2 Hz, 3H). LC-MS: [M+H] ⁺ = 506.8, 507.8.
94		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.46 (s, 1H), 8.24 (d, <i>J</i> = 9.4 Hz, 2H), 7.59 (dd, <i>J</i> = 12.8, 2.2 Hz, 1H), 7.49 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 7.29 (s, 1H), 7.13 (t, <i>J</i> = 8.7 Hz, 1H), 5.85 – 5.44 (m, 2H), 3.90 (s, 3H), 3.38 (s, 3H), 3.25 (q, <i>J</i> = 6.3 Hz, 1H), 3.06 (dd, <i>J</i> = 23.5, 11.4 Hz, 2H), 2.96 – 2.70 (m, 2H), 1.92 (dd, <i>J</i> = 15.7, 9.1 Hz, 1H), 1.69 (tdd, <i>J</i> = 24.3, 10.4, 6.2 Hz, 3H), 1.18 (d, <i>J</i> = 6.3 Hz, 3H). LC-MS: [M+H] ⁺ = 506.8, 507.8.
95		¹ H NMR (400 MHz, CD ₃ OD) δ 8.50 (s, 1H), 8.25 (d, <i>J</i> = 8.0 Hz, 2H), 7.76 (ddd, <i>J</i> = 12.1, 7.8, 2.2 Hz, 1H), 7.55 (ddt, <i>J</i> = 8.0, 3.8, 1.7 Hz, 1H), 7.37 – 7.26 (m, 2H), 5.73 – 5.61 (m, 2H), 3.47 – 3.39 (m, 1H), 3.05 (d, <i>J</i> = 8.1 Hz, 3H), 2.99 – 2.87 (m, 1H), 1.91 (tt, <i>J</i> = 9.6, 4.8 Hz, 1H), 1.84 – 1.70 (m, 1H), 1.59 (dt, <i>J</i> = 10.4, 5.3 Hz, 2H), 1.20 (d, <i>J</i> = 6.3 Hz, 3H). LC-MS: [M+H] ⁺ = 495.2.
96		¹ H NMR (400 MHz, CD ₃ OD) δ 1.65-1.74 (2H, m), 1.79-1.91 (5H, m), 2.73-2.83 (1H, m), 2.90-3.00 (2H, m), 3.23-3.27 (1H, m), 3.75 (3H, s), 3.77-3.78 (3H, m), 5.48-5.60 (2H, m), 6.96-7.05 (1H, m), 7.20 (1H, s), 7.38 (1H, d, <i>J</i> = 8.8 Hz), 7.47 (1H, dd, <i>J</i> = 8.8 Hz, 1.6 Hz), 8.14 (1H, d, <i>J</i> = 5.6 Hz), 8.37 (1H, s). LC-MS: [M+H] ⁺ = 520.3.

Example #	Structure	¹ H NMR & MS
97		¹ H NMR (CD ₃ OD) δ: 8.50 (s, 1H), 8.24 (d, J = 4.8 Hz, 2H), 7.86 – 7.52 (m, 2H), 7.46 – 7.12 (m, 2H), 5.88 – 5.49 (m, 2H), 3.38 (s, 3H), 3.30 – 3.14 (m, 2H), 3.15 – 2.65 (m, 4H), 2.06 – 1.47 (m, 4H), 1.18 (d, J = 6.4 Hz, 3H) LC-MS: [M+H] ⁺ = 495.2
98		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.48 (s, 1H), 8.27 (s, 1H), 8.21 (s, 1H), 7.72 (ddd, J = 12.0, 7.8, 2.2 Hz, 1H), 7.54 – 7.44 (m, 1H), 7.33 – 7.19 (m, 2H), 5.65 (d, J = 2.3 Hz, 2H), 3.48 (d, J = 4.7 Hz, 1H), 3.16 – 2.97 (m, 3H), 2.86 (t, J = 10.6 Hz, 1H), 2.11 – 1.88 (m, 2H), 1.81 – 1.57 (m, 3H), 1.02 (dd, J = 18.3, 6.8 Hz, 6H). LC-MS: [M+H] ⁺ = 509.3, 510.3.
99		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.48 (s, 1H), 8.23 (s, 1H), 8.21 (s, 1H), 7.80-7.70 (m, 1H), 7.59-7.50 (m, 1H), 7.34 (s, 1H), 7.32-7.24 (m, 1H), 5.64 (q, J = 12 Hz, 1H), 3.74-3.63 (m, 1H), 3.43-3.32 (m, 2H), 3.13-3.06 (m, 1H), 3.05-2.98 (m, 1H), 2.95-2.87 (m, 1H), 2.86-2.75 (m, 1H), 2.02-1.85 (m, 1H), 1.79-1.57 (m, 3H), 1.23-1.11 (m, 6H). LC-MS: [M+H] ⁺ = 509.2.
100		¹ H NMR (400 MHz, CD ₃ OD) δ 8.52 (s, 1H), 8.23 (d, J = 11.6 Hz, 2H), 7.75 (ddd, J = 12.0, 7.8, 2.2 Hz, 1H), 7.58 – 7.46 (m, 1H), 7.37 – 7.16 (m, 2H), 5.65 (d, J = 2.9 Hz, 2H), 3.57 – 3.42 (m, 2H), 2.99 (h, J = 10.8, 9.9 Hz, 3H), 2.10 – 1.94 (m, 2H), 1.94 – 1.79 (m, 3H), 1.79 – 1.57 (m, 7H). LC-MS: [M+H] ⁺ = 533.3
101		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.52 (s, 1H), 8.24 (d, J = 13.6 Hz, 2H), 7.74 (ddd, J = 12.0, 7.8, 2.2 Hz, 1H), 7.53 (dddd, J = 8.8, 3.9, 2.3, 1.4 Hz, 1H), 7.38 – 7.08 (m, 2H), 5.65 (s, 2H), 3.44 (d, J = 11.3 Hz, 1H), 3.24 (p, J = 6.8 Hz, 1H), 3.10 – 2.85 (m, 3H), 2.22 – 1.87 (m, 2H), 1.87 – 1.62 (m, 3H), 1.39 (dt, J = 13.8, 7.0 Hz, 1H), 1.09 (d, J = 6.7 Hz, 3H), 0.90 (t, J = 7.4 Hz, 3H). LC-MS: [M+H] ⁺ = 521.3, 522.3.


Example #	Structure	¹ H NMR & MS
102		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.53 (s, 1H), 8.24 (d, <i>J</i> = 15.4 Hz, 2H), 7.75 (ddd, <i>J</i> = 12.0, 7.8, 2.2 Hz, 1H), 7.53 (ddt, <i>J</i> = 8.2, 3.4, 1.6 Hz, 1H), 7.40 – 7.14 (m, 2H), 5.66 (s, 2H), 3.42 (d, <i>J</i> = 11.3 Hz, 1H), 3.23 (q, <i>J</i> = 6.8 Hz, 1H), 3.12 – 2.90 (m, 3H), 2.12 – 1.94 (m, 2H), 1.87 – 1.78 (m, 1H), 1.74 – 1.60 (m, 2H), 1.39 (dp, <i>J</i> = 14.3, 7.3 Hz, 1H), 1.08 (d, <i>J</i> = 6.7 Hz, 3H), 0.89 (t, <i>J</i> = 7.4 Hz, 3H). LC-MS: [M+H] ⁺ = 521.3, 522.3.
103		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.52 (s, 1H), 8.26 (d, <i>J</i> = 4.8 Hz, 1H), 8.22 (s, 1H), 7.77-7.72 (m, 1H), 7.56-7.52 (m, 1H), 7.34-7.25 (m, 2H), 5.72-5.61 (m, 2H), 3.46-3.38 (m, 1H), 3.06-2.92 (m, 3H), 2.62-2.54 (m, 1H), 2.04-1.97 (m, 2H), 1.82-1.64 (m, 2H), 1.19 (t, <i>J</i> = 6.4 Hz, 3H), 1.03-0.95 (m, 1H), 0.58-0.38 (m, 2H), 0.31-0.17 (m, 2H). LC-MS: [M+H] ⁺ = 533.1.
104		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.54 (d, <i>J</i> = 4.3 Hz, 1H), 8.26 (s, 1H), 8.22 (s, 1H), 7.75 (ddd, <i>J</i> = 12.0, 7.8, 2.2 Hz, 1H), 7.54 (ddt, <i>J</i> = 7.9, 3.8, 1.7 Hz, 1H), 7.38 – 7.21 (m, 2H), 5.65 (s, 2H), 3.51 – 3.36 (m, 2H), 3.01 (q, <i>J</i> = 12.6, 12.2 Hz, 3H), 2.13 – 1.92 (m, 2H), 1.85 – 1.67 (m, 2H), 1.10 (dd, <i>J</i> = 6.7, 4.1 Hz, 6H). LC-MS: [M+H] ⁺ = 507.3, 508.3.
105		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.51 (s, 1H), 8.24 (d, <i>J</i> = 9.2 Hz, 2H), 7.82-7.70 (m, 1H), 7.57-7.50 (m, 1H), 7.35-7.21 (m, 2H), 5.64 (s, 2H), 4.06-3.87 (m, 1H), 3.40 (d, <i>J</i> = 11.2 Hz, 1H), 3.08-2.86 (m, 3H), 2.38-2.24 (m, 2H), 2.19-1.95 (m, 5H), 1.89-1.72 (m, 2H), 1.68-1.59 (m, 1H). LC-MS: [M+H] ⁺ = 519.1.
106		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.53 (s, 1H), 8.26 (d, <i>J</i> = 2.0 Hz, 1H), 8.23 (s, 1H), 7.80-7.69 (m, 1H), 7.58-7.49 (m, 1H), 7.37-7.23 (m, 2H), 5.71-5.56 (m, 2H), 3.99-3.84 (m, 1H), 3.78-3.42 (m, 2H), 3.30-3.25 (m, 3H), 3.08-2.91 (m, 3H), 2.32-1.60 (m, 10H). LC-MS: [M+H] ⁺ = 563.1.

Example #	Structure	¹ H NMR & MS
107		¹ H NMR (400 MHz, CD ₃ OD): δ 8.50 (s, 1H), 8.26 (s, 1H), 8.22 (s, 1H), 7.75-7.70 (m, 1H), 7.52-7.50 (m, 1H), 7.30 (s, 1H), 7.29-7.23 (m, 1H), 5.70-5.60 (m, 2H), 3.45 (d, J = 11.6 Hz, 1H), 3.10-3.02 (m, 2H), 2.90-2.85 (m, 1H), 2.12-2.00 (m, 2H), 1.94-1.88 (m, 1H), 1.80-1.76 (m, 1H), 1.60 (s, 3H), 1.28-1.12 (m, 2H), 0.67-0.60 (m, 2H). LC-MS: [M+H] ⁺ = 519.2.
108		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.53 (s, 1H), 8.26 (s, 1H), 8.22 (s, 1H), 7.77-7.71 (m, 1H), 7.55-7.50 (m, 1H), 7.32-7.25 (m, 2H), 5.69-5.60 (m, 2H), 3.99-3.92 (m, 2H), 3.55-3.41 (m, 4H), 3.05-2.93 (m, 3H), 2.10-1.94 (m, 2H), 1.84-1.60 (m, 6H). LC-MS: [M+H] ⁺ = 549.1.
109		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.49 (s, 1H), 8.26 (s, 1H), 8.22 (s, 1H), 7.73 (ddd, J = 12.0, 7.8, 2.2 Hz, 1H), 7.51 (ddt, J = 7.9, 3.8, 1.6 Hz, 1H), 7.34 – 7.17 (m, 2H), 5.75 – 5.55 (m, 2H), 3.37 (d, J = 11.3 Hz, 1H), 3.14 – 3.00 (m, 2H), 2.84 (td, J = 11.4, 2.9 Hz, 1H), 2.15 – 1.97 (m, 2H), 1.88 – 1.78 (m, 1H), 1.74 (dq, J = 11.9, 3.2, 2.5 Hz, 1H), 1.34 (s, 9H). LC-MS: [M+H] ⁺ = 521.3, 522.3.
110		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.51 (s, 1H), 8.22 (s, 1H), 8.11 (s, 1H), 7.74-7.68 (m, 1H), 7.59 (d, J = 2.4 Hz, 1H), 7.50-7.47 (m, 1H), 7.30-7.21 (m, 2H), 6.81 (d, J = 2.4 Hz, 1H), 5.50-5.35 (m, 2H), 3.99 (s, 3H), 3.93-3.91 (m, 1H), 3.24-3.21 (m, 1H), 3.13-3.00 (m, 2H), 2.37-2.31 (m, 1H), 2.05-1.99 (m, 2H), 1.87-1.81 (m, 1H). LC-MS: [M+H] ⁺ = 545.4.
111		¹ H NMR (CD ₃ OD) δ: 8.57 – 8.43 (m, 1H), 8.31 – 8.06 (m, 2H), 7.78 (dddd, J = 12.7, 7.5, 5.1, 2.2 Hz, 1H), 7.59 (ddd, J = 9.0, 4.4, 2.3 Hz, 1H), 7.48 – 7.19 (m, 2H), 5.75 – 5.44 (m, 2H), 3.84 (ddd, J = 13.8, 11.2, 5.7 Hz, 1H), 3.63 – 3.45 (m, 1H), 3.43 – 3.32 (m, 1H), 3.24 (dt, J = 12.6, 4.1 Hz, 2H), 3.05 – 2.74 (m, 4H), 2.42 – 1.97 (m, 2H), 1.94 – 1.80 (m, 1H), 1.75 – 1.60 (m, 2H), 1.58 – 1.37 (m, 1H). LC-MS: [M+H] ⁺ = 535.3.

Example #	Structure	¹ H NMR & MS
112		¹ H NMR (400MHz, CD ₃ OD): δ 8.44 (s, 1H), 8.41 (s, 1H), 8.22 (s, 1H), 7.79-7.67 (m, 1H), 7.57-7.49 (m, 1H), 7.34-7.19 (m, 2H), 5.84-5.48 (m, 2H), 3.82-3.67 (m, 2H), 3.54-3.43 (m, 1H), 3.30-3.10 (m, 4H), 3.00-2.86 (m, 1H), 2.12-1.81 (m, 4H), 1.13 (s, 3H). LC-MS: [M+H] ⁺ = 535.0

Example 113: (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol

5 **Example 114: (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol**



To a solution of tert-butyl (3-(2,2-difluoro-1-hydroxyethyl)piperidin-3-yl)carbamate (Intermediate 113-5) (1.2g, 4.28 mmol) and methyl 2-(3,4-difluorophenyl)-5-fluoroisonicotinate (Intermediate A) (1.144 g, 4.28 mmol) in DMSO (30 mL) was added DIPEA (14.95 mL, 86 mmol) at rt, the reaction mixture was stirred at 120°C for 8 hr under N₂ atmosphere. LC-MS

5 monitored the reaction. The reaction mixture was diluted with water (40 mL), extracted with EtOAc (30 mL*3). The combined organic layers were washed with water (20 mL*3), brine (20 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to give a residue. The residue was purified by flash chromatography (elution gradient: 10% to 50% EtOAc in PE in 40mins) to afford methyl 5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)isonicotinate (113-6). LC-MS: [M+H]⁺ =528.2.

To a solution of methyl 5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)isonicotinate (113-6) (1.2g, 2.275 mmol) in THF (30 mL) and MeOH (30 mL), was added lithium chloride (1.929 g, 45.5 mmol) and sodium tetrahydroborate (1.721 g, 45.5 mmol) at 0°C, the reaction mixture was stirred at rt for 4 hours under N₂ atmosphere. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with 30ml of water, extracted with EtOAc (20 mL*3). The combined organic layers were washed with water (20 mL), brine (20 mL), concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 20% to 70% EtOAc in PE in 40mins) to afford tert-butyl (3-(2,2-difluoro-1-hydroxyethyl)-1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-3-yl)carbamate (113-7). LC-MS: [M+H]⁺ =500.2.

To a solution of tert-butyl (3-(2,2-difluoro-1-hydroxyethyl)-1-(6-(3,4-difluorophenyl)-4-(hydroxymethyl)pyridin-3-yl)piperidin-3-yl)carbamate (intermediate 113-7) (800 mg, 1.602 mmol), Intermediate B (645 mg, 1.922 mmol) and triphenylphosphine (1260 mg, 4.80 mmol) in THF (20 mL), was added DEAD (0.761 mL, 4.80 mmol) dropwise at 0 °C, after addition the reaction mixture was stirred at 0 °C for 0.5 hr under N₂ atmosphere. LCMS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with 20ml of water, extracted with EtOAc (20 mL*3). The combined organic layers were washed with water (20 mL), brine (20 mL), concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 20% to 70% EtOAc in PE in 50mins) to afford tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (113-8). LC-MS: [M+H]⁺ =817.2.



To a solution of tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (113-8) (600 mg, 0.735 mmol) in DCM (30 mL), was added TFA (10 mL), the reaction mixture was stirred at rt for 2 hr under N₂ atmosphere. LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was concentrated in vacuo to






give the crude product. The crude product was purified by Pre-HPLC (Basic condition, NH₃H₂O%=0.05%, MeOH/H₂O=0-95% in 10 mins) to afford 330mg of pure racemic product. The racemic product was isolated by SFC to afford (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl) piperidin-3-yl)-2,2-difluoroethan-1-ol (Example 113) and (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl) piperidin-3-yl)-2,2-difluoroethan-1-ol (Example 114).

Example 113: ¹H NMR (CD₃OD, 400M Hz) δ (ppm): 8.48 (s, 1H), 8.22 (d, 2H), 7.71-7.77(m,1H), 7.51-7.54(m,1H), 7.29 (s, 1H), 7.24-7.27(t,1H), 5.91-6.19 (t, 1H), 5.65 (s, 2H), 3.65(br, 1H), 3.20 (d, 1H), 2.99(m, 2H), 2.84 (t, 1H), 1.93-1.99 (m, 1H), 1.66~1.86 (m, 3H). LC-MS: [M+H]⁺ =517.2.






Example 114: ¹H NMR (CD₃OD-d₆, 400M Hz) δ (ppm): 8.49 (s, 1H), 8.22 (d, 2H), 7.69-7.75(m,1H), 7.48-7.51(m,1H), 7.24-7.31(t,1H), 7.21 (s, 1H), 5.89-6.18(t, 1H), 5.65 (s, 2H), 3.95(br, 1H), 3.25 (d, 1H), 2.90-3.10(b, 3H), 1.82-1.88 (m, 3H), 1.63 (br, 1H). LC-MS: [M+H]⁺ =517.2.

Example 115-155 can be prepared following procedures analogous to those described in Example 113 and 114.






Example #	Structure	¹ H NMR & MS
115		¹ H NMR (400MHz, CD ₃ OD): δ 8.49 (s, 1H), 8.23-8.20 (d, J = 104 Hz, 2H), 7.38-7.30 (m, 3H), 6.86-6.58 (m, 2H), 6.22-5.93 (m, 1H), 5.70 (s, 2H), 3.73-3.68 (m, 1H), 3.26-3.23 (m, 1H), 3.15-3.05 (m, 2H), 2.92-2.86 (m, 1H), 2.11 (s, 3H), 2.03-2.01 (m, 1H), 1.89-1.70 (m, 3H). LC-MS: [M+H] ⁺ = 545.4.
116		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.43 (s, 1H), 8.17 (d, J = 14.2 Hz, 2H), 7.81 -7.39 (m, 2H), 7.31-7.11 (m, 2H), 6.80 (t, J = 73.3 Hz, 1H), 5.98 (td, J = 55.4, 4.4 Hz, 1H), 5.60(s,2H), 3.90 (s, 1H), 3.17 (d, J = 11.3Hz,1H), 3.02-2.79 (m,3H), 1.92-1.51(m,4H). LC-MS: [M+H] ⁺ = 565.2, 566.2.

Example #	Structure	¹ H NMR & MS
117		¹ H NMR (400MHz, CD ₃ OD): δ 8.50 (s, 1H), 8.25 (s, 1H), 8.22 (s, 1H), 7.15 (dt, J=8.0, 11.2 Hz, 2H), 6.80 (s, 1H), 6.26 - 5.92 (m, 1H), 5.70 (s, 2H), 3.83 - 3.65 (m, 1H), 3.29 - 3.21 (m, 1H), 3.19 - 3.05 (m, 2H), 2.97 - 2.83 (m, 1H), 2.11 - 2.05 (m, 1H), 2.03 (s, 3H), 1.94 - 1.80 (m, 2H), 1.78-1.69 (m, 1H). LC-MS: [M+H] ⁺ = 531.4.
118		¹ H NMR (400MHz, CD ₃ OD) δ = 8.37 (s, 1H), 8.26 (s, 1H), 8.10 (s, 1H), 7.75 (ddd, J=2.1, 7.9, 11.6 Hz, 1H), 7.67 (br d, J=5.9 Hz, 1H), 7.42 - 7.31 (m, 1H), 6.18 - 5.84 (m, 1H), 5.62 (q, J=14.1 Hz, 2H), 3.82 (br s, 1H), 3.37 (s, 3H), 3.20 - 3.11 (m, 1H), 2.99 (br d, J=9.8 Hz, 1H), 2.94 - 2.87 (m, 1H), 2.85 - 2.76 (m, 1H), 1.91 - 1.60 (m, 4H). LC-MS: [M+H] ⁺ = 547.5.
119		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.49 (s, 1H), 8.24 (d, J = 7.9 Hz, 2H), 7.85 - 7.44 (m, 2H), 7.41 - 7.18 (m, 2H), 6.86 (t, J = 73.3 Hz, 1H), 6.05 (td, J = 55.1, 3.9 Hz, 1H), 5.65 (s, 2H), 3.67 (dd, J = 16.5, 6.6 Hz, 1H), 3.22 (d, J = 11.4 Hz, 1H), 3.02 (t, J = 13.5 Hz, 2H), 2.91 - 2.79 (m, 1H), 2.09 - 1.91 (m, 1H), 1.89 - 1.62 (m, 3H). LC-MS: [M+H] ⁺ = 565.2, 566.2.
120		¹ H NMR (400MHz, CD ₃ OD) δ = 8.57 (s, 1H), 8.23 (s, 1H), 8.20 (s, 1H), 7.74 (br dd, J=5.9, 10.7 Hz, 1H), 7.35 (dd, J=5.6, 10.7 Hz, 1H), 7.16 (s, 1H), 7.12 - 6.79 (m, 1H), 6.23 - 5.88 (m, 1H), 5.69 (s, 2H), 3.99 (br s, 1H), 3.27 (br s, 1H), 3.16 - 2.90 (m, 3H), 2.03 - 1.79 (m, 3H), 1.66 (br s, 1H). LC-MS: [M+H] ⁺ = 567.4.
121		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.43 (s, 1H), 8.24 (d, J=2.1 Hz, 2H), 7.82 (d, J=2.0 Hz, 1H), 7.60 (dd, J=2.0, 8.6 Hz, 1H), 7.24 (s, 1H), 7.08 (d, J=8.7 Hz, 1H), 6.23 - 5.86 (m, 1H), 5.64 (s, 2H), 3.89 (s, 3H), 3.74 - 3.61 (m, 1H), 3.20 (br d, J=11.5 Hz, 1H), 3.07 - 2.94 (m, 2H), 2.88=275 (m, 1H), 2.04 - 1.90 (m, 1H), 1.88 - 1.60 (m, 3H). LC-MS: [M+H] ⁺ = 545.4.

Example #	Structure	¹ H NMR & MS
122		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.47 (s, 1H), 8.24 (d, 2H), 7.93 (t, 1H), 7.65-7.7.68 (m, 1H), 7.32 (s, H), 7.24 (t, H), , 5.90-6.19 (t, 1H), 5.64 (s, 2H), 3.65 (br, 1H), 3.2 (d, 1H), 3.00 (m, 2H), 2.83 (t, 1H), 1.97 (m, 1H), 1.66~1.86 (m, 3H). LC-MS: [M+H] ⁺ = 532.9, 533.9.
123		¹ H NMR (400MHz, CD ₃ OD) δ = 8.51 (s, 1H), 8.22 (d, J=3.7 Hz, 2H), 8.10 - 7.97 (m, 2H), 7.31 (d, J=11.5 Hz, 1H), 7.10 (d, J=1.8 Hz, 1H), 6.27 - 5.90 (m, 1H), 5.69 (s, 2H), 4.01 (s, 3H), 3.78 - 3.64 (m, 1H), 3.24 (br d, J=11.5 Hz, 1H), 3.13 (br d, J=10.9 Hz, 1H), 3.05 (br d, J=11.4 Hz, 1H), 2.89 (br t, J=10.3 Hz, 1H), 2.09 - 1.96 (m, 1H), 1.92 - 1.76 (m, 2H), 1.70 (br d, J=10.4 Hz, 1H). LC-MS: [M+H] ⁺ =553.5.
124		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.50 (s, 1H), 8.24-8.23 (d, J= 6.0 Hz, 2H), 7.74-7.71 (m, 1H), 7.56-7.54 (m, 1H), 7.51-7.49 (m, 1H), 7.36 (s, 1H), 6.19-5.91 (m, 1H), 5.66 (s, 2H), 3.70-3.65 (m, 1H), 3.23-3.21 (d, J= 11.6 Hz, 1H), 3.07-3.00 (m, 2H), 2.87-2.82 (m, 1H), 2.01-1.98 (m, 1H), 1.86-1.70 (m, 3H).LC-MS: [M+H] ⁺ =533.4.
125		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.45 (s, 1H), 8.23 (d, J=8.8 Hz, 2H), 7.80 (d, J=2.1 Hz, 1H), 7.57 (dd, J=2.1, 8.6 Hz, 1H), 7.15 (s, 1H), 7.07 (d, J=8.7 Hz, 1H), 6.22 - 5.86 (m, 1H), 5.65 (s, 2H), 4.05-3.85 (m, 4H), 3.21 (br d, J=11.0 Hz, 1H), 3.05-2.90 (m, 3H), 1.96 - 1.72 (m, 3H), 1.71 - 1.56 (m, 1H). LC-MS: [M+H] ⁺ =545.4.
126		¹ H NMR (400MHz,CD ₃ OD): δ 8.44 (s, 1H), 8.22-8.17 (d, J = 7.6 Hz, 2H), 7.08-7.00 (m, 3H), 6.72 (s, 1H), 6.22-5.93 (m, 1H), 5.68 (s, 2H), 3.71 (m, 1H), 3.25-3.22 (m, 1H), 3.13-3.04 (m, 2H), 2.90-2.85 (m, 1H), 2.29 (s, 3H), 2.11-2.09 (m, 1H), 2.01 (s, 3H), 1.89-1.70 (m, 3H). LC-MS: [M+H] ⁺ =509.4

Example #	Structure	¹ H NMR & MS
127		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.45 (s, 1H), 8.23 (d, J = 9.2 Hz, 2H), 7.54 (dd, J = 12.7, 2.2 Hz, 1H), 7.43 (dd, J = 8.7, 1.6 Hz, 1H), 7.11 (dd, J = 17.6, 9.0 Hz, 2H), 6.04 (td, J = 55.4, 4.5 Hz, 1H), 5.65 (s, 2H), 3.95 (s, 1H), 3.88 (s, 3H), 3.22 (d, J = 11.0 Hz, 1H), 2.96 (d, J = 15.1 Hz, 3H), 1.86 (d, J = 13.5 Hz, 3H), 1.64 (s, 1H). LC-MS: [M+H] ⁺ = 529.0, 530.0.
128		¹ H NMR (400 MHz, DMSO-d ₆) δ ppm 8.53 (s, 1H), 8.26 (s, 1H), 8.11 (s, 1H), 7.83 (dd, J = 11.5, 7.2 Hz, 1H), 7.52 – 7.04 (m, 4H), 6.98 (d, J = 1.6 Hz, 1H), 6.18 (td, J = 55.8, 4.0 Hz, 1H), 5.72 (s, 1H), 5.56 (d, J = 2.4 Hz, 2H), 3.77 (s, 1H), 3.08 (dd, J = 30.6, 8.8 Hz, 2H), 2.93 (t, J = 9.6 Hz, 1H), 2.79 (d, J = 11.3 Hz, 1H), 1.80 (q, J = 27.0, 21.6 Hz, 5H), 1.48 (d, J = 9.8 Hz, 1H). LC-MS: [M+H] ⁺ = 582.9, 583.8.
129		¹ H NMR (400MHz, CD ₃ OD) δ = 8.50 (s, 1H), 8.23 (s, 1H), 8.20 - 8.14 (m, 1H), 7.42 (d, J=7.0 Hz, 1H), 7.10 (d, J=10.8 Hz, 1H), 7.07 - 6.75 (m, 2H), 6.24 - 5.90 (m, 1H), 5.69 (s, 2H), 3.70 (ddd, J=4.1, 8.3, 12.2 Hz, 1H), 3.24 (d, J=11.5 Hz, 1H), 3.13 (br d, J=11.4 Hz, 1H), 3.06 (br d, J=11.4 Hz, 1H), 2.94 - 2.84 (m, 1H), 2.06 (s, 3H), 2.04 - 1.98 (m, 1H), 1.91 - 1.77 (m, 2H), 1.72 (br d, J=15.3 Hz, 1H). LC-MS: [M+H] ⁺ = 563.4.
130		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.29 (s, 1H), 8.22 (s, 1H), 8.17 (s, 1H), 6.68 (s, 1H), 6.03 (td, J = 55.1, 3.9 Hz, 1H), 5.71 - 5.33 (m, 2H), 3.65 (d, J = 15.2 Hz, 1H), 3.15 (d, J = 11.4 Hz, 1H), 2.95 (dd, J = 19.0, 11.6 Hz, 2H), 2.78 (t, J = 10.6 Hz, 1H), 2.62 - 2.48 (m, 1H), 1.95 (q, J = 11.3, 10.8 Hz, 1H), 1.74 (d, J = 18.8 Hz, 7H), 1.40 - 1.24 (m, 5H), 1.22 - 0.84 (m, 1H). LC-MS: [M+H] ⁺ = 487.3, 488.3.
131		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.44 (s, 1H), 8.23 (d, J = 1.9 Hz, 2H), 7.56 (dd, J = 12.7, 2.2 Hz, 1H), 7.45 (ddd, J = 8.6, 2.3, 1.2 Hz, 1H), 7.24 (s, 1H), 7.10 (t, J = 8.7 Hz, 1H), 6.05 (td, J = 55.1, 3.9 Hz, 1H), 5.64 (d, J = 2.6 Hz, 2H), 3.75 - 3.60 (m, 1H), 3.20 (d, J = 11.4 Hz, 1H), 3.00 (t, J = 13.6 Hz, 2H), 2.88 - 2.75 (m, 1H), 1.97 (d, J = 12.3 Hz, 1H), 1.88 - 1.61 (m, 3H). LC-MS: [M+H] ⁺ = 529.0, 530.0.

Example #	Structure	¹ H NMR & MS
132		¹ H NMR (400MHz, CD ₃ OD) δ = 8.54 (d, J=1.6 Hz, 1H), 8.22 (s, 1H), 8.21 (s, 1H), 7.92-7.84 (m, 1H), 7.45-7.36 (m, 1H), 7.33-7.25 (m, 1H), 7.18 (s, 1H), 6.94 - 6.60 (m, 1H), 6.23 - 5.92 (m, 1H), 5.68 (s, 2H), 3.79 - 3.64 (m, 1H), 3.28-3.21 (m, 1H), 3.18 - 3.03 (m, 2H), 2.94-2.83 (m, 1H), 2.11 - 1.97 (m, 1H), 1.93 - 1.67 (m, 3H). LC-MS: [M+H] ⁺ = 549.5.
133		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.42 (s, 1H), 8.11 (d, J=4.3 Hz, 2H), 7.78 (t, J=8.4 Hz, 1H), 7.23 - 7.07 (m, 2H), 7.02 (s, 1H), 6.15 - 5.80 (m, 1H), 5.58 (s, 2H), 3.68 - 3.50 (m, 1H), 3.25 (s, 1H), 3.14 (d, J=11.4 Hz, 1H), 3.03 (d, J=10.9 Hz, 1H), 2.96 (d, J=11.4 Hz, 1H), 2.83 - 2.64 (m, 1H), 2.01-1.82 (m, 1H), 1.91 - 1.63 (m, 3H). LC-MS: [M+H] ⁺ = 533.4.
134		¹ H NMR (400MHz, CD ₃ OD) δ = 8.58 (s, 1H), 8.25 (s, 1H), 8.21 (s, 1H), 7.80-7.70 (m, 1H), 7.40-7.32 (m, 1H), 7.27 (s, 1H), 7.13 - 6.80 (m, 1H), 6.26 - 5.94 (m, 1H), 5.77 - 5.61 (m, 2H), 3.85 - 3.72 (m, 1H), 3.28 - 3.09 (m, 3H), 2.97 - 2.86 (m, 1H), 2.10-2.00 (m, 1H), 1.97 - 1.80 (m, 3H) LC-MS: [M+H] ⁺ = 567.4,
135		¹ H NMR (400MHz, CD ₃ OD) δ = 8.39 (s, 1H), 8.24 (s, 1H), 8.10 (d, J=2.0 Hz, 1H), 7.43 (t, J=8.5 Hz, 1H), 6.87 (dd, J=2.4, 8.6 Hz, 1H), 6.79 (dd, J=2.4, 12.2 Hz, 1H), 6.21 - 5.88 (m, 1H), 5.77 - 5.58 (m, 2H), 3.97 - 3.77 (m, 4H), 3.25 - 3.17 (m, 1H), 3.15-3.06 (m, 1H), 3.05 - 2.96 (m, 1H), 2.95 - 2.85 (m, 1H), 2.01 - 1.87 (m, 1H), 1.86 - 1.66 (m, 3H).). LC-MS: [M+H] ⁺ = 547.5.
136		¹ H NMR (400MHz, CD ₃ OD): δ 8.54 (s, 1H), 8.22 (d, J=5.6 Hz, 1H), 8.23 - 8.21 (m, 1H), 7.00 - 6.85 (m, 3H), 6.27 - 5.93 (m, 1H), 5.71 (s, 2H), 3.84 - 3.67 (m, 1H), 3.31 - 3.25 (m, 1H), 3.21 - 3.15 (m, 1H), 3.14 - 3.08 (m, 1H), 2.97 - 2.88 (m, 1H), 2.14 - 2.02 (m, 1H), 1.96 - 1.81 (m, 2H), 1.81 - 1.72 (m, 1H). LC-MS: [M+H] ⁺ = 549.4.


Example #	Structure	¹ H NMR & MS
137		¹ H NMR (400MHz, CD ₃ OD): δ 8.57 (s, 1H), 8.30 - 8.20 (m, 2H), 7.92 (t, <i>J</i> =8.0 Hz, 1H), 7.44 (d, <i>J</i> =8.0 Hz, 1H), 7.33 (d, <i>J</i> =11.2 Hz, 1H), 7.13 (s, 1H), 6.98 - 6.64 (m, 1H), 6.26 - 5.92 (m, 1H), 5.72 (s, 2H), 4.17 - 3.93 (m, 1H), 3.32 - 3.24 (m, 1H), 3.16 - 2.94 (m, 3H), 2.06 - 1.82 (m, 3H), 1.75-1.59 (m, 1H). LC-MS: [M+H] ⁺ = 549.4.
138		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.51 (s, 1H), 8.21 (d, <i>J</i> = 2.2 Hz, 2H), 7.81 (t, <i>J</i> = 8.8 Hz, 1H), 7.10 (d, <i>J</i> = 1.7 Hz, 1H), 7.08 - 6.71 (m, 3H), 6.06 (td, <i>J</i> = 55.1, 3.9 Hz, 1H), 5.68 (s, 2H), 3.70 (dd, <i>J</i> = 15.8, 8.2 Hz, 1H), 3.23 (d, <i>J</i> = 11.4 Hz, 1H), 3.12 (d, <i>J</i> = 11.1 Hz, 1H), 3.04 (d, <i>J</i> = 11.4 Hz, 1H), 2.88 (t, <i>J</i> = 10.6 Hz, 1H), 2.02 (t, <i>J</i> = 11.6 Hz, 1H), 1.91 - 1.75 (m, 2H), 1.70 (d, <i>J</i> = 13.5 Hz, 1H). LC-MS: [M+H] ⁺ = 565.2, 566.2.
139		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.49 (s, 1H), 8.21-8.24 (d, 2H), 7.91-7.93 (t, 1H), 7.65 (br, 1H), 7.22-7.28 (br, 2H), 5.89-6.18 (t, 1H), 5.65 (s, 2H), 3.94 (br, 1H), 3.25 (d, 1H), 2.95 (b, 3H), 1.88 (m, 3H), 1.63 (m, 1H). LC-MS: [M+H] ⁺ = 532.9, 533.9.
140		¹ H NMR: (400MHz, CD ₃ CN): δ 8.51 (s, 1H), 8.19 (s, 1H), 7.97 (s, 1H), 7.40 - 7.34 (m, 3H), 6.91 - 6.59 (m, 2H), 6.19 - 5.87 (m, 3H), 5.54 (s, 2H), 3.80 (m, 1H), 3.14 (m, 1H), 3.07 - 2.98 (m, 1H), 2.90 (m, 2H), 2.11 (s, 3H), 2.09 (m, 1H), 1.84 - 1.71 (m, 2H), 1.62 - 1.50 (m, 1H). LC-MS: [M+H] ⁺ = 545.5.
141		¹ H NMR (400MHz, CD ₃ OD): δ 8.56 (s, 1H), 8.23 (s, 1H), 8.21 (s, 1H), 8.02-7.98 (m, 1H), 7.56-7.54 (d, <i>J</i> = 8.0 Hz, 1H), 7.48-7.45 (d, <i>J</i> = 11.2 Hz, 1H), 7.21 (s, 1H), 6.22-5.93 (m, 1H), 5.69 (s, 2H), 3.73-3.67 (m, 1H), 3.27-3.24 (d, <i>J</i> = 11.6 Hz, 1H), 3.16-3.14 (m, 1H), 3.09-3.06 (d, <i>J</i> = 11.2 Hz, 1H), 2.92-2.87 (m, 1H), 2.07-2.02 (m, 1H), 1.89-1.79 (m, 2H), 1.74-1.70 (m, 1H). LC-MS: [M+H] ⁺ = 567.4.

Example #	Structure	¹ H NMR & MS
142		¹ H NMR (400MHz, CD ₃ OD) δ = 8.52 (s, 1H), 8.46 (s, 1H), 8.29 (s, 1H), 8.17 (d, J=2.4 Hz, 1H), 7.58 (dt, J=6.5, 8.5 Hz, 1H), 7.17 - 7.04 (m, 2H), 6.31 - 5.98 (m, 1H), 5.76 - 5.57 (m, 2H), 4.08 - 3.91 (m, 1H), 3.46 - 3.35 (m, 1H), 3.30-3.25 (m, 1H), 3.16 - 3.06 (m, 1H), 3.06 - 2.94 (m, 1H), 2.11 - 1.82 (m, 4H). LC-MS: [M+H] ⁺ = 535.4.
143		¹ H NMR (400MHz, CD ₃ OD) δ = 8.52 (s, 1H), 8.24 (s, 1H), 8.20 (s, 1H), 8.07 - 8.03 (m, 2H), 7.31 (d, J=11.5 Hz, 1H), 7.01 (d, J=2.0 Hz, 1H), 6.24 - 5.88 (m, 1H), 5.74 - 5.67 (m, 2H), 4.01 (s, 3H), 3.23-3.29 (m, 1H), 3.16 - 2.91 (m, 3H), 2.20-2.15 (m, 1H), 1.93-1.80 (m, 3H), 1.74 - 1.57 (m, 1H). LC-MS: [M+H] ⁺ = 553.4.
144		¹ H NMR (400MHz, CD ₃ OD) δ = 8.45 (s, 1H), 8.20 (d, J=9.6 Hz, 2H), 7.50 (m, 1H), 7.04 (s, 1H), 6.58 (m, 1H), 6.20 - 5.92 (m, 1H), 5.65 (s, 2H), 4.0 (s, 1H), 3.26-3.23 (m, 1H), 3.01-2.99 (m, 3H), 1.91 - 1.88 (m, 3H), 1.70 (br s, 1H). LC-MS: [M+H] ⁺ = 533.3.
145		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.29 (s, 1H), 8.20 (s, 1H), 8.18 (s, 1H), 6.59 (s, 1H), 6.03 (td, J = 55.4, 4.3 Hz, 1H), 5.61 (s, 2H), 3.95 (s, 1H), 3.19 - 3.11 (m, 1H), 2.91 (d, J = 18.5 Hz, 3H), 2.62 - 2.45 (m, 1H), 1.89 - 1.61 (m, 9H), 1.36 - 1.22 (m, 5H). LC-MS: [M+H] ⁺ = 487.3, 488.3.
146		¹ H NMR (400MHz, CD ₃ OD) δ = 8.56 (s, 1H), 8.23 (d, J=10.0 Hz, 2H), 7.70 (t, J=7.4 Hz, 1H), 7.43 (br t, J=7.2 Hz, 1H), 7.19 (d, J=1.0 Hz, 1H), 7.16 - 6.85 (m, 1H), 6.24 - 5.91 (m, 1H), 5.70 (s, 2H), 3.78 - 3.63 (m, 1H), 3.26 (m, 1H), 3.19 - 3.04 (m, 2H), 2.95 - 2.85 (m, 1H), 2.14 - 1.98 (m, 1H), 1.93 - 1.65 (m, 1H), 1.93 - 1.65 (m, 3H). LC-MS: [M+H] ⁺ = 567.4.

Example #	Structure	¹ H NMR & MS
147		¹ H NMR (400 MHz, CD ₃ OD) δ 8.51 (s, 1H), 8.21 (d, <i>J</i> = 15.3 Hz, 2H), 7.78 (td, <i>J</i> = 8.8, 6.5 Hz, 1H), 7.15 – 6.70 (m, 3H), 6.05 (td, <i>J</i> = 55.4, 4.4 Hz, 1H), 5.69 (s, 2H), 3.99 (s, 1H), 3.15 – 2.81 (m, 3H), 1.89 (d, <i>J</i> = 16.2 Hz, 3H), 1.65 (s, 1H). LC-MS: [M+H] ⁺ = 517.2, 518.2.
148		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.52 (s, 1H), 8.21 (d, <i>J</i> =13.9 Hz, 2H), 7.77 (t, <i>J</i> =8.4 Hz, 1H), 7.31 - 7.16 (m, 2H), 7.05 (s, 1H), 6.24 - 5.88 (m, 1H), 5.69 (s, 2H), 4.11 - 3.88 (m, 1H), 3.26 (m, 1H), 3.16 - 2.90 (m, 3H), 1.90 (m, 3H), 1.67 (m, 1H). LC-MS: [M+H] ⁺ = 533.4.
149		¹ H NMR (400MHz, CD ₃ OD) δ = 8.40 (s, 1H), 8.24 (s, 1H), 8.11 (s, 1H), 7.28 (dd, <i>J</i> =6.7, 11.3 Hz, 1H), 7.01 (dd, <i>J</i> =7.1, 11.4 Hz, 1H), 6.23 - 5.88 (m, 1H), 5.76 - 5.56 (m, 2H), 4.0-3.80 (m, 4H), 3.26 - 3.18 (m, 1H), 3.18 - 3.08 (m, 1H), 3.08 - 2.97 (m, 1H), 2.97 - 2.84 (m, 1H), 2.06 - 1.88 (m, 1H), 1.88 - 1.66 (m, 3H) LCMS: [M+H] ⁺ = 565.4
150		¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ ppm 8.52 (s, 1H), 8.26 (s, 1H), 8.11 (s, 1H), 7.83 (dd, <i>J</i> = 11.5, 7.2 Hz, 1H), 7.56 – 7.07 (m, 4H), 7.02 (d, <i>J</i> = 1.6 Hz, 1H), 6.19 (td, <i>J</i> = 55.4, 3.1 Hz, 1H), 5.62 (s, 1H), 5.58 (s, 2H), 3.54 (dd, <i>J</i> = 17.7, 9.3 Hz, 1H), 3.09 (d, <i>J</i> = 11.4 Hz, 2H), 2.94 – 2.75 (m, 2H), 1.98 (d, <i>J</i> = 12.5 Hz, 3H), 1.76 – 1.64 (m, 2H), 1.54 (d, <i>J</i> = 12.8 Hz, 1H). LC-MS: [M+H] ⁺ = 582.9, 583.8.
151		¹ H NMR (400 MHz, CD ₃ OD) δ 8.51 (s, 1H), 8.21 (d, <i>J</i> = 15.4 Hz, 2H), 7.78 (td, <i>J</i> = 8.9, 6.6 Hz, 1H), 7.09 – 6.87 (m, 3H), 6.05 (td, <i>J</i> = 55.4, 4.5 Hz, 1H), 5.69 (s, 2H), 3.99 (s, 1H), 3.25 (d, <i>J</i> = 1.9 Hz, 1H), 3.12 – 2.83 (m, 3H), 2.02 – 1.77 (m, 3H), 1.65 (s, 1H). LC-MS: [M+H] ⁺ = 517.2, 518.2.

Example #	Structure	¹ H NMR & MS
152		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.51 (s, 1H), 8.25-8.22 (d, J= 10.8 Hz, 2H), 7.72-7.69 (m, 1H), 7.54-7.49 (m, 2H), 7.27 (s, 1H), 6.18-5.90 (m, 1H), 5.66 (s, 2H), 3.95 (m, 1H), 3.24-3.22 (d, J= 11.2 Hz, 1H), 2.98 (m, 3H), 1.89-1.83 (m, 3H), 1.66 (m, 1H). LC-MS: [M+H] ⁺ =533.4.
153		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.51 (s, 1H), 8.21 (d, J = 10.4 Hz, 2H), 7.80 (t, J = 8.8 Hz, 1H), 7.12 - 6.67 (m, 4H), 6.05 (td, J = 55.5, 4.4 Hz, 1H), 5.68 (s, 2H), 3.99 (s, 1H), 3.26 (d, J = 11.5 Hz, 1H), 3.00 (dd, J = 29.4, 14.5 Hz, 3H), 1.89 (d, J = 13.5 Hz, 3H), 1.65 (s, 1H). LC-MS: [M+H] ⁺ = 565.2, 566.2.
154		¹ H NMR (400MHz, CD ₃ OD) δ = 8.59 (s, 1H), 8.35-8.25 (m, 1H), 8.21 (s, 1H), 7.80-7.70 (m, 1H), 7.40 - 7.31 (m, 1H), 7.30-7.20 (m, 1H), 7.12 - 6.78 (m, 1H), 6.32 - 5.88 (m, 1H), 5.82 - 5.58 (m, 2H), 3.97-3.80 (m, 1H), 3.33 - 3.32 (m, 1H), 3.21-3.10 (m, 1H), 3.00-2.80 (m, 1H), 2.18 - 1.79 (m, 4H) LC-MS: [M+H] ⁺ = 567.4,
155		¹ H NMR (400MHz, CD ₃ OD) δ = 8.50 (s, 1H), 8.39 (d, J=2.8 Hz, 1H), 8.31 (dd, J=4.6, 8.9 Hz, 1H), 8.26 (s, 1H), 8.22 (s, 1H), 7.76 (s, 1H), 7.65 (dt, J=2.9, 8.6 Hz, 1H), 6.24 - 5.93 (m, 1H), 5.70 (s, 2H), 3.78 - 3.63 (m, 1H), 3.26 (d, J=11.5 Hz, 1H), 3.18 - 3.12 (m, 1H), 3.10 - 3.04 (m, 1H), 2.96 - 2.84 (m, 1H), 2.14 - 1.98 (m, 1H), 1.93 - 1.76 (m, 2H), 1.76 - 1.65 (m, 1H). LC-MS: [M+H] ⁺ =500.2.

Example 156 and 157: (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,4,5-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol and (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,4,5-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol





Step 1. To a solution of 1-(3-amino-1-(4-(hydroxymethyl)-6-(2,4,5-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol (Intermediate **156-2**) (700 mg, 1.677 mmol, 1.0eq), Intermediate **B** (80 mg, 0.240 mmol, 1.5 eq) and *n*-Bu₃P (509 mg, 2.516 mmol, 1.5 eq) in anhydrous THF (7 mL) was added DIAD (509 mg, 2.516 mmol, 1.5 eq) under nitrogen at 0 °C. The reaction mixture was stirred at 0 °C for 30 min. LC-MS indicated the reaction was complete.. The reaction mixture was concentrated in vacuum and the residue was purified by Prep-HPLC (base) to give Intermediate **156-3** as a colorless oil. ¹H NMR (400MHz, CDCl₃) δ = 8.93 - 8.85 (m, 1H), 8.57 (s, 1H), 8.22 - 8.14 (m, 1H), 7.92 - 7.76 (m, 1H), 7.45 - 7.32 (m, 1H), 7.01 - 6.83 (m, 1H), 6.20 - 5.80 (m, 1H), 5.72 - 5.53 (m, 2H), 3.82 - 3.63 (m, 1H), 3.26 - 3.06 (m, 2H), 3.05 - 2.89 (m, 2H), 2.28 - 2.12 (m, 1H), 1.89 - 1.79 (m, 2H), 1.75 - 1.63 (m, 1H), 1.49 - 1.36 (m, 18H). LCMS: [M+H]⁺ = 735.5.

Step 2. To a solution of Intermediate **156-3** (630 mg, 0.858 mmol) in anhydrous DCM (15 mL) was added TFA (5 mL) and the reaction was stirred at 20 °C for 3 hours. LC-MS showed the reaction was complete. The reaction mixture was concentrated in vacuum and basified with ammonium hydroxide to pH=8, concentrated in vacuum. The residue was purified by Prep-HPLC (base) and SFC to give (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,4,5-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol (Example **156**) and (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,4,5-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol (Example **157**).


Example **156**: ¹H NMR (400 MHz, CD₃OD) δ ppm 8.52 (d, J = 1.9 Hz, 1H), 8.20 (dd, J = 5.6, 2.0 Hz, 2H), 7.78 (dddd, J = 11.4, 9.2, 7.1, 2.0 Hz, 1H), 7.42 - 7.05 (m, 2H), 6.35 - 5.80 (m, 1H), 5.67 (d, J = 2.0 Hz, 2H), 3.68 (d, J = 14.0 Hz, 1H), 3.22 (s, 1H), 3.14 - 3.00 (m, 2H), 2.88 (t, J = 11.2 Hz, 1H), 2.03 (t, J = 11.5 Hz, 1H), 1.82 (t, J = 12.9 Hz, 2H), 1.71 (d, J = 13.0 Hz, 1H). LC-MS: [M+H]⁺ = 535.2.

Example **157**: ¹H NMR (400 MHz, CD₃OD) δ ppm 8.55 (s, 1H), 8.25 (s, 1H), 8.21 (s, 1H), 7.87 - 7.74 (m, 1H), 7.25 - 7.15 (m, 1H), 7.09 (s, 1H), 6.26 - 5.88 (m, 1H), 5.70 (s, 2H), 4.10 - 3.90 (m, 1H), 3.30 - 3.20 (m, 1H), 3.17 - 2.87 (m, 3H), 2.03 - 1.80 (m, 3H), 1.75 - 1.60 (m, 1H). LC-MS: [M+H]⁺ = 535.4.

Examples 158 and 159 were prepared following procedures analogous to the preparation of Examples 156 and 157 (Step 2).

Example No.		¹ H NMR
158		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.51 (s, 1H), 8.20 (d, J = 2.5 Hz, 2H), 7.47 - 7.34 (m, 2H), 7.27 (td, J = 8.5, 2.5 Hz, 1H), 7.01 - 6.63 (m, 2H), 6.06 (td, J = 55.1, 3.8 Hz, 1H), 5.68 (s, 2H), 3.78 - 3.57 (m, 1H), 3.23 (d, J = 11.5 Hz, 1H), 3.12 (d, J = 11.3 Hz, 1H), 3.05 (d, J = 11.5 Hz, 1H), 2.88 (t, J = 10.8 Hz, 1H), 2.02 (dd, J = 13.6, 9.3 Hz, 1H), 1.83 (td, J = 14.9, 13.8, 6.8 Hz, 2H), 1.71 (d, J = 14.7 Hz, 1H). LC-MS: [M+H] ⁺ = 549.2.
159		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.52 (s, 1H), 8.20 (d, J = 8.5 Hz, 2H), 7.46 - 7.33 (m, 2H), 7.27 (td, J = 8.5, 2.6 Hz, 1H), 6.98 - 6.62 (m, 2H), 3.98 (s, 1H), 3.25 (s, 1H), 3.02 (dt, J = 27.3, 9.5 Hz, 3H), 1.89 (d, J = 15.4 Hz, 3H), 1.65 (s, 1H). LC-MS: [M+H] ⁺ = 549.2.

Example 160 and 161: (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol and (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol



To a solution of tert-butyl (tert-butoxycarbonyl)(9-((5-(3-((tert-butoxycarbonyl)amino)-3-(2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-2-(2,5-difluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (Intermediate **160-3**) (200 mg, 0.237 mmol) in DCM (18 mL), was added TFA (36 mL), and the reaction mixture was stirred at rt for 30 min under N₂ atmosphere. LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was


10

concentrated in vacuo to give the crude product. The crude product was purified by Pre-HPLC and SFC to afford (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol (Example 160) and (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol (Example 161).

Example 160: ^1H NMR (400 MHz, CD_3OD) δ ppm 8.48 (s, 1H), 8.20 (d, J = 1.6 Hz, 2H), 7.58 (dd, J = 12.2, 7.3 Hz, 1H), 7.11 (d, J = 1.3 Hz, 1H), 6.90 (dd, J = 12.6, 7.1 Hz, 1H), 6.06 (td, J = 55.1, 3.9 Hz, 1H), 5.67 (s, 2H), 3.87 (s, 3H), 3.75 - 3.58 (m, 1H), 3.25 - 2.75 (m, 4H), 2.26 - 1.60 (m, 4H). LC-MS: $[\text{M}+\text{H}]^+ = 547.2, 548.2$.

Example 161: ^1H NMR (400MHz, CD_3OD) δ = 8.51 - 8.44 (m, 1H), 8.24 - 8.16 (m, 2H), 7.62 - 7.48 (m, 1H), 7.03 (s, 1H), 6.93 - 6.79 (m, 1H), 6.25 - 5.86 (m, 1H), 5.71 - 5.59 (m, 2H), 4.00 (m, 1H), 3.88 - 3.80 (m, 3H), 3.28 - 2.87 (m, 4H), 1.99 - 1.56 (m, 4H). LC-MS: $[\text{M}+\text{H}]^+ = 547.4$.

Example 162 and 163: (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol and (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol








To a solution of intermediate 162-2 (57 mg, 0.129 mmol), Intermediate B (43.1 mg, 0.129 mmol) and PPh_3 (101 mg, 0.386 mmol) in THF (5 mL) was added DEAD (0.061 mL, 0.386 mmol). The reaction mixture was stirred at 0°C for 30 min under N_2 atmosphere. LC-MS monitored the reaction. The reaction mixture was quenched with water and extracted with EtOAc, the combined organic phase was washed with water, brine, dried over sodium sulfate, concentrated to give a crude product. The crude product was purified by flash chromatography (elution gradient: 0% to 10% MeOH in DCM in 30mins) to afford the intermediate. LC-MS: $[\text{M}+\text{H}]^+ = 761$.


To a solution of the intermediate (200 mg, 0.263 mmol) in DCM (18 mL) was added TFA (36 mL, 467 mmol), the reaction mixture was stirred at rt for 30min under N_2 atmosphere. The crude product was purified by Pre-HPLC (Basic condition, $\text{NH}_3\text{H}_2\text{O}\% = 0.05\%$, MeOH/ H_2O = 0-95% in 10 mins) to afford the pure product, and then further purified by to afford (R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol (Example 162) and (S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol (Example 163).

Example 162: ^1H NMR (400 MHz, CD_3OD) δ ppm 8.48 (s, 1H), 8.21 (d, $J = 3.7$ Hz, 2H), 7.34 – 7.26 (m, 1H), 7.17 (d, $J = 2.6$ Hz, 1H), 7.07 (dt, $J = 8.6, 1.8$ Hz, 1H), 6.95 – 6.61 (m, 2H), 6.07 (td, $J = 55.1, 3.9$ Hz, 1H), 5.68 (s, 2H), 3.76 – 3.61 (m, 1H), 3.22 (d, $J = 11.4$ Hz, 1H), 3.17 – 3.08 (m, 1H), 3.04 (d, $J = 11.4$ Hz, 1H), 2.93 – 2.81 (m, 1H), 2.02 (dd, $J = 13.9, 8.9$ Hz, 1H), 1.91 – 1.75 (m, 2H), 1.70 (d, $J = 12.7$ Hz, 1H). LC-MS: $[\text{M}+\text{H}]^+ = 560.9, 562.0$.






Example 163: ^1H NMR (400 MHz, CD_3OD) δ ppm 8.55 (s, 1H), 8.30 (d, $J = 14.6$ Hz, 2H), 7.34 (d, $J = 8.6$ Hz, 1H), 7.20 (d, $J = 2.6$ Hz, 1H), 7.10 (dd, $J = 8.6, 2.6$ Hz, 1H), 7.01 (s, 1H), 6.85 (t, $J = 55.3$ Hz, 1H), 6.19 (td, $J = 53.9, 2.6$ Hz, 1H), 5.68 (d, $J = 3.3$ Hz, 2H), 4.20 (s, 1H), 3.50 – 3.34 (m, 2H), 3.19 – 2.98 (m, 2H), 2.02 (d, $J = 42.5$ Hz, 4H). LC-MS: $[\text{M}+\text{H}]^+ = 560.9, 562.0$.







Examples 164-167 were prepared from Intermediate B and corresponding intermediates following procedures analogous to the preparation of Examples 162 and 163.




Example No.		Intermediate	LC-MS and/or ^1H NMR
164		 164-2	^1H NMR (400 MHz, CD_3OD) δ ppm 8.46 (s, 1H), 8.23 (d, $J = 6.6$ Hz, 2H), 7.56 – 7.37 (m, 2H), 7.32 (s, 1H), 6.05 (td, $J = 55.1, 3.9$ Hz, 1H), 5.64 (d, $J = 2.0$ Hz, 2H), 3.97 (d, $J = 1.1$ Hz, 3H), 3.66 (ddd, $J = 16.7, 8.5, 3.6$ Hz, 1H), 3.20 (d, $J = 11.4$ Hz, 1H), 3.09 – 2.89 (m, 2H), 2.82 (td, $J = 11.1, 2.7$ Hz, 1H), 2.10 – 1.86 (m, 1H), 1.85 – 1.58 (m, 3H). LC-MS: $[\text{M}+\text{H}]^+ = 547.2, 548.2$
165			^1H NMR (400 MHz, CD_3OD) δ ppm 8.48 (s, 1H), 8.23 (d, $J = 11.8$ Hz, 2H), 7.41 (d, $J = 9.3$ Hz, 2H), 7.22 (s, 1H), 6.03 (td, $J = 55.5, 4.5$ Hz, 1H), 5.64 (s, 2H), 3.97 (s, 4H), 3.22 (d, $J = 11.1$ Hz, 1H), 3.05 – 2.92 (m, 3H), 1.84 (d, $J = 22.8$ Hz, 3H), 1.63 (s, 1H). LC-MS: $[\text{M}+\text{H}]^+ = 547.2, 548.2$
166		 166-2	^1H NMR (400 MHz, CD_3OD) δ ppm 8.64 (d, $J = 5.5$ Hz, 1H), 8.53 (s, 1H), 8.21 (d, $J = 11.1$ Hz, 2H), 7.75 (ddd, $J = 12.1, 7.8, 2.2$ Hz, 1H), 7.67 – 7.48 (m, 2H), 7.38 – 7.17 (m, 2H), 5.70 – 5.47 (m, 2H), 3.62 (d, $J = 11.3$ Hz, 1H), 3.14 (d, $J = 11.3$ Hz, 2H), 3.01 (t, $J = 10.1$ Hz, 1H), 2.68 (s, 3H), 2.35 – 1.97 (m, 2H), 1.89 – 1.68 (m, 2H). LC-MS: $[\text{M}+\text{H}]^+ =$

Example No.		Intermediate	LC-MS and/or ¹ H NMR
			579.2, 580.2
167			¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.42 (s, 1H), 8.18 (d, J = 3.0 Hz, 2H), 7.51 - 7.00 (m, 3H), 6.70 (s, 1H), 6.08 (td, J = 55.0, 3.8 Hz, 1H), 5.68 (s, 2H), 3.85 (s, 3H), 3.79 - 3.53 (m, 1H), 3.28 - 3.03 (m, 3H), 2.88 (t, J = 11.1 Hz, 1H), 2.07 (d, J = 12.0 Hz, 1H), 1.94 - 1.59 (m, 3H). LC-MS: [M+H] ⁺ = 579.2, 580.2.


Examples 168-176 were prepared from corresponding intermediates following procedures analogous to the preparation of Example 168 and Example 169.

Example No.		Intermediate	LC-MS and/or ¹ H NMR
168		 168-3	¹ H NMR (400 MHz, CD ₃ OD) δ 8.54 (s, 1H), 8.29 (d, J = 13.7 Hz, 2H), 7.34 (d, J = 8.6 Hz, 1H), 7.20 (d, J = 2.6 Hz, 1H), 7.10 (dd, J = 8.6, 2.6 Hz, 1H), 7.02 (s, 1H), 6.92 (d, J = 55.4 Hz, 1H), 6.34 - 6.01 (m, 1H), 5.67 (d, J = 2.2 Hz, 2H), 4.19 (s, 1H), 3.85 (s, 3H), 3.49 - 3.37 (m, 2H), 3.16 - 3.02 (m, 2H), 2.02 (d, J = 43.7 Hz, 4H). LC-MS: [M+H] ⁺ = 545.2, 546.2.
169			¹ H NMR (400 MHz, CD ₃ OD) δ 8.44 (s, 1H), 8.20 (d, J = 11.9 Hz, 2H), 7.38 (d, J = 8.6 Hz, 1H), 6.98 - 6.87 (m, 3H), 6.08 (td, J = 55.0, 3.9 Hz, 1H), 5.69 (s, 2H), 3.80 (s, 3H), 3.69 (d, J = 14.0 Hz, 1H), 3.23 (d, J = 11.5 Hz, 1H), 3.18 - 3.11 (m, 1H), 3.05 (d, J = 11.5 Hz, 1H), 2.88 (t, J = 11.0 Hz, 1H), 2.03 (dd, J = 24.0, 9.4 Hz, 1H), 1.84 (q, J = 13.7 Hz, 2H), 1.72 (d, J = 14.5 Hz, 1H). [M+H] ⁺ = 545.2, 546.2.
170		 170-4	¹ H NMR (400MHz, CD ₃ OD): δ 8.53 (s, 1H), 8.22 (s, 1H), 8.21 (s, 1H), 7.62-7.57 (m, 1H), 7.39-7.35 (m, 1H), 6.95-6.68 (m, 2H), 6.21-5.93 (m, 1H), 5.68 (s, 2H), 3.71 (m, 1H), 3.27-3.24 (m, 2H), 3.10-3.07 (m, 1H), 2.92-2.87 (m, 1H), 2.05-2.00 (m, 1H), 1.89-1.72 (m, 3H). LC-MS: [M+H] ⁺ = 567.2.

Example No.		Intermediate	LC-MS and/or ^1H NMR
171			^1H NMR (400MHz, CD_3OD): δ 8.54 (s, 1H), 8.23 (s, 1H), 8.20 (s, 1H), 7.61-7.57 (m, 1H), 7.38-7.34 (m, 1H), 6.94-6.66 (m, 2H), 5.68 (s, 2H), 4.10-4.01 (m, 1H), 3.27 (m, 1H), 3.07-3.02 (m, 3H), 1.93-1.71 (m, 4H). LC-MS: $[\text{M}+\text{H}]^+ = 567.2$.
172		 172-4	^1H NMR (400MHz, CD_3OD) δ 8.54 (s, 1H), 8.25 (s, 1H), 8.23 (s, 1H), 7.62-7.56 (m, 1H), 7.25 - 7.14 (m, 1H), 7.13 (d, $J=1.3$ Hz, 1H), 6.26 - 5.92 (m, 1H), 5.70 (s, 2H), 3.79-3.66 (m, 1H), 3.30-3.23 (m, 1H), 3.20 - 3.04 (m, 2H), 2.96 - 2.85 (m, 1H), 2.15 - 1.99 (m, 1H), 1.94 - 1.78 (m, 2H), 1.76-1.68 (m, 1H). LC-MS: $[\text{M}+\text{H}]^+ = 535.4$.
173		 173-3	^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 8.44 (s, 1H), 8.26 (s, 1H), 8.14 (s, 1H), 7.77 (dd, $J = 8.7, 7.2$ Hz, 1H), 7.34 (s, 2H), 6.95 (s, 1H), 6.89 (dd, $J = 11.4, 2.5$ Hz, 1H), 6.81 (td, $J = 8.4, 2.5$ Hz, 1H), 6.19 (td, $J = 55.8, 4.0$ Hz, 1H), 5.74 (s, 1H), 5.54 (d, $J = 2.9$ Hz, 2H), 3.79 (s, 1H), 3.45 (s, 3H), 3.17 - 2.98 (m, 2H), 2.92 (d, $J = 8.5$ Hz, 1H), 2.75 (d, $J = 11.3$ Hz, 1H), 2.05 - 1.62 (m, 5H), 1.47 (d, $J = 5.5$ Hz, 1H). LC-MS: $[\text{M}+\text{H}]^+ = 529.0, 530.0$.
174			^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 8.43 (s, 1H), 8.26 (s, 1H), 8.14 (s, 1H), 7.77 (dd, $J = 8.6, 7.2$ Hz, 1H), 7.34 (s, 2H), 6.98 (s, 1H), 6.89 (dd, $J = 11.5, 2.5$ Hz, 1H), 6.81 (td, $J = 8.4, 2.5$ Hz, 1H), 6.20 (td, $J = 55.4, 3.1$ Hz, 1H), 5.64 (d, $J = 4.7$ Hz, 1H), 5.56 (s, 2H), 3.53 (d, $J = 15.7$ Hz, 1H), 3.46 (s, 3H), 3.06 (t, $J = 11.1$ Hz, 2H), 2.95 - 2.71 (m, 2H), 1.99 (s, 3H), 1.68 (dd, $J = 13.1, 8.3$ Hz, 2H), 1.53 (d, $J = 12.6$ Hz, 1H). LC-MS: $[\text{M}+\text{H}]^+ = 529.0, 530.0$.

Example No.		Intermediate	LC-MS and/or ^1H NMR
175		 175-3	^1H NMR (400 MHz, CD_3OD) δ 8.50 (s, 1H), 8.30 - 8.24 (m, 2H), 8.21 (s, 1H), 7.73 (t, $J=8.3$ Hz, 1H), 7.69 (s, 1H), 6.21 - 5.89 (m, 1H), 5.68 (s, 2H), 4.07 - 3.90 (m, 1H), 3.29 - 3.23 (m, 1H), 3.12 - 2.92 (m, 3H), 2.00 - 1.88 (m, 3H), 1.72 - 1.58 (m, 1H). LC-MS: $[\text{M}+\text{H}]^+ = 534.2$.
176			^1H NMR (400MHz, CD_3OD) δ 8.50 (s, 1H), 8.33 - 8.25 (m, 2H), 8.24 (s, 1H), 7.82 - 7.70 (m, 2H), 6.24 - 5.92 (m, 1H), 5.70 (s, 2H), 3.78 - 3.64 (m, 1H), 3.26 (d, $J=11.5$ Hz, 1H), 3.19 - 3.10 (m, 1H), 3.10 - 3.03 (m, 1H), 2.95 - 2.83 (m, 1H), 2.13 - 1.96 (m, 1H), 1.95 - 1.77 (m, 2H), 1.76 - 1.65 (m, 1H). LC-MS: $[\text{M}+\text{H}]^+ = 534.4$.





Example 177: 9-((5-(3-amino-3-(6-methylpyridin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine












- 5 A solution of tert-butyl (tert-butoxycarbonyl)(9-((2-(3,4-difluorophenyl)-5-(3-((methoxycarbonyl)amino)-3-(6-methylpyridin-2-yl)piperidin-1-yl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (177-7) (700 mg, 0.89 mmol, 1.0 eq) in HBr/AcOH (33%, 10 mL) was stirred at 25-30 °C for 16 hours. LCMS showed that the starting material was consumed completely. The reaction was concentrated in vacuo. The residue was purified by *prep*-HPLC (0.1% NH_4HCO_3 as additive) to give 9-((5-(3-amino-3-(6-methylpyridin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine (Example 177) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 8.53 (s, 1H), 8.29 (s, 1H), 8.14 (s, 1H), 7.93-7.82 (m, 1H), 7.72-7.65 (m, 1H), 7.64-7.59 (m, 1H), 7.56 (d, $J = 7.6$ Hz, 1H), 7.52-7.42 (m, 1H), 7.37 (s, 1H), 7.29 (brs, 2H), 7.12 (d, $J = 7.6$ Hz, 1H), 5.55 (dd, $J = 16.0$ Hz, 28.4 Hz, 2H), 3.44 (d, $J = 11.2$ Hz, 1H),
- 10

3.17-3.08 (m, 1H), 3.06-3.01 (m, 1H), 3.00-2.90 (m, 1H), 2.47 (s, 3H), 2.24-2.14 (m, 1H), 2.13-1.99 (m, 1H), 1.77-1.65 (m, 1H). LC-MS: $[M+H]^+ = 528.3$.






Examples 178-284 were prepared following procedures analogous to the preparation of Example 177 and corresponding intermediates.






Example #	Structure	^1H NMR & LC-MS
178		^1H NMR (400 MHz, CD_3OD) δ ppm 8.52 (s, 1H), 8.23 (s, 1H), 8.16 (s, 1H), 7.74 (ddd, $J = 12.1, 7.8, 2.2$ Hz, 1H), 7.68 (dd, $J = 8.3, 7.4$ Hz, 1H), 7.53 (ddd, $J = 10.2, 5.0, 2.9$ Hz, 1H), 7.34 – 7.24 (m, 2H), 7.20 (d, $J = 7.4$ Hz, 1H), 6.67 (d, $J = 8.2$ Hz, 1H), 5.69 – 5.53 (m, 2H), 3.93 (s, 3H), 3.54 (d, $J = 11.4$ Hz, 1H), 3.23 – 3.11 (m, 2H), 2.97 (t, $J = 10.2$ Hz, 1H), 2.27 (t, $J = 11.2$ Hz, 1H), 2.16 – 2.01 (m, 1H), 1.97 – 1.80 (m, 2H). LC-MS: $[M+H]^+ = 544.3, 545.3$
179		^1H NMR (400 MHz, CD_3OD) δ ppm 8.52 (s, 1H), 8.20 (d, $J = 14.3$ Hz, 2H), 7.82 (t, $J = 7.8$ Hz, 1H), 7.70 – 7.57 (m, 3H), 7.31 (t, $J = 7.9$ Hz, 2H), 7.24 (s, 1H), 5.74 – 5.54 (m, 2H), 5.07 (s, 4H), 3.61 (d, $J = 11.5$ Hz, 1H), 3.20 – 3.10 (m, 2H), 3.01 (t, $J = 9.7$ Hz, 1H), 2.28 (s, 1H), 2.15 – 1.99 (m, 1H), 1.86 (dq, $J = 9.5, 4.8$ Hz, 2H). LC-MS: $[M+H]^+ = 514.2, 516.1$.
180		^1H NMR (400 MHz, CD_3OD) δ ppm 8.52 (s, 1H), 8.44 (s, 1H), 8.41 – 8.37 (m, 1H), 8.17 – 8.10 (m, 2H), 7.76 (s, 1H), 7.58 (d, $J = 7.6$ Hz, 1H), 7.42 (s, 1H), 7.29 (d, $J = 8.0$ Hz, 1H), 5.61 – 5.42 (m, 2H), 4.48 (s, 2H), 3.55 (d, $J = 11.1$ Hz, 1H), 3.14 (m, 1H), 3.08 – 2.91 (m, 2H), 2.32 – 1.75 (m, 4H). LC-MS: $[M+H]^+ = 565.3$.
181		^1H NMR (400 MHz, CD_3OD) δ ppm 8.51 (s, 1H), 8.19 (d, $J = 15.0$ Hz, 2H), 7.82 (t, $J = 7.8$ Hz, 1H), 7.78 – 7.59 (m, 2H), 7.32 (d, $J = 7.9$ Hz, 1H), 7.02 (d, $J = 1.7$ Hz, 1H), 6.80 (dd, $J = 8.7, 2.5$ Hz, 1H), 6.68 (dd, $J = 13.3, 2.5$ Hz, 1H), 5.65 (t, $J = 13.3$ Hz, 2H), 3.79 (s, 3H), 3.66 – 3.54 (m, 1H), 3.18 (dt, $J = 18.0, 7.7$ Hz, 2H), 3.03 (dt, $J = 12.4, 6.2$ Hz, 1H), 2.30 (t, $J = 10.0$ Hz, 1H), 2.10 (d, $J = 12.2$ Hz, 1H), 1.88 (q, $J = 6.8, 5.8$ Hz, 2H). LC-MS: $[M+H]^+ = 560.3, 561.3$.






Example #	Structure	¹ H NMR & LC-MS
182		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.47 (s, 1H), 8.23 (s, 1H), 8.12 (s, 1H), 7.78 – 7.69 (m, 2H), 7.62 (t, J = 7.8 Hz, 1H), 7.37 (dd, J = 7.9, 0.9 Hz, 1H), 7.23 (s, 1H), 7.16 – 7.06 (m, 3H), 5.59 (s, 2H), 3.50 (d, J = 11.3 Hz, 1H), 3.13 (dd, J = 15.6, 11.4 Hz, 2H), 3.02 – 2.84 (m, 1H), 2.31 – 2.15 (m, 1H), 2.15 – 1.95 (m, 2H), 1.87 (t, J = 7.9 Hz, 2H), 1.07 – 0.86 (m, 4H). LC-MS: [M+H] ⁺ = 536.3, 537.3.
183		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.62 – 8.39 (m, 1H), 8.22 (q, J = 3.4 Hz, 1H), 8.19 – 8.04 (m, 1H), 7.86 (dd, J = 9.7, 5.6 Hz, 1H), 7.74 (qd, J = 7.7, 6.5, 3.8 Hz, 2H), 7.62 (q, J = 7.3, 5.7 Hz, 1H), 7.40 (dd, J = 7.5, 3.9 Hz, 1H), 7.23 (d, J = 6.1 Hz, 1H), 7.18 – 6.96 (m, 2H), 5.80 – 5.47 (m, 3H), 3.68 – 3.47 (m, 1H), 3.17 (d, J = 11.3 Hz, 2H), 2.97 (d, J = 11.6 Hz, 1H), 2.27 (s, 1H), 2.08 (s, 1H), 1.89 (s, 2H), 1.73 – 1.54 (m, 3H). LC-MS: [M+H] ⁺ = 542.3, 543.3.
184		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.54 (s, 1H), 8.32 – 8.06 (m, 3H), 7.97 (d, J = 1.4 Hz, 1H), 7.81 (t, J = 7.8 Hz, 1H), 7.74 – 7.58 (m, 3H), 7.43 – 7.22 (m, 2H), 5.65 (q, J = 16.2 Hz, 2H), 3.90 (s, 3H), 3.61 (d, J = 11.3 Hz, 1H), 3.14 (d, J = 11.5 Hz, 2H), 3.06 – 2.88 (m, 1H), 2.28 (t, J = 10.6 Hz, 1H), 2.05 (dq, J = 13.6, 5.3, 4.2 Hz, 1H), 1.92 – 1.78 (m, 2H). LC-MS: [M+H] ⁺ = 566.3, 568.3.
185		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.45 (s, 1H), 8.20 (d, J = 25.6 Hz, 2H), 7.81 (t, J = 7.8 Hz, 1H), 7.72 – 7.55 (m, 2H), 7.43 (dd, J = 8.4, 2.0 Hz, 1H), 7.31 (d, J = 7.8 Hz, 1H), 7.15 (s, 1H), 6.72 (d, J = 8.3 Hz, 1H), 5.61 (q, J = 16.3 Hz, 2H), 4.55 (t, J = 8.7 Hz, 2H), 3.58 (d, J = 11.3 Hz, 1H), 3.19 (t, J = 8.7 Hz, 2H), 3.11 (d, J = 11.3 Hz, 2H), 3.03 – 2.92 (m, 1H), 2.26 (d, J = 9.2 Hz, 1H), 2.11 – 1.99 (m, 1H), 1.92 – 1.77 (m, 2H). LC-MS: [M+H] ⁺ = 554.3, 555.2.






Example #	Structure	¹ H NMR & LC-MS
186		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.46 (s, 1H), 8.20 (d, J = 21.9 Hz, 2H), 7.81 (t, J = 7.8 Hz, 1H), 7.64 (d, J = 7.6 Hz, 1H), 7.32 (d, J = 7.8 Hz, 1H), 7.24 (d, J = 1.8 Hz, 1H), 7.20 – 7.12 (m, 2H), 6.82 (d, J = 8.1 Hz, 1H), 5.96 (s, 2H), 5.61 (q, J = 16.3 Hz, 2H), 3.58 (d, J = 11.3 Hz, 1H), 3.18 – 3.03 (m, 2H), 3.03 – 2.94 (m, 1H), 2.27 (s, 1H), 2.04 (dt, J = 11.1, 5.6 Hz, 1H), 1.84 (td, J = 12.2, 11.2, 4.7 Hz, 2H). LC-MS: [M+H] ⁺ = 556.3, 557.2.
187		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.53 (s, 1H), 8.20 (s, 1H), 8.17 (s, 1H), 7.87 – 7.78 (m, 1H), 7.66 (d, J=7.6 Hz, 1H), 7.58 (m, 1H), 7.32 (d, J=8.0 Hz, 1H), 7.09 (s, 1H), 6.89 (m, 1H), 5.72 – 5.55 (m, 2H), 3.86 (s, 3H), 3.69 – 3.54 (m, 1H), 3.25 – 3.12 (m, 2H), 3.10 – 2.97 (m, 1H), 2.36 – 2.23 (m, 1H), 2.19 – 2.04 (m, 1H), 1.88 (m, 2H). LC-MS: [M+H] ⁺ = 578.4.
188		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.47 (s, 1H), 8.21 (d, J = 15.8 Hz, 2H), 7.70 (d, J = 5.7 Hz, 2H), 7.54 (dd, J = 12.7, 2.2 Hz, 1H), 7.44 (dt, J = 8.6, 1.5 Hz, 1H), 7.22 (s, 1H), 7.08 (t, J = 8.6 Hz, 1H), 5.82 – 5.45 (m, 2H), 3.86 (s, 3H), 3.54 (d, J = 11.4 Hz, 1H), 3.11 (dd, J = 17.2, 8.3 Hz, 2H), 3.02 – 2.89 (m, 1H), 2.33 – 2.16 (m, 1H), 2.12 – 1.94 (m, 1H), 1.92 – 1.71 (m, 2H). LC-MS: [M+H] ⁺ = 578.3, 579.3.
189		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.52 (s, 1H), 8.49 (s, 1H), 8.25 (s, 1H), 8.21 (s, 1H), 7.79–7.76 (m, 3H), 7.64–7.60 (m, 1H), 7.28 (s, 1H), 7.14 (t, J = 8.8 Hz, 1H), 5.70–5.61 (m, 2H), 3.56 (d, J = 11.0 Hz, 1H), 3.23–3.15 (m, 2H), 3.00 (t, J = 10 Hz, 1H), 2.33–2.21 (m, 1H), 2.16–2.05 (m, 1H), 1.95–1.85 (m, 2H). LC-MS: [M+H] ⁺ = 514.3.
190		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.49 (s, 1H), 8.23 (s, 1H), 8.16 (s, 1H), 7.84 – 7.68 (m, 2H), 7.57 – 7.41 (m, 2H), 7.25 (s, 1H), 7.16 – 7.04 (m, 2H), 5.73 – 5.47 (m, 2H), 3.53 (d, J = 11.4 Hz, 1H), 3.15 (d, J = 11.3 Hz, 2H), 2.97 (td, J = 11.2, 10.5, 2.9 Hz, 1H), 2.48 (d, J = 3.0 Hz, 3H), 2.36 – 2.19 (m, 1H), 2.06 (dtt, J = 13.8, 8.3, 4.4 Hz, 1H), 1.95 – 1.76 (m, 2H). LC-MS: [M+H] ⁺ = 527.8, 528.8.

Example #	Structure	¹ H NMR & LC-MS
191		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.54 (s, 1H), 8.29 – 8.24 (m, 1H), 8.24 - 8.19 (m, 2H), 7.85 - 7.79 (m, 1H), 7.77 - 7.70 (m, 2H), 7.66 (d, J=7.7 Hz, 1H), 7.33 (d, J=7.7 Hz, 1H), 5.73 - 5.56 (m, 2H), 3.69 – 3.59 (m, 1H), 3.27 - 3.16 (m, 2H), 3.10 - 2.98 (m, 1H), 2.38 - 2.24 (m, 1H), 2.19 - 2.02 (m, 1H), 1.94 - 1.81 (m, 2H). LC-MS: [M+H] ⁺ = 565.1.
192		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.55 (s, 1H), 8.19 (d, J = 18.0 Hz, 2H), 7.74 (dd, J = 11.9, 8.1 Hz, 1H), 7.62 (t, J = 9.8 Hz, 1H), 7.57 – 7.49 (m, 1H), 7.44 – 7.35 (m, 1H), 7.29 (d, J = 16.6 Hz, 2H), 5.61 (s, 2H), 3.73 (d, J = 11.5 Hz, 1H), 3.25 (d, J = 11.6 Hz, 1H), 3.14 (d, J = 11.7 Hz, 1H), 2.99 (t, J = 10.5 Hz, 1H), 2.31 (d, J = 12.5 Hz, 1H), 2.11 (d, J = 10.7 Hz, 1H), 1.99 (d, J = 13.1 Hz, 1H), 1.87 (d, J = 12.5 Hz, 1H). LC-MS: [M+H] ⁺ = 566.2, 567.2.
193		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.51 (s, 1H), 8.23 (s, 1H), 8.17 (s, 1H), 7.83-7.71 (m, 3H), 7.70-7.61 (m, 1H), 7.23 (s, 1H), 7.13 (t, J = 8.8 Hz, 2H), 5.72-5.40 (m, 4H), 3.67-3.54 (m, 1H), 3.22-3.09 (m, 2H), 3.00 (t, J = 8.8 Hz, 1H), 2.39-2.23 (m, 1H), 2.13-2.02 (m, 1H), 1.94-1.79 (m, 2H). LC-MS: [M+H] ⁺ = 546.1.
194		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.51 (s, 1H), 8.25 - 8.21 (m, 2H), 8.18 - 8.13 (d, J=8.8 Hz, 1H), 7.85 - 7.78 (t, J=8.0 Hz, 1H), 7.72 (s, 1H), 7.68 - 7.63 (d, J=8.0 Hz, 1H), 7.54- 7.48 (d, J=8.0 Hz, 1H), 7.34- 7.31 (d, J=8.0 Hz, 1H), 5.71 - 5.59 (m, 2H), 3.94 (s, 3H), 3.67- 3.57 (m, 1H), 3.22- 7.15 (m, 2H), 3.09 - 2.99 (m, 1H), 2.35 - 2.25 (m, 1H), 2.15 - 2.04 (m, 1H), 1.94 - 1.83 (m, 2H). LC-MS: [M+H] ⁺ = 577.3.
195		¹ H NMR (400 MHz, CD ₃ OD): δ 8.59 (s, 1H), 8.25-8.20 (m, 2H), 8.05-8.01 (m, 2H), 7.91 (d, J = 6.8 Hz, 1H), 7.79-7.74 (m, 1H), 7.57-7.54 (m, 1H), 7.32-7.27 (m, 2H), 5.70-5.56 (m, 2H), 3.68 (d, J = 11.6 Hz, 1H), 3.28-3.05 (m, 3H), 2.40-2.31 (m, 1H), 2.12-1.90 (m, 3H). LC-MS: [M+H] ⁺ = 557.1






Example #	Structure	¹ H NMR & LC-MS
196		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.56 (s, 1H), 8.40 (d, J=2.3 Hz, 1H), 8.31 (dd, J=4.6, 9.0 Hz, 1H), 8.23 (d, J=5.5 Hz, 2H), 7.89 - 7.82 (m, 1H), 7.76 (s, 1H), 7.72 - 7.60 (m, 2H), 7.35 (d, J=7.9 Hz, 1H), 5.76 - 5.59 (m, 2H), 3.66 (d, J=11.0 Hz, 1H), 3.29 - 3.19 (m, 2H), 3.12 - 3.03 (m, 1H), 2.40-2.25 (m, 1H), 2.20-2.05 (m, 1H), 1.93-1.90 (m). LC-MS: [M+H] ⁺ =531.3.
197		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.51 (s, 1H), 8.22 (s, 1H), 8.15 (s, 1H), 7.95 (t, J = 7.9 Hz, 1H), 7.84 - 7.67 (m, 3H), 7.59 (dd, J = 7.8, 0.9 Hz, 1H), 7.22 (s, 1H), 7.18 - 7.02 (m, 2H), 5.79 - 5.43 (m, 2H), 3.60 (d, J = 11.3 Hz, 1H), 3.24 - 3.09 (m, 2H), 3.04 - 2.90 (m, 1H), 2.35 - 2.24 (m, 1H), 2.11 (t, J = 5.0 Hz, 1H), 2.01 (t, J = 18.7 Hz, 3H), 1.94 - 1.82 (m, 2H). LC-MS: [M+H] ⁺ = 560.3, 561.3.
198		¹ H NMR (400 MHz, DMSO-d ₆) δ ppm 8.50-8.56 (2H, m), 8.28 (1H, s), 8.13 (1H, s), 7.85-7.95 (1H, m), 7.78 (2H, d, J = 3.6 Hz), 7.55-7.65 (1H, m), 7.40-7.50 (1H, m), 7.36 (1H, s), 7.20-7.35 (3H, m), 5.55 (2H, dd, J = 23.2, 16.4 Hz), 3.45 (1H, d, J = 11.2 Hz), 3.15-3.07 (1H, m), 3.04 (1H, d, J = 11.2 Hz), 2.93 (1H, t, J = 10.8 Hz), 2.00-2.25 (2H, m), 1.60-1.80 (2H, m), 1.10-1.30 (2H, m). LC-MS: [M+H] ⁺ =514.2.
199		¹ H NMR (400 MHz, DMSO-d ₆) δ ppm 8.57 (s, 1H), 8.41-8.38 (m, 1H), 8.23 (s, 1H), 8.12 (s, 1H), 7.93-7.85 (m, 1H), 7.72-7.60 (m, 2H), 7.53-7.45 (m, 1H), 7.43-7.38 (m, 1H), 7.37 (s, 1H), 7.28 (s, 2H), 5.55-5.44 (m, 2H), 3.57 (d, J = 11.6 Hz, 1H), 3.25 (d, J = 11.6 Hz, 1H), 3.13-3.05 (m, 1H), 2.94 (t, J = 8.8 Hz, 1H), 2.20-2.07 (m, 2H), 1.94 (brs, 1H), 1.81-1.74 (m, 1H). LC-MS: [M+H] ⁺ =532.1.
200		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.54 (s, 1H), 8.24 (s, 1H), 8.19 (s, 1H), 7.83 (t, J = 7.6 Hz, 1H), 7.77-7.72 (m, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.57-7.50 (m, 1H), 7.35-7.24 (m, 3H), 5.67 (d, J = 16.0 Hz, 1H), 5.60 (d, J = 16.0 Hz, 1H), 3.61 (d, J = 11.2 Hz, 1H), 3.19-3.11 (m, 2H), 3.01 (t, J = 9.2 Hz, 1H), 2.34-2.24 (m, 1H), 2.14-2.02 (m, 1H), 1.94-1.82 (m, 2H). LC-MS: [M+H] ⁺ =548.3.





Example #	Structure	¹ H NMR & LC-MS
201		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.55 (s, 1H), 8.22 (d, <i>J</i> = 19.8 Hz, 2H), 7.96 (q, <i>J</i> = 8.1 Hz, 1H), 7.75 (ddd, <i>J</i> = 12.1, 7.8, 2.3 Hz, 1H), 7.64 – 7.49 (m, 2H), 7.41 – 7.19 (m, 2H), 6.95 (dd, <i>J</i> = 8.1, 2.9 Hz, 1H), 5.86 – 5.56 (m, 2H), 3.57 (d, <i>J</i> = 11.3 Hz, 1H), 3.16 (dd, <i>J</i> = 14.3, 10.2 Hz, 2H), 3.06 – 2.93 (m, 1H), 2.27 (dq, <i>J</i> = 14.8, 6.5, 5.3 Hz, 1H), 2.09 (tdd, <i>J</i> = 13.4, 8.4, 4.1 Hz, 1H), 1.95 – 1.68 (m, 2H). LC-MS: [M+H] ⁺ = 532.0, 533.0.
202		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.52 (d, <i>J</i> = 4.6 Hz, 1H), 8.22 (d, <i>J</i> = 34.2 Hz, 2H), 7.78 (ddd, <i>J</i> = 13.6, 7.9, 5.0 Hz, 3H), 7.50 (d, <i>J</i> = 7.9 Hz, 1H), 7.31 (s, 1H), 7.16 (td, <i>J</i> = 9.6, 8.7, 4.3 Hz, 3H), 5.63 (t, <i>J</i> = 10.3 Hz, 2H), 3.59 (d, <i>J</i> = 11.6 Hz, 1H), 3.24 – 3.15 (m, 2H), 3.03 (dt, <i>J</i> = 11.3, 5.9 Hz, 1H), 2.84 (q, <i>J</i> = 7.6 Hz, 2H), 2.32 (t, <i>J</i> = 11.3 Hz, 1H), 2.17 – 2.02 (m, 1H), 2.01 – 1.82 (m, 2H), 1.30 (q, <i>J</i> = 6.2, 4.7 Hz, 3H). LC-MS: [M+H] ⁺ = 524.0, 525.0.
203		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.53 (s, 1H), 8.30 – 8.20 (m, 1H), 8.17 (d, <i>J</i> = 7.5 Hz, 1H), 8.00 (q, <i>J</i> = 7.2, 6.5 Hz, 1H), 7.86 (d, <i>J</i> = 8.0 Hz, 1H), 7.77 (ddd, <i>J</i> = 9.2, 5.7, 2.9 Hz, 2H), 7.60 (d, <i>J</i> = 7.7 Hz, 1H), 7.23 (d, <i>J</i> = 7.5 Hz, 1H), 7.14 (td, <i>J</i> = 8.9, 4.5 Hz, 2H), 6.72 (td, <i>J</i> = 55.4, 7.7 Hz, 1H), 5.77 – 5.49 (m, 2H), 3.65 (d, <i>J</i> = 11.4 Hz, 1H), 3.19 (t, <i>J</i> = 9.9 Hz, 2H), 3.09 – 2.91 (m, 1H), 2.33 (q, <i>J</i> = 9.5, 6.1 Hz, 1H), 2.12 (dp, <i>J</i> = 14.5, 4.3 Hz, 1H), 1.99 – 1.80 (m, 2H). LC-MS: [M+H] ⁺ = 546.0, 547.0.
204		¹ H NMR (CD ₃ OD) δ: 8.24 (d, <i>J</i> = 18.9 Hz, 2H), 8.12 (s, 1H), 7.80 (t, <i>J</i> = 7.8 Hz, 1H), 7.63 (d, <i>J</i> = 7.8 Hz, 1H), 7.31 (d, <i>J</i> = 7.9 Hz, 1H), 6.61 (s, 1H), 5.54 (q, <i>J</i> = 16.5 Hz, 2H), 3.51 (d, <i>J</i> = 11.4 Hz, 1H), 3.04 (d, <i>J</i> = 11.2 Hz, 2H), 2.92 (t, <i>J</i> = 10.5 Hz, 1H), 2.25 (s, 1H), 2.00 (d, <i>J</i> = 10.4 Hz, 1H), 1.93 – 1.72 (m, 3H), 0.89 (dt, <i>J</i> = 8.3, 3.2 Hz, 2H), 0.84 – 0.67 (m, 2H). LC-MS [M+H] ⁺ = 476.3
205		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.50 (s, 1H), 8.24 (s, 1H), 8.18 (s, 1H), 7.81 (t, <i>J</i> = 8.0 Hz, 1H), 7.76-7.73 (m, 2H), 7.65 (d, <i>J</i> = 8.0 Hz, 1H), 7.32 (d, <i>J</i> = 8.0 Hz, 1H), 7.24 (s, 1H), 7.11 (t, <i>J</i> = 8.8 Hz, 2H), 5.69-5.58 (m, 2H), 3.59 (d, <i>J</i> = 11.2 Hz, 1H), 3.14 (d, <i>J</i> = 11.2 Hz, 1H), 2.98 (t, <i>J</i> = 9.6 Hz, 1H), 2.30-2.25 (m, 1H), 2.13-2.00 (m, 1H), 1.90-1.76 (m, 2H). LC-MS: [M+H] ⁺ = 530.1.






Example #	Structure	¹ H NMR & LC-MS
206		¹ H NMR (400MHz, CD ₃ OD): 8.57 (s, 1H), 8.26 (d, J=3.2 Hz, 2H), 7.83 - 7.73 (m, 1H), 7.67 - 7.52 (m, 1H), 7.45 (s, 1H), 7.35 - 7.21 (m, 1H), 6.67 (s, 1H), 6.00 (s, 1H), 5.68 - 5.56 (m, 2H), 3.54 - 3.44 (m, 1H), 3.14 - 2.97 (m, 2H), 2.28 - 2.15 (m, 1H), 2.10 - 1.95 (m, 2H), 1.89 - 1.85 (m, 2H). LC-MS: [M+H] ⁺ = 548.3.
207		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.45 (s, 1H), 8.23 (d, J = 6.2 Hz, 1H), 8.18 (s, 1H), 7.59 - 7.40 (m, 4H), 7.23 (s, 1H), 7.06 (t, J = 8.6 Hz, 1H), 5.68 - 5.49 (m, 2H), 3.86 (s, 3H), 3.49 (d, J = 11.3 Hz, 1H), 3.11 (dd, J = 11.6, 5.1 Hz, 2H), 2.92 (td, J = 15.9, 14.2, 8.1 Hz, 1H), 2.47 (d, J = 2.9 Hz, 3H), 2.21 (q, J = 8.5, 5.8 Hz, 1H), 2.04 (qd, J = 10.4, 9.8, 5.0 Hz, 1H), 1.92 - 1.74 (m, 2H). LC-MS: [M+H] ⁺ = 558.4.
208		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.55 (s, 1H), 8.23 (d, J = 9.6 Hz, 2H), 8.03 (d, J = 3.6 Hz, 2H), 7.77-7.72 (m, 2H), 7.53 (s, 1H), 7.30-7.25 (m, 2H), 5.69-5.59 (m, 2H), 3.66 (d, J = 11.2Hz, 1H), 3.21-3.13 (m, 2H), 3.03 (t, J = 10.0 Hz, 1H), 2.35-2.29 (m, 1H), 2.18-2.05 (m, 1H), 1.91-1.83 (m, 2H). LC-MS: 561.1 [M+Na] ⁺ .
209		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.53 (s, 1H), 8.46 (d, J = 2.7 Hz, 1H), 8.22 (d, J = 9.8 Hz, 2H), 7.84 - 7.71 (m, 2H), 7.65 (dd, J = 8.7, 2.8 Hz, 1H), 7.54 (ddd, J = 8.0, 4.0, 1.9 Hz, 1H), 7.39 - 7.19 (m, 2H), 6.92 (t, J = 73.1 Hz, 1H), 5.63 (s, 2H), 3.56 (d, J = 11.4 Hz, 1H), 3.18 (dd, J = 25.0, 11.9 Hz, 2H), 3.06 - 2.92 (m, 1H), 2.25 (q, J = 13.9, 12.5 Hz, 1H), 2.08 (q, J = 12.2 Hz, 1H), 2.01 - 1.82 (m, 2H). LC-MS: [M+H] ⁺ = 580.3, 581.3.
210		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.90 (d, J = 1.5 Hz, 1H), 8.54 (s, 1H), 8.21 (d, J = 15.3 Hz, 2H), 7.94 - 7.76 (m, 2H), 7.75 - 7.60 (m, 2H), 7.59 - 7.49 (m, 2H), 7.36 (s, 1H), 7.31 (d, J = 7.9 Hz, 1H), 5.84 - 5.50 (m, 2H), 3.60 (d, J = 11.3 Hz, 1H), 3.14 (dd, J = 11.4, 4.5 Hz, 2H), 3.02 - 2.90 (m, 1H), 2.26 (q, J = 9.5, 6.1 Hz, 1H), 2.06 (tp, J = 7.9, 4.4, 3.7 Hz, 1H), 1.84 (q, J = 7.8, 4.3 Hz, 2H). LC-MS: [M+H] ⁺ = 552.3, 553.2.

Example #	Structure	¹ H NMR & LC-MS
211		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.47 (s, 1H), 8.21 (d, <i>J</i> = 20.6 Hz, 2H), 7.82 (t, <i>J</i> = 7.8 Hz, 1H), 7.71 – 7.56 (m, 3H), 7.33 (d, <i>J</i> = 7.6 Hz, 1H), 7.17 (s, 1H), 7.01 – 6.83 (m, 2H), 5.62 (q, <i>J</i> = 16.4 Hz, 2H), 3.80 (s, 3H), 3.59 (d, <i>J</i> = 11.3 Hz, 1H), 3.12 (d, <i>J</i> = 11.4 Hz, 2H), 2.99 (t, <i>J</i> = 10.4 Hz, 1H), 2.27 (s, 1H), 2.04 (d, <i>J</i> = 9.8 Hz, 1H), 1.92 – 1.75 (m, 2H). LC-MS: [M+H] ⁺ = 542.3, 544.3.
212		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.50 (d, <i>J</i> = 4.2 Hz, 1H), 8.29 – 8.18 (m, 1H), 8.13 (s, 1H), 7.86 (dd, <i>J</i> = 10.1, 6.1 Hz, 1H), 7.75 (dd, <i>J</i> = 8.8, 5.0 Hz, 2H), 7.62 (d, <i>J</i> = 7.7 Hz, 1H), 7.39 (d, <i>J</i> = 7.4 Hz, 1H), 7.22 (d, <i>J</i> = 5.9 Hz, 1H), 7.18 – 7.00 (m, 2H), 5.79 – 5.50 (m, 3H), 3.57 (d, <i>J</i> = 11.3 Hz, 1H), 3.16 (d, <i>J</i> = 10.8 Hz, 2H), 3.01 (d, <i>J</i> = 13.3 Hz, 1H), 2.29 (s, 1H), 2.07 (s, 1H), 1.89 (d, <i>J</i> = 11.2 Hz, 2H), 1.77 – 1.55 (m, 3H). LC-MS: [M+H] ⁺ = 542.3, 543.3.
213		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.48 (s, 1H), 8.23 (s, 1H), 8.18 (s, 1H), 7.81 (t, <i>J</i> = 7.8 Hz, 1H), 7.64 (d, <i>J</i> = 7.7 Hz, 1H), 7.54 (dd, <i>J</i> = 12.7, 2.2 Hz, 1H), 7.44 (ddd, <i>J</i> = 8.6, 2.2, 1.1 Hz, 1H), 7.31 (d, <i>J</i> = 7.8 Hz, 1H), 7.21 (s, 1H), 7.08 (t, <i>J</i> = 8.7 Hz, 1H), 5.61 (q, <i>J</i> = 16.3 Hz, 2H), 3.87 (s, 3H), 3.66 – 3.50 (m, 1H), 3.12 (d, <i>J</i> = 11.4 Hz, 2H), 2.96 (d, <i>J</i> = 9.6 Hz, 1H), 2.25 (d, <i>J</i> = 10.5 Hz, 1H), 2.04 (ddt, <i>J</i> = 13.6, 9.6, 4.8 Hz, 1H), 1.88 – 1.68 (m, 2H). LC-MS: [M+H] ⁺ = 560.3, 561.2.
214		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.60 (s, 1H), 8.32 (s, 1H), 8.28 (s, 1H), 7.81 (ddd, <i>J</i> = 2.0, 7.9, 11.8 Hz, 1H), 7.62 (br d, <i>J</i> = 8.4 Hz, 1H), 7.52 (s, 1H), 7.46 – 7.39 (m, 2H), 7.37 – 7.26 (m, 1H), 5.65 (m, 2H), 3.59 – 3.52 (m, 1H), 3.48 – 3.41 (m, 1H), 3.13 – 3.01 (m, 2H), 2.38 – 2.17 (m, 2H), 2.09 – 1.91 (m, 2H). LC-MS: [M+H] ⁺ = 548.0.
215		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.56 (s, 1H), 8.26 (s, 1H), 8.19 (s, 1H), 8.12 – 8.02 (m, 1H), 7.83 – 7.73 (m, 1H), 7.62 (d, <i>J</i> = 7.6 Hz, 1H), 7.59 – 7.50 (m, 1H), 7.36 – 7.25 (m, 2H), 5.74 – 5.59 (m, 2H), 5.10 – 5.00 (m, 1H), 3.65 – 3.53 (m, 1H), 3.23 – 3.12 (m, 2H), 3.10 – 2.95 (m, 1H), 2.37 – 2.22 (m, 1H), 2.14 – 2.00 (m, 1H), 1.94 – 1.81 (m, 2H), 1.45 (d, <i>J</i> = 6.8 Hz, 1H), 1.41 (d, <i>J</i> = 6.4 Hz, 2H). LC-MS: [M+H] ⁺ = 576.3.

Example #	Structure	¹ H NMR & LC-MS
216		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.47 (s, 1H), 8.21 (d, <i>J</i> = 16.6 Hz, 2H), 7.71 (d, <i>J</i> = 5.8 Hz, 2H), 7.68 – 7.56 (m, 2H), 7.17 (s, 1H), 7.03 – 6.81 (m, 2H), 5.71 – 5.49 (m, 2H), 3.55 (d, <i>J</i> = 11.4 Hz, 1H), 3.11 (td, <i>J</i> = 9.8, 8.6, 4.4 Hz, 2H), 3.04 – 2.91 (m, 1H), 2.26 (t, <i>J</i> = 10.9 Hz, 1H), 2.04 (dq, <i>J</i> = 13.1, 8.6, 7.5 Hz, 1H), 1.91 – 1.74 (m, 2H). LC-MS: [M+H] ⁺ = 560.3, 561.3
217		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.52 (s, 1H), 8.29 (s, 1H), 8.23 (s, 1H), 7.75 (ddd, <i>J</i> = 11.8, 7.9, 2.1 Hz, 1H), 7.67 (dd, <i>J</i> = 8.9, 7.2 Hz, 1H), 7.54 (d, <i>J</i> = 8.8 Hz, 1H), 7.30 (dt, <i>J</i> = 16.6, 5.6 Hz, 2H), 6.78 (s, 1H), 6.51 (d, <i>J</i> = 8.9 Hz, 1H), 5.76 – 5.60 (m, 2H), 3.39 (d, <i>J</i> = 11.6 Hz, 1H), 3.21 (d, <i>J</i> = 11.3 Hz, 1H), 3.14 (d, <i>J</i> = 12.1 Hz, 1H), 3.01 (t, <i>J</i> = 10.8 Hz, 1H), 2.16 (d, <i>J</i> = 10.1 Hz, 2H), 1.89 (d, <i>J</i> = 17.2 Hz, 2H). LC-MS: [M+H] ⁺ = 530.3, 531.3.
218		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.51 (s, 1H), 8.23 (s, 1H), 8.18 (s, 1H), 7.92 (dd, <i>J</i> = 9.0, 3.6 Hz, 1H), 7.80 – 7.68 (m, 3H), 7.22 (s, 1H), 7.12 (t, <i>J</i> = 8.8 Hz, 2H), 6.87 (t, <i>J</i> = 53.6 Hz, 1H), 5.71 – 5.51 (m, 2H), 3.60 (d, <i>J</i> = 11.3 Hz, 1H), 3.15 (d, <i>J</i> = 17.2 Hz, 2H), 3.00 (t, <i>J</i> = 10.7 Hz, 1H), 2.30 (t, <i>J</i> = 11.7 Hz, 1H), 2.08 (d, <i>J</i> = 12.7 Hz, 1H), 1.94 – 1.79 (m, 2H). LC-MS: [M+H] ⁺ = 563.9.
219		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 7.83-7.78 (m, 1H), 7.63-7.61 (m, 1H), 7.51 (s, 1H), 7.34-7.27 (m, 1H), 6.72-6.71 (d, <i>J</i> = 1.6 Hz, 1H), 6.49-6.48 (d, <i>J</i> = 1.6 Hz, 1H), 5.67-5.59 (t, <i>J</i> ₁ = 16.4 Hz, <i>J</i> ₂ = 33.6 Hz, 2H), 3.55-3.52 (d, <i>J</i> = 12.0 Hz, 1H), 3.35 (s, 1H), 3.08-3.06 (m, 2H), 2.28-2.22 (m, 1H), 2.13-2.09 (m, 1H), 2.00-1.91 (m, 2H). LC-MS: [M+H] ⁺ = 564.3
220		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.54 (s, 1H), 8.32 – 8.06 (m, 3H), 7.97 (d, <i>J</i> = 1.4 Hz, 1H), 7.81 (t, <i>J</i> = 7.8 Hz, 1H), 7.74 – 7.58 (m, 3H), 7.43 – 7.22 (m, 2H), 5.65 (q, <i>J</i> = 16.2 Hz, 2H), 3.90 (s, 3H), 3.61 (d, <i>J</i> = 11.3 Hz, 1H), 3.14 (d, <i>J</i> = 11.5 Hz, 2H), 3.06 – 2.88 (m, 1H), 2.28 (t, <i>J</i> = 10.6 Hz, 1H), 2.05 (dq, <i>J</i> = 13.6, 5.3, 4.2 Hz, 1H), 1.92 – 1.78 (m, 2H). LC-MS: [M+H] ⁺ = 566.3, 568.3.

Example #	Structure	¹ H NMR & LC-MS
221		¹ H NMR (400 MHz, CD ₃ OD) δ 8.51 (s, 1H), 8.21 (d, <i>J</i> = 11.4 Hz, 2H), 7.80 – 7.66 (m, 4H), 7.23 (s, 1H), 7.18 – 7.08 (m, 2H), 5.71 – 5.52 (m, 2H), 3.57 (d, <i>J</i> = 11.4 Hz, 1H), 3.14 (t, <i>J</i> = 11.0 Hz, 2H), 2.99 (td, <i>J</i> = 10.7, 9.6, 2.8 Hz, 1H), 2.25 (d, <i>J</i> = 9.7 Hz, 1H), 2.12 – 1.97 (m, 1H), 1.91 – 1.77 (m, 2H). LC-MS: [M+H] ⁺ = 547.7.
222		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.99 (t, <i>J</i> = 4.9 Hz, 1H), 8.58 (q, <i>J</i> = 4.7 Hz, 1H), 8.22 (dq, <i>J</i> = 16.5, 4.4 Hz, 2H), 8.01 – 7.91 (m, 1H), 7.81 (dd, <i>J</i> = 11.4, 6.7 Hz, 1H), 7.65 (dh, <i>J</i> = 14.1, 7.6, 6.2 Hz, 3H), 7.44 – 7.24 (m, 2H), 6.61 (d, <i>J</i> = 6.6 Hz, 1H), 5.66 (d, <i>J</i> = 9.9 Hz, 2H), 3.62 (s, 1H), 3.15 (q, <i>J</i> = 7.6, 6.8 Hz, 2H), 3.02 (d, <i>J</i> = 9.4 Hz, 1H), 2.36 – 2.15 (m, 2H), 2.07 (s, 1H), 1.87 (s, 2H). LC-MS: [M+H] ⁺ = 552.3, 554.3.
223		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.60 (s, 1H), 8.20 (d, <i>J</i> = 7.6 Hz, 2H), 7.90 – 7.77 (m, 2H), 7.76 (d, <i>J</i> = 5.5 Hz, 2H), 7.65 (dd, <i>J</i> = 7.8, 0.7 Hz, 1H), 7.43 (s, 1H), 7.37 – 7.27 (m, 1H), 5.79 – 5.42 (m, 2H), 3.64 (d, <i>J</i> = 11.3 Hz, 1H), 3.18 (dd, <i>J</i> = 11.6, 6.3 Hz, 2H), 3.09 – 2.91 (m, 1H), 2.36 – 2.20 (m, 1H), 2.20 – 2.03 (m, 1H), 1.87 (dd, <i>J</i> = 11.3, 6.1 Hz, 2H). LC-MS: [M+H] ⁺ = 555.3, 557.2.
224		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.50 (s, 1H), 8.23 – 8.20 (m, 2H), 8.10 – 8.06 (d, <i>J</i> =8.0 Hz, 1H), 7.85 – 7.79 (t, <i>J</i> =8.0 Hz, 1H), 7.68 – 7.65 (d, <i>J</i> =8.0 Hz, 1H), 7.62 – 7.55 (m, 2H), 7.34 – 7.31 (d, <i>J</i> =8.0 Hz, 1H), 5.67 – 5.61 (m, 2H), 3.92 (s, 3H), 3.65 – 3.58 (m, 1H), 3.52 – 3.45 (m, 1H), 3.25 – 2.98 (m, 2H), 2.38 – 2.23 (m, 1H), 2.20 – 2.03 (m, 1H), 1.94 – 1.82 (m, 2H). LC-MS: [M+H] ⁺ = 561.3.
225		¹ H NMR (CD ₃ OD) δ: 8.51 (s, 1H), 8.22 (d, <i>J</i> = 13.4 Hz, 2H), 8.05 (dd, <i>J</i> = 27.2, 1.0 Hz, 2H), 7.93 – 7.74 (m, 2H), 7.60 (dd, <i>J</i> = 39.0, 8.3 Hz, 2H), 7.43 – 7.19 (m, 2H), 5.64 (q, <i>J</i> = 16.4 Hz, 2H), 4.04 (s, 3H), 3.59 (d, <i>J</i> = 11.4 Hz, 1H), 3.13 (d, <i>J</i> = 11.4 Hz, 2H), 3.07 – 2.83 (m, 1H), 2.32 – 1.99 (m, 2H), 1.84 (td, <i>J</i> = 11.9, 10.8, 4.6 Hz, 2H). LC-MS : [M+H] ⁺ = 566.3 : [M+H+2] ⁺ =568.3.






Example #	Structure	¹ H NMR & LC-MS
226		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.52 (s, 1H), 8.23 (s, 1H), 8.15 (s, 1H), 7.88 (t, J = 7.8 Hz, 1H), 7.74 (ddd, J = 12.1, 7.8, 2.3 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.53 (ddt, J = 8.2, 4.0, 1.6 Hz, 1H), 7.40 (d, J = 7.7 Hz, 1H), 7.33 – 7.22 (m, 2H), 5.68 – 5.52 (m, 2H), 5.51 (s, 1H), 5.39 (s, 1H), 3.59 (d, J = 11.6 Hz, 1H), 3.16 (dd, J = 11.7, 6.2 Hz, 2H), 3.00 (t, J = 10.0 Hz, 1H), 2.30 (t, J = 11.0 Hz, 1H), 2.08 (d, J = 9.5 Hz, 1H), 1.97 – 1.80 (m, 2H). LC-MS: [M+H] ⁺ = 545.9, 546.9.
227		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.53 (s, 1H), 8.22 (s, 1H), 8.16 (s, 1H), 7.99 (t, J = 7.8 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.73 (ddd, J = 11.8, 7.8, 2.1 Hz, 1H), 7.58 (d, J = 7.7 Hz, 1H), 7.56 – 7.43 (m, 1H), 7.27 (d, J = 9.6 Hz, 2H), 6.71 (t, J = 55.4 Hz, 1H), 5.72 – 5.50 (m, 2H), 3.63 (d, J = 11.4 Hz, 1H), 3.17 (t, J = 11.6 Hz, 2H), 3.09 – 2.94 (m, 1H), 2.31 (t, J = 11.5 Hz, 1H), 2.16 – 1.98 (m, 1H), 1.95 – 1.79 (m, 2H). LC-MS: [M+H] ⁺ = 564.3, 565.3.
228		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.54 (s, 1H), 8.20 (d, J = 16.4 Hz, 2H), 7.81 (t, J = 7.8 Hz, 1H), 7.77 – 7.68 (m, 1H), 7.65 (d, J = 7.8 Hz, 1H), 7.54 (d, J = 8.6 Hz, 1H), 7.40 – 7.24 (m, 3H), 6.87 (t, J = 73.3 Hz, 1H), 5.72 – 5.49 (m, 2H), 3.61 (d, J = 11.4 Hz, 1H), 3.14 (d, J = 11.1 Hz, 2H), 3.00 (t, J = 10.5 Hz, 1H), 2.35 – 2.17 (m, 1H), 2.06 (d, J = 10.1 Hz, 1H), 1.86 (q, J = 11.0, 8.6 Hz, 2H). LC-MS: [M+H] ⁺ = 596.3, 597.2.
229		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.79 (d, J = 2.3 Hz, 1H), 8.57 (s, 1H), 8.21 (d, J = 13.1 Hz, 2H), 8.08 (dd, J = 8.2, 2.4 Hz, 1H), 7.82 (t, J = 7.8 Hz, 1H), 7.65 (dd, J = 7.8, 0.7 Hz, 1H), 7.40 – 7.20 (m, 3H), 5.72 – 5.54 (m, 2H), 3.62 (d, J = 11.4 Hz, 1H), 3.15 (d, J = 11.0 Hz, 2H), 3.02 (t, J = 10.5 Hz, 1H), 2.29 (s, 1H), 2.08 (d, J = 12.8 Hz, 1H), 1.87 (d, J = 7.5 Hz, 2H). LC-MS: [M+H] ⁺ = 527.3, 528.3.

Example #	Structure	¹ H NMR & LC-MS
230		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.53 (s, 1H), 8.23 (s, 1H), 8.13 (s, 1H), 7.75-7.70 (m, 1H), 7.53-7.48 (m, 2H), 7.31-7.23 (m, 3H), 5.63-5.53 (q, 2H), 3.95 (s, 3H), 3.76-3.73 (m, 1H), 3.27 (s, 1H), 3.17-3.14 (m, 1H), 3.00-2.95 (m, 1H), 2.30-2.27 (m, 1H), 2.09-1.96 (m, 3H). LC-MS: [M+H] ⁺ = 578.4.
231		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.54 (s, 1H), 8.30 (d, J=1.9 Hz, 1H), 8.24 (s, 1H), 8.22 (s, 1H), 7.93 (dd, J=1.9, 11.4 Hz, 1H), 7.88 (br t, J=7.9 Hz, 1H), 7.70 (br d, J=7.7 Hz, 1H), 7.39 (br d, J=7.9 Hz, 1H), 7.35 (s, 1H), 5.80 - 5.49 (m, 2H), 4.01 (s, 3H), 3.58 (br d, J=10.3 Hz, 1H), 3.20 (br d, J=10.5 Hz, 1H), 3.12 (br d, J=10.3 Hz, 1H), 3.06 - 2.96 (m, 1H), 2.39 - 2.24 (m, 1H), 2.14 - 1.80 (m, 4H). LCMS: [M+H] ⁺ = 561.4
232		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.51 (s, 1H), 8.20 (s, 2H), 7.82 - 7.58 (m, 2H), 7.53 - 7.39 (m, 3H), 7.26 (dt, J = 10.4, 8.4 Hz, 1H), 7.19 (s, 1H), 5.84 - 5.33 (m, 2H), 3.87 - 3.39 (m, 2H), 3.13 (t, J = 5.3 Hz, 2H), 2.47 (s, 4H), 2.25 - 1.77 (m, 3H). LC-MS: [M+H] ⁺ = 544.2, 545.3
233		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.50 (s, 1H), 8.29 - 8.21 (m, 1H), 8.17 (s, 1H), 7.81 (t, J=7.8 Hz, 1H), 7.64 (d, J=8.0 Hz, 1H), 7.47 - 7.36 (m, 2H), 7.35 - 7.27 (m, 2H), 5.68 - 5.52 (m, 2H), 3.96 (s, 3H), 3.63 - 3.54 (m, 1H), 3.18 - 3.06 (m, 2H), 3.02 - 2.92 (m, 1H), 2.33 - 2.19 (m, 1H), 2.12 - 1.98 (m, 1H), 1.92 - 1.79 (m, 2H). LC-MS: [M+H] ⁺ = 578.0.
234		¹ H NMR (400MHz, CD ₃ OD) δ ppm 8.56 (s, 1H), 8.25 (s, 1H), 8.17 (s, 1H), 8.07 (d, J=8.2 Hz, 1H), 7.80 - 7.71 (m, 2H), 7.55 (br s, 1H), 7.35 - 7.27 (m, 2H), 5.66 - 5.57 (m, 2H), 5.11 (m, 1H), 3.66 (m, 1H), 3.22 - 3.14 (m, 2H), 3.05 (m, 1H), 2.34 (m, 1H), 2.08 (m, 1H), 1.91 (m, 2H), 1.35 (m, 3H). LC-MS: [M+H] ⁺ = 592.4

Example #	Structure	¹ H NMR & LC-MS
235		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.52 (s, 1H), 8.23 (s, 1H), 8.18 (s, 1H), 7.73 (ddd, <i>J</i> = 12.0, 7.8, 2.2 Hz, 1H), 7.58 – 7.44 (m, 1H), 7.32 (s, 1H), 7.27 (dt, <i>J</i> = 10.3, 8.4 Hz, 1H), 7.11 (d, <i>J</i> = 1.7 Hz, 1H), 6.49 (d, <i>J</i> = 1.8 Hz, 1H), 5.72 – 5.54 (m, 2H), 3.91 (s, 3H), 3.51 (d, <i>J</i> = 11.4 Hz, 1H), 3.11 (d, <i>J</i> = 10.8 Hz, 2H), 2.96 (t, <i>J</i> = 10.7 Hz, 1H), 2.21 (t, <i>J</i> = 10.8 Hz, 1H), 2.13 – 1.95 (m, 1H), 1.89 – 1.73 (m, 2H). LC-MS: [M+H] ⁺ = 562.0, 563.0.
236		¹ H NMR (400MHz, CD ₃ OD): δ 8.55 (s, 1H), 8.22 (s, 1H), 8.18(s, 1H), 7.86-7.82 (t, <i>J</i> = 8.0 Hz, 1H), 7.69-7.68 (d, <i>J</i> = 7.6 Hz, 1H), 7.35-7.34 (d, <i>J</i> = 7.6 Hz, 1H), 6.82 (s, 1H), 6.63-6.60 (m, 2H), 5.72-5.62 (m, 2H), 3.82 (s, 3H), 3.69-3.61 (m, 1H), 3.27-3.20 (m, 2H), 3.10-3.05 (m, 1H), 2.35-2.31 (m, 1H), 2.16-2.14 (m, 1H), 1.92-1.90 (m, 2H). LCMS: [M+H] ⁺ = 578.3.
237		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.57 (s, 1H), 8.20 (s, 1H), 8.18 (s, 1H), 7.85-7.81 (t, <i>J</i> = 8.0 Hz, 1H), 7.79-7.74 (m, 1H), 7.68-7.66 (d, <i>J</i> = 7.6 Hz, 1H), 7.34-7.32 (d, <i>J</i> = 8.0 Hz, 1H), 7.20-7.15 (m, 1H), 7.13(br, 1H), 5.69-5.60 (m, 2H), 3.65-3.62 (d, <i>J</i> = 11.2 Hz, 1H), 3.24-3.18 (m, 2H), 3.08-3.03 (m, 1H), 2.34-2.27 (m, 1H), 2.17-2.11 (m, 1H), 1.91-1.88 (m, 2H). LC-MS: [M+H] ⁺ = 566.4.
238		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.56 (s, 1H), 8.20 (s, 1H), 8.17 (s, 1H), 7.85-7.76 (m, 2H), 7.68-7.66 (d, <i>J</i> = 8.0 Hz, 1H), 7.34-7.32 (d, <i>J</i> = 7.6 Hz, 1H), 7.07-6.94 (m, 3H), 5.70-5.60 (m, 2H), 3.65-3.62 (d, <i>J</i> = 11.2 Hz, 1H), 3.23-3.13 (m, 2H), 3.07-3.02 (m, 1H), 2.31-2.28 (m, 1H), 2.13-2.11 (m, 1H), 1.90-1.88 (m, 2H). LC-MS: [M+H] ⁺ = 548.4.
239		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.49 (s, 1H), 8.27 (s, 1H), 8.22 (s, 1H), 7.74 (m, 1H), 7.58 - 7.51 (m, 1H), 7.34 (s, 1H), 7.27 (q, <i>J</i> =8.4Hz, 1H), 7.17 (dd, <i>J</i> =6.8, 8.8 Hz, 1H), 6.77 (dd, <i>J</i> =3.6, 8.4 Hz, 1H), 5.75 - 5.62 (m, 2H), 3.39-3.33 (m, 2H), 3.20 -3.13 (m, 1H), 2.90 (dt, <i>J</i> =2.8, 12.0 Hz, 1H), 2.43 – 2.42 (m, 1H), 2.19 - 2.07 (m, 1H), 1.99 - 1.82 (m, 2H). LC-MS: [M+H] ⁺ = 548.3.






Example #	Structure	¹ H NMR & LC-MS
240		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.59 (s, 1H), 8.38 (m, 1H), 8.28-8.23 (m, 1H), 8.24 (s, 1H), 8.18 (s, 1H), 7.83-7.80 (t, J= 8.0 Hz, 1H), 7.66-7.64 (d, J= 7.6 Hz, 1H), 7.23 (s, 1H), 7.33-7.31 (d, J= 7.6 Hz, 1H), 5.68-5.81 (m, 2H), 3.64-3.61 (d, J= 11.2 Hz, 1H), 3.18-3.13 (m, 2H), 3.04-3.00 (m, 1H), 2.32-2.27 (m, 1H), 2.10-2.06 (m, 1H), 1.86 (m, 2H). LC-MS: [M+H] ⁺ =549.2.
241		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.45 (s, 1H), 8.24 (s, 1H), 8.16 (s, 1H), 7.79 – 7.55 (m, 2H), 7.55 – 7.35 (m, 2H), 7.18 (s, 1H), 7.04 – 6.72 (m, 2H), 5.79 – 5.51 (m, 2H), 3.80 (s, 3H), 3.52 (d, J = 11.4 Hz, 1H), 3.13 (d, J = 11.3 Hz, 2H), 3.03 – 2.92 (m, 1H), 2.48 (d, J = 2.9 Hz, 3H), 2.24 (s, 1H), 2.13 – 1.97 (m, 1H), 1.86 (tq, J = 8.3, 4.4 Hz, 2H). LC-MS: [M+H] ⁺ = 540.3, 541.3.
242		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.54 (s, 1H), 8.22 (s, 1H), 8.19 (s, 1H), 7.88 - 7.80 (m, 1H), 7.70 -7.65(d, J=7.8 Hz, 1H), 7.53- 7.44 (dt, J=2.3, 8.7 Hz, 1H), 7.36 - 7.30 (m, 1H), 7.05 (s, 1H), 7.02 - 6.95 (m, 1H), 5.73 - 5.58 (m, 2H), 3.91 (s, 3H), 3.67 - 6.64 (m, 1H), 3.26 - 3.15 (m, 2H), 3.10 - 3.00 (m, 1H), 2.38 -2.25 (m, 1H), 2.20 – 2.06 (m, 1H), 1.95 - 1.90 (m, 2H). LC-MS: [M+H] ⁺ =578.3.
243		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 7.25 (s, 1 H) 7.02 (d, J=9.95 Hz, 1 H) 6.94 (s, 1 H) 6.92 (s, 1 H) 6.73 (d, J=12.35 Hz, 1 H) 6.57 (t, J=7.51 Hz, 1 H) 6.45 (s, 1 H) 6.40 (d, J=7.55 Hz, 1 H) 6.08 (d, J=7.82 Hz, 1 H) 4.31 - 4.41 (m, 2 H) 2.68 - 2.72 (m, 3 H) 2.36 (br d, J=11.49 Hz, 1 H) 1.90 - 1.99 (m, 2 H) 1.72 - 1.82 (m, 1 H) 1.00 - 1.08 (m, 1 H) 0.78 - 0.90 (m, 1 H). LC-MS: [M+H] ⁺ =561.3.
244		¹ H NMR (400 MHz, DMSO-d ₆) δ ppm 8.42 (s, 1H), 8.23 (s, 1H), 8.10 (s, 1H), 7.85 - 7.79 (m, 2H), 7.78 - 7.73 (m, 1H), 7.69 (m, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.23 (s, 3H), 5.57 - 5.36 (m, 2H), 3.05 - 2.78 (m, 4H), 2.19 - 1.91 (m, 2H), 1.64 (m, 2H). LC-MS: [M+H] ⁺ =547.3.






Example #	Structure	¹ H NMR & LC-MS
245		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.65 – 8.42 (m, 3H), 8.25 (d, J = 2.4 Hz, 2H), 7.84 – 7.63 (m, 3H), 7.60 – 7.47 (m, 1H), 7.39 – 7.20 (m, 2H), 5.67 (q, J = 16.3 Hz, 2H), 3.49 (d, J = 11.4 Hz, 1H), 3.16 (dd, J = 24.6, 11.6 Hz, 2H), 3.04 (dt, J = 11.3, 5.6 Hz, 1H), 2.24 – 1.96 (m, 2H), 1.86 (ddd, J = 32.2, 9.6, 4.8 Hz, 2H). LC-MS: [M+H] ⁺ = 514.0, 515.0.
246		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.59 (s, 1H), 8.37 (d, J = 5.4 Hz, 1H), 8.25 (s, 2H), 7.85 – 7.72 (m, 2H), 7.67 (dd, J = 5.4, 1.6 Hz, 1H), 7.55 (t, J = 5.9 Hz, 1H), 7.39 – 7.20 (m, 2H), 5.84 – 5.57 (m, 2H), 3.47 (d, J = 11.3 Hz, 1H), 3.21 – 2.92 (m, 3H), 2.22 – 1.96 (m, 2H), 1.86 (dt, J = 20.8, 9.4 Hz, 2H). LC-MS: [M+H] ⁺ = 547.9, 549.0.
247		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.58 (s, 1H), 8.41 (d, J = 5.5 Hz, 1H), 8.25 (d, J = 4.9 Hz, 2H), 7.77 (ddd, J = 11.9, 7.8, 2.1 Hz, 1H), 7.65 – 7.44 (m, 3H), 7.41 – 7.18 (m, 2H), 5.87 – 5.53 (m, 2H), 3.60 – 3.42 (m, 1H), 3.16 (t, J = 11.3 Hz, 2H), 3.07 – 2.90 (m, 1H), 2.25 – 1.97 (m, 2H), 1.97 – 1.75 (m, 2H). LC-MS: [M+H] ⁺ = 528.0, 529.0.
248		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.56 (s, 1H), 8.43 (d, J = 5.5 Hz, 1H), 8.23 (d, J = 4.9 Hz, 2H), 7.54-7.51 (m, 1H), 7.65 – 7.44 (m, 3H), 7.3-7.25 (m, 2H), 5.68 – 5.59 (m, 2H), 3.67 (m, 1H), 3.3 (m, 1H), 3.12 -3.0 (m, 2H), 2.3- 2.0 (m, 2H), 1.93 – 1.87 (m, 2H). LC-MS: [M+H] ⁺ = 532.0, 532.9.
249		¹ H NMR (400 MHz, CD ₃ OD) δ 8.55 (s, 1H), 8.22 (s, 2H), 8.06 (d, J = 9.1 Hz, 1H), 7.81 (d, J = 9.1 Hz, 1H), 7.75 (ddd, J = 12.0, 7.8, 2.1 Hz, 1H), 7.57 – 7.48 (m, 1H), 7.34 – 7.22 (m, 2H), 5.61 (s, 2H), 3.72 (d, J = 11.5 Hz, 1H), 3.28 (s, 1H), 3.17 – 3.08 (m, 1H), 3.05 – 2.92 (m, 1H), 2.34 (d, J = 12.0 Hz, 1H), 2.16 – 2.04 (m, 1H), 1.94 (dd, J = 8.4, 5.0 Hz, 1H), 1.82 (dd, J = 9.3, 4.5 Hz, 1H). LC-MS: [M+H] ⁺ = 548.7.






Example #	Structure	¹ H NMR & LC-MS
250		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.73 (s, 1H), 8.52 (s, 1H), 8.40 (s, 1H), 8.20 (d, J = 19.5 Hz, 2H), 7.89 – 7.61 (m, 2H), 7.24 (s, 1H), 7.21 – 7.01 (m, 2H), 5.79 – 5.47 (m, 2H), 3.62 (d, J = 11.3 Hz, 1H), 3.24 – 3.08 (m, 2H), 3.01 (t, J = 10.7 Hz, 1H), 2.87 (q, J = 7.6 Hz, 2H), 2.33 (t, J = 11.0 Hz, 1H), 2.09 (dt, J = 14.0, 6.8 Hz, 1H), 1.95 – 1.79 (m, 2H), 1.32 (t, J = 7.6 Hz, 3H). LC-MS: [M+H] ⁺ = 525.3, 526.3.
251		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.67 (d, J = 5.4 Hz, 1H), 8.52 (s, 1H), 8.21 (d, J = 12.9 Hz, 2H), 7.73 (ddd, J = 12.0, 7.8, 2.2 Hz, 1H), 7.65 – 7.46 (m, 2H), 7.40 – 7.03 (m, 2H), 5.81 – 5.43 (m, 2H), 3.62 (d, J = 11.2 Hz, 1H), 3.14 (t, J = 10.2 Hz, 2H), 2.96 (p, J = 7.6 Hz, 3H), 2.29 (t, J = 10.8 Hz, 1H), 2.08 (dq, J = 12.0, 7.5, 6.8 Hz, 1H), 1.93 – 1.72 (m, 2H), 1.34 (t, J = 7.6 Hz, 3H). LC-MS: [M+H] ⁺ = 543.5, 544.4.
252		¹ H NMR (400 MHz, CD ₃ OD) δ 8.54 (s, 1H), 8.28 (s, 1H), 7.68-7.73 (m, J = 7.9 Hz, 2H), 7.45 (d, J = 8.0 Hz, 1H), 7.14 (d, J = 6.0 Hz, 1H), 6.60 (d, J = 7.7 Hz, 1H), 6.46 (s, 1H), 5.53 (d, J = 9.4 Hz, 2H), 3.57 (d, J = 11.4 Hz, 1H), 3.10 (t, J = 11.5 Hz, 2H), 2.92 (td, J = 11.6, 10.5, 3.0 Hz, 1H), 2.78 (t, 2H), 2.30 (b, 1H), 2.10 (b, 1H), 1.97 – 1.75 (m, 3H), 1.28 (t, 3H), 0.94 – 0.80 (m, 2H), 0.79 – 0.65 (m, 2H). LC-MS: [M+H] ⁺ = 469.0, 470.0.
253		¹ H NMR (CD ₃ OD) δ: 9.10 (d, J = 4.9 Hz, 1H), 8.56 (s, 1H), 8.21 (d, J = 12.6 Hz, 2H), 8.06 (dd, J = 8.8, 1.5 Hz, 1H), 7.88 – 7.64 (m, 2H), 7.53 (s, 1H), 7.42 – 7.09 (m, 2H), 5.62 (s, 2H), 3.75 (d, J = 11.7 Hz, 1H), 3.20 – 2.85 (m, 3H), 2.37 (s, 2H), 2.02 – 1.69 (m, 2H). LCMS: [M+H] ⁺ = 514.9.
254		¹ H NMR (CD ₃ OD) δ: 8.89 (s, 1H), 8.57 (d, J = 10.5 Hz, 2H), 8.21 (d, J = 7.0 Hz, 2H), 7.89 – 7.70 (m, 1H), 7.53 (s, 1H), 7.29 (d, J = 15.7 Hz, 2H), 5.85 – 5.31 (m, 2H), 3.64 (d, J = 11.4 Hz, 1H), 3.16 – 3.01 (m, 3H), 2.42 – 2.04 (m, 2H), 2.00 – 1.74 (m, 2H). LC-MS: [M+H] ⁺ = 549.2.





Example #	Structure	¹ H NMR & LC-MS
255		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 9.16 (s, 1H), 8.77 (d, J = 5.6 Hz, 1H), 8.53 (s, 1H), 8.23 (s, 1H), 8.21 (s, 1H), 7.82 (d, J = 5.2 Hz, 1H), 7.76-7.71 (m, 1H), 7.54-7.52 (m, 1H), 7.32 (s, 1H), 7.27-7.23 (m, 1H), 5.66-5.57 (m, 2H), 3.63 (d, J = 11.2 Hz, 1H), 3.19 (d, J = 11.2 Hz, 1H), 3.13-3.09 (m, 1H), 3.02-2.97 (m, 1H), 2.31-2.26 (m, 1H), 2.09-2.03 (m, 1H), 1.88-1.81 (m, 2H). LC-MS: [M+H] ⁺ = 515.1.
256		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.73 (s, 1H), 8.53 (s, 1H), 8.40 (s, 1H), 8.19 (s, 1H), 7.68 (ddd, J = 7.1, 5.3, 1.7 Hz, 3H), 7.15 – 7.04 (m, 2H), 7.01 (s, 1H), 6.60 (d, J = 6.0 Hz, 1H), 5.64 (t, J = 12.5 Hz, 2H), 3.69 (d, J = 11.4 Hz, 1H), 3.21 (d, J = 11.4 Hz, 2H), 3.02 (ddd, J = 12.0, 9.6, 2.9 Hz, 1H), 2.87 (q, J = 7.6 Hz, 2H), 2.39 (t, J = 10.0 Hz, 1H), 2.16 (td, J = 12.4, 9.7, 5.7 Hz, 1H), 1.91 (t, J = 9.9 Hz, 2H), 1.35 – 1.30 (m, 3H). LC-MS: [M+H] ⁺ = 524.3, 525.3.
257		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.51 (s, 1H), 8.21 (d, J = 15.3 Hz, 2H), 7.78 (td, J = 8.8, 6.5 Hz, 1H), 7.15 – 6.71 (m, 3H), 6.05 (td, J = 55.4, 4.4 Hz, 1H), 5.69 (s, 2H), 3.99 (s, 1H), 3.25 (d, J = 1.6 Hz, 1H), 3.13 – 2.91 (m, 3H), 1.89 (d, J = 16.2 Hz, 3H), 1.65 (s, 1H). LC-MS: [M+H] ⁺ = 529.3, 530.3.
258		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.71 (s, 1H), 8.53 (s, 1H), 8.39 (s, 1H), 8.20 (d, J = 17.0 Hz, 2H), 7.73 (ddd, J = 12.0, 7.8, 2.2 Hz, 1H), 7.57 – 7.46 (m, 1H), 7.41 – 7.14 (m, 2H), 5.74 – 5.45 (m, 2H), 3.62 (d, J = 11.4 Hz, 1H), 3.16 (dd, J = 15.7, 11.5 Hz, 2H), 3.06 – 2.89 (m, 1H), 2.56 (s, 3H), 2.32 (t, J = 10.4 Hz, 1H), 2.18 – 2.02 (m, 1H), 1.96 – 1.79 (m, 2H). LC-MS: [M+H] ⁺ = 528.8, 529.8.
259		¹ H NMR (400MHz, CD ₃ OD): δ 8.95 (1H, s), 8.65 (1H, s), 8.54 (1H, s), 8.51 (1H, s), 8.23 (1H, s), 8.20 (1H, s), 7.70-7.80 (1H, m), 7.45-7.56 (1H, m), 7.25-7.35 (2H, m), 5.45-5.80 (2H, m), 3.55-3.65 (1H, m), 3.10-3.25 (2H, m), 2.90-3.05 (1H, m), 2.25-2.40 (1H, m), 2.05-2.20 (1H, m), 1.75-1.90 (2H, m). LC-MS: [M+H] ⁺ = 515.2.


Example #	Structure	¹ H NMR & LC-MS
260		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.54 (s, 1H), 8.16 (s, 1H), 7.98 (t, J = 7.8 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.72 – 7.62 (m, 2H), 7.57 (d, J = 7.7 Hz, 1H), 7.48 – 7.37 (m, 1H), 7.24 (dt, J = 10.3, 8.4 Hz, 1H), 7.07 (s, 1H), 6.88 – 6.52 (m, 2H), 5.59 (t, J = 12.3 Hz, 2H), 3.70 (d, J = 11.4 Hz, 1H), 3.20 (t, J = 9.4 Hz, 2H), 3.07 – 2.94 (m, 1H), 2.37 (t, J = 10.6 Hz, 1H), 2.21 – 2.05 (m, 1H), 2.01 – 1.83 (m, 2H). LC-MS: [M+H] ⁺ = 563.3, 564.2.
261		¹ H NMR (CD ₃ OD) δ: 8.51 (s, 1H), 8.15 (s, 1H), 7.68 (ddd, J = 7.7, 6.4, 3.6 Hz, 4H), 7.45 (d, J = 7.9 Hz, 1H), 7.22 – 6.96 (m, 4H), 6.62 (d, J = 6.0 Hz, 1H), 5.81 – 5.48 (m, 2H), 3.63 (d, J = 11.2 Hz, 1H), 3.33 (p, J = 1.6 Hz, 1H), 3.22 – 3.15 (m, 1H), 2.97 (ddd, J = 11.9, 9.3, 2.8 Hz, 1H), 2.51 (s, 3H), 2.38 – 2.25 (m, 1H), 2.17 – 2.09 (m, 1H), 1.90 (ddt, J = 19.9, 13.6, 4.8 Hz, 2H). LC-MS: [M+H] ⁺ = 509.0
262		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.57 (s, 1H), 8.20 (s, 1H), 7.96 (q, J = 8.1 Hz, 1H), 7.79 – 7.50 (m, 3H), 7.51 – 7.38 (m, 1H), 7.27 (dt, J = 10.4, 8.5 Hz, 1H), 7.09 (s, 1H), 6.96 (dd, J = 8.2, 2.8 Hz, 1H), 6.60 (d, J = 6.1 Hz, 1H), 5.77 – 5.53 (m, 2H), 3.67 (d, J = 11.4 Hz, 1H), 3.25 – 3.11 (m, 2H), 3.08 – 2.94 (m, 1H), 2.35 (t, J = 10.5 Hz, 1H), 2.23 – 2.06 (m, 1H), 1.91 (td, J = 12.1, 10.2, 5.6 Hz, 2H). LC-MS: [M+H] ⁺ = 531.0, 532.0.
263		¹ H NMR (400MHz, CD ₃ OD): δ 8.28 (s, 1H), 8.10 (s, 1H), 7.73-7.65 (m, 2H), 7.45 (d, J = 7.6 Hz, 1H), 7.13 (d, J = 7.6 Hz, 1H), 6.59 (d, J = 6.0 Hz, 1H), 6.46 (s, 1H), 5.60-5.45 (m, 2H), 3.57 (d, J = 10.8 Hz, 1H), 3.17-3.03 (m, 2H), 2.92 (t, J = 9.6 Hz, 1H), 2.52 (s, 3H), 2.37-2.24 (m, 1H), 2.15-2.03 (m, 1H), 1.97-1.80 (m, 3H), 0.93-0.84 (m, 2H), 0.77-0.70 (m, 2H). LC-MS: [M+H] ⁺ = 455.3
264		¹ H NMR (CD ₃ OD) δ: 8.28 (s, 1H), 8.10 (s, 1H), 7.97 (t, J = 7.9 Hz, 1H), 7.81 (d, J = 8.1 Hz, 1H), 7.66 (d, J = 6.0 Hz, 1H), 7.57 (d, J = 7.7 Hz, 1H), 6.87 – 6.48 (m, 2H), 6.43 (s, 1H), 5.49 (d, J = 9.4 Hz, 2H), 3.60 (d, J = 11.4 Hz, 1H), 3.10 (t, J = 11.6 Hz, 2H), 2.92 (td, J = 11.7, 10.5, 3.1 Hz, 1H), 2.33 (s, 1H), 2.16 – 2.03 (m, 1H), 1.99 – 1.64 (m, 3H), 0.92 – 0.81 (m, 2H), 0.78 – 0.65 (m, 2H). LC-MS: [M+H] ⁺ = 491.0

Example #	Structure	¹ H NMR & LC-MS
265		¹ H NMR (400 MHz, CD ₃ OD): δ 8.18 (s, 1H), 7.87-7.83 (m, 1H), 7.73-7.65 (m, 3H), 7.35 (d, J = 8.0 Hz, 1H), 6.70 (d, J = 5.2 Hz, 1H), 5.92 (s, 1H), 4.24 (t, J = 5.6 Hz, 2H), 3.61-3.47 (m, 1H), 3.38 (t, J = 5.6 Hz, 2H), 3.24-3.10 (m, 1H), 3.02 (d, J = 11.2 Hz, 1H), 2.88 (t, J = 9.6 Hz, 1H), 2.39-2.23 (m, 1H), 2.15-2.10 (m, 3H), 1.91-1.86 (m, 2H). LC-MS: [M+H] ⁺ = 490.1
266		¹ H NMR (400MHz, CDCl ₃): δ 8.58 (d, J = 4.4 Hz, 1H), 8.53 (s, 1H), 8.25 (s, 1H), 7.88-7.70 (m, 4H), 7.61 (d, J = 6.0 Hz, 1H), 7.32-7.26 (m, 1H), 7.22 (t, J = 8.8 Hz, 2H), 7.08 (s, 1H), 6.54 (d, J = 5.6 Hz, 1H), 6.24 (brs, 2H), 5.58 (m, 2H), 3.62-3.50 (m, 1H), 3.17-3.06 (m, 2H), 2.95-2.85 (m, 1H), 2.38-2.06 (m, 2H), 1.88-1.73 (m, 2H). LC-MS: [M+H] ⁺ = 495.3
267		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.40 (s, 1H), 8.16 (s, 1H), 7.83 (t, J = 7.6 Hz, 1H), 7.75-7.65 (m, 2H), 7.34 (d, J = 7.2 Hz, 1H), 6.56 (d, J = 6.0 Hz, 1H), 6.51 (s, 1H), 5.65-5.50 (m, 2H), 3.75-3.60 (m, 1H), 3.55-3.40 (m, 1H), 3.20-2.95 (m, 3H), 2.43-1.70 (m, 10H). LC-MS: [M+H] ⁺ = 489.2.
268		¹ H NMR (400MHz, CD ₃ OD): δ 8.28 (s, 1H), 8.12 (s, 1H), 7.81 (t, J = 8.0 Hz, 1H), 7.72-7.58 (m, 2H), 7.31 (d, J = 8.4 Hz, 1H), 6.55 (d, J = 6.0 Hz, 1H), 6.43 (s, 1H), 5.60-5.43 (m, 2H), 3.69-3.55 (m, 1H), 3.18-3.01 (m, 2H), 2.97-2.88 (m, 1H), 2.39-2.25 (m, 1H), 2.13-1.98 (m, 1H), 1.90-1.79 (m, 3H), 0.92-0.84 (m, 2H), 0.77-0.69 (m, 2H). LC-MS: [M+H] ⁺ = 475.1
269		¹ H NMR(DMSO 400MHz): δ 8.49 (s, 1H), 8.31 (s, 1H), 8.12 (s, 1H), 7.80-7.90 (m, 1H), 7.66 (s, 1H), 7.60-7.65 (m, 1H), 7.40-7.55 (m, 2H), 7.33 (s, 1H), 7.28 (brs, 2H), 5.45-5.65 (m, 2H), 3.77 (s, 3H), 3.00-3.10 (m, 3H), 3.80-3.90 (m, 1H), 1.95-2.05 (m, 1H), 1.65-1.85 (m, 3H). LC-MS: [M+H] ⁺ = 517.2.



Example #	Structure	¹ H NMR & LC-MS
270		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.53 (s, 1H), 8.23 (d, J = 13.8 Hz, 2H), 7.75 (ddd, J = 12.0, 7.8, 2.2 Hz, 1H), 7.69 (s, 1H), 7.61 (s, 1H), 7.54 (ddd, J = 9.2, 4.3, 2.2 Hz, 1H), 7.29 (d, J = 9.3 Hz, 2H), 5.78 – 5.49 (m, 2H), 3.88 (s, 3H), 3.27 (s, 1H), 3.19 (d, J = 11.3 Hz, 1H), 3.10 (d, J = 11.8 Hz, 1H), 3.02 – 2.87 (m, 1H), 2.13 – 1.87 (m, 3H), 1.82 (dq, J = 12.2, 4.0 Hz, 1H). LC-MS: [M+H] ⁺ = 516.3.
271		¹ H NMR (CDCl ₃ 400MHz): δ 8.85 (s, 1H), 8.56 (s, 1H), 8.46 (d, J = 4.4 Hz, 1H), 8.23 (s, 2H), 8.12 (d, J = 8.0 Hz, 1H), 7.76-7.70 (m, 1H), 7.53-7.50 (m, 1H), 7.46 (dd, J = 4.8 Hz and 8.0 Hz, 1H), 7.30 (s, 1H), 7.28-7.22 (m, 1H), 5.69 (d, J = 16 Hz, 1H), 5.62 (d, J = 16 Hz, 1H), 3.48 (d, J = 11.6 Hz, 2H), 3.24 (d, J = 11.6 Hz, 2H), 3.11 (d, J = 11.2 Hz, 1H), 3.01 (t, J = 10.8 Hz, 1H), 2.16-2.08 (m, 2H), 1.96-1.93 (m, 1H), 1.84-1.79 (m, 2H). LCMS: [M+H] ⁺ = 514.1
272		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.53 (s, 1H), 8.29 (s, 1H), 8.25 (s, 1H), 7.85-7.83 (m, 2H), 7.78-7.73 (m, 1H), 7.54-7.50 (m, 1H), 7.36 (s, 1H), 7.32-7.26 (m, 1H), 6.52-6.49 (t, J ₁ = 6.8 Hz, 1H), 5.68 (s, 2H), 3.77-3.74 (m, 1H), 3.38-3.35 (m, 1H), 3.17-3.14 (m, 1H), 3.04-2.99 (m, 1H), 2.27-2.07 (m, 3H), 1.96-1.93 (m, 1H). LC-MS: [M+H] ⁺ = 530.4.
273		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.51 (s, 1H), 8.22 (s, 1H), 8.13 (s, 1H), 8.00 (d, J = 2.8 Hz, 1H), 7.81 – 7.70 (m, 2H), 7.45 (t, J = 59.9 Hz, 1H), 7.25 (s, 1H), 7.13 (t, J = 8.8 Hz, 2H), 6.67 (d, J = 2.8 Hz, 1H), 5.63 (s, 2H), 3.51 (d, J = 11.5 Hz, 1H), 3.15 (dd, J = 19.7, 9.0 Hz, 2H), 2.97 (t, J = 10.2 Hz, 1H), 2.26 – 2.10 (m, 1H), 2.03 (s, 1H), 1.97 – 1.77 (m, 2H). LC-MS: [M+H] ⁺ = 535.3, 536.3.
274		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.49 (t, J = 6.3 Hz, 1H), 8.33 – 8.14 (m, 1H), 8.06 (s, 1H), 7.76 (ddd, J = 8.7, 5.5, 3.0 Hz, 2H), 7.58 (tt, J = 6.3, 2.9 Hz, 1H), 7.30 (dd, J = 8.0, 4.9 Hz, 1H), 7.13 (td, J = 8.5, 5.6 Hz, 2H), 6.38 (td, J = 6.1, 2.8 Hz, 1H), 5.76 – 5.48 (m, 2H), 4.48 (dt, J = 9.4, 4.9 Hz, 1H), 3.46 (d, J = 11.4 Hz, 1H), 3.14 (dd, J = 11.4, 6.0 Hz, 2H), 2.95 (d, J = 10.9 Hz, 1H), 2.17 (s, 1H), 2.03 (s, 1H), 1.96 – 1.79 (m, 2H), 1.43 (q, J = 7.2, 6.7 Hz, 6H). LC-MS: [M+H] ⁺ = 527.3, 528.3.





Example #	Structure	¹ H NMR & LC-MS
275		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.53 (s, 1H), 8.25 (s, 1H), 8.11 (s, 1H), 7.77 (ddd, <i>J</i> = 12.0, 7.8, 2.3 Hz, 1H), 7.65 – 7.46 (m, 2H), 7.39 (s, 1H), 7.31 (dt, <i>J</i> = 10.4, 8.5 Hz, 1H), 6.39 (d, <i>J</i> = 2.3 Hz, 1H), 5.86 – 5.36 (m, 2H), 3.87 (s, 3H), 3.58 – 3.42 (m, 1H), 3.17 (t, <i>J</i> = 10.8 Hz, 2H), 3.07 – 2.84 (m, 1H), 2.19 (dd, <i>J</i> = 23.5, 9.1 Hz, 1H), 2.06 (dd, <i>J</i> = 10.4, 4.1 Hz, 1H), 1.92 (q, <i>J</i> = 11.0, 9.3 Hz, 2H). LC-MS: [M+H] ⁺ = 517.0, 518.0.
276		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.41 – 8.18 (m, 1H), 8.05 (s, 1H), 7.79 – 7.41 (m, 2H), 6.62 (d, <i>J</i> = 5.9 Hz, 1H), 6.50 (d, <i>J</i> = 4.6 Hz, 1H), 6.37 (d, <i>J</i> = 3.1 Hz, 1H), 5.67 – 5.41 (m, 2H), 4.13 (ddd, <i>J</i> = 13.9, 9.0, 5.2 Hz, 2H), 3.40 (s, 1H), 3.07 (s, 2H), 2.86 (s, 1H), 2.10 (d, <i>J</i> = 66.2 Hz, 2H), 1.96 – 1.73 (m, 2H), 1.37 – 1.28 (m, 4H), 0.99 – 0.66 (m, 4H). LC-MS: [M+H] ⁺ = 458.3, 459.4.
277		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.52 (s, 1H), 8.13 (s, 1H), 7.75-7.64 (m, 3H), 7.59 (d, <i>J</i> = 2.0 Hz, 1H), 7.16-7.05 (m, 3H), 6.67 (d, <i>J</i> = 5.6 Hz, 1H), 6.41 (d, <i>J</i> = 2.0 Hz, 1H), 5.77-5.68 (m, 1H), 5.65-5.53 (m, 1H), 4.14 (q, <i>J</i> = 7.2 Hz, 2H), 3.57-3.46 (m, 1H), 3.25-3.14 (m, 2H), 3.03-2.92 (m, 1H), 2.32-2.19 (m, 1H), 2.16-2.04 (m, 1H), 2.02-1.83 (m, 2H), 1.39 (t, <i>J</i> = 7.2 Hz, 3H). LC-MS: [M+H] ⁺ = 512.3.
278		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.51 (s, 1H), 8.23 (s, 1H), 8.08 (br.s, 1H), 7.77-7.72 (m, 1H), 7.58 (d, <i>J</i> = 2.3 Hz, 1H), 7.54 (d, <i>J</i> = 6.8 Hz, 1H), 7.36 (s, 1H), 7.32-7.25 (m, 1H), 6.36 (d, <i>J</i> = 2.3 Hz, 1H), 5.69-5.59 (m, 2H), 3.61-3.55 (m, 1H), 3.46 (d, <i>J</i> = 11.5 Hz, 1H), 3.14 (d, <i>J</i> = 11.5 Hz, 2H), 2.94 (t, <i>J</i> = 9.5 Hz, 1H), 2.18-2.14 (m, 1H), 2.06-2.00 (m, 1H), 1.91-1.87 (m, 2H), 1.06-0.96 (m, 4H). LC-MS: [M+H] ⁺ = 543.1.
279		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.52 (s, 1H), 8.14 (s, 1H), 8.01 (d, <i>J</i> = 2.7 Hz, 1H), 7.74 – 7.61 (m, 3H), 7.43 (t, <i>J</i> = 59.8 Hz, 1H), 7.09 (dd, <i>J</i> = 17.5, 8.6 Hz, 3H), 6.65 (dd, <i>J</i> = 19.9, 4.4 Hz, 2H), 5.74 – 5.47 (m, 2H), 3.56 (d, <i>J</i> = 11.4 Hz, 1H), 3.18 (d, <i>J</i> = 11.2 Hz, 2H), 2.96 (t, <i>J</i> = 9.0 Hz, 1H), 2.26 (dd, <i>J</i> = 27.5, 15.2 Hz, 1H), 2.06 (s, 1H), 1.98 – 1.83 (m, 2H). LC-MS: [M+H] ⁺ = 534.3, 535.3.

Example #	Structure	¹ H NMR & LC-MS
280		¹ H NMR (400MHz, CD ₃ OD): δ 8.50 (s, 1H), 8.12 (s, 1H), 7.71-7.66 (m, 3H), 7.58 (d, J = 2.3 Hz, 1H), 7.10 (t, J = 9.6 Hz, 3H), 6.66 (d, J = 6.0 Hz, 1H), 6.37 (d, J = 2.4 Hz, 1H), 5.73-5.56 (m, 2H), 3.58-3.49 (m, 2H), 3.19-3.12 (m, 2H), 2.98-2.93 (t, J = 8.8 Hz, 1H), 2.25-2.20 (m, 1H), 2.09-2.04 (m, 1H), 1.94-1.85 (m, 2H), 1.02-0.93 (m, 4H). LC-MS: [M+H] ⁺ = 524.1
281		¹ H NMR (400MHz, CD ₃ OD): δ. 8.50 (s, 1H), 8.23 (s, 1H), 8.20 (s, 1H), 7.77-7.73 (m, 2H), 7.52 (s, 1H), 7.24 (s, 1H), 7.15-7.10 (m, 2H), 5.67-5.56 (m, 2H), 3.52-3.49 (m, 1H), 3.21-3.17 (m, 1H), 3.12-3.08 (m, 1H), 3.02-2.97 (m, 1H), 2.26-2.21 (m, 1H), 2.07-1.99 (m, 1H), 1.92-1.83 (m, 2H). LCMS: 536.3 [M+H] ⁺ = 536.3
282		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.51 (s, 1H), 8.23 (s, 1H), 8.17 (s, 1H), 7.98 (s, 1H), 7.73 (ddd, J = 2 Hz, 7.6 Hz, 11.6 Hz, 1H), 7.55-7.50 (m, 1H), 7.31-7.23 (m, 2H), 5.66-5.56 (m, 2H), 4.09 (s, 3H), 3.49 (d, J = 11.2 Hz, 1H), 3.23 (d, J = 11.2 Hz, 1H), 3.12-3.05 (m, 1H), 3.02-2.95 (m, 1H), 2.25-2.15 (m, 1H), 2.09-1.99 (m, 1H), 1.96-1.89 (m, 1H), 1.86-1.78 (m, 1H). LC-MS: [M+H] ⁺ = 518.1.
283		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.52 (s, 1H), 8.23 (s, 1H), 8.16 (s, 1H), 7.74 (ddd, J = 12.1, 7.8, 2.2 Hz, 1H), 7.53 (ddd, J = 8.0, 4.1, 2.0 Hz, 1H), 7.35 (s, 1H), 7.28 (dt, J = 10.4, 8.4 Hz, 1H), 6.31 (s, 1H), 5.61 (s, 2H), 3.46 (d, J = 11.4 Hz, 1H), 3.22 (d, J = 11.3 Hz, 1H), 3.12 - 3.05 (m, 1H), 2.97 (td, J = 11.8, 10.5, 3.2 Hz, 1H), 2.40 (s, 3H), 2.28 - 2.08 (m, 1H), 2.03 (d, J = 11.7 Hz, 1H), 1.98 - 1.80 (m, 2H). LC-MS: [M+H] ⁺ = 517.8, 518.8.
284		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.52 (s, 1H), 8.23 (s, 1H), 8.16 (s, 1H), 7.74 (ddd, J = 12.1, 7.8, 2.2 Hz, 1H), 7.53 (ddd, J = 8.0, 4.1, 2.0 Hz, 1H), 7.35 (s, 1H), 7.28 (dt, J = 10.4, 8.4 Hz, 1H), 6.31 (s, 1H), 5.61 (s, 2H), 3.46 (d, J = 11.4 Hz, 1H), 3.22 (d, J = 11.3 Hz, 1H), 3.12 - 3.05 (m, 1H), 2.97 (td, J = 11.8, 10.5, 3.2 Hz, 1H), 2.40 (s, 3H), 2.28 - 2.08 (m, 1H), 2.03 (d, J = 11.7

Example #	Structure	¹ H NMR & LC-MS
		Hz, 1H), 1.98 – 1.80 (m, 2H). LC-MS: [M+H] ⁺ = 517.8, 518.8.



Examples 285-291 were prepared following procedures analogous to those described in Example 47 from corresponding intermediates.

Example #	Structure	¹ H NMR & MS
285		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.46 (s, 1H), 8.20 (d, <i>J</i> = 10.0 Hz, 2H), 7.75 - 7.66 (m, 1H), 7.49 (s, 1H), 7.24 (d, <i>J</i> = 10.2 Hz, 2H), 5.69 - 5.53 (m, 2H), 4.40 (s, 1H), 3.96 - 3.73 (m, 2H), 3.15 (d, <i>J</i> = 11.5 Hz, 1H), 2.98 (d, <i>J</i> = 11.3 Hz, 2H), 2.85 (t, <i>J</i> = 10.7 Hz, 1H), 1.92 (s, 1H), 1.75 (d, <i>J</i> = 12.0 Hz, 2H), 1.67 (s, 1H). LC-MS: [M+H] ⁺ = 499.2.
286		¹ H NMR (400 MHz, CD ₃ OD) δ 8.54 (s, 1H), 8.21 (d, <i>J</i> = 11.9 Hz, 2H), 7.78 (ddd, <i>J</i> = 11.5, 9.1, 7.1 Hz, 1H), 7.17 (td, <i>J</i> = 10.5, 6.6 Hz, 1H), 7.13 - 7.11 (m, 1H), 5.71 - 5.63 (m, 2H), 4.62 - 4.43 (m, 1H), 4.01 - 3.81 (m, 2H), 3.21 (d, <i>J</i> = 11.3 Hz, 1H), 3.13 - 3.03 (m, 2H), 2.93 (t, <i>J</i> = 10.6 Hz, 1H), 2.08 - 1.96 (m, 1H), 1.82 (t, <i>J</i> = 10.7 Hz, 2H), 1.71 (d, <i>J</i> = 11.7 Hz, 1H). [M+H] ⁺ = 517.1


Example #	Structure	¹ H NMR & MS
287		¹ H NMR: (400MHz, CD ₃ OD): δ 8.53 - 8.48 (m, 1H), 8.26 - 8.19 (m, 2H), 7.78 - 7.70 (m, 1H), 7.57 - 7.50 (m, 1H), 7.34 - 7.23 (m, 2H), 5.70 - 5.59 (m, 2H), 3.18 (br d, J=11.1 Hz, 1H), 3.07 - 2.85 (m, 3H), 2.02 - 1.88 (m, 1H), 1.87 - 1.71 (m, 2H), 1.70 - 1.54 (m, 1H). LC-MS: [M+H] ⁺ =501.4.
288		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.49 (s, 1H), 8.23 (s, 2H), 7.76 (m, 1H), 7.54 (m, 1H), 7.34 (s, 1H), 7.29 (m, 1H), 5.74 - 5.55 (m, 2H), 3.85 (m, 1H), 3.77 - 3.65 (m, 2H), 3.63 - 3.56 (m, 1H), 3.55 - 3.47 (m, 1H), 3.17 - 3.07 (m, 2H), 3.01 (m, 1H), 2.95 (m, 1H), 2.91 - 2.79 (m, 1H), 2.00 - 1.86 (m, 1H), 1.83 - 1.70 (m, 2H), 1.69 - 1.57 (m, 1H), 1.10 (d, J=6.0 Hz, 3H). LC-MS: [M+H] ⁺ =537.4
285		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.46 (s, 1H), 8.20 (d, J = 10.0 Hz, 2H), 7.75 - 7.66 (m, 1H), 7.49 (s, 1H), 7.24 (d, J = 10.2 Hz, 2H), 5.69 - 5.53 (m, 2H), 4.40 (s, 1H), 3.96 - 3.73 (m, 2H), 3.15 (d, J = 11.5 Hz, 1H), 2.98 (d, J = 11.3 Hz, 2H), 2.85 (t, J = 10.7 Hz, 1H), 1.92 (s, 1H), 1.75 (d, J = 12.0 Hz, 2H), 1.67 (s, 1H). LC-MS: [M+H] ⁺ = 499.2.
290		¹ H NMR (400MHz, CD ₃ OD): δ8.52 (s, 1H), 8.20 (s, 2H), 7.82-7.75 (m, 1H), 7.21-7.09 (m, 2H), 5.68-5.62 (m, 2H), 3.91-3.81 (m, 2H), 3.78-3.54 (m, 5H), 3.19-3.11 (m, 2H), 3.00-2.97 (M, 1H), 2.91-2.86 (m, 1H). LC-MS: [M+H] ⁺ =541.4.

Example #	Structure	¹ H NMR & MS
291		¹ H NMR (, 400MHz, CD ₃ OD): δ 8.64 (s, 1H), 8.30 (s, 1H), 8.22 (s, 1H), 7.65-7.60 (m, 1H), 7.44-7.40 (m, 1H), 7.09 (s, 1H), 7.01-6.74 (d, J1= 54.8 Hz, J2= 109.6 Hz, 1H), 5.72-5.62 (m, 2H), 4.00-3.95 (m, 2H), 3.84-3.60 (m, 5H), 3.45-3.42 (m, 1H), 3.35 (m, 1H), 3.13-3.10 (m, 1H), 2.99-2.90 (m, 1H), 2.05-1.85 (m, 4H). [M+H] ⁺ = 573.4
292		¹ H NMR (400MHz, DMSO-d ₆): δ 8.48 (s, 1H), 8.36 (brs, 1H), 8.26 (s, 1H), 8.14 (s, 1H), 7.90-7.80 (m, 1H), 7.65-7.57 (m, 1H), 7.46 (t, J = 8.8 Hz, 1H), 7.35-7.25 (m, 3H), 5.53 (s, 2H), 4.24 (d, J = 8.4 Hz, 1H), 4.07 (d, J = 8.8 Hz, 1H), 3.15-3.03 (m, 2H), 2.95-2.80 (m, 2H), 1.85-1.77 (m, 1H), 1.76-1.60 (m, 3H). LC-MS: [M+H] ⁺ = 493.2.
293		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.50 (s, 1H), 8.22 (d, J = 1.7 Hz, 2H), 7.75 (ddd, J = 12.0, 7.8, 2.2 Hz, 1H), 7.54 (d, J = 9.1 Hz, 1H), 7.39 – 7.07 (m, 2H), 6.00 – 5.41 (m, 2H), 3.25 (s, 1H), 3.13 (d, J = 11.3 Hz, 1H), 2.95 (dt, J = 20.7, 11.5 Hz, 2H), 2.10 – 1.79 (m, 3H), 1.71 (t, J = 3.4 Hz, 4H). LC-MS: [M+H] ⁺ = 513.3, 514.3.
294		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.49 (s, 1H), 8.21 (s, 2H), 7.78-7.70 (m, 1H), 7.57-7.49 (m, 1H), 7.35-7.25 (m, 2H), 5.72-5.55 (m, 2H), 4.70-4.60 (m, 1H), 3.20-2.90 (m, 4H), 2.00-1.70 (m, 4H). LC-MS: [M+H] ⁺ = 499.2.

Example #	Structure	¹ H NMR & MS
295		¹ H NMR (400 MHz, CD ₃ OD) δ ppm 8.48 (s, 1H), 8.26 (s, 2H), 7.69 – 7.35 (m, 2H), 7.23 (s, 1H), 7.13 (t, <i>J</i> = 8.6 Hz, 1H), 5.88 – 5.54 (m, 2H), 3.90 (s, 3H), 3.21 – 2.87 (m, 4H), 1.93 (dt, <i>J</i> = 9.1, 4.4 Hz, 1H), 1.78 – 1.48 (m, 3H), 1.39 (dd, <i>J</i> = 25.1, 6.4 Hz, 4H). LC-MS: [M+H] ⁺ = 495.2, 496.2.
296		¹ H NMR (400 MHz, CDCl ₃) δ ppm 8.49 (s, 1H), 8.39 (s, 1H), 7.92 (s, 1H), 7.70-7.65 (m, 1H), 7.51 (s, 1H), 7.49-7.40 (m, 1H), 7.20-7.10 (m, 2H), 6.26 (s, 1H), 5.70-5.60 (m, 3H), 5.48 (d, <i>J</i> = 16 Hz, 1H), 4.45-4.35 (m, 1H), 4.19 (d, <i>J</i> = 14 Hz, 1H), 3.05-2.30 (m, 4H), 1.95-1.50 (m, 4H). LC-MS: [M+H] ⁺ = 517.3.
297		¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ ppm 8.50 (s, 1H), 8.30 (s, 1H), 8.13 (s, 1H), 7.90-7.80 (m, 1H), 7.63-7.55 (m, 1H), 7.52-7.42 (m, 1H), 7.36 (s, 1H), 7.28 (brs, 2H), 5.55 (s, 2H), 2.98-2.80 (m, 4H), 2.72 (s, 2H), 1.90-1.75 (m, 3H), 1.73-1.55 (m, 2H), 1.54-1.40 (m, 1H). LC-MS: [M+H] ⁺ = 497.2.
298		¹ H NMR (400MHz, DMSO- <i>d</i> ₆): δ 8.49 (s, 1H), 8.29 (s, 1H), 8.15 (s, 1H), 7.95-7.82 (m, 1H), 7.65-7.60 (m, 1H), 7.51 (q, <i>J</i> = 8.8 Hz, 1H), 7.38 (s, 1H), 7.30 (brs, 2H), 5.56 (s, 2H), 3.60-3.40 (m, 2H), 3.11 (s, 3H), 3.10-2.97 (m, 2H), 2.95-2.80 (m, 2H), 2.48-2.10 (m, 1H), 1.95-1.50 (m, 4H). LC-MS: [M+H] ⁺ = 529.2

Example #	Structure	¹ H NMR & MS
299		¹ H NMR (400 MHz, CDCl ₃) δ ppm 8.52 (s, 1H), 8.27 (s, 1H), 8.23 (s, 1H), 7.76 – 7.70 (m, 1H), 7.56 – 7.50 (m, 1H), 7.35 - 7.22 (m, 2H), 7.23 - 7.21 (m, 1H), 5.75 - 5.55 (m, 2H), 4.34 (s, 1H), 3.30 - 3.13 (m, 1H), 3.00 (s, 3H), 2.00 – 1.90 (m, 2H), 1.87 - 1.67 (m, 2H). LC-MS: [M+H] ⁺ = 535.4.
300		¹ H NMR (400 MHz, CD ₃ OD) δ 8.50 (d, J = 6.6 Hz, 1H), 8.27 - 8.20 (m, 2H), 7.75 (ddd, J = 12.0, 7.8, 2.2 Hz, 1H), 7.57 - 7.50 (m, 1H), 7.35 - 7.23 (m, 2H), 6.45 - 6.08 (m, 1H), 5.64 (d, J = 3.4 Hz, 2H), 4.89 - 4.41 (m, 1H), 3.21 (d, J = 11.4 Hz, 1H), 3.07 - 2.82 (m, 3H), 2.04 - 1.60 (m, 4H). LC-MS: [M+H] ⁺ = 519.2.

Example 301: 3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)-3-(2,2-difluoroethyl)piperidin-4-ol







5 To a solution of Intermediate B (104 mg, 0.311 mmol) and intermediate 301-8 (130 mg, 0.311 mmol) in DMF (10 mL) was added K₂CO₃ (215 mg, 1.556 mmol) at rt under N₂ atmosphere, the reaction was stirred at RT for 18 hr. LC-MS monitored the reaction and indicated the reaction was complete. The reaction mixture was diluted with water, extracted with EtOAc (20 mL*3), the combined organic phase was washed with water (20 mL*3), brine
10 (20 mL), dried over anhydrous sodium sulfate, concentrated in vacuum to give a residue. The residue was purified by flash chromatography (elution gradient: 0% to 10% MeOH in DCM in 30 mins) to afford intermediate 301-9. LC-MS: [M+H]⁺ = 311.1.

To a solution of intermediate 301-9 (60 mg, 0.084 mmol) in DCM (9 mL) was added TFA (3 mL, 38.9 mmol) at RT under N₂ atmosphere, the reaction was stirred at RT for 2 hr. LCMS
15 monitored the reaction and indicated the reaction was complete. The reaction mixture was


concentrated in vacuum to give a residue. The residue was purified by Pre-HPLC (Basic condition, $\text{NH}_3\text{H}_2\text{O}\%$ =0.05%, $\text{MeCN}/\text{H}_2\text{O}$ =0-95% in 12 mins) to afford 3-amino-1-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)-3-(2,2-difluoroethyl)piperidin-4-ol (Example 301). ^1H NMR (400 MHz, CD_3OD) δ 8.58 (s, 1H), 8.36 (s, 1H), 8.27 (s, 1H), 7.82 (ddd, J = 11.2, 8.1, 2.2 Hz, 1H), 7.63 (dt, J = 5.8, 2.9 Hz, 1H), 7.47 (s, 1H), 7.31 (dt, J = 10.2, 8.4 Hz, 1H), 6.41 (tt, J = 55.3, 4.7 Hz, 1H), 5.65 (s, 2H), 3.94 (dd, J = 10.4, 5.3 Hz, 1H), 3.50 - 3.38 (m, 2H), 3.11 - 2.93 (m, 2H), 2.69 - 2.36 (m, 2H), 2.07 (dd, J = 14.1, 4.8 Hz, 1H), 2.01 - 1.84 (m, 1H). LC-MS: $[\text{M}+\text{H}]^+ = 517.2$.

Examples 302-310 were prepared following procedures analogous to the preparation of Example 47 and the corresponding intermediates.

Example #	Structure	^1H NMR & MS
302		^1H NMR (400 MHz, CD_3OD) δ 8.54 (d, J = 5.6 Hz, 1H), 8.26 (d, J = 9.3 Hz, 2H), 7.83 - 7.68 (m, 3H), 7.52 (dddd, J = 8.6, 3.8, 2.2, 1.3 Hz, 1H), 7.33 - 7.23 (m, 3H), 5.79 - 5.61 (m, 2H), 4.39 (dd, J = 11.0, 5.1 Hz, 1H), 3.57 (d, J = 11.8 Hz, 1H), 3.18 (ddd, J = 7.2, 5.6, 2.4 Hz, 1H), 3.11 (td, J = 11.5, 2.7 Hz, 2H), 2.10 - 2.01 (m, 1H), 1.96 (ddt, J = 13.0, 5.7, 3.0 Hz, 1H). $[\text{M}+\text{H}]^+ = 564.2$.
303		^1H NMR (CD_3OD) δ 8.46 (s, 1H), 8.24 (d, J = 8.7 Hz, 2H), 7.58 (dd, J = 12.8, 2.2 Hz, 1H), 7.48 (dt, J = 8.6, 1.6 Hz, 1H), 7.27 (s, 1H), 7.11 (t, J = 8.6 Hz, 1H), 5.81 - 5.51 (m, 2H), 3.89 (s, 3H), 3.15 - 2.80 (m, 4H), 2.68 - 2.35 (m, 2H), 1.93 (d, J = 11.3 Hz, 1H), 1.76 (dt, J = 11.9, 6.4 Hz, 3H). LC-MS: $[\text{M}+\text{H}]^+ = 530.8$.
304		^1H NMR (400 MHz, CD_3OD) δ ppm 8.49 (s, 1H), 8.26 (d, J = 29.8 Hz, 2H), 7.73 (ddd, J = 11.3, 7.9, 2.0 Hz, 1H), 7.51 (q, J = 3.7 Hz, 1H), 7.43 - 7.12 (m, 2H), 5.95 - 5.47 (m, 2H), 3.35 (d, J = 11.6 Hz, 1H), 3.12 (d, J = 11.4 Hz, 1H), 3.01 (t, J = 9.8 Hz, 1H), 2.90 (d, J = 11.3 Hz, 1H), 2.84 (s, 1H), 1.98 (dd, J = 59.1, 12.9 Hz, 3H), 1.69 (t, J = 11.5 Hz, 1H). LC-MS: $[\text{M}+\text{H}]^+ = 461.2, 462.2$.





Example #	Structure	¹ H NMR & MS
305		¹ H NMR (400 MHz, DMSO-d ₆): δ 8.49 (s, 1H), 8.35 (s, 1H), 8.14 (s, 1H), 7.71 (d, J = 2.0 Hz, 1H), 7.68 (d, J = 2.0 Hz, 1H), 7.32 (s, 1H), 7.29 (brs, 2H), 7.24 (t, J = 8.8 Hz, 1H), 6.04 (t, J = 16.8 Hz, 1H), 5.53 (s, 2H), 3.86 (s, 3H), 3.05-2.80 (m, 4H), 2.05-1.85 (m, 3H), 1.75-1.60 (m, 2H), 1.55-1.43 (m, 1H). LC-MS: [M+H] ⁺ = 499.2.

Example 306: 9-((5-((3R,5R)-3-amino-5-(fluoromethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine



- 5 To a mixture of tert-butyl (tert-butoxycarbonyl)(9-((5-((3R,5R)-3-((tert-butoxycarbonyl)amino)-5-(fluoromethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-yl)carbamate (Intermediate 306-9) (0.15 g, 0.19 mmol) in DCM (1 mL) was added HCl/Dioxane (10.0 mL, 4M), and the resulting mixture was stirred at 25°C for 4 hours. LCMS showed the starting material was consumed completely. The mixture was
- 10 concentrated in *vacuo*. The residue was purified by *prep*-HPLC (0.1% NH₄HCO₃ as additive as additive) to afford 9-((5-((3R,5R)-3-amino-5-(fluoromethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine (Example 306) as a white solid. ¹H NMR (400MHz, DMSO-d₆): δ 8.48 (s, 1H), 8.33 (s, 1H), 8.14 (s, 1H), 7.67 (dd, J = 2.0 Hz, 12.8 Hz, 1H), 7.51 (d, J = 8.8 Hz, 1H), 7.30 (brs, 2H), 7.34-7.17 (m, 2H), 5.54 (s, 2H), 4.64-4.37 (m, 2H),
- 15 3.85 (s, 3H), 3.18-3.03 (m, 3H), 2.92-2.77 (m, 2H), 2.48-2.32 (m, 1H), 1.68-1.49 (m, 2H). LC-MS: [M+Na]⁺ = 481.2






Example 307-310 were prepared following procedures analogous to the preparation of Example 306 and the corresponding intermediates.


Example #	Structure	¹ H NMR & MS
307		¹ H NMR (400MHz, CD ₃ OD): δ 8.47 (s, 1H), 8.22 (s, 1H), 8.13 (s, 1H), 7.79-7.75 (m, 2H), 7.24 (s, 1H), 7.16-7.12 (m, 2H), 6.14 (tt, J = 56.8 Hz, 4.0 Hz, 1H), 5.61 (s, 2H), 3.08-3.06 (m, 2H), 2.83-2.80 (m, 1H), 2.52-2.38 (m, 1H), 2.33-2.27 (m, 1H), 2.25-2.16 (m, 1H), 2.03-2.00 (m, 1H), 1.95-1.91 (m, 1H), 1.09-1.02 (m, 1H), 0.91 (d, J = 6.8 Hz, 3H). LC-MS: [M+H] ⁺ = 497.3
308		¹ H NMR (400MHz, DMSO-d ₆): δ 8.48 (s, 1H), 8.32 (s, 1H), 8.13 (s, 1H), 7.90-7.80 (m, 1H), 7.63-7.55 (m, 1H), 7.47 (q, J = 8.4 Hz, 1H), 7.33 (s, 1H), 7.29 (brs, 2H), 5.54 (d, J = 2.0 Hz, 2H), 3.35-3.10 (m, 4H), 3.09-2.95 (m, 4H), 2.87-2.75 (m, 2H), 2.35-2.20 (m, 1H), 1.60-1.44 (m, 2H). LC-MS: [M+H] ⁺ = 481.2.
309		¹ H NMR (400 MHz, CD ₃ OD): δ 8.51 (s, 1H), 8.21 (s, 1H), 8.20 (s, 1H), 7.72 (ddd, J = 2.4 Hz, 8 Hz, 10 Hz, 1H), 7.54-7.47 (m, 1H), 7.32-7.22 (m, 2H), 5.72-5.55 (m, 2H), 4.81-4.75 (m, 1H), 3.39-3.34 (m, 1H), 3.28-3.25 (m, 1H), 3.17-3.07 (m, 2H), 2.91-2.80 (m, 1H), 2.36-2.24 (m, 1H), 1.80-1.65 (m, 1H). LC-MS: [M+H] ⁺ = 455.2.
310		¹ H NMR (400MHz, CD ₃ OD): δ 8.55 (s, 1H), 8.28 (s, 1H), 8.21 (s, 1H), 7.88-7.81 (m, 1H), 7.69-7.64 (m, 1H), 7.61 (s, 1H), 7.37-7.29 (m, 1H), 5.80 (d, J = 15.6 Hz, 1H), 5.37 (d, J = 15.6 Hz, 1H), 3.28-3.24 (m, 2H), 3.17-3.08 (m, 2H), 1.95-1.72 (m, 4H), 1.60-1.45 (m, 1H), 0.95-0.81 (m, 2H), 0.61 (d, J = 6 Hz, 3H). LC-MS: [M+H] ⁺ = 451.1.

Example 311-321 were prepared following procedures analogous to the preparation of Example 47 and the corresponding intermediates.


Example #	Structure	¹ H NMR & MS
-----------	-----------	-------------------------

Example #	Structure	¹ H NMR & MS
311		¹ H NMR (400 MHz, CD ₃ OD) δ 8.61 (s, 1H), 8.24 (s, 1H), 8.16 (s, 1H), 7.80 (ddd, J = 12.1, 7.8, 2.2 Hz, 1H), 7.64 – 7.57 (m, 1H), 7.47 (s, 1H), 7.31 (dt, J = 10.4, 8.4 Hz, 1H), 6.21 (t, J = 75.3 Hz, 1H), 5.72– 5.50 (m, 2H), 3.99 – 3.85 (m, 2H), 3.54 (td, J = 5.8, 3.1 Hz, 1H), 3.25 (dt, J = 6.7, 3.5 Hz, 1H), 3.00 – 2.84 (m, 2H), 1.76 (ddd, J = 15.8, 10.3, 5.7 Hz, 3H), 1.60 – 1.47 (m, 1H). LC-MS: [M+H] ⁺ = 517.2.
312		¹ H NMR (CD ₃ OD): δ 8.62 (s, 1H), 8.21 (d, J = 36.6 Hz, 2H), 7.83 (ddd, J = 12.0, 7.8, 2.2 Hz, 1H), 7.72 - 7.51 (m, 2H), 7.32 (dt, J = 10.3, 8.5 Hz, 1H), 5.79 (d, J = 15.6 Hz, 1H), 5.54 (d, J = 15.5 Hz, 1H), 3.72 - 3.45 (m, 2H), 3.43 - 3.31 (m, 2H), 3.00 - 2.71 (m, 2H), 1.87 - 1.75 (m, 2H), 1.73 - 1.43 (m, 2H) LC-MS: [M+H] ⁺ = 467.2.
313		¹ H NMR (DMSO-d ₆) : δ 8.60 (d, J = 5.0 Hz, 1H), 8.19 (dd, J = 44.6, 5.3 Hz, 2H), 7.89 - 7.14 (m, 4H), 5.95 - 5.36 (m, 3H), 3.70 - 3.36 (m, 5H), 3.24 (s, 1H), 2.98 - 2.68 (m, 2H), 1.98 - 1.41 (m, 4H). LC-MS: [M+H] ⁺ = 531.2.
314		¹ H NMR (400 MHz, CD ₃ OD) : δ 8.58 (d, J = 17.0 Hz, 2H), 8.27 (t, J = 17.6 Hz, 2H), 7.84 (ddd, J = 11.9, 7.8, 2.1 Hz, 1H), 7.64 (dd, J = 11.4, 4.7 Hz, 1H), 7.54 (s, 1H), 7.39 – 7.28 (m, 1H), 5.79 – 5.61 (m, 1H), 5.52 (t, J = 20.8 Hz, 1H), 3.67 – 3.36 (m, 5H), 2.91 (d, J = 11.9 Hz, 1H), 2.24 (d, J = 13.8 Hz, 1H), 1.91 (dd, J = 31.4, 16.3 Hz, 4H). LC-MS: [M+H] ⁺ = 481.1.
315		¹ H NMR (400 MHz, CD ₃ OD) : δ 8.47 (s, 1H), 8.27 (d, J = 3.0 Hz, 2H), 7.78 (ddd, J = 12.0, 7.8, 2.2 Hz, 1H), 7.58 (ddd, J = 10.4, 5.0, 2.4 Hz, 1H), 7.46 (s, 1H), 7.30 (dt, J = 10.4, 8.4 Hz, 1H), 5.74 (q, J = 15.8 Hz, 2H), 3.94 (d, J = 2.8 Hz, 1H), 3.25 (q, J = 2.8 Hz, 1H), 3.02 (d, J = 11.7 Hz, 1H), 2.75 (t, J = 9.9 Hz, 1H), 2.57 (s, 3H), 1.93 (d, J = 3.4 Hz, 1H), 1.79 (d, J = 9.2 Hz, 2H), 1.53 (d, J = 8.4 Hz, 1H). LC-MS: [M+H] ⁺ = 494.1.


Example #	Structure	¹ H NMR & MS
316		¹ H NMR (CD ₃ OD): δ 8.59 (s, 1H), 8.24 (s, 1H), 8.07 (s, 1H), 7.70 (ddd, J = 12.1, 7.8, 2.2 Hz, 1H), 7.53 - 7.34 (m, 1H), 7.37 - 7.17 (m, 2H), 5.78 - 5.44 (m, 2H), 4.59 (qd, J = 8.4, 3.1 Hz, 1H), 3.82 (dd, J = 11.7, 3.4 Hz, 1H), 3.66 (dd, J = 4.9, 3.2 Hz, 1H), 3.37 (dd, J = 11.9, 6.3 Hz, 1H), 3.03 (dt, J = 11.8, 4.3 Hz, 1H), 1.92 - 1.61 (m, 4H). . LC-MS: [M+H] ⁺ = 535.2.
317		¹ H NMR (400 MHz, CD ₃ OD): δ 8.46 (s, 1H), 8.27 (d, J = 9.7 Hz, 2H), 7.79 (ddd, J = 12.0, 7.8, 2.2 Hz, 1H), 7.63 - 7.54 (m, 1H), 7.48 (s, 1H), 7.30 (dt, J = 10.4, 8.4 Hz, 1H), 5.79 (dd, J = 99.4, 15.7 Hz, 2H), 4.62 (d, J = 2.5 Hz, 1H), 3.27 (d, J = 4.4 Hz, 1H), 3.20 - 3.09 (m, 3H), 2.95 (s, 16H), 2.80 (s, 5H), 2.01 - 1.88 (m, 1H), 1.82 (td, J = 12.4, 3.8 Hz, 1H), 1.71 (d, J = 11.9 Hz, 1H), 1.52 - 1.40 (m, 1H). LC-MS: [M+H] ⁺ = 508.2
318		¹ H NMR (CD ₃ OD): δ 8.53 (d, J = 12.3 Hz, 1H), 8.25 (d, J = 10.5 Hz, 2H), 7.84 - 7.70 (m, 1H), 7.67 - 7.53 (m, 1H), 7.46 (s, 1H), 7.30 (dt, J = 10.4, 8.4 Hz, 1H), 5.86 - 5.50 (m, 2H), 4.03 (d, J = 2.7 Hz, 1H), 3.48 (p, J = 1.7 Hz, 1H), 3.13 (p, J = 1.6 Hz, 1H), 2.98 - 2.71 (m, 1H), 1.93 (s, 1H), 1.81 (s, 2H), 1.53 (s, 1H) LC-MS: [M+H] ⁺ = 480.1.
319		¹ H NMR (400MHz, DMSO-d ₆): δ 8.57 (s, 1H), 8.26 (s, 1H), 8.15 (s, 1H), 7.89 - 7.71 (m, 1H), 7.56 - 7.49 (m, 1H), 7.49 - 7.39 (m, 1H), 7.29 (s, 2H), 7.11 (br s, 1H), 5.59 - 5.33 (m, 2H), 3.71 (br d, J=2.9 Hz, 1H), 3.60-3.50 (m, 1H), 3.05-2.90 (m, 2H), 2.00-1.85 (m, 1H), 1.85-1.70 m, 1H), 1.65-1.47 (m, 2H) LC-MS: [M+H] ⁺ = 481.3
320		¹ H NMR (CD ₃ OD): δ 8.54 (d, J = 7.8 Hz, 1H), 8.28 (d, J = 4.6 Hz, 1H), 8.17 (d, J = 3.7 Hz, 1H), 7.85 - 7.60 (m, 1H), 7.58 - 7.39 (m, 1H), 7.36 - 7.02 (m, 2H), 5.92 - 5.39 (m, 2H), 4.28 - 3.96 (m, 1H), 3.72 - 3.40 (m, 2H), 3.20 - 2.90 (m, 1H), 2.69 - 2.14 (m, 2H), 2.21 - 1.76 (m, 4H). LC-MS: [M+H] ⁺ = 494.1



Example #	Structure	¹ H NMR & MS
321 (326)		¹ HNMR (400MHz, DMSO-d ₆): δ 8.55 (s, 1H), 8.27 (s, 1H), 8.15 (s, 1H), 7.98-7.85 (m, 1H), 7.70-7.60 (m, 1H), 7.57-7.45 (m, 1H), 7.42 (s, 1H), 7.33 (brs, 2H), 5.54 (s, 2H), 3.85-3.50 (m, 3H), 3.49-3.37 (m, 1H), 3.28-3.13 (m, 1H), 3.10-2.70 (m, 5H), 1.85-1.48 (m, 4H). LC-MS: [M+H] ⁺ = 493.2.

Example 322: (S)-3-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-N,N-dimethylpropanamide



- 5 Example 322 was prepared following procedures analogous to the preparation of Example 89 and the corresponding intermediate. ¹H NMR (400 MHz, CD₃OD) δ: 8.50 (s, 1H), 8.24 (d, J = 10.8 Hz, 2H), 7.73 (ddd, J = 12.3, 7.7, 2.3 Hz, 1H), 7.51 (t, J = 5.7 Hz, 1H), 7.28 (d, J = 8.5 Hz, 2H), 5.85 – 5.51 (m, 2H), 3.10 (s, 3H), 2.99 (d, J = 19.4 Hz, 4H), 2.93 (s, 3H), 2.53 (t, J = 8.1 Hz, 2H), 2.08 – 1.71 (m, 4H), 1.71 – 1.41 (m, 2H). LC-MS: [M+H]⁺ = 535.8, 536.8.
- 10 Example 323-325 were prepared following procedures analogous to the preparation of Example 1 and the corresponding intermediates.

Example #	Structure	¹ H NMR & MS
323		¹ HNMR (400MHz, CD ₃ OD): δ d 8.51 (s, 2H), 8.44 (s, 1H), 8.27 (s, 1H), 8.16 (s, 1H), 7.68 (ddd, J=2.0, 8.0, 12.0 Hz, 1H), 7.53 - 7.47 (m, 1H), 7.39 - 7.33 (m, 3H), 7.29 - 7.23 (m, 3H), 7.23 - 7.17 (m, 1H), 5.61 (s, 2H), 4.20 (d, J=9.6 Hz, 1H), 3.53 - 3.44 (m, 1H), 3.18 - 3.07 (m, 1H), 2.94 - 2.85 (m, 1H), 2.39 - 2.27 (m, 1H), 2.07 - 1.87 (m, 2H), 1.81 - 1.71 (m, 1H). LC-MS: [M+H] ⁺ = 513.2.

Example #	Structure	HNMR & MS
324		¹ H NMR (400MHz, CD ₃ OD): δ 8.57 (s, 1H), 8.23 (s, 0.4H), 8.22 (s, 1H), 8.15 (s, 0.6H), 7.94-7.83 (m, 1H), 7.77-7.63 (m, 1.6H), 7.58 (s, 0.4H), 7.40-7.28 (m, 1H), 7.52-7.46 (m, 1H), 5.34 (d, J = 15.6 Hz, 1H), 3.86-3.75 (m, 1H), 3.60-3.51 (m, 1H), 3.48-3.41 (m, 0.6H), 3.36-3.34 (m, 0.4H), 2.29-1.72 (m, 4H). LC-MS: [M+H] ⁺ = 451.1.
325		¹ H NMR (400MHz, CD ₃ OD): δ 8.29 (d, J = 9.8 Hz, 2H), 8.13 (s, 1H), 7.72 (ddd, J = 12.3, 7.8, 2.2 Hz, 1H), 7.60 – 7.54 (m, 1H), 7.49 (s, 1H), 7.27 (dt, J = 10.4, 8.4 Hz, 1H), 5.42 (d, J = 2.0 Hz, 2H), 4.15 – 3.93 (m, 1H), 3.40 (qd, J = 13.1, 6.0 Hz, 2H), 2.53 – 2.23 (m, 3H), 2.04 – 1.80 (m, 1H). LC-MS: [M+H] ⁺ = 450.9.

Biological Assays

The compounds of the present invention may be evaluated for their ability to inhibit NSD2 using assays described below, as well as other assays known in the art.

5 LC-MS/MS-Based NSD2 Enzymatic Assay

This assay employed LC-MS/MS technology to monitor the SAH production from the NSD2 enzymatic reaction. The enzymatic reaction was performed in white proxiplate plus 384-well microplate (Perkin Elmer). The reaction mixture (10 μ L) were composed of 8nM NSD2 [1-1365], 1 μ M SAM (USB, 10601) and 400nM nucleosome (purified from mouse liver) in reaction buffer
 10 (20 mM Tris-HCl, pH at 8.0, 0.01% Tween 20, 10 mM MgCl₂, 50mM NaCl, 1mM DTT, 1mM TCEP (pH7.5)). After 90min incubation at room temperature, 3 μ L quenching solution containing 2.5% TFA with 320 nM d4-SAH was added to stop the reaction.

For the inhibition assay, compound solutions were transferred into the wells by MosquitoTM (TTP LabTech). The inhibition assays were carried out by preincubating various concentrations
 15 of the inhibitor with 5 μ L reaction mixture containing 16nM NSD2 [1-1365] and 2 μ M SAM (USB, 10601) in reaction buffer. After 20min preincubation, 5 μ L solution containing 800nM nucleosome (purified from mouse liver) in reaction buffer was added to initiate the reaction. The reaction was stopped by 3 μ L quenching solution containing 2.5% TFA with 320 nM d4-SAH after 90 min.

20 The SAH production from the enzymatic assays were monitored by LC-MS/MS on an API 4000 triple quadrupole mass spec with Turbolon Spray(Applied Biosystem) coupled with Prominenece UFLC(Shimazu). Liquid chromatography was performed on a Chromolith

FastGradient HPLC column (RP-18e, 25-2mm, from Merck) at a flow rate of 0.8ml/min. The column was connected directly to the turbo ion electrospray operating in the positive-ion mode. Mobile phase A is 0.1% FA and 2% methanol in water and mobile phase B is 0.1% FA in ACN. Injection volume was 3 μ l and the autosampler was kept at 4 degree. SAH and d4-SAH were simultaneously monitored. Data were acquired and processed by Analyst software.

To quantify the formed SAH, d4-SAH was added as internal standard (IS). A series of SAH (Sigma, A9384) solution at varying concentration (1-500nM in reaction buffer) was mixed with quenching solution mentioned above. Then LC-MS/MS was carried out on API 4000 LC/MS/MS system to detect both SAH and d4-SAH. The plot of SAH peak area/IS peak area vs SAH concentration was used to generate the normalization factor of SAH. The SAH production from real enzymatic reaction was derived from the standard curve of SAH. The down-limit of our system for the detection of SAH is around 1-2 nM, and the linear range can reach up to 500nM.

In one embodiment, the compounds of the invention has an NSD2 IC₅₀ < 0.01 μ M. In particular embodiments, the compounds of the invention has an NSD2 IC₅₀ between 0.001 μ M and 0.01 μ M, as exemplified in Table 2 ("+++"). In another embodiment, the compounds of the invention has an NSD2 IC₅₀ < 1 μ M. In particular embodiments, the compounds of the invention has an NSD2 IC₅₀ between 0.01 and 1 μ M., as exemplified in Table 2 ("++"). In yet another embodiment, the compounds of the invention has an NSD2 IC₅₀ > 1 μ M, as exemplified in Table 2 ("+").

H3K36me2 cellular FRET assay in KMS11-Par line

Fluorescence Resonance Energy Transfer (FRET) assay was used to test the ability of candidate compound to reduce cellular H3K36me2 level in multiple myeloma cell line KMS11 (t(4;14)+) (Horizon Discovery Ltd.). Cells are maintained in RPMI1640 media with 12.5% FBS and 50 U/ml Penicillin-Streptomycin. For assay compound treatment, single cell suspension was prepared in Opti-MEM supplemented with B-27 and N2 supplement (Invitrogen 11058-021, 17504-044, 17502-048). One day prior to cell treatment, 5,000 KMS11 cells were seeded into PDL coated TC plate (PerkinElmer #6007718) at the final volume of 30 μ L/well.

Cells were treated with tested compounds at the desired concentration for 48 hours. Crude histone lysate was extracted by 0.4M HCl following neutralization by 0.5M Sodium phosphate, dibasic (Na₂HPO₄), pH ~12.5. Histone extract was incubated with Eu labeled anti-H3K36me2 antibody (abcam #ab ab9049) and d2 labeled anti-H3 antibody (abcam #ab1791) for 1hour at room temperature. A Eu labeled anti-H3 antibody (CISBIO #64CUS000) was used for loading control. The abundancy of H3K36me2 or total H3was measured by fluorescence signal on Perkin Elmer Envision machine.

H3K36me2 cellular ELISA assay in CGTH-W-1 line

An ELISA (enzyme-linked immunosorbent assay) based assay was used to test the ability of candidate compound to reduce cellular H3K36me2 level in thyroid carcinoma cell line CGTH-W-1, carrying NSD2 E1099K gain of function mutation. CGTH-W-1 (DSMZ) cells are maintained in

RPMI1640 media with 10% FBS and 50 U/ml Penicillin-Streptomycin. For assay compound treatment, single cell suspension was prepared in Opti-MEM supplemented with B-27 and N2 supplement (Invitrogen 11058-021, 17504-044, 17502-048) for ELISA and in maintenance media for cellTiter Glo (CTG) viability assay. One day prior to cell treatment, 500 CGTH-W-1 cells were seeded into 384-well Greiner CellStar TC plate (Greiner #781086) at the final volume of 30 μ L/well.

Cells were treated with tested compounds at the desired concentration for 72 hours. Crude histone lysate was extracted by 0.4M HCl following neutralization by 0.5M Sodium phosphate, dibasic (Na_2HPO_4), pH ~12.5. Equal amount of histone lysate was loaded to Corning 384-well high binding plate (Corning #3577, black) for H3K36me2 and to Thermo 384-well high binding Nunc plate (Thermo #460372, white) for total H3 as loading control.

Histone bound plates were washed and blocked with 5%BSA. H3K36me2 and total H3 was detected by primary antibodies (H3K36me2 Abcam, #ab9049; total H3 Cell Signaling, #4499L) and further revealed by horseradish peroxidase (HRP) conjugated secondary antibody and ECL substrate. The abundance of H3K36me2 and total H3 was measured by Chemiluminescence on a plate reader. Cell viability was monitored on a parallel seeded plate with CellTiter-Glo reagent (Promega # G7573).

H3K36me2 cellular ELISA assay in KMS11-Par line

An ELISA (enzyme-linked immunosorbent assay) based assay was used to test the ability of candidate compound to reduce cellular H3K36me2 level in multiple myeloma cell line KMS11 (t(4;14)+). KMS11 (Horizon Discovery Ltd.) cells are maintained in RPMI1640 media with 12.5% FBS and 50 U/ml Penicillin-Streptomycin. For assay compound treatment, single cell suspension was prepared in Opti-MEM supplemented with B-27 and N2 supplement (Invitrogen 11058-021, 17504-044, 17502-048) for ELISA and in maintenance media for cellTiter Glo (CTG) viability assay. One day prior to cell treatment, 1,250 KMS11 cells were seeded into 384-well Greiner CellStar TC plate (Greiner #781086) at the final volume of 30 μ L/well.

Cells were treated with tested compounds at the desired concentration for 72 hours. Crude histone lysate was extracted by 0.4M HCl following neutralization by 0.5M Sodium phosphate, dibasic (Na_2HPO_4), pH ~12.5. Equal amount of histone lysate was loaded to Corning 384-well high binding plate (Corning #3577, black) for H3K36me2 and to Thermo 384-well high binding Nunc plate (Thermo #460372, white) for total H3.

Histone bound plates were washed and blocked with 5%BSA. H3K36me2 and total H3 was detected by primary antibodies (H3K36me2 Abcam, #ab9049; total H3 Cell Signaling, #4499L) and further revealed by horseradish peroxidase (HRP) conjugated secondary antibody and ECL substrate. The abundance of H3K36me2 and total H3 was measured by Chemiluminescence on a plate reader. Cell viability was monitored on a parallel seeded plate with CellTiter-Glo reagent (Promega # G7573).

H3K36me2 cellular ELISA assay in CGTH-W-1 line

An ELISA (enzyme-linked immunosorbent assay) based assay was used to test the ability of candidate compound to reduce cellular H3K36me2 level in thyroid carcinoma cell line CGTH-W-1, carrying NSD2 E1099K gain of function mutation. CGTH-W-1 (DSMZ) cells are maintained in RPMI1640 media with 10% FBS and 50 U/ml Penicillin-Streptomycin. For assay compound treatment, single cell suspension was prepared in Opti-MEM supplemented with B-27 and N2 supplement (Invitrogen 11058-021, 17504-044, 17502-048) for ELISA and in maintenance media for cellTiter Glo (CTG) viability assay. One day prior to cell treatment, 500 CGTH-W-1 cells were seeded into 384-well Greiner CellStar TC plate (Greiner #781086) at the final volume of 30 μ L/well.

Cells were treated with tested compounds at the desired concentration for 72 hours. Crude histone lysate was extracted by 0.4M HCl following neutralization by 0.5M Sodium phosphate, dibasic (Na_2HPO_4), pH ~12.5. Equal amount of histone lysate was loaded to Corning 384-well high binding plate (Corning #3577, black) for H3K36me2 and to Thermo 384-well high binding Nunc plate (Thermo #460372, white) for total H3 as loading control.

Histone bound plates were washed and blocked with 5%BSA. H3K36me2 and total H3 was detected by primary antibodies (H3K36me2 Abcam, #ab9049; total H3 Cell Signaling, #4499L) and further revealed by horseradish peroxidase (HRP) conjugated secondary antibody and ECL substrate. The abundance of H3K36me2 and total H3 was measured by Chemiluminescence on a plate reader. Cell viability was monitored on a parallel seeded plate with CellTiter-Glo reagent (Promega # G7573).

The NSD2 biochemical activity and H3K36me2 cellular activity of the compounds of the present invention in different assay formats and cell lines are summarized in Table 2.

Table 2

Ex No.		H3K36me2 FRET in KMS11-Par (μ M)	H3K36me2 ELISA in CGTH-W-1 (μ M)	H3K36me2 ELISA in KMS11-Par (μ M)	NSD2 biochemical IC ₅₀ (μ M)
1	(R)-9-((5-(3-aminopiperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	3.03	0.75	4.09	++
2	9-(((3S,4R)-3-amino-4-fluoropiperidin-1-yl)-2-(2-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	11.07	n/a	n/a	++
3	(3S,4R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-4-ol	n/a	8.25	33.3	++
4	(R)-9-((5-(3-aminopiperidin-1-yl)-2-(3-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	4.12	n/a	n/a	++

Ex No.		H3K36me2 FRET in KMS11-Par (μ M)	H3K36me2 ELISA in CGTH-W-1 (μ M)	H3K36me2 ELISA in KMS11-Par (μ M)	NSD2 biochemical IC ₅₀ (μ M)
5	9-((5-((3S,4R)-3-amino-4-fluoropiperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	6.46	1.77	n/a	++
6	(R)-9-((5-(3-aminopiperidin-1-yl)-2-(2-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	10.0	n/a	n/a	++
7	(R)-4-(4-((6-amino-9H-purin-9-yl)methyl)-5-(3-aminopiperidin-1-yl)pyridin-2-yl)-2-chlorobenzonitrile	15.1	n/a	n/a	++
8	9-((5-((3S,4R)-3-amino-4-fluoropiperidin-1-yl)-2-(3-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	5.26	n/a	n/a	++
9	4-(5-((2S,3R)-3-amino-2-(methoxymethyl)piperidin-1-yl)-4-((6-amino-9H-purin-9-yl)methyl)pyridin-2-yl)-2-fluorobenzonitrile	9.90	n/a	n/a	++
10	9-((5-((3S,4R)-3-amino-4-fluoropiperidin-1-yl)-2-(2-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	7.63	n/a	n/a	++
11	(R)-9-((5-(3-aminopiperidin-1-yl)-2-(4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	11.2	n/a	n/a	++
12	9-((5-((3S,4R)-3-amino-4-fluoropiperidin-1-yl)-2-(3-chlorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	12.2	n/a	n/a	++
13	4-(5-((3S,4R)-3-amino-4-fluoropiperidin-1-yl)-4-((6-amino-9H-purin-9-yl)methyl)pyridin-2-yl)-2-fluorobenzonitrile	20.7	n/a	n/a	++
14	9-((5-((3S,4R)-3-amino-4-fluoropiperidin-1-yl)-2-(2,3-dihydrobenzofuran-5-yl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++
15	9-((5-(3-amino-4-methoxypiperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	18.7	n/a	n/a	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
16	(R)-9-((5-(5-amino-3,3-difluoropiperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++
17	9-((5-(3-amino-4,4-difluoropiperidin-1-yl)-2-(3-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	154	n/a	n/a	+
18	3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidine-4-carbonitrile	n/a	n/a	n/a	+
19	(R)-1-((5-(3-aminopiperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-7-chloro-1H-imidazo[4,5-c]pyridin-4-amine	3.90	n/a	n/a	++
20	(R)-9-((5-(3-amino-3-methylpiperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	2.95	n/a	n/a	++
21	(R)-1-((5-(3-aminopiperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	20.8	n/a	n/a	++
22	(R)-9-((5-(3-amino-3-(cyclopropoxymethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	0.214	n/a	n/a	+++
23	(R)-9-((5-(3-amino-3-(methoxymethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	0.160	n/a	n/a	+++
24	(R)-9-((5-(3-amino-3-(methoxymethyl)piperidin-1-yl)-2-(3-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	0.451	n/a	n/a	+++
25	(R)-9-((5-(3-amino-3-(isopropoxymethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	0.995	n/a	n/a	+++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
26	(R)-9-((5-(3-amino-3-(methoxymethyl)piperidin-1-yl)-2-(5-chloro-2-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	0.248	n/a	0.375	+++
27	(R)-9-((5-(3-amino-3-(methoxymethyl)piperidin-1-yl)-2-(3-chlorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	0.501	n/a	n/a	+++
28	(R)-9-((5-(3-amino-3-(methoxymethyl)piperidin-1-yl)-2-(3-chloro-4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	+++
29	(R)-9-((5-(3-amino-3-(methoxymethyl)piperidin-1-yl)-2-(2,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	0.225	n/a	n/a	+++
30	(R)-9-((5-(3-amino-3-(cyclobutoxymethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	0.569	0.659	2.03	+++
31	(R)-9-((5-(3-amino-3-(cyclopropoxymethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	+++
32	(R)-9-((5-(3-amino-3-(cyclobutoxymethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	0.270	0.196	0.728	+++
33	(R)-9-((5-(3-amino-3-(methoxymethyl)piperidin-1-yl)-2-(2-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	1.03	n/a	n/a	+++
34	(R)-9-((5-(3-amino-3-(isopropoxymethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	1.03	n/a	n/a	+++
35	(R)-9-((5-(3-amino-3-(cyclobutoxymethyl)piperidin-1-yl)-2-(3-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	0.610	n/a	n/a	+++
36	(R)-9-((5-(3-amino-3-	0.416	n/a	n/a	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
	(cyclobutoxymethyl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine				
37	(R)-9-((5-(3-amino-3-(isopropoxymethyl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	0.614	n/a	1.40	++
38	(R)-9-((5-(3-amino-3-(methoxymethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	0.721	n/a	n/a	++
39	(R)-9-((5-(3-amino-3-((2,2,2-trifluoroethoxy)methyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	2.56	n/a	n/a	++
40	(R)-9-((5-(3-amino-3-((difluoromethoxy)methyl)piperidin-1-yl)-2-(3-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	0.770	n/a	n/a	++
41	(R)-9-((5-(3-amino-3-((difluoromethoxy)methyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	1.09		2.31	++
42	(R)-9-((5-(3-amino-3-((difluoromethoxy)methyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	1.23	0.789	10.7	++
43	(R)-9-((5-(3-amino-3-((2,2,2-trifluoroethoxy)methyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	1.24	n/a	n/a	++
44	(R)-9-((5-(3-amino-3-((difluoromethoxy)methyl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	1.62	n/a	n/a	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
45	(R)-9-((5-(3-amino-3-((2,2,2-trifluoroethoxy)methyl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	0.705	n/a	n/a	++
46	(R)-1-((5-(3-amino-3-(methoxymethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	0.315	n/a	n/a	+++
47	(S)-9-((5-(3-amino-3-(2,2-difluoroethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	1.18	0.377	1.54	++
48	(S)-1-((5-(3-amino-3-(thiazol-2-ylmethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	0.464	+++
49	(S)-1-((5-(3-amino-3-((1-methyl-1H-pyrazol-3-yl)methyl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	12.7	+++
50	(S)-1-((5-(3-amino-3-(pyridin-2-ylmethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	0.895	+++
51	(S)-1-((5-(3-amino-3-(pyridin-2-ylmethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	1.53	+++
52	(S)-9-((5-(3-amino-3-(oxazol-2-ylmethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	1.20	0.541	1.32	+++
53	(S)-9-((5-(3-amino-3-	0.327	n/a	n/a	+++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
	(thiazol-2-ylmethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine				
54	(S)-9-((5-(3-amino-3-(pyridin-2-ylmethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	0.450	n/a	0.780	+++
55	(S)-9-((5-(3-amino-3-((6-methylpyridin-2-yl)methyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	0.910	+++
56	(S)-9-((5-(3-amino-3-((1-methyl-1H-pyrazol-3-yl)methyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.273	0.234	+++
57	(S)-1-((5-(3-amino-3-(thiazol-2-ylmethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	0.610	+++
58	(S)-2-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-fluorophenyl)pyridin-3-yl)piperidin-3-yl)acetic acid	2.64	n/a	n/a	+++
59	(S)-2-(3-amino-1-(4-((4-amino-1H-imidazo[4,5-c]pyridin-1-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-N,N-dimethylacetamide	33.3	n/a	n/a	+++
60	9-((5-(3-amino-3-(2-methoxyethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
61	(S)-9-((5-(3-amino-3-(2,2-difluoroethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	1.42	0.643	n/a	++
62	(S)-2-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)acetamide	n/a	n/a	n/a	++
63	(S)-1-((5-(3-amino-3-(oxazol-2-ylmethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	7.91	++
64	N-(4-(5-(3-amino-3-(2,2-difluoroethyl)piperidin-1-yl)-4-((6-amino-9H-purin-9-yl)methyl)pyridin-2-yl)phenyl)-3-bromopropanamide	n/a	n/a	7.00	++
65	9-((5-((S)-3-amino-3-((R)-1-(pyridin-2-yl)ethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	1.13	++
66	2-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-N-methylacetamide	118	n/a	n/a	++
67	2-(3-amino-1-(4-((4-amino-7-chloro-1H-imidazo[4,5-c]pyridin-1-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-N-methylacetamide	4.25	n/a	n/a	++
68	2-(3-amino-1-(4-((4-amino-7-chloro-1H-imidazo[4,5-c]pyridin-1-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-N,N-dimethylacetamide	n/a	n/a	n/a	++
69	9-((5-(3-amino-3-((6-fluoropyridin-2-yl)methyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	1.15	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
70	(S)-2-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-N,N-dimethylacetamide	9.44	n/a	n/a	++
71	(S)-9-((5-(3-amino-3-(2,2-difluoroethyl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	0.849	n/a	n/a	++
72	2-(3-amino-1-(4-((4-amino-1H-imidazo[4,5-c]pyridin-1-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-N-methylacetamide	250	n/a	n/a	++
73	methyl (S)-2-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-fluorophenyl)pyridin-3-yl)piperidin-3-yl)acetate	n/a	n/a	n/a	++
74	(S)-9-((5-(3-amino-3-(pyrazin-2-yl)methyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	4.22	++
75	N-(4-(5-(3-amino-3-(2,2-difluoroethyl)piperidin-1-yl)-4-((6-amino-9H-purin-9-yl)methyl)pyridin-2-yl)benzyl)-2-chloroacetamide	n/a	n/a	n/a	++
76	N-(4-(5-(3-amino-3-(2,2-difluoroethyl)piperidin-1-yl)-4-((6-amino-9H-purin-9-yl)methyl)pyridin-2-yl)phenyl)acrylamide	n/a	n/a	2.12	++
77	2-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)acetonitrile	n/a	n/a	n/a	+
78	(R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-fluorophenyl)pyridin-3-yl)-N-methylpiperidine-3-carboxamide	n/a	0.012	0.078	+++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
79	methyl (R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-fluorophenyl)pyridin-3-yl)piperidine-3-carboxylate	0.473	n/a	n/a	+++
80	(R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-fluoro-4-methoxyphenyl)pyridin-3-yl)-N,N-dimethylpiperidine-3-carboxamide	4.95	n/a	n/a	+++
81	isopropyl (R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-fluoro-4-methoxyphenyl)pyridin-3-yl)piperidine-3-carboxylate	0.115	n/a	n/a	+++
82	(R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidine-3-carboxamide	n/a	n/a	n/a	++
83	tert-butyl (R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-fluoro-4-methoxyphenyl)pyridin-3-yl)piperidine-3-carboxylate	0.956	n/a	n/a	++
84	(R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl(pyrrolidin-1-yl)methanone	n/a	n/a	n/a	++
85	3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)piperidine-3-carboxamide	n/a	2.08	6.49	++
86	(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)(piperidin-1-yl)methanone	n/a	8.69	33.3	++
87	(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)(2-methylpiperidin-1-yl)methanone	n/a	1.60	6.42	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
88	(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)(2-methylpyrrolidin-1-yl)methanone	n/a	n/a	n/a	++
89	1-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,3-dimethylbutan-1-one	n/a	0.245	0.684	++
90	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-fluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)ethan-1-ol	n/a	0.239	0.432	+++
91	9-((5-((R)-3-amino-3-((S)-fluoro(pyridin-2-yl)methyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.121	0.890	+++
92	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-fluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)ethan-1-ol	n/a	2.11	4.89	+++
93	9-((5-((R)-3-amino-3-((S)-1-methoxyethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	1.39	3.21	3.97	++
94	9-((5-((R)-3-amino-3-((R)-1-methoxyethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	3.04	1.09	1.20	++
95	9-((5-((R)-3-amino-3-((S)-1-methoxyethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	1.82	1.65	3.03	++
96	(E)-1-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-fluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)ethan-1-one O-methyl oxime	2.40	n/a	n/a	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
97	9-((5-((R)-3-amino-3-((R)-1-methoxyethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	1.50	1.16	1.24	++
98	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2-methylpropan-1-ol	n/a	1.50	6.26	++
99	9-((5-(3-amino-3-((R)-1-ethoxyethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	21.0	++
100	(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)(cyclopentyl)methanone	n/a	n/a	n/a	+++
101	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2-methylbutan-1-one	n/a	0.040	0.034	+++
102	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2-methylbutan-1-one	n/a	0.060	0.252	++
103	1-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2-cyclopropylpropan-1-one	n/a	0.138	0.379	++
104	(R)-1-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2-methylpropan-1-one	n/a	0.026	0.060	++
105	(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)(cyclobutyl)methanone	n/a	0.067	0.140	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
106	(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)(3-methoxycyclopentyl)methanone	n/a	0.501	1.43	++
107	(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)(1-methylcyclopropyl)methanone	n/a	0.446	3.02	++
108	(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)(tetrahydro-2H-pyran-4-yl)methanone	n/a	0.772	1.96	++
109	(R)-1-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-dimethylpropan-1-one	n/a	2.092	2.729	++
110	(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)(1-methyl-1H-pyrazol-3-yl)methanone	n/a	1.359	6.340	++
111	(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)(tetrahydrofuran-3-yl)methanone	n/a	n/a	n/a	+
112	(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)(3-methyloxetan-3-yl)methanone	n/a	n/a	n/a	+
113	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.145	0.753	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
114	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.443	1.94	++
115	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-(difluoromethyl)-2-methylphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.088	0.927	+++
116	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-(difluoromethoxy)-3-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.168	1.35	+++
117	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4,5-difluoro-2-methylphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.067	1.32	+++
118	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)-5-methoxypyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	n/a	n/a	+++
119	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-(difluoromethoxy)-3-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.228	1.49	+++
120	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-(difluoromethyl)-2,5-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	n/a	n/a	+++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
121	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-chloro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.683	2.61	+++
122	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-chloro-4-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.496	1.83	+++
123	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(6-fluoro-1-methyl-1H-indazol-5-yl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	1.49	7.85	+++
124	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-chloro-3-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.159	0.848	+++
125	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-chloro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.775	3.95	+++
126	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,4-dimethylphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.469	1.11	+++
127	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-fluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.262	0.901	+++
128	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-(difluoromethoxy)-2,5-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.060	0.693	+++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
129	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-(difluoromethyl)-5-fluoro-2-methylphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	n/a	n/a	+++
130	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-cyclohexylpyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.321	3.52	+++
131	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-fluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.142	0.887	+++
132	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-(difluoromethyl)-2-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.264	1.23	+++
133	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-chloro-2-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.177	1.61	++
134	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-(difluoromethyl)-2,5-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.601	0.830	++
135	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-5-fluoro-6-(2-fluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	n/a	n/a	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
136	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(1,6-dimethyl-1H-indazol-5-yl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	n/a	8.80	++
137	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-(difluoromethyl)-2-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	n/a	n/a	++
138	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-(difluoromethoxy)-2-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.132	1.57	++
139	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-chloro-4-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.669	2.84	++
140	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-(difluoromethyl)-2-methylphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	n/a	n/a	++
141	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-fluoro-4-(trifluoromethyl)phenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	1.15	7.70	++
142	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,4-difluorophenyl)-5-fluoropyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	n/a	n/a	++
143	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(6-fluoro-1-methyl-1H-indazol-5-yl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	n/a	n/a	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
144	4-(5-((R)-3-amino-3-((S)-2,2-difluoro-1-hydroxyethyl)piperidin-1-yl)-4-((6-amino-9H-purin-9-yl)methyl)pyridin-2-yl)-2,5-difluorophenol	n/a	2.58	10.4	++
145	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-cyclohexylpyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.990	8.11	++
146	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4,5-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.723	5.04	++
147	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.044	2.49	++
148	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-chloro-2-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.671	2.16	++
149	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,5-difluoro-4-methoxyphenyl)-5-fluoropyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	n/a	n/a	++
150	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-(difluoromethoxy)-2,5-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.307	1.67	++
151	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.8415	4.19	++
152	(S)-1-((R)-3-amino-1-(4-((6-	n/a	0.0687	1.77	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
	amino-9H-purin-9-yl)methyl)-6-(4-chloro-3-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol				
153	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-(difluoromethoxy)-2-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.217	5.08	++
154	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3-(difluoromethyl)-2,5-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	2.93	9.11	++
155	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-5'-fluoro-[2,2'-bipyridin]-5-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	1.17	16.4	++
156	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,4,5-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.041	0.574	+++
157	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,4,5-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.385	1.31	+++
158	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.100	0.802	+++
159	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4-fluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.140	1.13	+++
160	(R)-1-((R)-3-amino-1-(4-((6-	n/a	0.035	0.434	+++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
	amino-9H-purin-9-yl)methyl)-6-(2,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol				
161	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.073	0.502	+++
162	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.086	0.440	+++
163	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.204	1.85	+++
164	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.130	1.06	+++
165	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.218	1.08	+++
166	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-methoxy-2-(trifluoromethyl)phenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.432	8.51	+++
167	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-methoxy-2-(trifluoromethyl)phenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.559	6.12	++
168	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-	n/a	0.997	4.78	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
	yl)methyl)-6-(2-chloro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol				
169	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-chloro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.426	2.99	++
170	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4,5-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.161	1.47	++
171	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2-(difluoromethyl)-4,5-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.886	5.52	++
172	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,3,4-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	1.20	8.93	++
173	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	1.04	12.8	++
174	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(4-fluoro-2-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	1.16	10.6	++
175	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6'-chloro-5'-fluoro-[2,2'-bipyridin]-5-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol	n/a	0.534	11.3	++
176	(R)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6'-chloro-5'-	n/a	0.953	8.97	++

Ex No.		H3K36me2 FRET in KMS11-Par (μ M)	H3K36me2 ELISA in CGTH-W-1 (μ M)	H3K36me2 ELISA in KMS11-Par (μ M)	NSD2 biochemical IC ₅₀ (μ M)
	fluoro-[2,2'-bipyridin]-5-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol				
177	9-((5-(3-amino-3-(6-methylpyridin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	0.407	+++
178	(R)-9-((5-(3-amino-3-(6-methoxypyridin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.230	n/a	+++
179	9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(1,3-dihydroisobenzofuran-5-yl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	1.42	n/a	++
180	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-5'-chloro-6'-fluoro-[2,3'-bipyridin]-4-yl)methyl)-9H-purin-6-amine	n/a	1.459	5.49	++
181	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(2-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	1.56	1.98	++
182	(R)-9-((5-(3-amino-3-(6-cyclopropylpyridin-2-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.0975	0.142	+++
183	9-((5-((R)-3-amino-3-(6-((S)-1-fluoroethyl)pyridin-2-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.159	0.455	++
184	9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(4-(difluoromethoxy)phenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.592	n/a	++
185	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(2,3-dihydrobenzofuran-5-yl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
186	9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(benzo[d][1,3]dioxol-5-yl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.967	n/a	++
187	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(2,5-difluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.383	0.815	++
188	(R)-9-((5-(3-amino-3-(6-chloro-5-fluoropyridin-2-yl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	1.01	1.91	+++
189	9-((5-(3-amino-3-(5-fluoropyridin-2-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++
190	(R)-9-((5-(3-amino-3-(5-fluoro-6-methylpyridin-2-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.258	0.687	+++
191	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-6'-chloro-5'-fluoro-[2,2'-bipyridin]-4-yl)methyl)-9H-purin-6-amine	n/a	1.38	4.56	++
192	(R)-9-((5-(3-amino-3-(6-chloro-3-fluoropyridin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.731	2.18	++
193	9-((5-(3-amino-3-(5-fluoro-6-(fluoromethyl)pyridin-2-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.876	1.85	++
194	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-6'-chloro-5'-methoxy-[2,2'-bipyridin]-4-yl)methyl)-9H-purin-6-amine	n/a	0.805	3.28	++
195	6-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)picolinamide	n/a	4.92	n/a	++
196	(R)-9-((5-(3-amino-3-(6-	n/a	0.637	2.69	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
	chloropyridin-2-yl)piperidin-1-yl)-5'-fluoro-[2,2'-bipyridin]-4-yl)methyl)-9H-purin-6-amine				
197	(R)-9-((5-(3-amino-3-(6-(1,1-difluoroethyl)pyridin-2-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++
198	(R)-9-((5-(3-amino-3-(pyridin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.0177	0.041	+++
199	(R)-9-((5-(3-amino-3-(3-fluoropyridin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	0.846	+++
200	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.18	0.33	+++
201	(R)-9-((5-(3-amino-3-(6-fluoropyridin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.123	0.286	+++
202	(R)-9-((5-(3-amino-3-(6-ethylpyridin-2-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	0.264	+++
203	(R)-9-((5-(3-amino-3-(6-(difluoromethyl)pyridin-2-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	0.389	+++
204	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-cyclopropylpyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++
205	9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	0.632	+++
206	(R)-2-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-	n/a	0.117	1.16	+++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
	difluorophenyl)pyridin-3-yl)piperidin-3-yl)-6-fluoropyridin-4-ol				
207	(R)-9-((5-(3-amino-3-(5-fluoro-6-methylpyridin-2-yl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++
208	6-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)picolinonitrile	n/a	2.78	n/a	++
209	(R)-9-((5-(3-amino-3-(5-(difluoromethoxy)pyridin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.324	n/a	+++
210	9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(imidazo[1,2-a]pyridin-6-yl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++
211	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.387	n/a	+++
212	9-((5-((R)-3-amino-3-(6-((R)-1-fluoroethyl)pyridin-2-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.132	0.289	++
213	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.258	0.387	+++
214	6-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2-fluoropyridin-3-ol	n/a	0.444	2.426	++
215	1-(6-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2-fluoropyridin-3-yl)ethan-1-ol	n/a	n/a	n/a	++
216	(R)-9-((5-(3-amino-3-(6-chloro-5-fluoropyridin-2-	n/a	1.88	2.57	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
	yl)piperidin-1-yl)-2-(4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine				
217	(R)-6-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)pyridin-2-ol	n/a	2.241	n/a	+++
218	(R)-9-((5-(3-amino-3-(6-(difluoromethyl)-5-fluoropyridin-2-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.1011	n/a	++
219	(R)-2-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-6-chloropyridin-4-ol	n/a	0.407	3.45	+++
220	9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(1-methyl-1H-benzo[d]imidazol-6-yl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++
221	(R)-9-((5-(3-amino-3-(6-chloro-5-fluoropyridin-2-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.269	1.29	+++
222	9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(pyrazolo[1,5-a]pyridin-6-yl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++
223	9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(pyrazolo[1,5-a]pyridin-6-yl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++
224	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-6'-fluoro-5'-methoxy-[2,2'-bipyridin]-4-yl)methyl)-9H-purin-6-amine	n/a	0.348	1.71	+++
225	9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(1-methyl-1H-indazol-5-yl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	1.96	n/a	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
226	(R)-9-((5-(3-amino-3-(6-(fluoromethyl)pyridin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.0668	0.169	+++
227	(R)-9-((5-(3-amino-3-(6-(difluoromethyl)pyridin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.133	0.302	++
228	9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(4-(difluoromethoxy)-3-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.611	n/a	++
229	9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-6'-methyl-[2,3'-bipyridin]-4-yl)methyl)-9H-purin-6-amine	n/a	1.97	7.49	++
230	(R)-9-((5-(3-amino-3-(6-chloro-3-methoxypyridin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	1.65	9.98	++
231	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-5'-fluoro-6'-methoxy-[2,3'-bipyridin]-4-yl)methyl)-9H-purin-6-amine	n/a	2.15	7.44	++
232	(R)-2-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-6-methylpyridine 1-oxide	n/a	1.47	7.65	++
233	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(3,5-difluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.341	1.1	+++
234	1-(6-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2-chloropyridin-3-yl)ethan-1-ol	n/a	1.62	5.99	++
235	(R)-9-((5-(3-amino-3-(6-fluoro-4-methoxypyridin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-	n/a	0.705	0.97	+++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
	yl)methyl)-9H-purin-6-amine				
236	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(2,6-difluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	1.39	6.30	++
237	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(2,6-difluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.825	2.02	++
238	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(2,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.588	1.341	+++
239	(R)-2-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-6-fluoropyridin-3-ol	n/a	0.353	1.54	+++
240	9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-5',6'-difluoro-[2,3'-bipyridin]-4-yl)methyl)-9H-purin-6-amine	n/a	0.821	5.93	++
241	(R)-9-((5-(3-amino-3-(5-fluoro-6-methylpyridin-2-yl)piperidin-1-yl)-2-(4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	1.19	4.08	++
242	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(2,3-difluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	2.714	8.19	++
243	(R)-9-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-4'-fluoro-5'-methoxy-[2,2'-bipyridin]-4-yl)methyl)-9H-purin-6-amine	n/a	0.541	2.44	+++
244	5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-4-((6-amino-9H-purin-9-yl)methyl)-5'-fluoro-[2,3'-bipyridin]-6'-ol	n/a	12.5	33.3	++
245	(S)-9-((5-(3-amino-3-(pyridin-4-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-	n/a	n/a	2.15	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
	yl)methyl)-9H-purin-6-amine				
246	(S)-9-((5-(3-amino-3-(2-chloropyridin-4-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	16.7	++
247	(S)-9-((5-(3-amino-3-(2-methylpyridin-4-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	33.3	++
248	(S)-9-((5-(3-amino-3-(3-fluoropyridin-4-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	2.88	++
249	9-((5-(3-amino-3-(6-chloropyridazin-3-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	+++
250	(R)-9-((5-(3-amino-3-(6-ethylpyrazin-2-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++
251	(R)-9-((5-(3-amino-3-(2-ethylpyrimidin-4-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.440	1.52	++
252	(R)-1-((5-(3-amino-3-(6-ethylpyridin-2-yl)piperidin-1-yl)-2-cyclopropylpyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	7.25	++
253	9-((5-(3-amino-3-(pyridazin-3-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.357	n/a	++
254	9-((5-(3-amino-3-(6-chloropyrazin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	1.54	++
255	9-((5-(3-amino-3-(pyrimidin-4-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.232	n/a	++
256	(R)-1-((5-(3-amino-3-(6-ethylpyrazin-2-yl)piperidin-	n/a	n/a	n/a	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
	1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine				
257	(R)-9-((5-(3-amino-3-(2-methylpyrimidin-4-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.435	1.20	++
258	(R)-9-((5-(3-amino-3-(6-methylpyrazin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.434	n/a	++
259	9-((5-(3-amino-3-(pyrazin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	3.54	++
260	(R)-1-((5-(3-amino-3-(6-(difluoromethyl)pyridin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	1.52	++
261	(R)-1-((5-(3-amino-3-(6-methylpyridin-2-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	0.235	+++
262	1-((5-(3-amino-3-(6-fluoropyridin-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	1.33	++
263	1-((5-(3-amino-3-(6-methylpyridin-2-yl)piperidin-1-yl)-2-cyclopropylpyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	4.17	++
264	(R)-1-((5-(3-amino-3-(6-(difluoromethyl)pyridin-2-yl)piperidin-1-yl)-2-cyclopropylpyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	9.63	++
265	1-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-(azetidin-1-yl)pyridin-4-yl)methyl)-1H-	n/a	n/a	n/a	+

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
	imidazo[4,5-c]pyridin-4-amine				
266	1-((5-(3-amino-3-(pyridin-2-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	0.436	+++
267	1-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-cyclobutylpyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	1.91	++
268	1-((5-(3-amino-3-(6-chloropyridin-2-yl)piperidin-1-yl)-2-cyclobutylpyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	n/a	++
269	(S)-9-((5-(3-amino-3-(1-methyl-1H-pyrazol-4-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	5.68	+++
270	1-((5-(3-amino-3-(1-methyl-1H-pyrazol-4-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	15.3	++
271	9-((5-(3-amino-3-(pyridin-3-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	33.3	+
272	(S)-3-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)pyridin-2(1H)-one	n/a	1.746	10.5	+++
273	(R)-9-((5-(3-amino-3-(1-(difluoromethyl)-1H-pyrazol-3-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	+++
274	(R)-9-((5-(3-amino-3-(1-isopropyl-1H-pyrazol-3-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	5.54	+++
275	(R)-9-((5-(3-amino-3-(1-methyl-1H-pyrazol-3-yl)piperidin-1-yl)-2-(3,4-	n/a	n/a	n/a	+++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
	difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine				
276	(R)-1-((5-(3-amino-3-(1-ethyl-1H-pyrazol-3-yl)piperidin-1-yl)-2-cyclopropylpyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	n/a	++
277	1-((5-(3-amino-3-(1-ethyl-1H-pyrazol-3-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	2.20	++
278	9-((5-(3-amino-3-(1-cyclopropyl-1H-pyrazol-3-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	0.475	+++
279	(R)-1-((5-(3-amino-3-(1-(difluoromethyl)-1H-pyrazol-3-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	n/a	+++
280	1-((5-(3-amino-3-(1-cyclopropyl-1H-pyrazol-3-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-1H-imidazo[4,5-c]pyridin-4-amine	n/a	n/a	1.49	+++
281	9-((5-(3-amino-3-(2-chlorothiazol-4-yl)piperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.826	n/a	++
282	9-((5-(3-amino-3-(1-methyl-1H-1,2,3-triazol-4-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	1.53	n/a	++
283	(R)-9-((5-(3-amino-3-(2-methyl-2H-1,2,3-triazol-4-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.11	1.02	+++
284	(R)-9-((5-(3-amino-3-(5-methylisoxazol-3-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.1108	0.254	+++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
285	(R)-2-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2-fluoroethan-1-ol	n/a	0.0437	0.885	+++
286	(R)-2-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,4,5-trifluorophenyl)pyridin-3-yl)piperidin-3-yl)-2-fluoroethan-1-ol	n/a	0.0059	0.655	+++
287	9-((5-(3-amino-3-(1,2-difluoroethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++
288	9-((5-((R)-3-amino-3-((2R,6S)-6-methyl-1,4-dioxan-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	2.39	5.72	++
289	9-((5-((R)-3-amino-3-((R)-1,4-dioxan-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.492	2.67	+++
290	9-((5-((R)-3-amino-3-((R)-1,4-dioxan-2-yl)piperidin-1-yl)-2-(2,4,5-trifluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.421	0.954	++
291	9-((5-((R)-3-amino-3-((R)-1,4-dioxan-2-yl)piperidin-1-yl)-2-(2-(difluoromethyl)-4,5-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	0.812	1.69	++
292	(R)-7-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)-3-oxa-1,7-diazaspiro[4.5]decan-2-one	n/a	n/a	n/a	++
293	(S)-9-((5-(3-amino-3-(1,1-difluoroprop-1-en-2-yl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	1.3	3.21	++
294	9-((5-(3-amino-3-(2,2-difluorovinyl)piperidin-1-yl)-2-(3,4-	n/a	n/a	9.44	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
	difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine				
295	9-((5-(3-amino-3-(1-fluoroethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	2.332	n/a	1.86	++
296	(R)-9-((5-(3-((1H-pyrazol-1-yl)methyl)-3-aminopiperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	0.336	n/a	1.41	++
297	9-((5-(3-amino-3-((methylthio)methyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	2.354	n/a	n/a	++
298	9-((5-(3-amino-3-((methylsulfonyl)methyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	+
299	(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-2,2,2-trifluoroethan-1-ol	n/a	1.155	9.83	++
300	9-((5-(3-amino-3-(1,2,2-trifluoroethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++
301	3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)-3-(2,2-difluoroethyl)piperidin-4-ol	n/a	n/a	n/a	++
302	(3R,4R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)-3-(6-chloropyridin-2-yl)piperidin-4-ol	n/a	n/a	0.563	++
303	(S)-9-((5-(3-amino-3-(2,2,2-trifluoroethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	5.37	n/a	n/a	++
304	(S)-9-((5-(3-amino-3-ethynylpiperidin-1-yl)-2-(3,4-	n/a	0.101	0.592	++

Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
	difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine				
305	(R)-9-((5-(3-amino-3-(difluoromethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	3.40	4.80	++
306	9-((5-((3R,5R)-3-amino-5-(fluoromethyl)piperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	6.46	n/a	++
307	9-((5-((3S,5S)-3-amino-3-(2,2-difluoroethyl)-5-methylpiperidin-1-yl)-2-(4-fluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	+
308	9-((5-(3-amino-5-(methoxymethyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	27.5	++
309	9-((5-((3R,5S)-3-amino-5-fluoropiperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++
310	9-((5-((2S,5R)-5-amino-2-methylpiperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	+
311	9-((5-((2S,3R)-3-amino-2-((difluoromethoxy)methyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++
312	((2S,3R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-2-yl)methanol	n/a	n/a	n/a	++
313	9-((5-((2S,3R)-3-amino-2-((2,2-difluoroethoxy)methyl)piperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	++
314	2-((2R,3R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-2-yl)ethan-1-ol	n/a	n/a	n/a	++


Ex No.		H3K36me2 FRET in KMS11-Par (μM)	H3K36me2 ELISA in CGTH-W-1 (μM)	H3K36me2 ELISA in KMS11-Par (μM)	NSD2 biochemical IC ₅₀ (μM)
315	(2S,3R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)-N-methylpiperidine-2-carboxamide	n/a	n/a	n/a	+
316	(R)-1-((2S,3R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-2-yl)-2,2,2-trifluoroethan-1-ol	n/a	n/a	n/a	+
317	(2S,3R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)-N,N-dimethylpiperidine-2-carboxamide	n/a	n/a	n/a	+
318	(2S,3R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidine-2-carboxamide	n/a	n/a	n/a	+
319	(2S,3R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidine-2-carboxamide	n/a	n/a	n/a	+
320	2-((2R,3R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-2-yl)acetamide	n/a	n/a	n/a	+
321 (326)	9-((2-(3,4-difluorophenyl)-5-(4-oxa-1,8-diazaspiro[5.5]undecan-8-yl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	+
322	(S)-3-(3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-3-yl)-N,N-dimethylpropanamide	n/a	n/a	>33.70	++
323	9-((5-((2R,3R)-3-amino-2-phenylpiperidin-1-yl)-2-(3,4-difluorophenyl)pyridin-4-yl)methyl)-9H-purin-6-amine	n/a	n/a	n/a	+
324	3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-	n/a	n/a	n/a	+

Ex No.		H3K36me2 FRET in KMS11-Par (μ M)	H3K36me2 ELISA in CGTH-W-1 (μ M)	H3K36me2 ELISA in KMS11-Par (μ M)	NSD2 biochemical IC ₅₀ (μ M)
	yl)piperidin-2-one				
325	(R)-5-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(3,4-difluorophenyl)pyridin-3-yl)piperidin-2-one	n/a	n/a	n/a	+

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited
5 herein are hereby incorporated by reference for all purposes.

CLAIMS

1. A compound of Formula (I)



or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof;
wherein:

A is N or CR⁹ wherein R⁹ is hydrogen or halo;

L is a bond or C₁₋₄ alkylene;

R¹ is H; or

R¹ and R² together with NH forms a 5-8 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S as ring members; wherein said 5-8 membered heterocyclyl is unsubstituted or substituted by an oxo substituent;

R² is selected from the group consisting of:

(i) hydrogen, C₁₋₆ alkyl, haloC₁₋₆ alkyl, hydroxyC₁₋₆ alkyl, hydroxyhaloC₁₋₆ alkyl, C₁₋₆alkoxyC₁₋₆alkyl, haloC₁₋₆ alkoxyC₁₋₆ alkyl or C₃₋₈ cycloalkoxy(C₁₋₆ alkyl);

(ii) cyano; cyanoC₁₋₆ alkyl; C₁₋₆ alkylthioC₁₋₆alkyl; C₂₋₆ alkenyl; haloC₂₋₆ alkenyl; C₂₋₆ alkynyl; C₁₋₄ alkylSOC₁₋₄alkyl; C₁₋₄ alkylSO₂C₁₋₄alkyl; -SO₂R⁸ or -C(C₁₋₄ alkyl)=N-O(C₁₋₄ alkyl);

(iii) C₁₋₄alkylcarbonyl; -(CR^aR^b)_p-C(=O)-OR¹⁰; or -C(=O)-(CR^aR^b)_qR¹¹; wherein R¹¹ is C₃₋₇ cycloalkyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl, each of which is

independently unsubstituted or substituted with C₁₋₆ alkyl or C₁₋₆ alkoxy;

(iv) -(CR^aR^b)_r-C(=O)-NR¹²R¹³ wherein R¹² is hydrogen or C₁₋₆ alkyl; R¹³ is hydrogen, C₁₋₆ alkyl or a 5-6 membered heterocyclic ring; or R¹² and R¹³ together form a 5-6 membered heterocyclic ring; wherein said 5-6 membered heterocyclic ring is unsubstituted or substituted with C₁₋₄ alkyl;

(v) 5-6 membered heterocyclylC₀₋₆alkyl or 5-6 membered heterocyclyl(haloC₁₋₄ alkyl)

wherein each said heterocyclyl radical is unsubstituted or substituted by oxo; and

(vi) 5-9 membered heteroarylC₀₋₆alkyl or 5-9 membered heteroaryl(haloC₁₋₄alkyl), wherein each said heteroaryl radical is unsubstituted or substituted by C₁₋₄ alkyl, haloC₁₋₄ alkyl, hydroxyC₁₋₄ alkyl, C₁₋₄ alkoxy, haloC₁₋₄ alkoxy, halo, hydroxy, cyano, oxido, aminocarbonylC₀₋₆alkyl, C₁₋₄alkylaminocarbonylC₀₋₆alkyl, diC₁₋₄alkylaminocarbonylC₀₋₆alkyl or C₃₋₇ cycloalkyl;

R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^{5a} , R^{5b} , R^{6a} and R^{6b} are independently hydrogen, halo, cyano, hydroxyl, C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl, halo C_{1-6} alkoxy C_{1-6} alkyl, hydroxyhalo C_{1-6} alkyl, aryl, $-C(=O)-OR^{14}$ or $-(CR^aR^b)_s-C(=O)-NR^{15}R^{16}$; or

R^{3a} and R^{3b} , R^{4a} and R^{4b} , R^{5a} and R^{5b} or R^{6a} and R^{6b} forms an oxo substituent;

5 R^7 is H, C_{1-4} alkoxy, halo or C_{1-4} alkyl; or 3-8 membered heterocyclyl, which is unsubstituted or substituted by halo;

R^8 is C_{3-8} cycloalkyl(C_{0-6} alkyl); 4-6 membered heterocyclyl C_{0-6} alkyl comprising 1-3 heteroatoms selected from N, O and S; aryl or 5-9 membered heteroaryl C_{0-6} alkyl comprising 1-3 heteroatoms selected from N, O and S; wherein R^8 is unsubstituted or substituted by 1-3 R^{17} ;

10 R^{17} is halo, hydroxy, cyano, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, $-NR^aC(=O)CR^c=C(R^c)_2$ or $-(CR^aR^b)_t-NR^a-C(=O)-R^{18}$;

R^a , R^b , R^c , R^{10} , R^{14} , R^{15} and R^{16} are independently hydrogen or C_{1-4} alkyl;

R^{18} is C_{1-4} alkyl or C_{1-4} haloalkyl; and

p, q, r, s and t are independently 0-4.

15 2. The compound of Formula (I) in claim 1 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein A is N.

3. The compound of Formula (I) in claim 1 or 2, or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt; wherein

R^{3a} is hydrogen or halo; and R^{3b} is hydrogen, halo, hydroxyl, C_{1-6} alkoxy or cyano; or

20 R^{4a} is hydrogen or halo; and R^{4b} is hydrogen, halo, C_{1-6} alkoxy C_{1-6} alkyl, C_{1-6} alkyl or halo C_{1-6} alkyl; or

R^{5a} is hydrogen and R^{5b} is hydrogen or C_{1-6} alkyl; or

R^{5a} and R^{5b} together form an oxo substituent.

25 4. The compound of Formula (I) in any one of claims 1-3 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt; wherein:

R^{6a} is hydrogen or halo;

R^{6b} is hydrogen, halo C_{1-6} alkoxy C_{1-6} alkyl, hydroxy C_{1-6} alkyl, hydroxyhalo C_{1-6} alkyl, carboxyl, phenyl or $-(CR^aR^b)_t-C(O)-NR^{15}R^{16}$;

R^a , R^b , R^{15} and R^{16} are independently hydrogen or C_{1-4} alkyl; and


30 t is 0-1; or

R^{6a} and R^{6b} together form an oxo substituent.

5. The compound of Formula (I) in any one of claims 1-4 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R^7 is H, C_{1-4} alkoxy or halo.

35 6. The compound of Formula (I) in any one of claims 1-5 or a pharmaceutically acceptable salt thereof; wherein R^1 , R^{3a} , R^{3b} , R^{4a} , R^{4b} , R^{5a} , R^{5b} , R^{6a} , R^{6b} and R^7 are hydrogen.

7. The compound of Formula (I) in claim 1, wherein said compound is a compound of Formula (II):





or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof.

8. The compound according to any one of claims 1-7 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R^2 is hydrogen, C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, hydroxyhalo C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkyl, halo C_{1-6} alkoxy C_{1-6} alkyl or C_{3-8} cycloalkoxy(C_{1-6} alkyl).

9. The compound according to any one of claims 1-7 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R^2 is hydrogen; 2,2-difluoroethyl; 2-methyl-propan-1-olyl; ethan-1-olyl; 2,2-difluoroethan-1-olyl; 2-fluoroethan-1-olyl; 2,2,2-trifluoroethan-1-olyl; difluoromethoxyl; or 2,2,2-trifluoroethoxyl.

10. The compound according to any one of claims 1-7 or an enantiomer, an enantiomeric

mixture, or a pharmaceutically acceptable salt thereof; wherein R^2 is  or .

11. The compound according to any one of claims 1-7 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R^2 is C_{1-4} alkylcarbonyl; $-(CR^aR^b)_p-C(O)-OR^{10}$ wherein R^{10} is hydrogen or C_{1-4} alkyl; $-C(O)-(CR^aR^b)_q-R^{11}$ wherein R^{11} is C_{3-6} cycloalkyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl, each of which is independently unsubstituted or substituted with C_{1-6} alkyl or C_{1-6} alkoxy; or $-(CR^aR^b)_r-C(O)-NR^{12}R^{13}$; wherein R^{12} is hydrogen or C_{1-6} alkyl; R^{13} is hydrogen, C_{1-6} alkyl or a 5-6 membered heterocyclic ring; or R^{12} and R^{13} together form a 5-6 membered heterocyclic ring; wherein said 5-6 membered heterocyclic ring is unsubstituted or substituted with C_{1-4} alkyl; and R^a , R^b and R^{11} are independently hydrogen or C_{1-4} alkyl; and

p, q and r are independently 0-2.

12. The compound according to any one of claims 1-7 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R² is selected from the group:

pyridin-2-yl, (pyridin-2-yl)methyl or (pyridin-2-yl)ethyl, wherein said pyridin-2-yl is

independently unsubstituted or substituted with 1-2 C₁₋₄ alkyl, C₁₋₄ haloalkyl, hydroxyl, hydroxyC₁₋₄ alkyl, cyano, C₁₋₄ alkoxy, C₁₋₆alkoxyC₁₋₆alkyl, haloC₁₋₄ alkoxy, halo or C₃₋₇ cycloalkyl;

thiazol-4-yl, thiazol-2-ylmethyl, oxazol-2-yl, oxazol-2-ylmethyl, pyridazin-3-yl, pyridazin-3-ylmethyl, pyrazin-2-yl, pyrazin-2-ylmethyl, pyrimidin-4-yl, pyrimidin-4-ylmethyl, each of which is independently unsubstituted or substituted with C₁₋₄ alkyl or halo;

1H-pyrazol-3-yl, (1H-pyrazol-3-yl)methyl, 1-methyl-1H-pyrazol-4-yl, (1,2,3-triazol-4-yl), isoxazol-3-yl, each of which is independently unsubstituted or substituted with C₁₋₄ alkyl, halo or C₃₋₇ cycloalkyl;

1,4-dioxan-2-yl;

pyridin-2(1H)-onyl; and

pyridin-1-oxide-2-yl.

13. The compound according to any one of claims 1-12 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R⁸ is cyclopropyl; cyclobutyl; cyclohexyl or azetidiny.

14. The compound according to any one of claims 1-12 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R⁸ is 2,3-dihydrobenzofuran-5-yl; 1,3-dihydroisobenzofuran-5-yl; benzo[d][1,3]dioxol-5-yl; imidazo[1,2-a]pyridin-6-yl or pyrazolo[1,5-a]pyridine-6-yl.

15. The compound according to any one of claims 1-12 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R⁸ is pyridyl, unsubstituted or substituted with 1-2 halo, C₁₋₆ alkyl or C₁₋₆ alkoxy; 1H-indazol-5-yl unsubstituted or substituted with 1-2 halo or C₁₋₆ alkyl; or 1H-benzo[d]-imidazol-6-yl unsubstituted or substituted with C₁₋₆ alkyl.

16. The compound according to any one of claims 1-12 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R⁸ is phenyl substituted with 1-3 R¹⁷;

R¹⁷ is halo, hydroxy, cyano, C₁₋₆ alkyl, haloC₁₋₆ alkyl, C₁₋₆ alkoxy, haloC₁₋₆ alkoxy, -NR^dC(O)CR^d=C(R^d)₂ or -(CR^aR^b)_t-NR^d-C(O)-R¹⁸;

R^a, R^b and R^d are independently hydrogen or C₁₋₄ alkyl;

R¹⁸ is C₁₋₄ haloalkyl; and

t is 0-1.

17. The compound according to any one of claims 1-12 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein R⁸ is phenyl substituted with 1-3 R¹⁷; and R¹⁷ is halo, hydroxy, C₁₋₆ alkyl, haloC₁₋₆ alkyl, C₁₋₆ alkoxy or haloC₁₋₆ alkoxy.

18. The compound according to claim 1 or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein said compound is selected from a compound in Table 2, or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising a compound according to any one of claims 1-18 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carrier.

20. A combination comprising a compound according to any one of claims 1-18 or a pharmaceutically acceptable salt thereof, and one or more therapeutically active agent.

21. The combination according to claim 20, wherein said one or more therapeutically active agent is an anti-cancer agent, an analgesic or an anti-inflammatory agent.

22. A method for treating a disease or condition that benefit from or is treatable by inhibition of nuclear SET domain-containing protein 2 (NDS2), comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound according to any of claims 1-18 or a pharmaceutically acceptable salt thereof.

23. The method of claim 22, wherein said disease or condition that benefit from or is treatable by inhibition of NSD2 is selected from solid tumors, leukemia, myeloma, lymphoma and hypertension.

24. The method of claim 23, wherein said disease or condition that benefit from or is treatable by inhibition of NSD2 is breast cancer, cervical cancer, skin cancer (particularly skin squamous cell carcinoma), ovarian cancer, gastric cancer, prostate cancer, pancreatic cancer, lung cancer, hepatocellular carcinoma, head and neck cancer, peripheral nerve sheath tumor, osteosarcoma, multiple myeloma, neuroblastoma, leukemia (particularly acute lymphoblastic leukemia), non-Hodgkin's lymphoma (particularly mantle cell lymphoma), and pulmonary arterial hypertension.

24. The method of claim 23, wherein said leukemia or lymphoma that benefit from or is treatable by inhibition of NSD2 is acute lymphoblastic leukaemia, skin squamous cell carcinoma, mantle cell lymphoma.

25. Use of a compound according to any one of claims 1-18 and optionally in combination with a second therapeutic agent, in the manufacture of a medicament for a disease or condition that benefit from or is treatable by inhibition of nuclear SET domain-containing protein 2 (NSD2).

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2019/100542

A. CLASSIFICATION OF SUBJECT MATTER

C07D 473/34(2006.01)i; C07D 473/32(2006.01)i; C07D 473/26(2006.01)i; A61K 31/52(2006.01)i; A61P 35/00(2006.01)i; A61P 35/02(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D; A61K; A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CNABS, CNTXT, DWPI, USTXT, CNKI, STN(REGISTRY), STN(MARPAT), STN(CAPLUS), Purin+, pyridine+, piperidin+, cancer, tumor, DSD2, nuclear SET, domain, protein.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CN 1512992 A (DAINIPPON SUMITOMO PHARMA CO LTD) 14 July 2004 (2004-07-14) claims 1-11 and 14	1-25
A	JP 2004137157 A (SUMITOMO PHARMA CO LTD) 13 May 2004 (2004-05-13) claims 1-9, abstract	1-25
A	CN 1684966 A (DAINIPPON SUMITOMO PHARMA CO LTD) 19 October 2005 (2005-10-19) claims 1-34 and 38	1-25
A	CN 1688580 A (MEMORY PHARM CORP) 26 October 2005 (2005-10-26) claims 1-26	1-25
A	CN 102666541 A (GILEAD SCI INC) 12 September 2012 (2012-09-12) claims 1-14 and 20-21	1-25
A	CN 101679433 A (DAINIPPON SUMITOMO PHARMA CO LTD et al.) 24 March 2010 (2010-03-24) claims 1-21 and 25	1-25



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

“A” document defining the general state of the art which is not considered to be of particular relevance

“E” earlier application or patent but published on or after the international filing date

“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

“O” document referring to an oral disclosure, use, exhibition or other means

“P” document published prior to the international filing date but later than the priority date claimed

“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

“&” document member of the same patent family

Date of the actual completion of the international search

10 April 2020

Date of mailing of the international search report

24 April 2020

Name and mailing address of the ISA/CN

National Intellectual Property Administration, PRC
6, Xitucheng Rd., Jimen Bridge, Haidian District, Beijing
100088
China

Authorized officer

SHI,Boying

Facsimile No. (86-10)62019451

Telephone No. 86-(10)-53962169

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2019/100542

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **22-24**
because they relate to subject matter not required to be searched by this Authority, namely:
[1] Claims 22-24 are directed to the method for treating diseases, but the report is based on the use of the compound for the preparation of medicaments for treating the corresponding diseases.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/CN2019/100542

Patent document cited in search report			Publication date (day/month/year)	Patent family member(s)		Publication date (day/month/year)	
CN	1512992	A	14 July 2004	KR	20040008156	A	28 January 2004
				US	7521454	B2	21 April 2009
				EP	1386923	A1	04 February 2004
				ES	2314042	T3	16 March 2009
				KR	100892614	B1	09 April 2009
				TW	I331150	B	01 October 2010
				EP	1386923	A4	31 August 2005
				US	2007037832	A1	15 February 2007
				JP	4331944	B2	16 September 2009
				JP	WO2002085905	A1	12 August 2004
				US	2004132748	A1	08 July 2004
				CN	1250548	C	12 April 2006
				US	7157465	B2	02 January 2007
				AT	404561	T	15 August 2008
				WO	02085905	A1	31 October 2002
				EP	1386923	B1	13 August 2008
				CA	2444130	A1	31 October 2002
				CA	2444130	C	21 December 2010
				DE	60228229	D1	25 September 2008
JP	2004137157	A	13 May 2004	None			
CN	1684966	A	19 October 2005	US	7754728	B2	13 July 2010
				NO	20052038	L	24 May 2005
				NO	20052038	A	24 May 2005
				WO	2004029054	A1	08 April 2004
				NZ	539064	A	28 September 2007
				AU	2003271064	B2	17 June 2010
				BR	0314761	A	26 July 2005
				US	2010256118	A1	07 October 2010
				ES	2387388	T3	21 September 2012
				JP	4768263	B2	07 September 2011
				EP	1550662	B1	04 July 2012
				KR	101111085	B1	12 April 2012
				KR	20050062562	A	23 June 2005
				US	8148371	B2	03 April 2012
				AU	2003271064	A1	19 April 2004
				TW	I349671	B	01 October 2011
				MX	PA05003193	A	08 June 2005
				US	2006052403	A1	09 March 2006
				TW	200413374	A	01 August 2004
				CA	2497765	A1	08 April 2004
				EP	1550662	A4	07 March 2007
				US	2012178743	A1	12 July 2012
				ZA	200501920	B	30 November 2005
				JP	WO2004029054	A1	26 January 2006
				EP	1550662	A1	06 July 2005
CN	1688580	A	26 October 2005	US	7332486	B2	19 February 2008
				AT	449099	T	15 December 2009
				AU	2003264017	B2	27 May 2010
				CA	2494028	A1	19 February 2004
				US	2010004236	A1	07 January 2010

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/CN2019/100542

Patent document cited in search report			Publication date (day/month/year)	Patent family member(s)		Publication date (day/month/year)
				DE	60330150 D1	31 December 2009
				EP	1529049 B1	18 November 2009
				US	2008139583 A1	12 June 2008
				AU	2003264017 A1	25 February 2004
				WO	2004014913 A3	29 July 2004
				WO	2004014913 A2	19 February 2004
				EP	1529049 A2	11 May 2005
				JP	2005538134 A	15 December 2005
				US	2007093510 A1	26 April 2007
CN	102666541	A	12 September 2012	WO	2011049825 A1	28 April 2011
				NZ	598933 A	26 April 2013
				EP	2491035 B1	30 August 2017
				US	2011098248 A1	28 April 2011
				CR	20120255 A	02 July 2012
				AP	201206227 D0	30 April 2012
				JP	5694345 B2	01 April 2015
				US	8507507 B2	13 August 2013
				CN	102666541 B	25 November 2015
				BR	112012009329 A2	07 June 2016
				IL	218747 A	29 February 2016
				US	2015126509 A1	07 May 2015
				CO	6531469 A2	28 September 2012
				CA	2777824 A1	28 April 2011
				SI	2491035 T1	30 October 2017
				IN	2984DEN2012 A	31 July 2015
				KR	101793300 B1	02 November 2017
				IL	218747 D0	28 June 2012
				PT	2491035 T	30 October 2017
				ES	2644286 T3	28 November 2017
				US	9161934 B2	20 October 2015
				PE	20121091 A1	17 August 2012
				PE	10912012 A1	17 August 2012
				MX	2012004706 A	08 June 2012
				KR	20120105448 A	25 September 2012
				AP	3103 A	31 January 2015
				AU	2010310813 A1	03 May 2012
				EP	2491035 A1	29 August 2012
				PL	2491035 T3	31 January 2018
				EA	020488 B1	28 November 2014
				JP	2013508373 A	07 March 2013
				US	2014128389 A1	08 May 2014
				US	8962652 B2	24 February 2015
				CA	2777824 C	29 November 2016
				EC	SP12011915 A	31 July 2012
				SG	10201406813R A	27 November 2014
				ZA	201202858 B	27 December 2012
				AP	201206227 A0	30 April 2012
				NO	2491035 T3	27 January 2018
				EA	201290131 A1	30 August 2012
				AU	2010310813 B2	18 June 2015

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/CN2019/100542

Patent document cited in search report			Publication date (day/month/year)	Patent family member(s)			Publication date (day/month/year)
CN	101679433	A	24 March 2010	MX	2009010024	A	12 October 2009
				WO	2008114817	A1	25 September 2008
				UY	30966	A1	31 October 2008
				KR	20090125774	A	07 December 2009
				PE	20081887	A1	16 January 2009
				ZA	200906253	B	27 January 2010
				RU	2009138471	A	27 April 2011
				BR	PI0809134	A2	26 August 2014
				US	2010093998	A1	15 April 2010
				ZA	200906253	A	27 January 2010
				US	2011028715	A1	03 February 2011
				EC	SP099638	A	30 October 2009
				CO	6220972	A2	19 November 2010
				CA	2680397	A1	25 September 2008
				NZ	579744	A	29 June 2012
				PE	18872008	A1	16 January 2009
				CL	2008000789	A1	17 October 2008
				EP	2133353	A1	16 December 2009
				AR	065784	A1	01 July 2009
				IL	200831	D0	17 May 2010
				AU	2008227500	A1	25 September 2008
				EP	2133353	A4	31 August 2011
				JP	WO2008114817	A1	08 July 2010
				TW	200902018	A	16 January 2009